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Abstract 
Doctor of Philosophy 
Superparamagnetic Iron Oxide Nanoparticles: foundations for novel bioconjugate species 
and multimodal contrast agents 
By Geraint Rhys Dafydd Roberts 
The properties of superparamagnetic iron oxide nanoparticles (SPION) have led to them 
being a major area of research within the ‘nano-revolution’. A number of SPION species 
have been used in disease imaging, including multimodal contrast agents active in positron 
emission tomography (PET) and magnetic resonance imaging (MRI), as well as bioconjugate 
species where biomolecules have been immobilised on the nanoparticle’s surface. The 
western world faces an epidemic of conditions for which monoclonal antibodies (mAbs) 
have become seen as a ‘magic bullet’. However, the expense of mAb therapy, possible side 
effects and the desire to maximise treatment success require improvements in patient 
stratification and selection. 
Chapter 1 introduces the field of biomedical imaging and immunotherapy and describes how 
research into immunoPET and PET/MRI imaging overlap in the following chapters. 
Chapter 2 describes the development of reliable, reproducible methods of synthesising 
SPION and introducing a number of biocompatible coatings with useful functionalities. 
These techniques underlie the chemistry to be discussed in Chapter 3- the immobilisation of 
biomolecules on the surface of SPION. Typical linker chemistry is discussed, with the 
relative merits of different approaches expanded upon. The effect of initial reaction 
stoichiometry on enzymatic activity is explored as a model for later experiment design.
Chapter 4 incorporates several of the aspects examined in earlier chapters to describe the 
synthesis of radiolabelled SPION bioconjugated to the clinically approved antibody 
trastuzumab to give a novel immunoPET contrast agent. Fluorescence activated cell sorting 
(FACS) analysis and fluorescence microscopy confirm the in vitro validation of these agents. 
In vivo experiments show how these agents require further development before reaching a 
human clinical context. 
Chapter 5 relates the effort to synthesise novel coordination systems based on the hypoxia-
selective imaging agent 64Cu-ATSM. The co-ordination chemistry of these systems with 
several metals is described. 
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Chapter 1: Molecular imaging for diagnosis and designed therapy 
1.1 Introduction 
Superparamagnetic iron oxide nanoparticles (SPION) have been known since the early 
1980s,1 and a number of SPION-based species are now used clinically for the imaging of 
disease.2  They have been the study of much research in a variety of contexts; their ability to 
adsorb and incorporate heavy metal atoms has already been reported in environmental clean-
up,3–5 but is still relatively unexplored in terms of radiolabelled nanoparticles with medical 
applications.6,7 Similarly, although biomolecules have been immobilised onto the surface of 
such nanoparticles, reported approaches have tended to be quite distinct from one another, 
and discerning trends to inform design is difficult. In this thesis, a proof of concept will be 
demonstrated: biomolecule functionalised iron oxide nanoparticles, synthesised reproducibly 
on a large scale and radiolabelled with the medically relevant isotope 89Zr. The progression 
to an in vivo study from nanoparticle formation via the validation of bioconjugate 
methodologies bears evidence to how inorganic chemistry can fit into the future of medicine. 
1.2 Cancer – diagnosis, treatment, morbidity and mortality 
In 2012, published projections of cancer prevalence in the UK predicted that the number of 
people living with cancer will increase by approximately 1 million per decade to 5.3 million 
in 2040.8 By 2021, the cost to the UK for the diagnosis and treatment of cancer is predicted 
to rise to £ 15.3 billion.9 In cases where cancer is allowed to become metastatic, survival rates 
are significantly depressed (Fig. 1).3 Early detection, characterisation and treatment is key in 
improving survival rates among cancer patients, selecting the most appropriate treatment 
regimen is crucial.   
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Figure 1. Five Year relative survival rates (%) for selected forms of cancer. Local 
describes a tumour confined to the organ of origin. Regional describes a tumour that has 
spread to neighbouring organs, tissues and/or local lymph nodes. Distant refers to a 
tumour that has spread to regions distant to the organ of origin.10
There are a wide range of therapies available- depending on the form of cancer, most patients 
will have a combination of two or more. These may include surgery, radiotherapy, 
chemotherapy and hormone therapy. Radiotherapy and chemotherapy (the use of radiation 
and small molecule chemical species respectively to treat cancer or ease symptoms) can be 
effective but have common side-effects which can diminish patient quality-of-life.11 One of 
the greatest medical success stories of the past century is the development of 
immunotherapy, the use of antibodies to treat diseases including many forms of cancer. 
However, the expense of immunotherapeutic drugs and the ever-increasing population of 
cancer patients have contributed to a need to refine how patients are selected to receive 
treatment. It will become necessary to stratify potential patients based on their likely response 
to immunotherapy.12 In recent years, there has a been great interest in the development of 
imaging agents based on immunotherapeutics to achieve this.12
1.3 Monoclonal antibody (mAb) therapy 
In 1906, the German scientist Paul Erhlich hypothesised that a chemical stain which showed 
selectivity for a given bacteria could also be used to deliver a toxic agent to kill its target, 
acting in effect as a ‘magic bullet’.13 Antibodies (part of the body’s immune response to 
foreign antigens) seemed like an obvious candidate for the development of an arsenal of 
‘magic bullets’; however, antibodies are naturally heterogeneous and offer a variety of binding 
responses to a target antigen. The development of methods to produce homogeneous 
antibodies sample from a single source (i.e. monoclonal antibodies) along with subsequent 
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humanisation of murine antibodies made Ehrlich’s dream a reality and in the 1990s FDA-
approval was granted for Rituximab,12 leading to clinical success for a number of mAb-based 
therapies.6
Antibodies are large immunoglobulin proteins, consisting of at least 4 subunits. They are 
produced as part of the body’s immune response to foreign macromolecules. There are five 
classes of antibodies: IgG, IgM, IgA, IgD and IgE.14 IgG is the most common 
immunoglobulin class in the body and is the most frequently used in cancer immunotherapy, 
and will therefore be the focus of the discussion below. Such mAbs consist of 2 identical 
approximately 23 kDa domains known as ‘light chains’, and 2 identical 53-75 kDa heavy 
chains, arranged in the familiar Y-shape (Fig. 2). The subunits associate with each other via 
disulphide bonds along with local non-covalent interactions. The ‘arms’ of the molecule 
consist of two identical ‘Fragment antigen binding’ (Fab) regions, while the ‘stem’ consists 
of the ‘Fragment crystallisable’ (Fc) region. The Fc regions of different antibodies are largely 
constant within a given host.  
Selectivity of these antibodies is controlled primarily by the antigen binding sites of the light 
and heavy chains.14 Variation in the amino acid sequences of antibodies (‘hypervariable 
sequences’) occurs predominantly in three flexible loops at the end of the chains, allowing 
specific antigen binding. The Fc region may bind to effector molecules as part of an immune 
response; glycosylation in this region is a common post-translational modification, and is 
believed to play an important part in mediating the effect of the antibody.7,8 
Figure 2. Simplified structure of a typical mAb. Not shown are regions of folding, N- and 
C-terminals, glycosylation and disulphide bonds between light and heavy chains. 
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Administration of mAb therapies is now commonplace, with many new mAb species being 
granted FDA approval every year.13,14 A 2015 report on the global market for mAb products 
hypothesised that with a conservative FDA-approval rate of approximately 4 therapeutic 
formulations per year, by 2020 the global market will be worth $125 billion.15 Many mAb-
based therapies are so-called ‘block-buster drugs’, with their efficacy leading to significant 
profits for the parent company. As an example, trastuzumab (Herceptin®) is a mAb 
preparation which binds to the Her-2 receptor which is over-expressed in  approximately 25 
% of breast cancers.16 Although its specific mode of action is still a subject of some debate, 
dramatic reductions in tumour size have been reported, leading to trastuzumab therapy being 
recommended for first-time, re-current and metastatic breast cancers.16 Breast cancer is the 
most common form of cancer in women worldwide, and trastuzumab is the world’s best-
selling breast cancer drug. With a year of trastuzumab treatment typically costing over 
$50,000, the cost to healthcare systems for breast cancer treatment alone runs into the 
billions of dollars.9
While remarkable clinical successes have been shown, poor patient-to-patient performance 
has been reported for some mAb-based treatments. In the case of trastuzumab, Her-2 
overexpression in a patient’s tumour may be determined histologically, but does not give an 
accurate indication of the likely efficacy of trastuzumab. Concurrently, side effects including 
dose-independent cardiac dysfunction has been reported.17 There is a need to develop 
methods of pre-selecting patients for mAb therapy. The benefits of improved patient 
stratification and selection are manifold; not only is the healthcare system spared the expense 
of administering a drug that may be of limited effect, but the patient is more quickly referred 
to the most suitable treatment regimen for them, improving their chances of a successful 
outcome.12 The modification of an already clinically approved mAb agent to act as an imaging 
agent would be an elegant solution. Depending on the imaging mode used (see below), an 
imaging dose would be a pharmacologically insignificant, limiting cost and side effects while 
allowing the observation of in vivo behaviour and assessment of mAb therapy suitability. 
Additionally, the path to FDA-approval may prove easier given the prior use of the parent 
species. 
1.4 Molecular imaging, contrast agents and multi-modal approaches 
The non-invasive visualisation of biological processes and targets at the molecular level in 
vivo has revolutionised the diagnosis of disease, with a positive effect on patient survival rates 
and quality of life. There are a range of established and emerging imaging modalities available 
to the researcher or clinician and almost all require the use of an administered chemical 
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species (known as a contrast agent) to either create or enhance contrast between tissues of 
interest and the background to allow the diagnosis of disease. Novel imaging agents based 
on molecules which exhibit a behaviour in response to external stimuli (e.g. magnetic 
particles in an applied magnetic field, or fluorescent molecules under irradiation with specific 
wavelengths of light) provide innovative approaches to better understand biological 
processes within tissues and to aid diagnosis. Together with the need to improve on current 
agents, there is a demand for chemists to design and synthesise novel species in response to 
the increased understanding of disease pathologies.18,19
Unfortunately, no single mode of imaging is perfect, with each having specific advantages 
and disadvantages (see Table 1).19 Those with high resolution usually show low sensitivity, 
while high sensitivity is generally associated with poor spatial resolution. Depth of 
penetration can severely limit a technique’s application. It is now universally accepted that 
the best approach is to interrogate a biological subject with two or more imaging modes, 
using their complementary abilities in a synergistic manner to overcome their individual 
disadvantages. Administering a single agent, active in multiple imaging modes, is preferable 
to administering several singly active species. Fewer clinical interventions, reduced biological 
disruption and ensured co-localisation are just a few benefits of using a multi-modal agent.18
Although the scientific literature contains numerous examples of bimodal imaging agents, a 
full discussion of all possible combinations of modalities would be inappropriate, and the 
interested reader is referred to some of the many excellent reviews published to date.18–21
Attention in the current instance will be focussed on the individual modes of PET and MRI, 
the development of combined PET/MRI agents (due to the large potential benefits to be 
gained from combining high sensitivity and high resolution), and how this has led to SPION 
being at the forefront of the field. 
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Modality Typical agents Physical basis Advantages Disadvantages
CT Iodine- or barium-containing 
agents
X ray detection and computer 
analysis
Deep penetration, high 
resolution
Low sensitivity, ionising 
radiation
MRI Gd chelates, SPION Differences in water proton 
relaxivity in a magnetic field
Deep penetration, high 
resolution, no ionising radiation
Low sensitivity, expensive set-
up costs
PET Radioisotopes Detection of γ-rays arising from 
positron annihilation
Deep penetration, extremely 
sensitive
Poor resolution, ionising 
radiation, expensive set-up
SPECT Radioisotopes Detection of γ-rays Deep penetration, extremely 
sensitive
Poor resolution, ionising 
radiation, expensive set-up
Optical Imaging Lumophores Detection of emitted 
visible/NIR photons
Inexpensive, short timescale of 
observation
Shallow penetration, 
autofluorescence
Table 1. Comparison of some common imaging modalities.19
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1.5 Positron Emission Tomography 
Positron Emission Tomography (PET) is a non-invasive molecular imaging technique based 
on the decay of positron emitting radionuclides within a living target. The collision of emitted 
positrons with endogenous electrons results in an annihilation event and the emission of 
gamma rays that are detected and which inform the observer of the site of annihilation. It is 
relatively commonly used in a clinical setting worldwide. In contrast to other diagnostic 
techniques (e.g. Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI)) a 
contrast agent is always necessary, as there are no naturally occurring sources of positrons 
within the human body. This naturally low background contributes to the excellent sensitivity 
of PET (blood-agent concentrations as low as 10-12 mol.L-1 yield sufficient contrast).19 Such 
high sensitivity explains the prevalence of PET; although the cost of establishing a PET 
centre is high due to the requirement for a small medical cyclotron and laboratories suitable 
for radiochemical work, it is outweighed by the quality of the information to be gained from 
PET imaging with small quantities of agent. The exposure of the patient to ionising radiation 
is less than for CT.22 PET contrast agents can be designed to accumulate at biological targets 
of interest, such as those associated with disease; up-regulated glucose metabolism,23 over-
expressed cell surface receptors24 and hypoxic cell environments25 are all indicative of forms 
of cancer. 
PET isotopes are synthesised by the use of a cyclotron. A target consisting of a naturally 
occurring element is bombarded by high energy protons, deuterons or helium particles. The 
bombarding particle combines with the target nucleus to give a compound nucleus of the 
radioisotope in an unstable, energetically excited state which is isolated and incorporated into 
an imaging probe for rapid use.26,27 Decay of unstable nuclei can occur via multiple pathways, 
but ‘PET active’ nuclei decay mainly by the conversion of an extra proton to give a neutron, 
a neutrino, and an emitted positron, β+, the equivalent antiparticle of an electron. Inelastic 
interactions with surrounding species cause rapid slowing of the positron until collision with 
an electron occurs (an ‘annihilation’ event). The conservation of momentum and energy 
results in the remaining mass of the positron and the electron being converted to two 511 
keV photons, emitted at 180 ° to each other as gamma rays.21 PET scanners consist of 
concentric, closed circle detectors enclosing a subject. The impact of gamma rays on the 
detectors is converted first to an electrical signal, then to a sinogram, then correlated to a 
tomographic image to give a corrected representation of the source of the gamma rays. This 
allows the approximate anatomical locale of the tracer to be determined. As the annihilation 
event occurs at a point distinct from the emission of the positron, PET suffers from limited 
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resolution; the mean free path of the positron is on the mm scale.28 Different PET active 
isotopes have different positron ranges which can effect resolution (see Fig. 3c).29
Figure 3a. Schematic of events giving rise to gamma ray emission for detection. b. Small 
animal PET images showing accumulation of tracer in a tumour, adapted from Zeglis et 
al.30 c. Comparison of end-point-coordinates for the decay of different isotopes.29
Historically, the most commonly used radioisotope for clinical PET has been 18F (t1/2 = 109.7 
min; β+ = 0.64 MeV), most regularly as 18F-fluorodeoxyglucose (FDG). Although ideal for 
visualising the location of upregulated glucose metabolism, this fluorinated sugar is not 
directed to cancer specific markers , so may accumulate in healthy tissues with high metabolic 
need and may not accumulate in slow growing tumours.16, 23 The short radioactive half-life of 
18F limits its practical use to almost immediately upon production, and renders it not suitable 
for use with longer time-scale biological processes, such as with slow-clearing high molecular 
weight biomolecules (e.g. mAbs). In the last decade, there has been an effort within the 
research community to develop PET agents utilising long half-life metallic radioisotopes 
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which are better suited to investigating long time-scale processes. As a result of the increasing 
number of small medical cyclotrons in clinical settings, a range of isotopes are available to 
today’s researchers, allowing properties such as physical half-life or emission energy to be 
selected to complement the biological half-life of the target or delivery vector. The loss of 
signal of a radiopharmaceutical is affected by radiological (‘tr’) and biological (‘tb’) half-lives, 
and so the agent has an effective half-life, te: 
Contrast agents with rapid clearance can be labelled with 68Ga (t1/2 ~ 68 min), whereas species 
which accumulate or which are slower to clear molecules such as mAbs (e.g. biological half-
life of cetuximab is 114 h)30 may be labelled with 89Zr (t1/2 = 78.5 h) to give a desirable te.32,33
Isotope Half-
life/ 
h
Source Production 
reaction
Decay 
mode (% 
branching 
ratio)
Common 
oxidation 
states
Common 
coordination 
numbers
18 F 1.8 Cyclotron 18O(p, n)18F β+ (97)
EC (3)
1- 1
61Cu 3.3 Cyclotron 61Ni(p,n)61Cu β+ (62)
EC (38)
1+, 2+ 4, 5, 6
64Cu 12.7 Cyclotron 64Ni(p,n)64Cu β+ (19
EC (41)
β- (40)
1+, 2+ 4, 5, 6
66Ga 9.5 Cyclotron 63Cu(α,nγ)66Ga β+ (56)
EC (44)
3+ 4, 5, 6
86Y 14.7 Cyclotron 86Sr(p,n)86Y β+ (33)
EC (66)
3+ 8, 9
89Zr 78.5 Cyclotron 89Y(p,n)89Zr β+ (23)
EC (77)
4+ 8
Table 2. Physical characteristics of some common metallic radioisotopes; 18F included 
for comparison. Data adapted and combined from multiple sources.26,32,34
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To date, 89Zr has become the favoured isotope for the purpose of radiolabelling mAbs, a 
field known as immunoPET.12,35–37 The long half-life of the isotope is not only on a similar 
timescale to whole antibody circulation times, but it allows for production at a location 
distant to the point of administration to a patient, so the isotope is available commercially.38
Shorter lived isotopes (e.g. 64Cu) are better suited to antibody fragments or small molecules.36
Positrons emitted from 89Zr have relatively low energy (Emean = 395 keV) which yields high 
resolution images.37 The chemistry of zirconium in its +IV oxidation state is also important 
to understand its popularity for immunoPET- the ion is relatively large for a hard cation, 
allowing it to accommodate up to eight of its favoured anionic oxygen donors. This has been 
exploited in the past in nuclear fuel recovery by the use of derivatives of a naturally occurring 
bacterial iron chelator, desferrioxamine (DFO), which has six hydroxamate groups with 
which to coordinate Zr4+ in a highly stable manner (two water molecules complete the 
coordination sphere) necessary to maximise retention of the radioisotope by the vector 
molecule and to aid the analysis of resultant PET scans. Derivatives of DFO are still 
commonly employed in immunoPET but toxicity issues arising from release of 89Zr and 
subsequent sequestration in bone has led to the search for improved methods of 
radiolabelling mAbs.36,37
The development of bifunctional chelators which conjugate to biomolecules and coordinate 
metal centres has given rise to a degree of modularity. Biomolecules can be rapidly prepared 
for radiolabelling by the use of commercially available species (e.g. the DFO based Df-Bz-
NCS (Fig. 4)39,40 or the more stable HOPO-Bz-NCS developed by  Lewis et al.)41,42 Versatile 
chelators such as DTPA, DOTA and NOTA (Fig. 5) have the ability to coordinate to 
different metals, such that the radiometal may be exchanged (without need to change the 
synthesis of the bioconjugate) to give imaging and therapeutic companion agents.32 An 
imaging agent can be structurally identical to a therapeutic analogue, differing only in the 
nature of the coordinated metal. However, regardless of the nature of the group or the metal 
centre, the number of chelating groups that may be introduced per biomolecule is limited by 
the need to not change the in vivo behaviour of the vector.39,43 The process of radiometal 
coordination is typically rapid, requiring mild conditions and relatively facile purification 
methods. By contrast, organic radioisotopes normally require harsh, multistep reaction 
schemes with complicated purifications, increasing the complexity of the operation and 
eating into the usable time of the unstable isotopes.32
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Figure 4. Simplified depiction of Df-Bz-NCS, a metal-coordinating ligand based on DFO, 
coordinating 89Zr and coupled directly to a mAb. Note the short timeframe of the 
synthesis. Adapted from Vosjan et al.40
Figure 5. Common chelating moieties within inorganic radiochemistry. 
A final desirable characteristic of radiometals is their tendency to residualise in target cells.37
Retention at the target site and long radioactive half-lives gives the opportunity for sequential 
scans of a subject over long periods of time (multiple half-lives). This allows for the real-time 
imaging of disease development and/or treatment, with a minimum of interventions, but 
must be considered against the inherent risks of radiodrugs e.g. cytotoxicity.32
Several radiometal agents are used in clinical PET imaging today, and two are of direct 
relevance to the current work. 89Zr-based immunoPET imaging will be discussed further in 
Chapter 4. The agent 64Cu-ATSM has been used for the PET imaging of hypoxia (indicative 
of a cancerous cell environment) since 2002.44 The interesting chemistry of this agent and 
the chemical family to which it belongs is discussed in Chapter 5. 
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1.6 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is one of the most commonly used imaging modes in 
healthcare systems around the world, offering unlimited depth of penetrations, high spatial 
resolution (< 1 mm in clinical contexts) and potentially real-time observation of cellular 
behaviour. However, it displays poor sensitivity, with large quantities of contrast agents being 
required to achieve contrast sufficient to aid diagnosis.21 To understand how contrast is 
enhanced by chemical agents such as SPION requires a brief description of the fundamentals 
of the technique. The reader is referred to literature for further information beyond the scope 
of this introduction.45–47
MRI is based upon the concept of the nuclear spin of hydrogen atoms (protons) present in 
water molecules in living tissue.45,46 Protons are considered as rotating, charged particles, and 
therefore have a magnetic moment (B) with vector properties. In the absence of an external 
magnetic field, a sample consists of an equal number of α- and β-spins (spin-up and spin-
down respectively) with random orientation in space and zero net magnetisation. The 
energies of the two spin states change when an external magnetic field (Bo) is applied, as does 
the population at equilibrium (as predicted by a Boltzmann distribution for a given 
temperature and field strength), resulting in a small majority of the lower energy α-spins 
aligning parallel to the field and giving a net longitudinal magnetisation, Mz. A smaller number 
of higher energy β-spins align anti-parallel to the field. Both spin states precess about the z-
direction (Fig. 6). 
Figure 6. In the presence of an applied magnetic field (Bo) in the z-direction, a small 
majority of spins align and precess about the z-direction to give a net magnetisation, Mz. 
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Precession about the z-axis occurs at a rate dependent upon the strength of the applied field 
and the gyromagnetic ratio of the proton. This rate is the Larmor frequency and is given by 
the Larmor equation: 
where ωo is the Larmor frequency in MHz, γo is the gyromagnetic ratio for protons, 42.577 
MHz.T-1, and Bo is the strength of the magnetic field in Tesla.45,46
Exciting a sample with radio waves equal to the Larmor frequency for a sufficient time tips 
the longitudinal magnetisation into the xy-plane (a 90° radiofrequency (RF) pulse), giving 
transverse magnetisation, Mxy. Precession in this plane about the z-axis induces a voltage in 
receiver coils set up around the direction of magnetisation, which is interpreted as an MR 
signal.  
The signal intensity at any point following excitation depends on the degree of transverse 
magnetisation, and is related to proton density and relaxation rates. Following the 90° RF 
pulse, the transmitter is turned off. The spins now existing in an excited state seek to relax 
by dissipating energy. Realigning with the applied field causes a decrease in Mxy and free 
induction decay in the intensity of the MR signal. 
Three relaxation mechanisms contribute to decay in the Mxy and therefore loss of signal 
intensity. Realignment of the spins with the z-direction is known as ‘longitudinal’ or ‘spin-
lattice’ relaxation (Fig. 7), and has an exponential time constant T1. Energy is lost from the 
spins to their surroundings, allowing recovery of Mz. The time T1 is the length of time taken 
for a 63 % recovery, and is generally of the order of seconds at 1.5 T for water in biological 
tissues. It is dependent on Bo and Brownian motion within the sample. 
Figure 7. T1 Relaxation – realignment of spins with field direction. 
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‘Spin-spin’ or ‘transverse’ relaxation causes signal decay due to loss of phase coherence (Fig. 
8). Following the 90° RF pulse, all the proton spins in a sample are initially aligned in the 
transverse direction coherently, i.e. in the same place in the precessional path around the z-
axis. Spins are able to exchange energy with each other, leading to different precessional 
rates, eventually causing proton spins to go ‘out of phase’. The individual magnetisation 
vectors no longer sum to give a net magnetisation in one direction, and the measured signal 
decays with exponential time constant T2 (the ‘transverse relaxation time’, the time taken for 
63 % loss of transverse magnetisation). Transverse relaxation occurs in the first few hundred 
milliseconds after the 90° RF pulse, before longitudinal relaxation has occurred to a 
significant degree. 
Figure 8. T2/T2* Relaxation – loss of phase coherence between spins. 
Local field inhomogeneities also result in different spins having different precession rates, 
but can be compensated for. The properties of an individual scanner or patient can affect 
dephasing and loss of MR signal with time constant T2* (the ‘effective transverse relaxation 
time’), but this may be limited by appropriate experiment design. The three relaxation 
mechanisms occur simultaneously but independently.46
Protons in water in different tissues have different T1 and T2 relaxation rates. At a given time 
following a 90° RF pulse their respective MR signals will have different intensities, leading 
to contrast in reconstructed images. An image can be weighted to achieve maximum contrast 
by highlighting T1 or T2 differences (i.e. if tissues have similar T1 times, using T2 differences 
to generate contrast may be more useful diagnostically) (see Fig. 9b).48 A T1-weighted image 
is obtained by using a repetition time (time between RF excitations) that is shorter than the 
T1 times of the tissues being contrasted. A fast recovering spin (short T1) will have a larger 
transverse magnetisation component following the second RF pulse than a slow recovering 
spin, leading to a more intense, brighter signal on the MRI image.46 A T2-weighted image is 
derived using a gated technique; a short interval of time (echo time) separates the excitation 
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pulse and collection of the MR signal, during which time loss of phase coherence has 
occurred to different degrees in different environments. A short T2 time results in a greater 
loss of signal (darker image) than a longer T2 time.46
Figure 9a. T1 weighted images show contrast based on T1 times. Here, the black vector 
represents a spin with short T1 time and the red vector represents a spin with a long T1
time. The faster relaxing black vector has more longitudinal magnetisation before the 
second 90 ° RF pulse, and so more transverse magnetisation afterward, giving a brighter 
signal.45 b. Comparison between T1- and T2-weighted images.48
Natural contrast between different tissues is often not sufficient to allow clear imaging. MR 
contrast media are molecules that have characteristics that make them useful in enhancing contrast: 
controlled/predictable biodistribution, low toxicity and excretability, and high molar relaxivity.45 
Most common MR contrast agents are based on paramagnetic or superparamagnetic metal systems 
where unpaired electronic spins of the metal atoms generate a magnetic moment that when 
appropriately functionalised cause an enhancement/acceleration of water proton relaxation rates in 
the target tissue.45,46,49 ‘Relaxivity’ is a measure of the efficiency with which a contrast agent 
enhances T1 or T2 relaxation times, based on its concentration and the observed increase in 
relaxation rates.45 The values of the relaxivity quantities R1 and R2 can be measured and are known 
to relate to T1 and T2: 
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where R has units s-1.46 The higher the relaxivity of the agent, the faster the rate of relaxation of the 
proton, which underlies signal intensity in both T1 and T2 weighted images.46 Changing signal 
intensity inherently affects contrast between tissues. Often relaxivities of agents are quoted as rx
with units of L.mmol-1.s-1 at a given temperature, and so measured values of Rx and agent 
concentration c are related by the equation:50
There are multiple contributing mechanisms to the relaxivity induced by the use of contrast 
agents. In a tissue, the local magnetic field experienced by protons is dependent on the 
applied field and fluctuations arising from the tumbling of nearby molecules with a magnetic 
moment. The speed of molecular tumbling affects the efficiency of relaxation processes. For 
both paramagnetic and superparamagnetic contrast agents, T1 and T2 relaxation rates can be 
enhanced by the agent changing the local magnetic field and slowing water tumbling in the 
inner and outer coordination spheres. Agents are often referred to as T1- or T2 agents based 
upon the relaxation mode upon which they have most effect. Paramagnetic MRI contrast 
agents will typically consist of a metal ion with unpaired electrons, coordinated to a ligand 
that allows exchange of coordinated water with the surroundings. The most common metals 
used in this context are Gd in its +III oxidation state and Mn in its +II oxidation state, 
having 7 and 5 unpaired electrons respectively. Such agents are administered to patients in 
gram quantities, but there has been a desire to develop alternatives to the use of gadolinium 
species due to their association with nephrogenic systemic fibrosis.51 Manganese species have 
also been plagued by toxicity issues,52 despite the metal being present as a trace mineral in 
the body used in metabolism, nerve function and in other roles.52,53 Nevertheless, several 
species have been FDA-approved, from the simple salt MnCl2 (as ‘Lumenhance’) to complex 
ions such as Mn-DPDP (‘Teslascan’). 
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Figure 10. Three FDA-approved paramagnetic MRI contrast agents. The use of Gd and 
Mn can cause toxicity issues in some patients.51–53
Iron-based contrast agents are particularly desirable for several reasons. Iron is present in the body 
in large quantities and has low toxicity; iron oxides are known to degrade in the body with few 
repercussions due to the existing mechanisms of iron metabolism (e.g. ferritin), although a target of 
research is to optimise the biological lifetime of the agent so that it is excreted before significant 
degradation occurs.20 The most successful form of ferrous contrast agents to date are 
superparamagnetic iron oxide nanoparticles. Typically consisting of iron in both its +II and +III 
oxidation states in a lattice with oxygen, the large number of  unpaired spins arising from the metal 
atoms results in each particle having a net magnetisation vector greater than any individual Gd- or 
Mn-complex. These particles display superparamagnetism and high relaxivity values, making them 
excellent MRI contrast agents. A more thorough discussion of SPION and superparamagnetism is 
given in Chapter 2. The first in vivo trials using SPION were carried out in the 1980’s,32–34  and 
several SPION-based MRI agents have since been FDA-approved (e.g. Feridex, Resovist and 
Sinarem). 
1.7 PET/MRI bimodal imaging and agents 
As has been discussed above, all imaging modes have some limitations, and thus multiple 
techniques are often used in diagnosis. Since 2001, sales of PET scanners have been 
overtaken by sales of combined PET/CT scanners, which have become the favoured 
approach for clinical imaging.54,55 CT compensates for the poor resolution of PET, but both 
result in exposure to radiation. MRI can be viewed as a superior alternative; the use of suitable 
agents increases contrast relative to CT and radiation dosage is lessened.55–57 Modern 
PET/MRI combined scanners can provide anatomical and functional information via both 
imaging modes.57 For widespread acceptance and integration of PET/MRI over PET/CT or 
separate, sequential scanning in different modes, PET/MRI must meet unmet clinical needs 
or provide significant advantages. Some of these advantages are inherent to the technique; 
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for example, MRI is superior to CT for the imaging of liver, bone and brain cancers. 
Simultaneous acquisition allows for more accurate analysis of in vivo behaviour and 
distribution,57 and PET/MRI may also be more suitable where there are concerns over the 
ionising radiation used in CT scanning.56 To take full advantage of the techniques’ synergy 
the contrast agent administered must be active in both imaging modes, but the markedly 
different sensitivities of the two techniques imposes a design limitation; as MRI is less 
sensitive, the addition of a small quantity of PET isotope to an MRI agent is required, rather 
than the addition of an MRI active group to a PET agent.58
PET/MRI bimodal agents can be divided into two categories- small molecule species and 
nanomaterials. The first species to be reported that displayed MRI and PET activity was in 
the 2010 publication by Caravan et al., a Gd-DOTA complex with fluorinated moiety (see 
Fig. 11).59 Although other species have been reported since,60 research into small molecules 
for PET/MRI has somewhat stagnated. Research into nanomaterials has dominated the field 
due to the many advantages they offer: their sizes and surface areas can be easily modified, 
the surfaces can be functionalised with multiple chemical groups of interest, and many 
nanomaterials have inherent characteristics that make them suitable.55
Figure 11. The inclusion of a 18F bearing moiety via ‘click chemistry’ imbues PET activity 
on an MRI agent that was previously known to offer pH sensitivity. Adapted from Caravan 
et al.59
Nanomaterials have already seen use as contrast agents in particular imaging modes e.g. 
SPION for MRI. They have large surface areas which can be functionalised with multiple 
moieties per nanoparticle. They can also be designed as responsive agents; for example, 
releasing drugs or contrast agents as a response to specific stimuli (internal or external).2,61
Designing a bimodal agent based on an existing nanomaterial agent effectively gives 
researchers an advantage over small molecule design from first principles.55
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There are four commonly reported methods for incorporating radionuclides into 
nanomaterials summarised in Table 3. The ideal method of the future will have high 
radioactive yields, generate stable products, have short preparation and purification time, 
and, importantly, ensure low exposure to radiation for the researcher or technician 
performing the reaction.62
Method Advantage Disadvantage Ref.
Surface chelation
Surface groups 
coordinate a radioisotope 
directly.
Simple, efficient, 
inexpensive.
Dissociation of the isotope can 
limit analysis and can have 
health impact.
63,64
Post-synthesis 
proton/neutron 
bombardment
Nanomaterials are 
synthesised ‘cold’, then 
subjected to 
bombardment in a 
cyclotron.
Stable species 
limits loss of 
radioactivity.
Expensive, requiring dedicated 
instrumentation
65,66
Use of radioactive 
precursors
Nanomaterials are 
synthesised using 
radioactive materials in 
early stages of synthesis
Typically highly 
stable species.
Often associated with high 
radiation exposure during 
production.
67,68
Post-synthesis absorption 
or exchange
Radiometal ions adsorb 
to the surface of the 
nanomaterial directly 
without additional 
chelating groups
Inexpensive and 
simple.
Currently limited to certain 
species; poor stability and 
yields.
6,69
Table 3. Four common methods for incorporating radioisotopes in nanomaterials.55
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Although agents based on other nanomaterials have been reported, SPION have been the 
most popular foundation for PET/MRI species, and have been functionalised with a range 
of PET isotopes.63,64,70–72 This has typically been via conjugation or derivatisation of the 
surface coating, although some notable cases stand out: the adsorption of radio-arsenic6 and 
-germanium7 isotopes onto the iron oxide surface of poly(acrylic acid) coated SPION 
illustrate not only the issue of coating porosity, but also the potential to directly label the 
inorganic core of the particles themselves with a range of medically significant radioisotopes. 
This concept will be discussed further in Chapter 2. When designing immunoPET agents the 
number of chelating species (ergo, the number of radioisotopes) per antibody must be limited 
to prevent changes to the structure and pharmacokinetics, but the large size and surface area 
of a nanoparticle allow for the accommodation of significantly more radioisotopes, 
increasing the sensitivity and contrast to be observed per molecule while decreasing the need 
for excretion events.73 While PET/MRI is an exciting area of research which will surely 
become more common in clinics, what has already been reported in the literature presents 
an intriguing question: can radiolabelled SPION be linked to clinical mAbs to give a novel 
immunoPET agent that avoids the limitations of directly radiolabelled mAbs, and which 
offers flexibility in terms of number and nature of radioisotopes? 
Figure 12a. Cross-reaction between the FDA-approved Ferumoxytol and the 
commercially available DFO-p-SCN allows for direct labelling with a radioisotope.63 b.
A 64Cu coordination complex (shown) has been used to bind to the surface of the dextran-
coated species Endorem via pendant bisphosphonates.71 c. pH dependant adsorption of 
69Ge to iron oxide allowed a chelator-free synthesis of a PET/MRI active species.7
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1.8 Summary 
The western world faces an epidemic of diseases arising from lifestyle and longevity. The use 
of monoclonal antibodies in therapy has been increasing annually since the approval of the 
first generation of agents in the 1990s and will continue to increase as new antibody based 
agents are developed, new disease-specific targets become known, and more people develop 
illnesses that require their use. The need for personalised treatment regimens will grow ever 
greater and so the development of novel imaging probes to stratify patients and aid in 
diagnosis is crucial.74 The design of immunoPET agents incorporating long half-life metallic 
radioisotopes, such as 89Zr, has already been validated by preclinical and clinical studies and 
is a thriving area of research.75,76
At the same time, the use of bimodal imaging to take advantage of synergistic qualities of 
different imaging modes will increase; the benefits are clear and the disadvantages few. 
Combined PET/CT scanners have already largely replaced individual PET and CD 
machines, and PET/MRI is likely to become more common going forwards, for the reasons 
discussed above.55–57 Superparamagnetic iron oxide nanoparticles, already established as MRI 
contrast agents in the clinic, have been at the forefront of PET/MRI agent research and have 
shown their suitability for further study.  
The following chapters describe the design and synthesis of SPION nanoparticles with useful 
surface functionality that allow for the immobilisation of biomolecules including clinically 
relevant monoclonal antibodies. These nanoparticles were first synthesised ‘cold’ in the 
chemistry laboratory in order to characterise the surface species, stability and retained 
biological activity of the immobilised enzymes and mAbs. The in vitro validation of SPION 
bearing the Her-2 targeting mAb trastuzumab by FACS and confocal microscopy is shown 
to lead to in vivo studies where immuno-SPION species were radiolabelled with 89Zr to give 
a novel immunoPET and which were applied to nude mice bearing Her-2 positive and Her-
2 negative xenograft tumours. In addition to this, the development of novel ligands (based 
on Cu-ATSM) for use as haptens in catalytic antibody development is described and 
discussed. 
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Chapter 2: Synthesis, coating and characterisation of water soluble 
superparamagnetic iron oxide nanoparticles (SPION) 
2.1 Introduction 
Superparamagnetic iron oxide nanoparticles (SPION) have been used clinically as T2 contrast 
agents in MRI. They typically consist of an inorganic core of Fe3O4 with an organic coating 
that imbues solubility in a given solvent and which can give a basis for the inclusion of 
functional groups on the particle surface. Since the first published synthesis of SPION by 
Massart,1 there have been thousands of publications describing the synthesis, coating or 
functionalisation of iron oxide nanoparticles. Many review articles with differing emphases 
have also been written and the reader is invited to refer to these for more information on 
particular aspects and routes.2–10 In this chapter, the syntheses and characterisation of two 
forms of biocompatible SPION are reported, along with initial experiments to incorporate 
PET-active radiotracers into such particles. The criteria by which such material should be 
judged if they are to be used as foundations for in vivo agents are discussed. 
2.1.1 SPION structure and characteristics 
While there are many iron oxides and hydroxides found in nature, only two species are 
commonly encountered within the context of molecular imaging. Magnetite (Fe3O4) is the 
more commonly reported form and is more strongly magnetic as a bulk material but can be 
oxidised to the less common, less strongly magnetic maghemite (γ-Fe2O3). This review will 
focus on the former and except where explicitly stated will use ‘iron oxide’ and ‘magnetite’ 
interchangeably. 
The terms ‘magnet’ and ‘magnetite’ share a common origin in the observation of attractive 
forces between stones from ‘Magnesia’, as the magnetite-rich region of western Turkey was 
known to the Ancient Greeks. Magnetite as a bulk mineral exhibits a permanent (or 
‘remanent’) form of ‘cooperative’ magnetism called ‘ferrimagnetism’.11 All forms of 
magnetism are ultimately derived from the behaviour of electrons in materials and Fe3O4 is 
no exception. Fe2+ and Fe3+ are d6 and d5 metal centres respectively and when coordinated in 
high spin octahedral complexes can have multiple unpaired electrons and large magnetic 
dipole moments as paramagnetic centres (Fig. 1). 
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Figure 1. Electronic configurations of iron centres in different oxidation states and 
coordination geometries. 
Fe3O4 consists of an ‘inverse spinel’ structure where tetrahedral sites are occupied by Fe3+
and octahedral sites are occupied equally by Fe3+ and Fe2+ (Fig. 2).12 The two sub-lattices are 
not equivalent and contain differing numbers of atoms. Coupling between atoms within the 
sub-lattices to minimise energy results in all of the spins within each sub-lattice aligning 
parallel to each other but anti-parallel to the other lattice. The Fe3+ ions in the sub-lattices 
counteract each other but the Fe2+ ions are uncompensated for, resulting in a net 
magnetisation vector. 
Figure 2. The inverse spinel structure of Fe3O4 (left) and the ferrimagnetic coupling 
observed in a [1,1,1] plane of the same (right). Adapted from Gossuin et al.12
The bulk material is divided into regions called Weiss domains as a result of the spontaneous 
ordering of the spins. Within Weiss domains, spins are aligned to give a net vector but the 
vectors of different domains may be random. The bulk material is ferrimagnetic because 
most vectors are approximately aligned. However, if a sample of Fe3O4 is smaller than the 
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Weiss domain limit of the bulk mineral (~ 100 nm), then the sample will behave as a single 
domain with a random moment orientation. A population of nanoparticles is therefore a 
population of single domains that do not interact with each other to give ordered magnetism 
as in the bulk material. They can align with applied magnetic fields, but in the absence of 
such a field the random orientation of moments results in zero magnetic remanence. This is 
termed ‘superparamagnetism’ as the behaviour is analogous to paramagnetism but for 
particles on a nanometre scale rather than small molecules measured in Angstroms. 
Figure 3. Simplified depiction of Weiss domains within bulk Fe3O4. As the nanoparticle 
(the small sphere) is smaller than a Weiss domain, it exhibits superparamagnetism. 
Superparamagnetism allows SPION to be used as MRI contrast agents. Contrast in MRI 
images is derived from differences in the relaxation rates of the protons in water in different 
chemical environments. When administered to a patient, SPION will preferentially 
accumulate in a target environment. When an external magnetic field is applied, the 
nanoparticles’ magnetic moments align with it, creating a difference in the local magnetic 
field strength in their locality. The protons in water molecules are affected by this with a 
resulting change in the efficiency of relaxation rates.3 Because of the particles’ high values of 
magnetisation their effect on relaxation rates is large, requiring smaller quantities of SPION 
to be administered to achieve contrast than for paramagnetic complexes. The magnetic 
behaviour of SPION samples and their relaxivity at different field strengths may be studied 
using Fast Field Cycling (FFC) relaxometry (discussed below) to give an NMRD (nuclear 
magnetic relaxation dispersion) profile for the agent.13 Characterisation methods for 
crystallite size and shape (discussed below) have allowed for mathematical models defining 
the contribution and effect of particle parameters on relaxation rates to be developed, but 
are beyond the scope of this project.3
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Fe3O4 nanoparticles are not stable towards oxidation and aggregation. In an oxygen-rich 
environment magnetite may be oxidised to maghemite resulting in a loss in magnetic 
responsiveness.14 The crystal structure of a nanoparticle of Fe3O4 terminates in hydroxyl 
groups at the surface; as nanoparticles have large surface area:volume ratios, there is a 
significant contribution from hydroxyl groups to interfacial tension which 
thermodynamically results in particles aggregating, undergoing dehydration and growing 
together to minimise interfacial tension (Ostwald ripening).3 Taken to an extreme, the 
particles may grow larger than the Weiss domain limit and thus become ‘bulk mineral’. Both 
of these effects can be prevented by incorporating a coating moiety onto the nanoparticle 
surface either following or during a given synthetic route to stabilise the particles. 
2.1.2 Methods of SPION synthesis 
There have been hundreds of synthetic accounts to generate SPION reported. Several 
reviews of SPION syntheses have been published.2,4,5,8,14 While some methods are 
considerably different in their approach to others, most vary in the manipulation of 
experimental parameters or the use of different solvents or starting materials and fall into 
one of several groups. The relative merits of some of the more commonly reported 
approaches are discussed below with a focus on their suitability for use in biomedical 
contexts. Gas phase methods have also been reported but require specialist equipment and 
offer low product yields and so are not discussed.14
Co-precipitation (‘wet’ methods)
The original method reported by Massart is still the most commonly utilised approach.1 To 
an aqueous solution of Fe3+ and Fe2+ salts in a non-oxidising atmosphere is added a strong 
base: 
Fe2+ + 2Fe3+ + 8OH- Fe3O4 + 4H2O 
The uncoated oxide species precipitates as a black solid and may be collected magnetically 
or by centrifugation and washed prior to stabilisation. The major advantages of this approach 
are simplicity and scalability. A range of salt precursors and bases may be used, the reaction 
is quick to perform and the product is relatively easy to isolate and purify. Although the 
reaction is nominally air-sensitive, oxidation to maghemite is limited even if the experiment 
is carried out in air, as will be shown in the results section of this chapter. The reaction can 
be performed from the milligram to the kilogram scale.  
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Nanoparticle synthesis can be considered as a two-stage process consisting of an initial 
nucleation step followed by diffusion of ions to the surface of the particles to allow growth.2,15
To achieve monodispersity these processes must either be sequential and not simultaneous 
(i.e. a defined number of particles form and then all have equal time within which to grow 
to their final size, as described by LaMer (see Fig. 4))16 or be succeeded by an ‘equilibration’ 
phase (see below). The original Massart method does not meet either criteria, and so the 
product particles are inherently polydisperse before stabilisation by coating. Improved 
methods where the use of size-selection techniques post-coating  have been reported but are 
generally not as commonly utilised as the original approach or syntheses by methods other 
than co-precipitation.17,18
Figure 4. LaMer diagram depicting the ideal case of sequential nucleation and growth 
of nanoparticles. Adapted from LaMer and Dinegar.16
Although the particles produced by co-precipitation are polydisperse, the effect of numerous 
parameters (e.g. pH, ionic strength and reactant concentration) on average particle size, shape 
and constitution have been determined such that by changing experimental parameters, one 
can alter average particle size from between 2 and 20 nm.2 Formation via co-precipitation is 
most desirable when the nanoparticles are required to be of a given average size and when 
the quantity of the product is more important than monodispersity. Particles formed by co-
precipitation have previously been used in commercial products such as Feridex®.19
The co-precipitation method may be modified to substitute other heavy metals (e.g. Mn, Co) 
into the inverse spinel structure of Fe3O4 without significant effects on size or magnetic 
behaviour and with high efficiency of doping (isomorphous substitution).20,21 As the levels 
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of dopant metal needed to achieve a stoichiometric labelling are much higher than would be 
practically used when considering radiolabelling nanoparticles, the co-precipitation method 
lends itself well to the idea of incorporating radiotracers into SPION.  
High-temperature formation (‘thermal’ methods)
Numerous methods of synthesising highly crystalline, highly monodisperse Fe3O4 
nanoparticles have been reported where precursor species (e.g. iron oleate, iron 
acetylacetonate, iron pentacarbonyl) undergo decomposition at elevated temperatures and 
pressures in an organic solvent and in the presence of a capping agent.22–25 Often the nature 
of the capping agent results in the particles being coated and stabilised but hydrophobic and 
incompatible with biological systems.25 Additional steps such as the replacement of the 
coating or the use of surfactants are required to make them hydrophilic. 
Figure 5a. Schematic depiction of monodisperse SPION formation via thermal 
decomposition of iron oleate, adapted from Park et al.22 b. Left to right, 5, 9 and 12 nm 
nanoparticles formed as described above using increasing reaction temperature.22
The high temperatures used (e.g. 300 °C) results in monodispersity. Particle nucleation and 
growth processes compete for materials from solution and their rates would appear to have 
different temperature dependencies with the latter taking precedence at high temperature.26
It is also possible that both processes are in a state of equilibrium with decomposition at high 
temperatures. The monodispersity of the hydrothermal product can be speculated to derive 
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from an ‘averaging’ of particle size by the interplay of nucleation, decomposition and growth 
over relatively long reaction times. The particles formed by this method could be viewed as 
a ‘thermodynamic’ product in contrast to the ‘kinetic’ products formed by co-precipitation.  
The size and morphology of the particles made by these methods are easily modified by the 
manipulation of experimental parameters. For example, in the work by Sun et al. the size of 
the oleic acid-coated product is increased by changing the solvent and therefore increasing 
the temperature at which reflux is achieved.23 The ability to control the average size of a 
highly monodisperse sample is the major advantage of thermal decomposition methods. 
Thermal decomposition approaches are generally more reproducible than co-precipitation 
methods as the extreme conditions used generally out-compete the more subtle factors 
affecting low temperature methods, but due to the high temperatures used air-sensitive 
techniques must be rigorously adhered to or else the reaction will not yield a strongly 
magnetic product. Safety issues arising from the high temperatures and flammable solvents 
contribute to the limited scale upon which these reactions are performed. Equipment is 
required that is commonplace in the chemistry laboratory but which are not easily transferred 
to or used in other contexts such as ‘hot cells’ used in radioactive work. 
Synthesis in constrained environments 
The synthesis of SPION in constrained environments can be considered an overarching term 
for a number of different routes such as sol-gel syntheses,27,28 microemulsions19 and 
bacteriological approaches.8 All attempt to limit the volume and time within which particles 
can form. The monodispersity achieved by these methods is not as high as that achieved by 
thermal decomposition methods and the yields are generally low compared to co-
precipitation methods.19,29 The syntheses are also subject to a wide variety of parameters that 
affect the characteristics and behaviour of the product particles, which require strict control 
to achieve reproducibility and may require purification procedures to render particle surfaces 
suitable for further synthetic steps.30
The use of flow injection techniques to achieve rapid mixing has previously been reported 
to give greater control over particle size and polydispersity.30–34 Rapid mixing of reagents in 
a known volume over a known time act as confinements on experimental parameters that 
may be difficult to control when performing a classical ‘Massart’ approach. In the work by 
Liu et al., the use of a rapid mixing head gave magnetite particles with an average core size of 
8.5 nm and which could be coated with biologically useful species shortly after collection 
from the reactor.31 Reproducing such experiments requires specialist equipment that is not 
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easily obtained. In Additional Experimental Section I of this thesis, an attempt to use a 
custom-built injector with limited success is described.  
2.1.3 Coating materials 
SPION are coated to prevent oxidation and aggregation, to imbue solubility and stability in 
media and to provide functional groups for covalent modification.2,4,8 Coating can either 
occur in the same reaction step as particle formation or as an additional step following 
collection and washing of the uncoated particles. Any species used to coat SPION serves to 
stabilise the particles in terms of sterics and/or electrostatics by preventing the iron oxide 
surfaces of the particles from coming into contact and combining. For biological purposes 
steric stabilisation is preferred to electrostatic stabilisation as the latter is more strongly 
influenced by the properties of the medium the particles are dispersed in.35 A wide range of 
species have been used to stabilise SPION (Table 1) and the properties of the coating species 
(e.g. solubility in organic or aqueous solvents) contributes to the properties of the coated 
particles. Not all are of immediate use in biological contexts and some are more desirable 
than others when considering later bioconjugation. Nanoparticles are typically described as 
‘Coating agent@SPION’ when coated with a particular species e.g. Dextran@SPION. 
Organic species that yield solubility in non-polar solvents require an additional surfactant 
species to make them biocompatible, introducing an additional step into the synthetic 
pathway. Many organic monomeric and polymeric species are associated with the surface of 
SPION via non-covalent interactions and can be made to desorb from the magnetite surface 
under certain conditions.2  Nevertheless, dextran and carboxymethyl-dextran (CMD) (Fig. 6) 
have seen use in commercially available SPION-based contrast agents and are still commonly 
used in novel agent development with the latter offering a carboxylate group as a target for 
further reaction.36
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Class Examples Notes Ref.
Organic, 
monomeric 
species
Oleic acid, oleylamine Product not water soluble; 
unsuitable for biological use 
without an additional surfactant.
23
Dimercaptosuccinic acid Water soluble product with up to 
two targets for bioconjugation. 
37,38
Citric acid Product is water soluble; 
increasing citrate concentration 
controls size and dispersity.
18
Organic, 
polymeric 
species
Dextran Soluble in aqueous media over a 
range of pH values. Hydroxyl 
groups used in bioconjugation.
39,40
Poly(vinyl alcohol) Nanoparticles have low toxicity 
when assessed by cell viability.
41,42
Inorganic 
species
Silica/silane species Silica layer forms by condensation 
reactions between monomers and 
surface hydroxyl groups. Easily 
modified for bioconjugation.
43–45
Gold Deposition of gold gives a surface 
with a high affinity for thiol 
groups, allowing direct 
immobilisation of proteins.
46
Table 1. Examples of SPION coating species reported in the literature with some relevant 
literature examples. 
Figure 6. Monomers of dextran and carboxymethyl-dextran (CMD), common reagents 
used to stabilise SPION for biological uses.
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Silica and silane species are among the most commonly reported methods of stabilising and 
functionalising SPION with 3-Aminopropyltriethoxysilane (APTES) being of particular 
note.47,48 It has also seen use commercially in the synthesis of a number of assay platforms.47,49
Like many silanes used in surface modification or bioconjugation, APTES has unstable ether 
groups that can be hydrolysed under heat or in aqueous conditions to generate reactive silanol 
groups. These groups react with neighbouring APTES monomers or with hydroxyl groups 
on surfaces (e.g. silica nanoparticles, glass, uncoated SPION) to form covalent links. The 
process of surface attachment is commonly referred to as silanisation. When APTES is used 
the surface becomes amino-functionalised.47 Amine groups are a common motif within 
bioconjugation with a variety of methods available to achieve surface modification.48 The 
chemistry of bioconjugation is discussed in more detail in Chapter 3. From the perspective 
of SPION biocompatibility, surface amines may be protonated under acidic aqueous 
conditions, rendering such particles soluble. 
Figure 7. Three mechanisms by which APTES can be bound to a hydroxyl functionalised 
surface. Note that horizontal (left) and vertical (central) polymerisations are not mutually 
exclusive. 
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Silanisation commences with the hydrolysis of the ethoxy groups of APTES. APTES 
monomers covalently bind to a hydroxy-functionalised surface via dehydration and undergo 
horizontal polymerisation giving a monolayer of crosslinked APTES on the surface.50 They 
may also undergo vertical polymerisation with APTES monomers that are not directly 
associated with the surface, allowing for multilayers to build away from the initial surface.45
Silanisation is a complex process that is heavily influenced by reaction conditions. For 
example, when a monolayer is desired the concentration of APTES in dry organic solvents 
such as toluene must be tightly controlled along with reaction time and temperature.47
Reported methods of APTES-coating can be grouped into ‘wet chemical’ or ‘chemical 
vapour deposition’ (CVD) methods and the former may be sub-divided into organic and 
aqueous silanisation methods. Aqueous silanisation methods are more likely to generate 
multilayers but are generally preferred for the coating of SPION due to their relative 
simplicity.45,51–53
While the kinetics of APTES silanisation are still the subject of research, the amine-
functionalising of surfaces has been proven and utilised in multiple bioconjugate contexts: 
antibodies for ELISA assays,54 monoclonal antibodies for biorecognition55  and numerous 
enzyme species have all been immobilised to APTES-functionalised SPION using typical 
bioconjugation methods.
2.1.4 Applications of SPION: in vivo, in vitro and beyond biomedicine  
While the best known application of SPION to date has been the in vivo enhancement of 
contrast in MRI scans, molecular imaging can be viewed as the tip of the iceberg in terms of 
the potential uses of such particles. Early research showed that particles with a biocompatible 
coating were well-suited to imaging of the liver and lymph nodes due to their tendency to 
accumulate in these organs in the absence of additional directing functionalities.36,56
Intravenous administration is followed by rapid absorption of the particles by the 
reticuloendothelial system (RES) and subsequent accumulation at the liver, spleen and 
lymphatic system.57 The characteristics of FDA-approved agents can be markedly different: 
Feridex® consists of particles coated with dextran with hydrodynamic radii of between 120-
180 nm, while Resovist® consists of carboxydextran coated particles with 45-60 nm 
hydrodynamic radii.36 The two agents may be used in broadly similar contexts and it may be 
concluded that the prediction of a potential agent’s utility based on physical characteristics 
alone is not advisable. 
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Figure 8. Contrast observed in the liver due to the effects of Feridex®, an FDA-approved 
SPION agent. Adapted from Edmundson et al.58
More recently, the immobilisation of biomolecules on biocompatible SPION species has 
allowed for directed imaging both in vivo and in vitro of a multitude of biological markers e.g. 
amyloid plaques in Alzheimer’s Disease,59,60 apoptotic cells61 and different forms of cancer 
by use of immobilised antibodies.62,63
SPION have also been used to achieve therapeutic benefit. The coating layer of 
biocompatible SPION may be modified to incorporate drug molecules which may be 
delivered via the nanoparticle to a site within the body where they are most effective in the 
treatment of disease. Targeting may be achieved either by including a biological vector on 
the particle surface or by control of the physical properties of the nanoparticles. Targeted 
drug delivery is desirable because it can reduce systemic side effects of a therapy while 
improving local treatment, as well as improving the biophysical characteristics of a drug 
molecule such as circulation time.35
Drug release can be designed to be responsive to stimuli, e.g. the presence of a magnetic field 
or an increase in temperature64 and is often discussed alongside hyperthermia therapy, with 
which synergistic advantages can be obtained. Hyperthermia therapy is the use of elevated 
temperatures to destroy diseased cells. Cancer cells are known to be more sensitive to heat 
than healthy cells and significant cell death can be achieved when a tumour is heated to 42-
46 °C.35 Hyperthermia can also disrupt drug resistance mechanisms.64 SPION may 
accumulate at a given tumour within a patient due to a targeting functionality or due to the 
EPR effect (‘Enhanced Permeability and Retention’ i.e. extravasation through ‘leaky’ blood 
vessels). The magnetic moments of the particles align with an applied external magnetic field. 
When the field direction is flipped the nanoparticles must realign, resulting in some loss of 
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energy as heat to the particle’s surroundings. Realignment can be achieved by the flipping of 
the magnetic moment (Néel relaxation) or by the physical rotation of the particle (Brownian 
relaxation); in the latter heat is transferred to the fluid surroundings (essentially by friction) 
and in the former heat is transferred directly to the solid lattice of the tumour cell.65 Brownian 
relaxation can be prevented by restricting the particle’s movement (e.g. by cellular uptake or 
by binding to a cell surface)66 increasing the efficiency with which energy can be passed to 
the solid cell or tumour. If the external field is made to oscillate rapidly the particles can cause 
significant tissue damage through the generation of heat.67,68
SPION have not only been of interest to scientists developing novel methods of imaging 
and treating disease. As stated in Chapter 1, the adsorption of a variety of heavy metal ions 
by SPION in environmental clean-up has been well-reported; electrostatic attraction between 
ions such as Co2+, Cu2+, Cr6+ and SPION allow for the facile removal of these pollutants from 
industrial effluent due to efficient adsorption and the ease with which magnetic particles can 
be abstracted from solution.69 The promiscuous nature of SPION as adsorbent surfaces has 
also been investigated for the uptake of PET active radioisotopes of arsenic and 
germanium.70,71 A study of chelator free 89Zr-labelled mesoporous silica nanoparticles 
concluded that the presence of O- species enabled the efficient binding of the hard metal 
cation72 which is similar to the likely mechanism of iron oxide’s ability to adsorb heavy metals, 
but to date no study of chelator free 89Zr-labelling of SPION has been reported in the 
literature. It was observed that 89Zr can be detached in vivo from the surface of dense silica 
nanoparticles by the action of endogenous chelators due to a reduced number of 
coordinating groups available on the surface.72 In the case of radiolabelling SPION, two 
methods could be envisaged: adsorption onto preformed particles or incorporation during 
particle formation. While the high surface area: volume ratio of nanoparticles is of benefit in 
the context of environmental clean-up, when considering the formation of PET-active 
SPION it would be preferable to achieve quantitative incorporation with little chance of the 
radioisotope being released from the particle.  
2.1.5 Characterisation of nanoparticles 
Methods of characterisation typically used in the study of small molecules are not always 
available to use in the field of nanotechnology. In the case of biocompatible SPION, the 
magnetic nature of the iron oxide core prevents the use of NMR spectroscopy to investigate 
the nature of organic coatings. Mass spectrometry does not yield useful data as even the most 
monodisperse of samples will have an enormous range of masses present. As a black, highly 
absorbent material, UV-Vis spectroscopic analysis shows significant absorption at all 
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wavelengths; indeed, molecules on the surface of the particles with large extinction 
coefficients (i.e. dyes) can be detected only when present in large numbers and not in a 
quantitative sense. The characterisation of SPION is focussed mainly on the determination 
of the size, shape, morphology and surface nature of the particles. Other parameters may be 
of interest in different contexts and there are many other techniques which can be used to 
characterise nanomaterials, but the following section will focus on techniques used and 
discussed later in this chapter. Multiple techniques can be used to determine the same 
parameter, the comparison of which can be useful in its own right. 
Transmission Electron Microscopy (TEM) 
TEM is a microscopy technique that uses a beam of short wavelength electrons to visualise 
high magnification, high resolution images of a target.73 Electrons are emitted from a source 
at the top of the microscope into a vacuum where they are focussed into a beam by 
electromagnetic lenses. The incident beam passes through a thin sample before impacting on 
a detector. Electrons may be stopped or diffracted by the sample material which results in a 
‘shadow’ on the bright image field. How dark a material appears is related to the sample 
thickness and how efficiently electrons are stopped by it. Heavier atoms scatter electrons 
more efficiently and appear darker. For iron oxide nanoparticles bearing a coating of 
significant thickness and with sufficient difference in electron density to the iron oxide core, 
this can allow the measurement of the core size and the thickness of the coating layer as the 
two materials will appear markedly different shades (Fig. 9), although instrumental factors 
can affect this. 
Figure 9. Example TEM image of commercially available silica-coated gold 
nanoparticles. Note the contrast between the core and surface coating arising from 
differences in electron density.74
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Samples are prepared by drying nanoparticles onto a carbon-coated copper grid with known 
dimensions. Particle sizes are determined by comparison against an internal standard. 
Although the image obtained by TEM is two dimensional the approximate shape of the 
particles can be assessed; for SPION, spherical nanoparticles are most common but other 
structures such as cubes and rods have been reported for other nanomaterials. Image analysis 
software (such as the software ImageJ75) can be used to determine important statistical 
quantities such as average particle size, size distribution and standard deviation within a 
population of nanoparticles. These values are important for comparing SPION made using 
different methodologies and for assessing the reproducibility of a given synthetic approach.  
TEM has limitations that should be noted if the particles are intended for biological uses. 
TEM images show particles in the solid state; how particles dry from the solution phase onto 
the support in sample preparation is dependent on many factors such that any agglomeration 
observed cannot be used to assess the behaviour of particles in solution. This is more 
accurately assessed using dynamic light scattering, discussed below. Particles may sinter 
together during drying and it may be difficult to determine individual particles. The selection 
of particles to form part of the statistical population should be made at random and their 
diameter taken at a fixed angle; over a suitable population size, the resulting statistics can be 
judged to be representative. 
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X-Ray Diffraction (XRD) 
XRD is the most popular method of identifying an unknown iron oxide. The interaction of 
electromagnetic radiation with wavelengths (λ) on the order of Angstroms (10-10 M) with 
atoms in a regular solid can allow for the determination of interatomic distances based on 
the diffraction of these X-rays.76 At certain angles of incidence (θ) constructive interference 
can occur and X-rays can be diffracted from materials in a manner described by Bragg’s Law:
where d is the interatomic spacing and n is an integer (constructive interference can only 
occur when the extra distance travelled by one photon is equal to an integer number of 
wavelengths). Plotting diffraction intensity against the angle θ yields a diffractogram that is 
unique to a given arrangement of atoms in a solid and which functions as a ‘fingerprint’ of 
the form of iron oxide present in a sample of SPION. XRD only considers the iron oxide 
core of the particle. 
Figure 10. Comparison of standard diffractograms of magnetite and maghemite. 
Although peaks occur at similar values, relative intensities can be used to unequivocally 
identify unknown samples. Adapted from Cornell and Schwertmann.77
Comparison to standard diffractograms can allow the assessment of proportions of different 
oxides in a mixture. Diffractograms can also allow the assessment of crystal size (i.e. 
nanoparticle size) from the broadening of XRD peaks by application of the Scherrer 
equation:76,77
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where K is a shape factor of 0.9 for spherical crystallites, λ is the wavelength of the X-rays 
used (determined from their source material), θ is the angle of incidence in radians for the 
peak in question, and Bstructural is the instrument broadening for the peak in question 
determined by: 
where Bobserved is the ‘full width at half maximum’ (FWHM) of the sample peak in radians and 
Bstandard is the FWHM in radians of the Si(111) peak from a SiO2 standard for the apparatus 
used. The crystallite size determined using the Scherrer equation is a volume average for the 
sample being studied but gives no information on polydispersity or deviation within the 
sample. The value can be of use in assessing the reproducibility of a synthetic route however.  
Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) measures the size and polydispersity of nanoparticles in 
solution or suspension. A typical experimental set up is shown in Fig. 11a. For a full 
mathematical approach to DLS, the reader is directed to dedicated articles;78,79 in practice, all 
calculations are performed by DLS equipment and/or software. 
Figure 11a. Typical experimental set-up for DLS analysis, adapted from Goldberg.78 b. 
Example output screen, showing diameter and dispersity for a known standard.  
Lasers undergo Rayleigh scattering upon interaction with particles on the nanoscale. A 
photodetector positioned at 90 ° to the incident laser beam will only detect light scattered 
from a sample. Nanoparticles in solution undergo Brownian motion; as particles move 
through solution and cross the laser beam, the intensity of scattered light fluctuates.79 The 
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decay of scattered light intensity as particles diffuse out of the beam path is exponential and 
the decay rate can be used to give the particles’ translational diffusion coefficient (DT). The 
movement of particles through solution is affected by the temperature of the solution (T), 
solution viscosity (η), Boltzmann’s constant (kB) and their translational diffusion coefficient 
(DT) and can be correlated to their size by the Stokes-Einstein equation: 
where Dh is the hydrodynamic diameter i.e. the diameter of a theoretical sphere that diffuses 
in the same manner as the sample particle.80 As particles are solvated, Dh is not a ‘true’ 
measure of the particle size and is often an overestimation.79,80 This effect can be 
compounded if the particle is not a perfect sphere or if the sample particles are flocculating 
in solution. As the value of Dh is a mean average, the presence of aggregate species can skew 
Dh to much higher values than the actual dimensions of the nanoparticle. 
Infra-red Spectroscopy (IR) 
The most rapid method of characterising the surface nature of a nanoparticle is IR 
spectroscopy, familiar to all chemical scientists. Magnetite consists almost entirely of Fe-O-
Fe bonds, and so the IR spectrum of uncoated SPION is dominated by absorptions 
associated with these bonds at approximately 580 cm-1.77 When a coating agent is applied, the 
presence of other bonds (e.g. Si-O-Si, N-H in the case of APTES) can be determined 
spectroscopically by IR. The shortcoming of this technique is that the information gained is 
qualitative; IR spectroscopy cannot determine coating thickness, extent of coating (i.e. 
coverage) or the exact functional nature of the surface groups.   
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Nuclear Magnetic Relaxation Dispersion Spectroscopy (NMRD)/Relaxometry 
Biocompatible (i.e. hydrophilic) SPION have typically been investigated in the pursuit of 
novel MRI-active contrast agents and are often characterised by FFC relaxometry. An 
aqueous sample of SPION of known concentration is transferred into a relaxometer and the 
T1 relaxation rates of the protons in the water molecules determined at different applied field 
strengths, allowing for the calculation of the molar relaxivity r1 which is crucial to describing 
the efficacy of the species as a contrast agent.13 The technique is also known as Nuclear 
Magnetic Relaxation Dispersion (NMRD) Spectroscopy and the data as an NMRD profile.  
NMRD profiles cover field strengths from MHz to KHz. In the case of weak, fixed field 
strength NMR, signal detection can be poor due to a loss of sensitivity. This is overcome by 
field cycling where the field strength is rapidly (on the order of milliseconds) modulated 
electromagnetically throughout the experiment. T1 relaxation times are determined via 
inversion recovery using pulse sequences. Under a magnetic field, almost all spins will align 
with the direction of the magnetic field, the z-axis. Applying a 180 ° RF pulse results in an 
inversion of the net magnetisation. After a delay period (τ) during which the spins start to 
realign with the applied field, a 90 ° RF pulse is applied which causes the net magnetisation 
to align either above or below the xy-plane (i.e. transverse magnetisation that generates signal, 
see Chapter 1). As the delay period varies, the degree of transverse magnetisation (hence 
signal intensity) varies; plotting τ against signal intensity allows the calculation of T1 and R1. 
At low field strengths, the population of spins initially aligned with the applied magnetic field 
direction will not produce sufficient signal following the pulse sequence to allow for 
calculation of T1. Field cycling overcomes this by initially using a strong field, BP, to ‘pre-
align’ or polarise the spins (see Fig. 12a). The field strength is rapidly lowered to the required 
value at which relaxation is to occur, Br. The field strength is then increased to a significantly 
higher value (Bd) at which the desired RF pulse sequence is applied, signal monitored and 
relaxation times calculated. The field strength returns to BP for a delay to allow complete 
realignment and the process repeated. 
An example NMRD profile for SPION in aqueous solution is shown in Fig. 12b. NMRD 
profiles can be analysed via mathematical models to yield a value for average particle radius,2
but this is uncommon in the literature. 
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Figure 12a. Schematic representation of a typical FFC-NMRD experimental approach. 
Adapted from Kimmich and Anoardo.13 b. Example NMRD profile of SPION in aqueous 
solution. 
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2.1.6 Aims and objectives 
The development of SPION can be viewed as a modern incarnation of our ancient 
fascination with magnetism. From their clinical use as MRI contrast agents to more novel 
applications such as hyperthermia therapy67,68 and drug delivery,64,81 SPION research is a rich 
and varied field. While there are many methods of synthesising SPION, when direct 
radiolabelling of nanoparticles with PET-active radiotracers is desired only co-precipitation 
methods are truly practicable at the time of writing. Thermal decomposition approaches 
require rigorously inert conditions which are achievable in a dedicated chemistry laboratory 
but are not easily maintained in a hot cell using radioactive materials. Other methods of 
SPION synthesis require specialist equipment that introduce additional cost and which limit 
the scale on which particles can be produced. Although co-precipitation techniques have 
limitations, they can be made to be satisfactorily reproducible under controlled conditions. 
Subsequent silanisation with APTES is an ideal next step due to the elegance by which 
stability, solubility and reactivity are introduced simultaneously. The ultimate aim of this 
research was therefore to develop a reproducible method of generating biocompatible 
SPION in a manner which could be transferred for use in a hot cell. 
In the results and discussion section below, the method by which APTES was immobilised 
on SPION to give a stable, water-dispersible entity is discussed and such nanoparticles 
characterised. In addition, the use of carboxymethyl-dextran (CMD) as a coating agent is 
described and evaluated. The radiolabelling of SPION coated with APTES or CMD is 
discussed. Efforts to render hydrophobic nanoparticles (synthesised by thermal 
decomposition of an organometallic precursor) soluble in water by the use of common 
surfactants are reported. 
Standard operating protocols for the production, storage, handling and use of radioisotopes 
for PETIC, University Hospital Wales, Cardiff are included as Appendix I to this thesis. As 
the pre-requisite for nanoparticles intended for introduction into biological systems is water-
solubility, multiple approaches based on literature methods that gave nanoparticles that were 
not suitably water-soluble and which were not characterised fully are described in Additional 
Experimental Section I. 
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2.2 Experimental 
2.2.1 Material and methods 
Reactions were performed with the use of vacuum line and Schlenk techniques where 
appropriate. Reagents were commercial grade and were used without further purification. All 
reagents and solvents were purchased from Alfa Aesar or Sigma Aldrich, except APTES 
which was purchased from TCI Chemicals. FeCl2.4H2O and APTES were stored under inert 
atmospheres.  Powder X-Ray diffraction was performed on an X’Pert PRO panalytical using 
a Cu radiation source and analysed using X’Pert Highscore Plus. IR spectra were recorded 
as solid samples on a Shimadzu IRAffinity-1 FTIR spectrometer. Transmission electron 
microscopy was carried out on a Philips CM12 Transmission Electron Microscope; 80kV. 
Digital photomicrographs were captured with a Megaview III digital TEM camera and iTEM 
software (Soft Imaging System GmbH, Münster, Germany) and analysed using ImageJ. 
Dynamic light scattering analysis was performed on a Brookhaven Instruments Corporation 
‘Zetaplus’. Relaxometry was performed on a Stelar FFC-2000 fast field cycling NMR 
spectrometer. Radioactivity was assessed using a Capintec CRC®-25 PET dose calibrator. 
Radiolabelling was performed in the research laboratory of PETIC, University Hospital of 
Wales, Cardiff. 
2.2.2 Synthesis and analytical techniques 
APTES@SPION (1) Method adapted from that of Yamaura et al. 45
Figure 13. Synthetic route for APTES@SPION. i) 5 M NaOH (5 mL), H2O (10 mL), room 
temperature, 5 min. ii) Glycerol (3 mL), APTES (0.8 mL), H2O (7.2 mL), Acetic acid (0.8 
mL), 75 °C, 3 h. 
FeCl2.4H2O (0.5 g, 2.5 mmol) and FeCl3.6H2O (1.352 g, 5 mmol) were dissolved in H2O (10 
mL) and the solution stirred. 5M NaOH (5 mL) was added and the reaction mixture stirred 
for 5 mins at room temperature. The precipitated nanoparticles were collected using a 
permanent magnet (1 T) and washed with distilled water until the pH of the washings were 
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pH 7. As much water as possible was removed by use of a permanent magnet and a pipette 
prior to the next step. Glycerol (3 mL) was added and the reaction mixture homogenised. 
APTES (0.8 mL, 3.4 mmol) was added to water (7.2 mL) and the pH adjusted to 4 with 
glacial acetic acid (0.8 mL) and then added to the nanoparticle dispersion. The reaction 
mixture was stirred at 75 °C for 3 h. The reaction mixture was allowed to cool and then 
transferred to a volumetric flask and made up to 50 mL with H2O. Adding this solution to 
MeCN (75 mL) caused the coated nanoparticles to precipitate. The particles were collected 
magnetically and were washed with fresh, cold MeCN (3 × 10 mL) and then dried in vacuo to 
give the title product as a black powder (0.53 g). XRD analysis confirmed phase identity as 
magnetite, average crystalline size = 6.5 nm. TEM analysis showed approximately spherical 
nanoparticles, average diameter = 8.1 ± 1.7 nm. DLS analysis showed aggregate species, 
hydrodynamic diameter = 264.1 nm, polydispersity = 0.245. IR (ATP) υ = 1541 (NH2
bending), 1404 (CH2 bending), 1098 (Si-OH), 1050 (Si-OH), 962 (Si-O-Si), 570 (Fe-O) cm-1. 
89Zr-APTES@SPION (2) 
FeCl2.4H2O (0.1 g, 0.5 mmol) and FeCl3.6H2O (0.270 g, 1 mmol) were dissolved in H2O (2 
mL) and the solution stirred. 89Zr oxalate solution* (100 µL, 6.50 MBq) was brought to pH 7 
by addition of saturated Na2CO3 solution and was added to the iron-containing solution. 5M 
NaOH (1 mL) was added, and the reaction mixture stirred for 5 mins at room temperature. 
The precipitated nanoparticles were collected using a permanent magnet (1 T) and washed 
with distilled water until the pH of the washings were pH 7. As much water as possible was 
removed by use of a permanent magnet and a pipette prior to the next step. Glycerol (0.6 
mL) was added and the reaction stirred to homogenise. APTES (160 µL) was added to water 
(1.44 mL) and the pH adjusted to 4 with glacial acetic acid (160 µL), and then added to the 
nanoparticle dispersion. The reaction mixture was stirred at 75 °C for 3 h. After 3 hours the 
reaction mixture was allowed to cool, transferred to a volumetric flask and made up to 10 
mL with H2O. Adding this solution to MeCN (15 mL) caused the coated nanoparticles to 
precipitate. These were washed with cold MeCN (3 × 5 mL) and then dried in air to give the 
title product as a black powder (0.138 g, 4.70 MBq, 72 % radiolabelling efficiency). TEM 
analysis showed approximately spherical nanoparticles, average diameter = 9.3 ± 2.0 nm. 
DLS analysis showed aggregate species, hydrodynamic diameter = 254.5 nm, polydispersity 
* Radioisotope production and purification is described in Appendix I of this thesis and discussed in greater detail in 
Chapter 4.
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= 0.257. IR (ATP) υ = 1540 (NH2 bending), 1404 (CH2) bending, 1094 (Si-OH), 1047 (Si-
OH), 962 (Si-O-Si), 571 (Fe-O) cm-1.
CMD@SPION (3) Method adapted from that of Pardoe et al. 82
FeCl3.6H2O (0.068 g, 0.28 mmol) and FeCl2.4H2O (0.028 g, 0.14 mmol) was dissolved in 
H2O (1 mL). Carboxymethyl-dextran sodium salt (100 mg) was dissolved in H2O (1 mL) and 
added to the iron solution. The mixture was shaken and observed to congeal. 1M NaOH 
solution (1 mL) was added and the reaction mixture vortexed in an Eppendorf thermomixer 
(15 min., 60 °C, 550 rpm). EtOH (3 mL) was added to precipitate the coated nanoparticles 
and vortexing continued (1 min., 60 °C, 550 rpm). The reaction mixture was centrifuged (5 
min., 21 °C, 900 rpm) and the supernatant decanted. The pellet was then dissolved in PBS 
buffer, pH 7.4 (5 mL). The solution was centrifuged to remove insoluble material (5 min., 21 
°C, 900 rpm). The supernatant was decanted to give the title compound as a solution in PBS 
buffer. TEM analysis showed approximately spherical nanoparticles, average diameter = 7.6 
± 1.8 nm. DLS analysis showed aggregate species, hydrodynamic diameter = 141.3 nm, 
polydispersity = 0.257. IR (ATP) υ = υ = 3589-3000 (OH stretching), 2920 (CH2 stretching), 
1593 (CH2 bending), 1415 (CH2 bending), 1002 (C-OH stretching), 568 (Fe-O), 527 (Fe-O)
cm-1.
89Zr-CMD@SPION (4)
FeCl3.6H2O (0.068 g, 0.28 mmol) and FeCl2.4H2O (0.028 g, 0.14 mmol) was dissolved in 
H2O (1 mL). 89Zr oxalate solution (75 µL, 9.90 MBq) was added, and the mixture 
homogenised.  Carboxymethyl-dextran sodium salt (100 mg) was dissolved in H2O (1 mL) 
and added to the iron solution. The mixture was shaken, and observed to congeal. 1M NaOH 
solution (1 mL) was added, and the reaction mixture vortexed in an Eppendorf thermomixer 
(15 min., 60 °C, 550 rpm). EtOH (3 mL) was added to precipitate the coated nanoparticles 
and vortexing continued (1 min., 60 °C, 550 rpm). The reaction mixture was centrifuged (5 
min., 21 °C, 900 rpm) and the supernatant decanted. The activity of the pellet was measured 
(9.24 MBq) and the pellet was then dissolved in PBS buffer, pH 7.4 (5 mL). The solution 
was centrifuged to remove insoluble material (5 min., 21 °C, 900 rpm). The supernatant was 
decanted and the activity measured (9.00 MBq, 91 % radiolabelling efficiency) to give the title 
compound as a solution in PBS buffer. Characterisation data could not be obtained due to the 
radioactive nature of the particles. 
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Iron (III) acetylacetonate (Fe(acac)3) (5)
FeCl3.6H2O (12.43 g, 46 mmol) was dissolved in water (100 mL). KOH (20 % aqueous 
solution) was added dropwise with stirring until pH 8. The brown precipitate formed was 
left to settle and was then removed by filtration under suction, washed with ice cold water 
and left to dry on the pump overnight. The brown solid was transferred to a conical flask 
and acetylacetone (15.8 mL, 154 mmol) added. The reaction mixture was stirred at room 
temperature for 30 minutes, then chilled for 1 hour without stirring. A crimson solid was 
isolated by filtration under suction and dried in vacuo. The solid was dissolved in a minimum 
of hot chloroform and the bright orange solution filtered while hot. The filtered solution was 
warmed to 50 °C and room temperature hexane was added until crystallisation was observed. 
The reaction mixture was left to crystallise overnight. Bright red crystals formed and were 
isolated by filtration under suction and dried on the pump. The crude solid was recrystallised 
from hot methanol and room temperature water. The product was isolated by filtration under 
suction and dried on the pump to give the title compound as a red powder (8.04 g, 22.8 mmol, 
50 %); IR (ATP) υ = 1566 (CO), 1520 (CO), 1420 (CO), 1352 (CC), 1273 (CC), 1188 (CC), 
1015 (CC), 928(CC), 800 (CH), 770 (CH), 665 (CH), 653 (CH).
Oleic acid@SPION (OA@SPION) (6) Method adapted from that of Sun et al. 23
Figure 14. Synthetic scheme for thermal decomposition of [Fe(acac)3] to give 
OA@SPION. i) Phenyl ether, 200 °C, 30 min, N2(g). ii) Phenyl ether, reflux, 30 min, N2(g). 
Crystalline [Fe(acac)3] was finely powdered using a pestle and mortar. Fe(acac)3 (0.706 g, 2 
mmol), 1,2-hexadecanediol (2.58 g, 10 mmol), oleic acid (1.94 mL, 6 mmol) and oleylamine 
(2.04 mL, 6 mmol) were mixed in phenyl ether (20 mL) and stirred under inert conditions in 
a Schlenk tube. The reaction mixture was heated to 200 °C by use of an oil bath for 30 
minutes, then heated to reflux under nitrogen by use of a Bunsen burner for 30 minutes. The 
solution was seen to turn black. The reaction mixture was allowed to cool to room 
temperature. Ethanol (40 mL) was added to encourage precipitation. The mixture was shaken 
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and left to settle for 1 hour. Solvent was removed until approximately 20 mL remained and 
the precipitate re-suspended. The precipitate was separated through centrifugation (6000 
rpm, 10 minutes) and left to dry overnight, then dissolved in hexane (20 mL) in the presence 
of oleic acid (0.05 mL) and oleylamine (0.05 mL). The solution was centrifuged (8000 rpm, 
10 minutes) and any pellet discarded. The supernatant was kept and the product precipitated 
by addition of ethanol (20 mL). The product was isolated by centrifugation (13200 rpm, 10 
minutes) to give superparamagnetic iron oxide nanoparticles as a black powder (0.196 g, 76 
%). TEM analysis showed approximately spherical nanoparticles, average diameter = 4.3 ± 
0.4 nm.
Dispersion of OA@SPION using commercial surfactants 
A solution of OA@SPION in Et2O (2 mL, 5 mg.mL-1) was added to an aqueous solution of 
one of nine surfactants (Brij®-35, Brij®-98 or TritonTM X-100, 2 mL, 25 mM; and Brij®-30, 
Brij®-56, Brij®-96, Tween® 20,  2mL, 50 mM). The two phase system was sonicated and 
allowed to settle. The ether layer was allowed to evaporate slowly over three hours with 
regular sonication to ensure dispersion of SPION into the aqueous layer and addition of 
small quantities of diethyl ether to redisperse precipitated nanoparticles to give brown 
solutions of surfactant-dispersed OA@SPION in water (5 mg.mL-1) in the cases of Brij®-35, 
Brij®-96 and Tween® 20. These suspensions were characterised by FFC-NMRD relaxometry. 
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2.3 Results and discussion 
2.3.1 Synthesis and characterisation of APTES@SPION and 89Zr-APTES@SPION 
Synthetic considerations 
In the work published by Yamaura et al.,45 SPION were prepared by a co-precipitation 
method from hydrated iron chloride salt solutions by the addition of a strong base. The 
particles were washed thoroughly before glycerol was added as a co-solvent and the particles 
heated to 70 °C for 3 h in the presence of a freshly prepared APTES aqueous solution (pH 
4). This procedure did not specify a reaction time allowed for the initial formation of the 
nanoparticles. The particles were characterised by XRD, TEM and IR. Analysis of the 
diffractograms of APTES@SPION using the Scherrer equation allowed the calculation of 
an average core size of 12 nm, while TEM images gave a value of 15 nm, which the authors 
concluded as signifying an APTES coating layer 3 nm thick. The IR spectrum showed 
multiple peaks between 1100 and 900 cm-1 corresponding to Si-O-Si and Si-O-H bonds, but 
perhaps the most indicative of the success of the coating step would be the bands at 3417 
and 1625 cm-1 for NH stretching and NH2 bending respectively.  
For any technique developed on the lab bench to be transferable to the ‘hot cells’ of a PET 
research laboratory, it must be reproducible, reliable and relatively simple to perform by use 
of remote manipulators. It must also be able to be scaled down without affecting the kinetics 
of the reaction. The formation of magnetite nanoparticles (described in Equation 1) could 
not require the use of rigorously inert conditions that could not be attained in the hot cell.  
Fe2+ + 2Fe3+ + 8OH- Fe3O4 + 4H2O (1) 
Therefore, initial attempts to repeat the work of Yamaura et al. had to ignore the stated need 
to maintain inert conditions throughout the synthesis to prevent oxidation of magnetite to 
maghemite (Fe2O3).To limit the extent of oxidation in the reaction system, the reaction was 
performed as quickly as possible. The Fe2+ salt was added to the reaction mixture almost 
immediately before the addition of the base. Reaction time (i.e. the delay between adding the 
base and magnetic collection and washing of the particles) was kept low at 5 min.  
Following the coating step, the particles were dried in vacuo and appeared as a black solid that 
showed a strong attraction to a permanent magnet. Reaction yields were consistent at a given 
reaction scale; as reaction scale was varied, yield varied linearly. The product particles were 
characterised and observed to be of comparable dimensions (see below).
52
XRD Analysis 
Initial analysis of diffraction patterns yielded phase identification that showed that Fe3O4 was 
the major constituent of the coated particles’ core. No peaks corresponding to other iron 
oxide phases could be determined against background noise. Diffractrograms were analysed 
using the Scherrer equation: 
Bstructural was found by subtracting the FWHM of the 111 peak of SiO2 at 2θ = 28.4 ° from 
the FWHM of the magnetite 311 peak at 2θ = 35.5 °.83  For spherical nanoparticles K = 0.9, 
and the Cu source used emitted X-rays with λ = 1.542 Å. Fig. 15 shows a typical measured 
diffractogram, the standard silica diffractogram used to determine Bstructural for all samples, 
and the derivation of the average crystallite size of the shown sample. Average values and 
absolute error were determined by taking multiple calculations of Bobserved at FWHM utilising 
outlying values of θ. Table 2 shows calculated average crystallite sizes for multiple samples 
of APTES@SPION prepared as described and on a larger scale.  
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Maximum intensity(SPION(311)) 335 (2θ = 35.5 °)
Half maximum(SPION(311)) 167.5 (2θ = 35.5 °)
FWHM(SPION(311)) 36.1 - 34.7 = 1.4 ° = 2.44 × 10-2 rad
FWHM(Si(111)) 2.16 × 10-3 rad
Bstructural 2.22 ×10-2 rad
Average crystallite size (Å) 65 Å
Figure 15. XRD patterns of APTES@SPION (Sample 1), silica reference, and the 
derivation of average crystallite size for Sample 1. 
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APTES@SPION Sample No. (Reaction 
scale)
Calculated crystallite size ± error  / 
nm 
1 (5 mmol of FeCl3.6H2O) 6.5 ± 0.4
2 (5 mmol of FeCl3.6H2O) 6.3 ± 0.6
3 (5 mmol of FeCl3.6H2O) 6.3 ± 0.4
4 (5 mmol of FeCl3.6H2O) 6.2 ± 0.7
5 (25 mmol of FeCl3.6H2O) 7.6 ± 0.8
6   (25 mmol of FeCl3.6H2O) 9.1 ± 0.9
7   (25 mmol of FeCl3.6H2O) 9.1 ± 0.8
Table 2. Calculated average crystallite sizes of APTES@SPION samples synthesised on 
different reaction scales. 
Taking the values of the samples produced on the ‘5 mmol’ scale, the size of particles range 
from 5.5 to 6.9 nm with most being approximately 6.3 nm. Although this value is 
approximately half of the value calculated from XRD data by Yamaura et al.,45 it is likely that 
the 5 minute reaction time used here is less than for the published work; a longer reaction 
time would allow for more Ostwald ripening within the reaction system and an increase in 
average particle size. When performed on a larger scale, the synthetic approach described 
yields particles with a larger average size and with a greater deviation in calculated values. 
This may be due to the longer time required to wash the greater mass of particles until the 
washings were of pH 7, allowing for more particle growth.  
During the synthesis of 89Zr-radiolabelled particles (described as (2) in the accompanying 
experimental section), to achieve a maximum radiolabel loading of the particles while 
maintaining safety and to facilitate synthesis the scale of the reaction was decreased by a 
factor of five. The mass of nanoparticles obtained per experiment was insufficient to allow 
XRD analysis; however, based on the XRD data above and data from other techniques 
discussed below, it would be expected that the core sizes would be approximately 7-8 nm. 
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TEM Image Analysis
Select samples of APTES@SPION synthesised cold in the chemistry laboratory and samples 
of 89Zr-labelled APTES@SPION (suitably decayed as to render them safe for transit and 
study) were dispersed in distilled water and dried onto a suitable support prior to microscopy. 
Digital images were taken and analysed using the software package ImageJ. The scale was set 
by reference to the internal standard and a square grid pattern was overlaid onto the image. 
Where the vertical and horizontal grid markings intersected on top of a particle, the particle 
was selected to be part of a statistical population of 30 particles per sample and the horizontal 
diameter of the particle measured based on contrast to the field. The average particle size 
and standard deviation per population were then calculated (see Table 3).  
For APTES@SPION, an approximate value for coating thickness can be found by 
subtracting TEM-observed diameter from the calculated core diameter from XRD analysis, 
which yields values between 1.5 and 1.8 nm. This method was applied by Yamaura et al. and 
gave an estimated value of 3 nm for 12 nm iron oxide core;45 the particles described here can 
be estimated as having a 1.5 nm coating on a 6.5 nm core. Limited resolution in the TEM 
images does not allow for the clear visualisation of the coating layer. Based on typical bond 
lengths and taking into account experimental error and the movement of atoms within 
molecules this thickness would be the approximate equivalent of two monomers of APTES 
(see Fig. 16).  
Figure 16. Calculation of approximate monolayer thickness based on average bond 
lengths.84
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APTES@SPION Sample No. (Reaction scale) Average diameter ± S.D. / nm (n = 30) Approx. coating thickness / nm
1 (5 mmol of FeCl3.6H2O) 8.1 ± 1.7 1.6
2 (5 mmol of FeCl3.6H2O) 7.8 ± 1.7 1.5
3 (5 mmol of FeCl3.6H2O) 8.0 ± 1.2 1.7
4 (5 mmol of FeCl3.6H2O) 8.0 ± 1.3 1.8
89Zr-APTES@SPION Sample No. (Reaction 
scale)
Average diameter ± S.D. / nm (n = 30) Approx. coating thickness / nm
1 (1 mmol of FeCl3.6H2O) 9.3 ± 2.0 N/A
2 (1 mmol of FeCl3.6H2O) 8.7 ± 1.5 N/A
3 (1 mmol of FeCl3.6H2O) 8.7 ± 1.9 N/A
Table 3. Average diameters of APTES@SPION and 89Zr-APTES@SPION as determined from TEM analysis. Approximate coating thickness calculated 
by comparison of TEM and XRD determined diameters. For 89Zr-APTES@SPION, sample masses were insufficient to obtain XRD data, hence coating 
thickness is not provided.
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Figure 17. TEM images of APTES@SPION, average size = 8.1 ± 1.7 nm. Scale bar in 
both images corresponds to 50 nm. Polydispersity (from DLS, see below) = 0.245. 
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Figure 18. TEM images of 89Zr-APTES@SPION, average size = 9.3  ± 2.0 nm. Scale bar 
in both images corresponds to 100 nm. Polydispersity (from DLS, see below) = 0.257. 
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The radiolabelled particles would be expected to have a greater average particle size and 
greater standard deviation than the unlabelled particles as a result of the more accurate 
temperature control available due to the apparatus used in the hot cell and a longer period 
of time prior to coating during which Ostwald ripening can occur. The differences in 
calculated average diameter sizes between the classes of samples was typically within one 
standard deviation and can be determined to be statistically insignificant. The methodology 
was highly reproducible and any sample could be used in subsequent experiments with 
reasonable confidence that it was representative in terms of particle size.  
Dynamic Light Scattering analysis 
Samples of APTES@SPION synthesised cold in the chemistry laboratory and samples of 
89Zr-labelled APTES@SPION were dispersed in distilled water at a concentration of 0.1 
mg.mL-1 and analysed by DLS at 25 °C (see Table 4). More concentrated and more dilute 
solutions were unsuitable as they did not yield reliable data. Under the conditions used, all 
samples had hydrodynamic radii much greater than the particle diameter determined from 
TEM image analysis, showing aggregation between particles although the dispersions 
appeared stable to the eye over 48 hrs.  
For the SPION dispersions studied, the measured value of hydrodynamic diameter is highly 
dependent on the conditions of the sample and degree of aggregation. This could be varied 
by sonicating a sample and disturbing the aggregate species; the measured diameters would 
vary markedly for a short period of time before equilibrium would be restored and the 
diameters would again be consistent with the aggregation of the particles. It can be concluded 
that the data shown below describes an equilibrium state of aggregation that occurs under 
the conditions used and can therefore only truly be used to make qualitative statements about 
the behaviour of different samples. More accurate data about individual particles may be 
obtained by changing the conditions (e.g. lowering pH to increase the charge on particle 
surfaces) but this was not achieved. All samples were seen to behave similarly, forming large 
aggregates of between 10 and 20 nanoparticles with a polydispersity of between 0.24 and 
0.28, indicating that the aggregates are not monodisperse but are not so polydisperse as to 
be unsuitable for DLS analysis.80 The behaviour of the radiolabelled particles was analogous 
to that of the unlabelled particles. It can be concluded that bioconjugation experiments 
performed using unlabelled particles would yield results that could be used to make 
predictions about the behaviour of labelled particles in similar experiments as long as care is 
taken to counteract aggregation which may limit reaction rates. 
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APTES@SPION Sample No. 
(Reaction scale)
Hydrodynamic diameter ± S.E. / 
nm (n = 3)
Half width ± S.E. / nm Polydispersity
1 (5 mmol of FeCl3.6H2O) 264.1 ± 1.0 130.7 ± 0.9 0.245
2 (5 mmol of FeCl3.6H2O) 250.2 ± 1.8 128.1 ± 1.7 0.263
3 (5 mmol of FeCl3.6H2O) 224.5 ± 2.0 109.8 ± 1.3 0.240
4 (5 mmol of FeCl3.6H2O) 172.5 ± 1.2 83.8 ± 0.9 0.236
89Zr-APTES@SPION Sample No. 
(Reaction scale)
Hydrodynamic diameter ± S.E. / 
nm (n = 3)
Half width ± S.E. / nm Polydispersity
1 (5 mmol of FeCl3.6H2O) 254.5 ± 1.6 129.0 ± 1.3 0.257
2 (5 mmol of FeCl3.6H2O) 291.9 ± 6.4 154.6 ± 3.9 0.281
3 (5 mmol of FeCl3.6H2O) 208.5 ± 2.6 102.3 ± 2.7 0.240
Table 4. DLS data for APTES@SPION and 89Zr-APTES@SPION. It is likely that these values reflect aggregate species and not truly colloidal stabilised 
dispersions. 
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IR Spectroscopy 
All samples of APTES@SPION and 89Zr-APTES@SPION gave almost identical IR spectra; 
a typical spectrum is shown with that of an uncoated SPION sample for comparison (Fig. 
19). A broad peak at 570 cm-1 arises due to the Fe-O bonds of magnetite in both spectra.77
For the coated species, peaks can be observed at 1098, 1050 and 962 cm-1 corresponding to 
Si-O-H and Si-O-Si bond.45 Peaks observed at 1541 and 1404 cm-1 correspond to NH2 and 
CH2 bending and are prominent and indicative of the success of coating. NH2 stretching at 
~3400 cm-1 can be difficult to observe due to the hygroscopic nature of the particles.  
Figure 19. IR spectra of APTES@SPION (blue) and uncoated SPION prepared by co-
precipitation (orange) 
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2.3.2 Summary for APTES@SPION and 89Zr-APTES@SPION 
APTES@SPION were synthesised ‘cold’ and initially characterised by IR (to confirm the 
nature of the coating) and XRD to observe the effect of reaction scale on the core size. 
Performing the reaction on the smaller scale gave a smaller average core size with a narrower 
size distribution and it was concluded that the synthesis of a radiolabelled analogue should 
be performed on a small scale to minimise polydispersity. TEM image analysis showed no 
significant difference in average particle diameter between ‘cold’ particles prepared on a ‘5 
mmol’ scale and the radiolabelled species prepared on a ‘1 mmol’ scale and the calculated 
coating thicknesses of an ‘average particle’ were similar in all samples. DLS analysis allowed 
for a qualitative assessment of the stability of a dispersion of such particles and insight into 
their behaviour under certain conditions. It was concluded that the cold APTES@SPION 
synthesised could be used as model systems in protocol development with confidence that 
any methods could be successfully adapted for use with radiolabelled particles. 
Combined Data for APTES@SPION, Sample 1
Core diameter ± error / 
nm
Total diameter ± S.D. / 
nm
Hydrodynamic diameter ± S.E. / 
nm
6.5 ± 0.4 8.1 ± 1.7 264.1 ± 1.0
Table 5. APTES@SPION, Sample 1 was selected for protocol development described in 
Chapter 3 and 4 due to its representative physical characteristics. The hydrodynamic 
diameter reflects aggregation is occurring. 
All samples, regardless of reaction scale or their degree of radiolabelling, showed comparable 
physical characteristics and gave stable dispersions in water and physiologically relevant 
buffers. The incorporation of 89Zr into uncoated SPION was initially quantitative; a decrease 
in final radiolabelling efficiency to 72 % was due primarily to the loss of labelled particles 
during washing and drying steps mainly due to difficulties using remote manipulators. Given 
the amine-functionality present on the surface of APTES@SPION, it was judged that the 
method reliably gave a nanoparticle species that could be radiolabelled with high efficiency 
and which bore surface functionalities suitable for bioconjugation. Due to technical 
difficulties, relaxometry studies were not performed for these particles. 
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2.3.3 Synthesis and characterisation of CMD@SPION and 89Zr-CMD@SPION 
Synthetic considerations 
CMD-coated SPION were synthesised in a manner based on that described by Pardoe et al.82
Stabilisation occurred immediately upon formation due to the presence of CMD in solution 
that adsorbed onto the hydroxylated surface of magnetite.  The resulting particles were well 
dispersed in distilled water, pH 7.4 buffer and Dulbecco’s Modified Eagle Medium (DMEM). 
When the reaction was performed in the presence of radiotracers for incorporation into the 
iron oxide lattice, radiolabelling occurred with 91 % efficiency with most losses due to 
transfer during isolation and purification of the produce particles. In comparison to the 
method described for the synthesis of 89Zr-APTES@SPION, the preparation of 89Zr-
CMD@SPION was considerably more time efficient, easier to perform when using remote 
manipulators and occurred with higher radiolabelling efficiency. 
However, this method is not as desirable for the synthesis of bioconjugates. CMD@SPION 
are negatively charged and cells have a negatively charged surface, potentially limiting the 
adsorption of nanoparticles.85 This could impact on the binding ability of an immobilised 
antibody and/or prevent internalisation. Also, although carboxylic acid groups are used in 
bioconjugation (discussed in Chapter 3), they are generally not as common as other 
functionalities (e.g. amines, thiols) because of their need for carbodiimides and/or active 
ester intermediates. Most troublingly, the method described was found to be unreliable in 
terms of yield and magnetic responsiveness of the particles when the reaction scale was 
altered, and once the particles were dispersed in a suitable medium they could not be 
precipitated and re-dispersed. The particles formed on the scale described were analysed by 
TEM, DLS and IR, but at the scale used final masses were insufficient to allow XRD analysis. 
As is shown below, they are physically of a similar size to APTES@SPION and appear to 
behave somewhat similarly in solution, but the practical limitations of their use in method 
development render them undesirable for further study in a bioconjugate context. 
The radiolabelled species could not be characterised until sufficiently decayed. Upon return, 
the particles were visibly aggregated and showed little magnetic response. Characterisation 
was not performed. 
TEM Image Analysis
Samples were prepared, treated and analysed analogously to the APTES-coated particles 
discussed above. The particles were observed to be approximately spherical, with an average 
size of 7.6 ± 1.8 nm (n = 30). The CMD@SPION are comparable in solid state diameter to 
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APTES@SPION, although qualitatively they have a greater tendency to aggregate into 
tightly packed structures during TEM sample preparation. It may be this tendency that 
prevents the redispersal of precipitated nanoparticles and which limits the usefulness of these 
particles for the synthesis of magnetically responsive bioconjugate species. 
Figure 20. TEM images of CMD@SPION, average size = 7.6 ± 1.8 nm. Scale bar 
corresponds to 100 nm. 
Dynamic Light Scattering analysis 
Because a known mass of CMD@SPION could not be dissolved to a known concentration 
due to the difficulty of redispersing precipitated particles, aqueous samples were prepared by 
dilution to an estimated concentration of 0.1 mg.mL-1 based on expected yields and analysed 
by DLS at 25 °C. As was observed for APTES@SPION, all samples had hydrodynamic radii 
much greater than the particle diameter determined from TEM image analysis (typically 
values are between approximately 140 and 190 nm) and for a given sample analysed multiple 
times the standard error was typically greater than APTES@SPION. Given the sensitivity of 
DLS to environmental conditions it is difficult to draw any conclusions from this data other 
than the seemingly reproducible behaviour in solution of nanoparticles prepared as similarly 
as possible.  
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CMD@SPION
Sample No. 
Hydrodynamic 
diameter ± S.E. / 
nm (n = 3)
Half width ± S.E. / 
nm
Polydispersity
1 141.3 ± 5.8 71.4 ± 1.5 0.257
2 138.2 ± 3.4 68.2 ± 0.6 0.245
3 188.1 ± 3.4 96.6 ± 0.6 0.264
Table 6. DLS data for CMD@SPION. It is likely that these values reflect aggregate 
species and not truly colloidal stabilised dispersions.  
IR Spectroscopy 
The IR spectra of CMD@SPION is markedly different from that of uncoated magnetite but 
similar to spectra reported elsewhere in the literature, confirming the in situ adsorption of the 
biopolymer following nanoparticle formation.86,87 The broad band between 3589 and 3000 
cm-1 is indicative of the O-H stretch of the hydroxyl groups of the sugar, while the broadened 
peak centred at 2920 cm-1 is due to CH2 stretching. The carboxylic acid group would be 
expected to give absorbance around 1700 cm-1 but this was not seen, probably due to their 
relatively low quantity relative to other functional groups. The two absorbances at 1593 and 
1415 cm-1 are due to CH2 bending forms, while the most prominent peak centred around 
1002 cm-1 is due to the C-O stretch of the sugar ether groups.87
Figure 21. IR spectra of CMD@SPION (blue) and uncoated SPION prepared by co-
precipitation (orange). 
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2.3.4 Summary for CMD@SPION and 89Zr-CMD@SPION 
The synthesis of CMD@SPION had several practical advantages over the synthesis of the 
amine-functionalised APTES@SPION. However, the physical characteristics and behaviour 
of the end particles rendered them less attractive for use as a foundation upon which to 
design bioconjugate species. Further research could find a use for these particles; for 
example, incorporating a second coating layer on top of the CMD layer may aid the stability 
of these particles and give them preferable surface characteristics while retaining the relative 
ease and efficiency with which radiolabelled particles can be synthesised. 
2.3.5 Synthesis, dispersion and relaxometry studies of OA@SPION 
Oleic acid coated SPION were synthesised from [Fe(acac)3] via the highly cited method 
described by Sun et al.23 The hydrophobic particles were characterised by TEM image analysis 
to have an average diameter of 4.3 ± 0.4 nm and can be seen to not form large aggregate 
‘islands’ as observed for APTES- and CMD-coated particles.   
Figure 22. TEM images of OA@SPION, average size = 4.3 ± 0.4 nm. Scale bar 
corresponds to 100 nm. 
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As part of the current work, several common non-ionic surfactant species were investigated 
to assess their ability to render hydrophobic OA@SPION dispersible in water to give a 
monodisperse species that could form a basis for bioconjugation or for a drug delivery 
system. All of the species (shown in Fig. 23) were commercially available and used without 
further purification.  
Complete solubilisation of OA@SPION was observed with Brij®-35, Brij®-96 and Tween®
20. Brij® and Tween® species have low toxicity and have been studied in a drug-delivery 
context previously.88 The dispersions were stable over 72 h. DLS analysis did not yield useful 
data, possibly because the species in solution were not aggregating and the spectrometer used 
could not analyse the monomeric species due to the limits of detection. The dispersions were 
studied by relaxometry to provide evidence of the solubilisation of OA@SPION and to 
assess the relaxivity of the particles. 
Figure 23. Non-ionic surfactants studied as part of OA@SPION solubilisation 
experiments. Complete solubilisation occurred with Brij®-35, Brij®-96 and Tween®-20. 
All of the surfactant species consist of a hydrophobic tail and a polar head group. As the 
ether layer evaporates, OA@SPION becomes concentrated and the formation of emulsion 
droplets by sonication allows for the insertion of the surfactant alkyl chains into the 
hydrophobic coating of the nanoparticles. Comparing the surfactant species it would be 
expected that when the hydrophobic tail groups are common (as between Brij®-30 and Brij®- 
35), the more efficient surfactant will have the more polar head group. Under the conditions 
trialled, the remaining surfactants (Brij®-30, Brij®-56, Brij®-98 and TritonTM- X-100) did not 
solubilise OA@SPION completely and did not allow for the accurate measuring of relaxivity 
values for a known mass of particles (hence molar relaxivity). Further experiments could 
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optimise the approach taken to find the conditions under which these species may solubilise 
OA@SPION. 
The NMRD profiles below show that when experimental temperature increases, the 
measured maximum value of R1 for a sample decreases as temperature influences the rate of 
diffusion within the sample, which limits the ability of a contrast agent to slow molecular 
tumbling.89 As the quantity of iron oxide present in the samples is identical, and the particles 
present were taken from the same initial stock, differences in the shown NMRD profiles 
(Fig. 24-26) arise as a result of how solubilisation using the different surfactants affects the 
efficiency with which the nanoparticles increase relaxation rates. In each studied dispersion 
of 2 mL volume, 10 mg of OA@SPION were dispersed; reported analysis of similar particles 
allow an estimation of inorganic content of 70 % such that in each sample 7 mg of Fe3O4,  
corresponding to 9 × 10-2 mmol of Fe is present.90 The concentration of Fe is therefore 45.3 
mmol.L-1, and the values of r1 (the molar relaxivity) in Table 7 can be calculated according to 
the equation: 
Where c is the concentration of the contrast agent (here the iron within the nanoparticles). 
Surfactant used
([Fe] / mmol.L-1)
r1  ± error/ L.mmol-1.s-1 
(T = 25 °C, B = 10 MHz ) 
r1 ± error / L.mmol-1.s-1 
(T = 37 °C, B = 10 MHz)
Brij®-35 (45.3) 5.18 ± 0.13 4.82 ± 0.03
Brij®-96 (45.3) 7.02 ± 0.10 6.61 ± 0.03
Tween® 20 (45.3) 4.82 ± 0.03 4.49 ± 0.03
Commercial species r1 ± error / L.mmol-1.s-1 
(T = 37 °C, B = 20 MHz)
Feridex® 4.7 ± 0.30
Resovist® 8.7 ± 0.50
Table 7. Calculated values of r1 at 10 MHz for OA@SPION solubilised using 
commercially available non-ionic surfactants. Relaxivity values for commercially 
available SPION-based species are shown for comparison.91
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Figure 24. NMRD profiles of Brij 35-solubilised OA@SPION in water (5 mg.mL-1) at   
25 °C (blue) and 37 °C (orange). 
Figure 25. NMRD profiles of Brij 96-solubilised OA@SPION in water (5 mg.mL-1) at 
25 °C (blue) and 37 °C (orange). 
Figure 26. NMRD profiles of Tween-20-solubilised OA@SPION in water (5 mg.mL-1) at 
25 °C (blue) and 37 °C (orange). 
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The calculated relaxivity values compare favourably to values for commercial SPION-based 
contrast agents under similar conditions (Table 7).91 Further experiments could be performed 
to further optimise stability of the dispersion, to investigate methods of enhancing relaxivity 
further and to explore how values of r1 for such species would change in vivo. In terms of 
drug delivery, the ability of dispersed particles to respond to an oscillating magnetic field as 
used in therapeutic hyperthermia would be of great interest. From a bioconjugation 
perspective, OA@SPION solubilised by surfactant materials do not make for an immediately 
attractive foundation species, especially when considering the possibility of radiolabelling.  
2.4 Conclusion 
Three methods of preparing water-dispersible SPION have been discussed in the above 
pages. Thermal decomposition of an organometallic precursor yields monodisperse 
hydrophobic particles that can be solubilised in water by use of surfactant species but the 
methodology is not transferrable to a hot cell. SPION can be coated in situ with CMD to 
yield highly water soluble species and the technique can be readily modified to enable 
radiolabelling, but the product particles are not suitable for further bioconjugation 
experiments because they cannot be manipulated with accuracy. SPION coated with APTES 
are water dispersible, have a desirable surface functionality for bioconjugation, can be 
manipulated post-synthesis easily, can be radiolabelled with high efficiency and the synthetic 
approach can be deemed to be highly reproducible and transferrable to hot cells with minimal 
risk to the researcher. APTES@SPION synthesised in the manner described above appears 
to be an ideal candidate for further study in the design and development of bioconjugated, 
radiolabelled nanoparticles. 
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Chapter 3: Bioconjugation of enzymes and antibodies with 
APTES@SPION 
3.1 Introduction 
In this chapter, different approaches to the immobilisation of biomolecules (enzymes, 
antibodies and conjugates thereof) on APTES@SPION synthesised as described in Chapter 
2 will be discussed.   
Bioconjugation is the attachment of one molecule to another, typically through covalent 
bond formation, where at least one molecule is a biomolecule e.g. an enzyme or antibody.1
The other may be a second biomolecule,2 a small molecule that imbues a particular 
functionality on the product conjugate,3 or a surface (referred to as ‘immobilisation’, even 
when the surface in question is a mobile nanoparticle).4,5  Linking is often achieved via 
crosslinking agents that react in reliable ways to particular functionalities present in the 
molecules to be conjugated. The field of bioconjugation is dominated by a relatively limited 
number of reactive groups and approaches to achieve linking which are discussed below.  
A crucial consideration in the synthesis of a nanoparticle agent incorporating a monoclonal 
antibody is the effect of immobilisation; the product must retain the function of its parent 
species and antibodies, as proteins, are susceptible to denaturation.6 Changes to their tertiary 
structures, specifically in their antigen binding sites, will limit or remove their ability to 
selectively bind their target. Any immobilisation reaction used must be shown to not have 
an excessively deleterious effect on the antibody’s function. The heterogeneous nature of 
nanoparticles in general and the UV-Vis absorption profile of SPION in particular render 
many common methods of interrogating protein structure unusable. The inclusion of a dye 
would serve to locate the antibody but would give no information on its condition,7 and the 
use of cell line studies is arguably inappropriate as an initial method of characterisation. 
In chemical biology the actions and activities of enzymes are often followed 
spectroscopically. A colorimetric assay can give kinetic data which may be related back to 
known standards, giving an indication of the environment or condition of an enzyme.8,9
While enzymes are not perfect models, they may be susceptible to the same conditions that 
can cause denaturation in antibodies. It was hypothesised that a method developed to 
immobilise enzymes onto SPION with limited effect on function could be transferred to 
achieve the immobilisation of antibodies in a similar way. 
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3.1.1 The reactions of bioconjugation 
In ‘Bioconjugate Techniques’ by Greg Hermanson, to which the reader is directed for a 
thorough introduction to the theory and typical protocols of bioconjugation, it is stated that 
there are less than ten reactive groups used commonly in the construction of the majority of 
bioconjugates.1 Although there are hundreds of commercially available crosslinkers, the 
novelty of their design is in their physical properties (e.g. solubility, stability to different 
conditions, linker length) not their targeted functionalities. 
The functional groups that underpin most bioconjugate syntheses are amines, thiols, 
carboxylic acids, hydroxyls, aldehydes and ketones.1, 2 All are commonly found in peptides, 
proteins, carbohydrates and nucleic acids or can be relatively easily introduced without 
detriment to the molecule’s function. Examples of how these groups typically react are 
shown below. 
Amine reactions 
Nearly all biomolecules will have at least one reactive amine residue available for reaction. 
As an example, the Fab region of cetuximab has been shown to have 23 amine-bearing lysine 
residues in its primary structure, including a single lysine in the antigen binding region.11
Because amines are common, reactive groups sensitive to them (e.g. isothiocyanates, 
succinimidyl esters) are the most common functionalities incorporated into cross linkers. 
Amines typically couple rapidly via alkylation or acylation, giving secondary amines or amides 
(Fig. 1a).  
Thiol reactions 
Thiol-sensitive reactive groups are the second most common functionalities seen in 
crosslinkers.1 Thiols typically react via alkylation or disulphide interchange, often in a two-
step process. The thioether and disulphide bonds that result from these reactions are stable 
(Fig. 1b). 
76
Figure 1. Selected typical (a) amine and (b) thiol reactions for bioconjugation.  
Carboxylic acid reactions 
Carboxylate groups in aqueous solution are relatively poor targets for nucleophiles. Their use 
in bioconjugation is dominated by the need to activate them and enhance their reactivity to 
nucleophiles. Carbodiimides are commonly used to facilitate amine-to-acid linking (Fig. 2), 
although other species are available.1 They can be used on their own or to produce active 
ester groups (e.g. with N-hydroxysuccinimide), yielding an intermediate with increased 
stability to hydrolysis and enhancing reactivity against amines. 
Figure 2. Structural mechanism for amine-to-acid linking facilitated by carbodiimides. 
Although EDC is shown here, the mechanism is general to all such species. 
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Hydroxyl, aldehyde and ketone reactions 
Hydroxyl-reactive species are available not only for direct reaction with hydroxyls but also 
for the activation of the group to a more reactive form e.g. aldehydes or ketones. These 
groups are not commonly found in native proteins or biomolecules but are often introduced 
deliberately to achieve a desired linkage. Of most relevance to the current work is the ability 
to oxidise a hydroxyl group of a biomolecule (e.g. a sugar or sugar side chain) to give aldehyde 
functionalities that can react with amines (Fig. 3a). The Schiff base formed may be reduced 
to a secondary amine to stabilise the linkage, a protocol described as reductive amination 
(Fig. 3b).1
Figure 3a. Depending on the nature of the diol, oxidation with sodium periodate can 
yield different results. b. Reduction of the Schiff base formed by reaction between 
aldehydes and amines is necessary to prevent hydrolysis in aqueous conditions. 
Reductive amination has been a popular method for the synthesis of enzyme-antibody 
conjugates12,13 and for immobilising antibodies on nanoparticles.14 The immobilisation of 
antibodies on dextran-functionalised nanoparticles has been reported, where the internal diol 
of the nanoparticles’ carbohydrate surface coating is the subject of oxidation.15
3.1.2 Homo- and heterobifunctional crosslinkers 
Bioconjugation almost always uses some form of crosslinking agent. These may form a 
physical link between the two molecules in the final product or may be used to activate a 
functionality for reaction. Crosslinkers may be divided broadly into two classes, 
homobifunctional and heterobifunctional. Homobifunctional species are symmetrical and 
have two reactive groups designed to react with the same class of target; a classic example 
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would be glutaraldehyde (Fig. 4a) which is discussed in detail below. While they are 
inexpensive, the main disadvantage of homobifunctional linkers is the limited control 
available to the researcher even over multi-step procedures. The result can often be a 
heterogeneous mixture of poorly defined species.  
Heterobifunctional chelators such as SPDP (Fig. 4b) have two reactive ends designed to react 
with two different functional groups on proteins or macromolecules (e.g. amine-to-thiol 
crosslinking). The use of heterobifunctional species typically requires multistep reactions and 
the careful manipulation of reaction conditions but offers greater control and improved 
reaction outcomes. Correspondingly, they can be very expensive when considering the 
quantities needed for method development. The most populous group of heterobifunctional 
crosslinkers are amine-to-thiol species, typically expressing amine reactive active ester groups 
for amide bond formation and an alkylating agent capable of forming disulphide or thioether 
bonds.1 The greater stability of the sulfhydryl-reactive group relative to the amine-reactive 
ester allows for control over crosslinking. 
Figure 4a. Glutaraldehyde has two aldehyde groups, and is able to react with two amine 
groups. b. SPDP has an NHS-ester group (amine-reactive) and a 2-pyridyldithiol group 
(thiol-reactive). 
3.1.3 Glutaraldehyde as a crosslinker 
Glutaraldehyde has become a work-horse within the field of bioconjugation. Because of its 
multitude of uses outside of research it is produced on an industrial scale and is inexpensive 
in large quantities.16 It is common to find glutaraldehyde used as a crosslinker despite the 
drawbacks inherent with homobifunctional species and its complex aqueous chemistry; 
glutaraldehyde exists not just as a monomer but has many possible forms in aqueous solution 
which can react differently depending on reaction conditions.16 Glutaraldehyde’s reactivity 
can be difficult to predict or reproduce. In its simplest form, the linear dialdehyde would be 
expected to react with two amine groups to give Schiff bases. Reduction of the Schiff bases 
would be required to stabilise them to hydrolysis but this is often not carried out. Rather, it 
is believed that the glutaraldehyde forms a cyclic hemiacetal at acidic and neutral pH values 
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which reacts with amines by nucleophilic substitution (see Fig. 5), explaining the increased 
stability of glutaraldehyde-conjugates over what would be expected in the absence of 
reduction.8, 9 The tendency of glutaraldehyde to polymerise and/or form crosslinked 
aggregates make it a difficult reagent to control but nevertheless a useful tool with which to 
commence experiments in bioconjugation. 
Figure 5. Proposed reaction between cyclic form of glutaraldehyde with amine-
containing groups at acidic and neutral pH.16
3.1.4 Enzymes in bioconjugation 
Enzymes are biological catalysts that carry out a range of reactions in vivo. While the study of 
the role and activity of enzymes in living systems has been instrumental in our understanding 
of biology, enzymes are now routinely used ex vivo in biotechnology. One of the most well-
known applications is ELISA (enzyme-linked immunosorbent assay), where an enzyme’s 
action on a substrate gives a colorimetric response to indicate the presence of an analyte to 
which the enzyme has been bound.18 The two enzymes most commonly used for ELISA are 
also the most commonly found enzymes in bioconjugate chemistry and are discussed below.  
3.1.5 Enzyme structure and mechanism 
A brief overview of how enzymes perform their function is necessary to understand how 
they may be of use to researchers and why care must be taken with experiment design. For 
further detail, introductory texts abound.19
Enzymes are proteins, having a primary structure (their amino acid sequence), a secondary 
structure (regions of local order) and a tertiary structure (a three-dimensional shape arising 
from how the separate regions interact). A quaternary structure may be present where an 
enzyme consists of ‘subunits’ of associated polypeptide chains. The tertiary structure 
throughout a protein is formed by Van der Waals forces, hydrogen bonding, electrostatics 
and hydrophobic interactions. Most significantly in the case of enzymes is the inclusion of a 
region in the 3D structure described as an ‘active site’ that is near complementary to the 
shape of a substrate molecule and which can form necessary non-covalent interactions with 
the substrate.20 The site undergoes conformational change upon binding to give the necessary 
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specificity for enzymatic catalysis, described as an induced fit. The ability of the active site to 
change shape explains why enzymes can have multiple substrates with different structures 
rather than a single exact match. Once bound, the substrate undergoes whichever reaction 
the enzyme in question catalyses. In the case of metalloenzymes, metals are coordinated 
within the active site in a deliberately strained (or ‘entatic’) state with sufficient transferrable 
energy to essentially preform the transition state of the reaction, achieving efficient catalysis 
under relatively mild conditions.21
The active site can be changed by environmental conditions: changes in pH, temperature, 
ionic strength or the presence of other chemicals can break the non-covalent interactions 
giving its shape. This ‘denaturing’ results in partial or total loss of the enzyme’s ability to 
perform its function. Enzymes have optimum conditions which are typically similar to their 
natural environment, where activity is maximised due to maintenance of the active site. 
Catalytic activity can be used as a proxy-measurement for the condition of an enzyme; a 
significant decrease in catalytic rates from optimal figures when other factors are controlled 
can signify loss of active site shape. 
3.1.6 ‘Unit’, ‘specific activity’ and issues pertaining to immobilised enzymes
Within enzymology, there are several units of which researchers must be aware. An enzyme 
‘unit’ is defined as the amount of enzyme required to convert 1 µmol of a given substrate to 
product per minute. While concentration of proteins is typically quoted in milligrams per 
millilitre (mg.mL-1), the ratio of the number of units in a sample to its concentration gives 
units.mg-1, a quantity known as ‘specific activity’. The ‘turnover number’ is defined as the 
number of µmoles of substrate converted, per µmole of enzyme, per second.20 It is important 
to distinguish between the non-specific term ‘activity’ meaning ‘enzyme action in a sample’ 
and the defined quantity ‘specific activity’. 
In the present work, the protein concentration of dispersions of enzyme-functionalised 
nanoparticles cannot be determined spectroscopically due to the presence of the 
nanoparticles and therefore the specific activity cannot be calculated. While a value of ‘units’ 
could be determined for the free- and for the nanoparticle-conjugated- enzyme, the 
definition of unit does not take into account that an immobilised enzyme is in effect a 
different species and the absolute value of units cannot be fairly compared. A calculation of 
units per milligram of solid support is also of limited use. 
For reaction rates to be used as a proxy measurement for the effect of immobilisation on 
enzyme shape, they must be normalised against the number of enzyme molecules present in 
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a sample.9 Given certain assumptions which are discussed in the ‘Results’ section of this 
chapter, judgements can be made as to the approximate number of enzymes immobilised in 
a sample and their condition and therefore the suitability of the immobilisation method for 
transfer to monoclonal antibody immobilisation. 
3.1.7 Horseradish Peroxidase (HRP) 
Horseradish peroxidase (HRP) is a 44 kDa protein with a diameter of approximately 3 nm,22
that catalyses the reduction of H2O2 when in the presence of an electron donor: 
where AH2 is a reducing substrate and AH· is the radical product.23 Many donors are 
commercially available which when oxidised give a coloured product which strongly absorbs 
in the UV region. HRP is a robust and stable enzyme; although the pH optimum for the 
enzyme’s activity is 7.0, activity can be observed at higher and lower pH values and purified 
species can be stored for months at 4 °C with limited loss of activity through degradation.1
The most common isoform has pI = 5.7.24
HRP contains two types of metal centres: iron present in heme (making the enzyme a 
hemoprotein) and two seven-coordinate calcium ions.23 All contribute to giving the active 
site its shape, but only the redox active iron centre contributes to the catalytic pathway 
proposed in Fig. 6,25 the exact details of which are beyond the scope of this discussion but 
which is included for completeness.  
Figure 6. Proposed catalytic mechanisms for HRP activity, showing the peroxidase cycle 
(on the left) and the oxidase cycle (on the right) which occurs in the presence of excess 
peroxide. Both Compounds I and II are strong oxidants. Combined and adapted from 
Berglund et al and Veitch.23,25
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Multiple substrates exist for use with HRP in both colorimetric and chemiluminescent assays 
such that depending on experiment design one substrate may be preferred over others.  3, 
3’, 5, 5’-tetramethylbenzidine (TMB) is a common substrate which gives a blue colour as a 
result of HRP activity (see Fig. 7). The blue dimer produced has two absorbance maxima at 
370 nm and 652 nm. The addition of acid stops the reaction and gives a yellow colour that 
can be measured at 420 nm.26
HRP has just two amine groups from lysine residues that are free to react which is extremely 
low for a protein and which can limit the use of amine-reactive crosslinkers with HRP.1
Glutaraldehyde is still often used to achieve conjugation,27 but is not ideal for the reasons 
discussed above. In addition, glutaraldehyde is an inhibitor of HRP and excess reagent must 
be removed prior to kinetic studies on a modified enzyme.28 HRP is a glycoprotein, bearing 
sugar side chains attached to eight asparagine residues, although the exact quantity and nature 
of these sugars varies between isoenzymes and samples.23 This renders it suitable for 
conjugation via reductive amination following oxidation of a sugar chain.  
Figure 7. Scheme of formation of coloured species by sequential oxidation of TMB. 
HRP’s robust nature, long term stability, relatively low molecular weight and high activity 
even upon modification has resulted in it being the most popular enzyme for use in 
bioconjugate systems, used in approximately 80 % of antibody-enzyme conjugates.1
The conjugation of HRP to other biomolecules has most commonly been achieved via 
glutaraldehyde- or periodate-mediated approaches with the latter typically giving products 
with higher retained enzymatic activities.1,29,30 The immobilisation of the enzyme on 
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nanomaterials using glutaraldehyde has been reported27 along with non-covalent methods of 
attachment e.g. adsorption, although the effects of non-covalent immobilisation upon 
enzymatic activity vary between sources.31–33
3.1.8 Alkaline phosphatase 
The Alkaline phosphatases are a large family of related enzymes. Mammals express two 
forms of AP, both having optimal activity at pH 8-10, both being activated by divalent 
cations and both being inhibited by similar species e.g. phosphate ions.1,33 The most 
commonly encountered form of AP, Calf Intestinal AP, is the second most common used 
enzyme in commercial conjugate species but is generally not as desirable as HRP. 
Modification of the enzyme with crosslinker molecules or when forming conjugate species 
lowers enzyme activity significantly even when following known methods.1,9,34 AP’s lack of 
reliability in this sense make it a poor species for method development.  
3.1.9 Purifying and characterising proteins and bioconjugate species 
An overview of bioconjugate technology would be incomplete without discussing methods 
of purifying and characterising bioconjugate species. The approach taken is largely dictated 
by the nature of the desired product. However, the potential for denaturation introduces 
limitations to the techniques and conditions which may be used. The manipulation of 
proteins is dominated by chromatographic methods; the techniques used in the current work 
are discussed below. 
Size-exclusion chromatography (SEC) 
The separation of molecules based on their molecular weight or molecular size is a 
fundamental technique of biochemistry. While it may be used as an analytical method for the 
determination of the size of an unknown protein, it is most commonly encountered as a 
preparative method to separate large biomolecules from small molecules, for buffer exchange 
or for de-salting.35 A diagram of how size-exclusion or gel-filtration chromatography works 
is shown in Fig. 8. A column consists of a solid phase of porous beads. Small molecules 
and/or salts are able to enter the pores of the beads such that when an eluting medium is 
applied to the solid phase, the small molecules experience a greater column volume than 
large molecules that cannot enter the pores. The large molecules move through the interstitial 
spaces between beads and are eluted before the small molecules.36
84
Figure 8. Size exclusion chromatography. Large molecules cannot enter pores, and so 
elute first. 
SEC column media can be purchased from commercial suppliers for the preparation of 
bespoke columns, although pre-packaged columns such as PD-10 desalting columns 
containing crosslinked porous dextran gel are common.37 These columns can be used with 
gravity and with centrifugation and have well-defined elution profiles. 
The eluted protein fractions of size-exclusion columns (and the fractions of IMAC 
chromatography discussed below) are often dilute and require concentration prior to use or 
storage. Although multiple methods for protein concentration exist (such as dialysis) a fast 
method which also allows for buffer exchange is the use of protein concentrator ‘spin 
columns’. These consist of a centrifuge tube divided into upper and lower compartments 
separated by a semi-permeable membrane with a defined molecular weight cut-off (MWCO). 
Upon centrifugation, molecules with a higher mass than the MWCO remain in the upper 
compartment while smaller molecules pass through the membrane and collect below. 
Immobilised metal affinity chromatography (IMAC) 
This method of purifying biomolecules is common in the synthesis of custom peptide 
sequences but is also used in the purification of mAb-based species.1 For example, in the 
synthesis of enzyme-antibody conjugates such as for ELISA assays, an excess of enzyme is 
used relative to the amount of antibody. As the product and excess starter molecules are 
large, pre-packed SEC columns may give insufficient separation which can affect the study 
of the final sample.  A more effective method utilises a form of affinity chromatography 
where the solid phase media consists of a matrix bearing chelating groups which coordinate 
a metal ion but which do not fill the coordination sphere. While several metal ions have been 
reported (e.g. Co2+, Ni2+, Cu2+, Zn2+),38 the most commonly used matrix-metal couplings 
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today are nickel-nitrilotriacetic acid (Ni2+-NTA)39 and cobalt-carboxylmethylaspartate (Co2+-
CMA).40 Both matrices fill four coordination sites on the approximately octahedral metal 
centres, leaving two sites available to allow the binding of a biomolecule of interest (see Fig. 
9).38 The molecule to be purified is often modified by the inclusion of a stretch of six histidine 
residues at the N- or C-terminal termed a His-tag. For the purification of His-tagged proteins 
or peptides Ni2+-NTA is typically used as nickel forms strong interactions with the imidazole 
side chain of histidine residues such that the binding is specific, but which are not strong 
enough to prevent relatively facile elution of the protein with only minor changes to buffer 
conditions.36 Ni2+-NTA can be viewed as a ‘general purpose’ IMAC media because while 
other metal-matrix pairings may give superior recovery or purification for a given protein or 
peptide, their use would require optimisation of conditions. Generally, Cu2+ is too strongly 
binding and Co2+ too weak, while Co3+ (as a d6 metal centre) would form a low spin kinetically 
inert complex from which the protein could not be recovered.40,41 Ni2+ is a d8 metal and does 
not form kinetically inert octahedral complexes, allowing for ligand substitution and protein 
recovery to occur at useful rates under experimentally achievable conditions. NTA is the 
preferred matrix because it is associated with reduced metal leaching into the final sample 
and greater end purity.42
IMAC has been shown to be applicable to IgG-class antibodies and enzyme-antibody 
conjugates because of a common histidine rich sequence in the Fc region of the antibody 
that functions similarly to a His-tag.21,22 When applied to the column, antibody-containing 
species become bound to the stationary phase and excess enzymes or small molecules may 
be washed away. Elution of the bound species can be achieved by applying an elution buffer 
which changes the pH, increases the ionic strength or which includes a competitive species 
(such as imidazole) which can displace the histidines. 
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Figure 9. Diagram showing the interaction between the approximately octahedral 
immobilised Ni2+ ion of a Ni-NTA resin and histidine residues on a suitably tagged protein 
(whole His-tag not shown). Adapted from Block et al.42
Measuring protein concentration 
Protein concentration within a sample may be determined spectroscopically.45 This is crucial 
for determining reaction stoichiometry. Proteins absorb at 280 nm due to the aromatic amino 
acids tyrosine and tryptophan and disulphide bonds present in their structure. Absorbance 
at a wavelength is related to concentration by the Beer-Lambert law: 
where A is absorbance, ε is the molar extinction coefficient, c is the concentration of the 
species, and l is the experimental pathlength (typically 1 cm). The molar absorptivity at 280 
nm, or ε280, can be calculated if the protein structure is known: 
where the number of each group in the protein is multiplied by an estimated molar extinction 
coefficient. The values of ε280 for common proteins such as HRP are known and can be 
referred to as standards. In the case of monoclonal antibodies, the number of groups that 
absorb at 280 nm do not differ greatly between given species and so average or typical values 
may be used with confidence. The concentration of a protein sample may be found using a 
UV-spectrometer or by the use of a ‘NanoDrop’-type microvolume spectrophotometer.46
The latter, although less accurate, is able to determine trends over eluted column fractions. 
As micro-volumes are used it is ideal for use in an on-going experiment.  
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Circular dichroism 
Many techniques for the characterisation of proteins exist. One which is less commonly 
applied outside of the study of biomolecules is circular dichroism (CD) spectroscopy, the 
specifics of which are outside the scope of the current work.36,47–49
Briefly, a plane of polarised light can be considered as two components of equal magnitude 
but with opposite circular polarisation (counter clockwise or left-handed and clockwise or 
right-handed). Absorption of both components equally by a sample would give an incident 
beam of the same initial polarity. Chiral chromophores absorb left- and right-handed 
radiation differently, such that the incident beam is distorted away from the initial plane of 
polarity; an effect known as ‘elliptical polarisation’.47 The ability of a compound to absorb 
with different intensity at a given wavelength depending on chirality is known as circular 
dichroism (CD) and may be calculated by: 
where A is absorbance, λ is the wavelength and L and R refer to the direction of polarisation. 
CD spectroscopy measures the value of CD over a range of wavelengths, converts this value 
to ‘ellipticity’ and then normalises it by considering concentration and the number of amino 
acid residues in the protein to give the mean residue ellipticity, θMR, allowing comparisons 
between proteins of different sizes.  
As CD arises as the result of chirality, CD spectroscopy is well suited to measure the 
secondary and tertiary structures of proteins which make these biomolecules chiral. As α-
helices, β-sheets and other features of a protein’s structure can have signature effects on the 
CD spectrum (Fig. 10), information derived from  CD spectroscopy can be used to estimate 
protein structure,49 or as a method of checking on the structural integrity of a known protein. 
Denaturation causes significant differences in the CD spectrum of a protein, while minor 
modifications may be difficult to observe.48
In the context of the current work, CD spectroscopy can be of use confirming the retention 
of structure following bioconjugation of two proteins (e.g. an antibody-enzyme conjugate) 
or following fluorescent labelling of a protein. Unfortunately, because of the absorbance 
properties of SPION, CD spectroscopy cannot be used to characterise immobilised proteins. 
88
Figure 10. CD signatures of selected structural elements: α-helix (red), β-sheet (blue), 
denatured protein (green).48
3.1.10 Aims and objectives 
‘Bioconjugation’ is where chemical biology and synthetic chemistry meet. Although still a 
relatively young field of research, its impact has been huge and continues to grow. The 
present work was intended to answer the following three questions:  
 How can biomolecules be immobilised on SPION?  
 How can their structural integrity post-immobilisation be assessed??  
 How many should be immobilised onto nanoparticles to maximise effect in later in 
vitro and in vivo experiments?  
The solutions to the above questions form a synthetic approach to a radiolabelled, antibody-
directed nanoparticle species. The discussion in the preceding pages provides the context to 
how these questions were addressed experimentally, the results of which are discussed below. 
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3.2 Experimental 
3.2.1 Materials and Methods 
All reactions were performed with the use of vacuum line and Schlenk techniques where 
appropriate. Reagents were commercial grade and were used without further purification. All 
reagents and solvents were purchased from Alfa Aesar or Sigma Aldrich. HRP was of 
commercial grade and was stored as lyophilised solids at - 4°C prior to use. The antibody 
trastuzumab was obtained via generous donation from Velindre Cancer Centre, Cardiff, and 
were stored as solutions of 21 mg.mL-1 in a suitable buffer at 4 °C. UV-Vis studies were 
performed on a Jasco V-570 spectrophotometer in H2O or in a suitable aqueous buffer.  
Enzymatic activity studies were carried out on a BMG LabTech FLUOstar Omega plate 
reader. All absorbance experiments were carried out in triplicate, at 298 K, and the results 
averaged. Protein concentrations were determined spectroscopically by A280 on a Thermo 
Scientific NanoDrop 1000 UV-Vis Spectrophotometer. CD spectroscopy was carried out on 
an Applied Photophysics Chirascan CD spectrometer and analysed with Chirascan software. 
Dynamic light scattering analysis was performed on a Brookhaven Instruments Corporation 
‘Zetaplus’. HisPur Ni-NTA IMAC column media was purchased from ThermoFisher and 
was used without modification according to typical protocols. 
3.2.2 Synthesis and analytical techniques 
Preparation of TMB assay solution 
3, 3’, 5, 5’-tetramethylbenzidine (TMB) was dissolved in DMSO (1 mg.mL-1) and was diluted 
tenfold in a volumetric flask with pH 5 phosphate citrate buffer to give the inactive assay 
solution. The assay solution was activated immediately prior to use by addition of 30 % H2O2
(2 µL). 
Assessment of free HRP activity 
Horseradish peroxidase, type I (Mw = 44 kDa) was dissolved in 0.1 M sodium phosphate 
buffer, 0.15 M NaCl, pH 6.8 (10 mg.mL-1). The concentration was reduced to 1 × 10-4 mg.mL-
1 by serial dilution. 20 µL of the dilute enzyme solution was added to each well of a 96-well 
plate. Active TMB assay solution (180 µL) was added with mixing in a plate reader to each 
well in sequence. The absorbance of each well at 370 nm was measured over 10 min to assess 
the activity of the fresh free enzyme.  
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Analogous experiments were carried out using HRP that had been dissolved 24 hours prior 
to reaction with TMB assay solution to assess how enzyme activity changes over time when 
there is no addition of reactant species. 
Assessment of glutaraldehyde-activated HRP activity 
To a fresh solution of HRP in 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 6.8  (100 
µl, 10 mg.mL-1) was added glutaraldehyde, 50 % wt. in water (2.52 µL). The reaction mixture 
was mixed for 24 hours at room temperature. The solution was transferred to a centrifuge 
tube and centrifuged (1 min, 13200 rpm) to remove any insoluble precipitates. The solution 
was diluted to 1 × 10-4 mg.mL-1, and 20 µL added to each of three wells prior to the addition 
of TMB assay (180 µL). Analysis was carried out as for fresh HRP, described above. 
Assessment of reduced HRP activity 
To a fresh solution of HRP in 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 6.8  (100 
µl, 10 mg.mL-1) was added NaBH4 to a final concentration of 26 mg.mL-1. The reaction 
mixture was vortexed gently and allowed to react at 4 °C for 1 h. Excess reductant was 
removed via desalting by use of a protein concentrator column (30 kDa MWCO) and 
washing with fresh buffer (3 × 1 mL). The reaction mixture was concentrated, the protein 
concentration measured from A280, and an aliquot taken and diluted by serial dilution to 1 × 
10-4 mg.mL-1.  To each of three wells was added 20 µL prior to the addition of TMB assay 
(180 µL). Analysis was carried out as for fresh HRP, described above. 
Synthesis of HRP-APTES@SPION by use of glutaraldehyde  
HRP was dissolved in 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 6.8 (1 mL, 10 
mg.mL-1). Glutaraldehyde, 50 % wt. in H2O was added to a final percentage of 1.25 % of the 
crosslinker (26.1 µL) and the reaction mixture stirred overnight at room temperature. After 
24 h, the reaction mixture was purified by size-exclusion chromatography on a PD-10 
desalting column using 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 6.8 as an elution 
buffer. Elution yielded activated enzyme solution (3.5 mL, 2.86 mg.mL-1). Centrifugation was 
applied to remove the insoluble glutaraldehyde-based polymers (2 min, 13200 rpm). 
APTES@SPION was dispersed in 0.1 M sodium phosphate buffer, 0.15 M NaCl pH 6.8 (10 
mg.mL-1). Differing volumes of nanoparticles suspension and enzyme solutions were mixed 
to achieve differing maximum loadings of enzyme per nanoparticle (see below). The reaction 
mixtures were mixed overnight at 4 °C by use of an inverting carousel mixer. To each was 
added NaBH4 in 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 6.8 (200 µL, 20 mg.mL-
1) and the mixture stirred for 1 h at 4 °C to reduce Schiff bases. The particles were collected 
91
by centrifugation (2 min, 13200 rpm) and washed with distilled water (5 × 1 mL) to remove 
unbound enzyme. The particles were dispersed in 0.1 M sodium phosphate buffer, 0.15 M 
NaCl, pH 6.8 (1 mL), homogenised and diluted 100-fold. 20 µL of each dispersion was 
transferred to a well of a 96-well plate. Active TMB assay solution (180 µL) was added to 
each with mixing and the absorbance at 370 nm measured over an hour. All experiments 
were carried out in triplicate. The enzymatic activity of each sample was determined based 
on the estimated number of particles in the well and the initial reaction stoichiometry. DLS 
studies yielded inconclusive data. 
Synthesis of HRP-APTES@SPION via reductive amination 
HRP was dissolved in 0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 7.2 (10 mg.mL-1). 
NaIO4 (22 mg) was dissolved in H2O (1 mL, 88 mM) in the dark. 100 µL of the periodate 
solution was added per 1 mL of enzyme solution. The reaction mixture was mixed and 
allowed to react in the dark for 20 min. Excess NaIO4 was quenched by addition of Na2SO3
(2.5 molar equivalents). A PD-10 column was equilibrated using 0.1 M sodium phosphate 
buffer, 0.15 M NaCl, pH 7.2, and the reaction mixture applied. Elution was achieved using 
aliquots of buffer (0.5 mL). The concentration of the activated enzyme was determined 
spectroscopically and the most concentrated fraction selected for use in immobilisation. 
APTES@SPION was dispersed in H2O (10 mg.mL-1). Differing volumes of nanoparticle 
suspension and enzyme solution were mixed to achieve differing loadings of enzyme per 
nanoparticle (see below), and allowed to react at room temperature for 2 h. 5 M NaCNBH3
in 1M NaOH was added (10 µL per 1 mL of reaction mixture) to reduce Schiff bases by 
reaction at room temperature for 30 min. 1 M ethanolamine, pH 9.6 (50 µL per 1 mL of 
reaction mixture) was added and reaction continued at room temperature for 30 min. The 
particles were collected by centrifugation (2 min, 13200 rpm) and washed with distilled water 
(5 × 1 mL) to remove any unbound enzyme. For all samples, the particles were dispersed in 
H2O (1 mL), homogenised, and a sample diluted 1000-fold. 20 µL of each sample dispersion 
was transferred to a well of a 96-well plate. Active TMB assay solution (180 µL) was added 
to each with mixing and A370 measured over an hour. All experiments were carried out in 
triplicate. The enzymatic activity of each sample was determined based on the estimated 
number of particles in the well and the initial reaction stoichiometry. DLS studies yielded 
inconclusive data. 
Conjugation of HRP and trastuzumab by reductive amination 
Trastuzumab was dissolved in 10 mM sodium phosphate, 0.15 M NaCl, pH 7.2 (10 mg.mL-
1). NaIO4 (22 mg) was dissolved in H2O (1 mL) in the dark and 100 µL of the periodate 
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solution added per 1 mL of the antibody solution. The mixture was allowed to react in the 
dark at room temperature for 20 min, and the excess periodate quenched by the addition of 
Na2SO3 (2.5 molar equivalents). The reaction mixture was applied to a PD-10 column 
equilibrated with 100 mM sodium phosphate, 0.15 M NaCl, pH 7.2, and the activated 
antibody collected by elution in the same buffer using fractions of 0.5 mL. A280 was used to 
monitor antibody concentration and the activated antibody was used immediately. HRP was 
dissolved in 0.2 M sodium carbonate buffer, pH 9.6 (10 mg.mL-1). The enzyme solution was 
added to the antibody solution to achieve a 15-fold molar excess of the enzyme. The mixture 
was allowed to react for 2 h at room temperature. 5 M NaCNBH3 in 1 M NaOH was added 
(10 µL per 1 mL) and allowed to mix for 30 min at room temperature. Excess aldehyde 
groups were blocked by the addition of 1 M ethanolamine, pH 9.6 (50 µL per 1 mL) and 
allowed to react for 30 min at room temperature. The reaction solution was then applied to 
a PD-10 column equilibrated with 10 mM sodium phosphate, 0.15 M NaCl, pH 7.2, and 
elution carried out with the same buffer using 1.0 mL fractions. The absorbance at 280 nm 
was monitored to determine the most concentrated fractions, which were combined. HisPur 
Ni-NTA resin was used to ensure separation of the conjugate species from excess enzyme. 
Briefly, a short column (2 mL) was prepared and washed with H2O (10 × 2 mL) to remove 
storage buffer, then equilibrated with 10 mM sodium phosphate, 0.15 M NaCl, pH 7.0 (3 × 
2 mL). The reaction mixture (2 mL) was applied to the resin and the eluent discarded. The 
resin was washed with 0.15 M NaCl (10 × 2 mL) until the absorbance of the fractions at 280 
nm was negligible. The bound immunoconjugate species was eluted by the addition of 100 
mM sodium phosphate, 0.5 M NaCl, pH 5.0 (10 × 1 mL). The most concentrated fractions 
were determined spectroscopically, combined, buffer exchanged into 100 mM sodium 
phosphate, 0.15 M NaCl and concentrated by use of a protein concentrator (10,000 MWCO) 
to ~5 mg.mL-1 as determined by A280. Circular dichroism spectroscopy suggested a 1:1 
conjugate species (see below). The enzymatic activity of the conjugate was determined 
similarly to the free enzyme above. 
Immobilisation of HRP-trastuzumab conjugates on APTES@SPION 
To HRP-trastuzumab in 100 mM sodium phosphate, 0.15 M NaCl, pH 7.2 was added a 
periodate solution (100 µL per 1 mL of antibody solution) prepared by dissolving NaIO4 (22 
mg) in H2O (1 mL) in the dark. The reaction was allowed to proceed for 20 min, then excess 
periodate was quenched with Na2SO3 (2.5 molar equivalents). A PD-10 column was 
equilibrated with 100 mM sodium phosphate, 0.15 M NaCl, pH 7.2, and the reaction mixture 
applied. The same buffer was used for elution in fractions of 0.5 mL. A280 was used to 
determine the most concentrated sample, which was selected for the next step of the 
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reaction. APTES@SPION was dispersed in H2O (10 mg.mL-1), and quantities of the 
activated immuno-conjugate solution added to achieve the desired stoichiometric loading of 
the product particles (see section 3.3.4). The reaction was allowed to mix at room 
temperature for 2 h. 5 M NaCNBH3 in 1 M NaOH was added (10 µL per 1 mL) and reaction 
allowed to proceed for 30 min at room temperature. 1 M ethanolamine, pH 9.6 was added 
(50 µL per 1 mL) and reaction allowed to proceed for 30 min at room temperature. The 
particles were collected by centrifugation (1 min, 1000 rpm), and washed with 10 mM sodium 
phosphate, 0.15 M NaCl, pH 7.2 (5 × 1 mL). The particles were dispersed in H2O (1 mL), 
homogenised, and a sample diluted a 1000-fold. 20 µL of each sample dispersion was 
transferred to a well of a 96-well plate. Active TMB assay solution (180 µL) was added to 
each with mixing and the absorbance at 370 nm measured over an hour. All experiments 
were carried out in triplicate. The enzymatic activity of each sample was determined based 
on the estimated number of particles in the well and the initial reaction stoichiometry. DLS 
studies yielded inconclusive data. 
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3.3 Results and discussion 
3.3.1 Glutaraldehyde activation and immobilisation of HRP 
‘Free’ HRP activity measurements
As stated above, HRP has an unusually low number of free amine groups available for 
reaction with glutaraldehyde; just two for a protein of over 300 amino acid residues.1 This 
has been shown to be sufficient to allow bioconjugation via the homobifunctional agent 
glutaraldehyde, and given the ready availability of the agent, use of glutaraldehyde is a clear 
starting point for the development of methods of immobilisation. 
As the structure of enzymes immobilised on SPION cannot be studied directly, how catalytic 
activity is changed post-immobilisation serves as a measure of the ‘health’ of the protein. 
Initial experiments focussed on measuring the catalytic activity of the free enzyme in a range 
of conditions: prepared freshly before reaction, after 24 h in solution, after 24 h incubation 
with glutaraldehyde and after reduction by NaBH4. The measured enzymatic activity of the 
different samples were compared to the free, freshly prepared enzyme to determine the 
effects of different treatments on the enzyme in a manner similar to that reported by Mark 
et al.9 HRP was dissolved in a suitable buffer at 10 mg.mL-1, diluted by serial dilution to 1 × 
10-4 mg.mL-1, then 20 µL of this solution diluted to 1 × 10-5 mg.mL-1 in the wells of the 96 
well plate by addition of the TMB assay solution. All samples were treated analogously. A 
negative control consisting of glutaraldehyde with no HRP present gave no measurable 
increase in A370 over the time scale of the experiments and is not discussed in the figures 
below. 
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Figure 11. Absorbance at 370 nm versus time for HRP in different states (freshly 
prepared, glutaraldehyde (GA) activated, NaBH4-reduced and 24 hours post-
preparation). Error bars show standard error (n = 3). 
Measuring A370 over time allowed the determination of the rate of formation of the blue 
TMB dimer in units of A.s-1 (Fig. 11). The number of enzyme molecules per well can be 
calculated from concentration and molecular mass: 
The contribution to the observed rate per enzyme molecule present can then be calculated 
and used as a point of reference for similar calculations to be performed as part of later 
experiments. Full calculations are shown in section 1 of Appendix II. 
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Observed rate ± 
S.E.
/ A.s-1
Rate per enzyme ± 
S.E.
/ A.s-1.enz-1 
Activity relative to 
freshly prepared, 
free HRP (%)
Freshly prepared 
HRP
7.51 ± 0.11 × 10-3 2.74 ± 0.04 × 10-13 100
24 hour post-
preparation HRP
2.33 ± 0.02 × 10-2 8.50 ± 0.07 × 10-13 310 ± 3
GA-activated HRP 1.55 ± 0.04 × 10-2 5.66 ± 0.15 × 10-13 207 ± 6
NaBH4-reduced 
HRP
2.33 ± 0.08 × 10-3 8.50 ± 0.27 × 10-14 31 ± 1
Table 1. Rates and relative activities of samples of free HRP. Standard deviation of mean 
observed rates used to determine variance in calculated quantities. Activity of freshly 
prepared HRP set at an absolute value of 2.74 ×10-13 A.s-1.enz-1for expediency of later 
analysis.(n = 3) 
The relative activity of HRP dissolved in a suitable buffer 24 hours prior to study is over 
three times that of HRP dissolved immediately prior (see Table 1). When HRP has been 
incubated with glutaraldehyde for 24 hours, activity is increased approximately twofold 
relative to freshly dissolved HRP. In the proposed mechanism given in Fig. 6, oxidation of 
the iron centre of the ‘ground state’ enzyme from Fe3+ to Fe4+ (formally Fe5+) in an oxyferryl 
centre (‘Compound I’) is the first step.25 When freshly dissolved HRP is used in the method 
described, the initial oxidation occurs by action of H2O2. When in solution for an extended 
period of time oxidation can occur due to O2 in solution prior to addition of the assay 
solution. Numerous oxidants with less oxidising power than O2 have been shown to initiate 
catalysis by HRP.30, 31 The effect is similar to what would be observed if a greater quantity of 
oxidant were added to ‘activate’ the TMB assay solution. A greater proportion of the enzyme 
molecules are activated away from the ground state and are able to catalyse TMB 
dimerisation, leading to a higher measured rate while the smaller increase observed after 24 
hour in solution with glutaraldehyde is likely due to some denaturation and/or the action of 
glutaraldehyde as an inhibitor of HRP.28 The inverse is seen following incubation with the 
reductant NaBH4. The relative activity measured is less than a third of the value observed 
for freshly prepared HRP in its native state. 
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Incubation of HRP with glutaraldehyde does not result in a complete denaturation of the 
enzyme. Qualitatively, aggregation is not observed although the observed decrease in activity 
may be due to crosslinking between enzyme molecules on a microscopic scale. Loss at this 
point is not so severe as to prevent attempts at immobilisation. NaBH4 results in a loss of 
relative enzymatic activity (expected from the proposed catalytic mechanism) but not so 
much as to preclude the use of this reducing agent in the synthesis of bioconjugates 
incorporating HRP. The use of freshly prepared HRP as the control to which later 
experiments are referenced may be justified when considering that the degree of oxidation 
that occurs over 24 hours in solution may differ between samples despite attempts to limit 
such differences. 
Calculation of immobilisation stoichiometry 
The immobilisation protocol used was based on a two-step glutaraldehyde-mediated method 
first reported by Avrameas and Ternynck.52 Overnight incubation of the enzyme with the 
crosslinker was followed by size exclusion chromatography and centrifugation to remove any 
insoluble precipitates. The concentration of the activated enzyme was measured 
spectroscopically prior to addition to a dispersion of nanoparticles. Using characterisation 
data described in Chapter 2 of the present work, the number of nanoparticles per mg solid 
could be estimated; assuming spherical particles of diameter equivalent to the experimental 
determined average and with equal surface coverage with APTES allows an approximate 
reaction stoichiometry to be determined. The polydisperse nature of the nanoparticles means 
that a ‘theoretical average’ particle must be used in the calculations in Table 2 below, which 
describe the approach used in designing these experiments.  
The APTES@SPION sample used in all experiments was characterised to have an average 
inorganic (Fe3O4) core diameter of 6.5 ± 0.4 nm by application of the Scherrer equation to 
the Powder X-Ray diffraction pattern. Random selection of a cohort of 30 particles from 
TEM images gave an average whole particle diameter of 8.1 ± 1.7 nm (see Chapter 2). The 
‘theoretical average’ particle used has a whole diameter of 8.1 nm and a Fe3O4 core diameter 
of 6.5 nm, with the difference due to SiO2 coating. Standard densities of these materials were 
used to calculate the mass of the ‘theoretical average particle’.
Taking into account the deviation in particle size parameters when estimating ‘particles per 
milligram’ introduces considerable variance (over 50 % relative to the value stated below and 
used in this work). For the sake of clarity this is omitted, however the reader should note 
that the stoichiometric labelling described below as enzyme:nanoparticle ratios and 
percentage labelling are not absolute values, but are reflective of the changing quantities of 
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protein (either enzyme or antibody) being used relative to an ideal population of ‘theoretical 
average particles’. As all experiments were performed in triplicate and good agreement in 
quantitative data was observed (see below), this approach would appear sound. 
d(SiO2) = 2.00 g.cm-3, d(Fe3O4) = 5.17 g.cm-3.53,54
8.1 nm SiO2 Sphere 6.5 nm SiO2 Sphere 6.5 nm Fe3O4 Sphere
For an 8.1 nm nanoparticle having a 6.5 nm Fe3O4 core, the remainder being 
assumed to be of comparable density to SiO2:
Table 2. Calculating approximate number of nanoparticles per mg solid for reaction 
stoichiometry. 
Table 3 shows how the desired reaction stoichiometries were achieved. The diameter of HRP 
is approximately 3 nm; if the immobilisation of biomolecules on a surface is approached as 
a sphere packing problem and the enzyme HRP is considered as a sphere with a ‘footprint’ 
of 7 nm2, then an approximately spherical nanoparticle with a diameter of 8.1 nm and with a 
surface area of 206 nm2 could theoretically accommodate a maximum of 22 enzyme 
molecules with 74 % packing efficiency. However, steric clashes would prevent this 
maximum from being reached and hindrance between enzymes would have a marked effect 
at levels well below saturation. For this reason, reaction stoichiometries were kept low so 
that the effect of increasing the number of singly enzyme-labelled particles in a population 
(expressed as a percentage) was studied. This would exclude the effects of inter-enzyme steric 
clashes that would not be immediately applicable to antibodies.  
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V(APTES@SPION) 
/µL (conc. /mg.mL-1)
No. of nanoparticles V(HRP)
/µL (conc. /mg.mL-1)
No. of enzymes Enzyme:nanoparticle 
ratio (% singly labelled)
180 (10) 1.78 × 1015 20 (0.286) 7.83 × 1013 1:22 (~ 5 %)
160 (10) 1.58 × 1015 40 (0.286) 1.57 × 1014 1:10 (~ 10 %)
140 (10) 1.38 × 1015 60 (0.286) 2.35 × 1014 1:6 (~ 17 %)
180 (10) 1.78 × 1015 20 (2.860) 7.83 × 1014 1:2.3 (~ 43 %)
160 (10) 1.58 × 1015 40 (2.860) 1.57 × 1015 1:1 (~ 100 %)
140 (10) 1.38 × 1015 60 (2.860) 2.35 × 1015 1.7:1 (170 % i.e. 70 % bear 
two enzymes)
Table 3. Volumes of nanoparticle and HRP solutions and resulting enzyme:nanoparticle ratio (glutaraldehyde method).
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Relative activities of immobilised enzymes 
After immobilisation, the coated particles were dispersed in 1 mL of buffer and a sample was 
diluted 100-fold. 20 µL of this sample was transferred to a well plate for study. From Fig. 12, 
the initial rates of A370 vs. time for the different samples may be derived from the initially 
linear response.55 Mathematical treatment allows the calculation of the theoretical 
contribution of each enzyme to this figure, assuming the immobilisation step went to 
completion (see Table 4). Comparison against the relative activity of the freshly prepared, 
free enzyme (found in Table 1) is achieved by the formula: 
Full calculations are shown in the Appendix II. As the degree of oxidation within a sample 
of HRP has been shown to affect activity, great care was taken to ensure that all samples 
were measured at approximately the same time post-initial dissolution of the solid enzyme in 
an attempt to ensure that in all samples the degree of oxidation was comparable. 
Figure 12. Absorbance vs. time for nanoparticles having different percentage labelling 
with HRP immobilised via glutaraldehyde. Error bars show standard error (n = 3) 
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Enzyme:nanoparticle ratio 
(% singly labelled)
Observed rate ± S.E.
/ A.s-1 
No. of enzymes Rate per enzyme ± S.E.
/ A.s-1.enz-1 
Activity relative to freshly 
prepared, free HRP ± S.E. 
(%)
1:22 (~ 5 %) 1.77 ± 0.29 × 10-5 1.62 × 1010 1.09 ± 0.18 × 10-15 0.40 ± 0.07
1:10 (~ 10 %) 2.86 ± 0.16 × 10-5 3.16 × 1010 9.05 ± 0.51 × 10-16 0.33 ± 0.02
1:6 (~ 17 %) 5.75 ± 0.32 × 10-5 4.68 × 1010 1.23 ± 0.07 × 10-15 0.45 ± 0.03
1:2.3 (~ 43 %) 2.35 ± 0.01 × 10-4 1.54 × 1011 1.53 ± 0.07 × 10-15 0.56 ± 0.02
1:1 (~ 100 %) 4.78 ± 0.09 × 10-4 3.16 × 1011 1.51 ± 0.03 × 10-15 0.57 ± 0.01
1.7:1 (170 % i.e. 70 % bear 
two enzymes)
6.61 ± 0.01 × 10-4 4.68 × 1011 1.41 ± 0.002× 10-15 0.51 ± 0.001
Table 4. Calculation of immobilised enzyme activity relative to the free species (glutaraldehyde method) (n = 3).
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The immobilised enzymes gave measurable rates of catalysis at all theoretical loadings (Fig. 
12 and Table 4). In all cases the enzymatic activity relative to that of the free enzyme is 
approximately 0.5 %, representing significant activity loss; no trend in activity can be 
discerned as initial stoichiometry increases, because the activity is so low that error renders 
the calculated differences between samples statistically insignificant.  
Crosslinking between enzymes prior to immobilisation is not likely to be occurring. The low 
number of available amine groups on HRP makes cross-reaction with the more numerous 
surface amine groups of the nanoparticles more likely than either inter- or intra-enzyme 
crosslinking.  
Although glutaraldehyde is known to be an inhibitor of HRP,28 multiple washes post-
immobilisation would be expected to have removed excess glutaraldehyde from the active 
sites. Incubation of HRP overnight in the presence of glutaraldehyde does not have an effect 
similar to that seen in Table 4; similarly the action of the reductant NaBH4 diminishes the 
observed activity of the free enzyme but not to the degree noted for the nanoparticle-
immobilised species (see Table 1).  
If it is considered that steric hindrance, crosslinking, inhibition, reduction and denaturation 
are not likely to be the causes of the lowered activity, then it may be that glutaraldehyde is 
causing the enzyme to bind to the surface in such a way as to impede the formation of a 
substrate-enzyme complex. HRP is a relatively small protein; glutaraldehyde’s short length 
may cause the active site to be either close to or oriented towards the highly charged, 
hydrophilic surface of the nanoparticle thus making it difficult for substrate molecules to 
enter. Antibodies have many lysine residues which would be free to link to the nanoparticle 
surface; attachment via multiple residues per protein could occur. If the crosslinker’s length 
is the cause of HRP’s reduced activity, it would be expected that using glutaraldehyde to 
achieve antibody immobilisation would result in the mAb being bound tightly to the surface, 
possibly via multiple points of attachment. If the antigen binding region were to be oriented 
toward or parallel to the particle surface, this would greatly decrease the ability of the mAb 
to bind its target receptor. 
The approach described above would be unsuitable for mAb immobilisation. Antibodies are 
significantly larger than HRP (10 nm vs. 3 nm, or a ‘spherical footprint’ of 78.5 nm2 vs. 7 
nm2) and so a maximum of two antibodies could be accommodated, although realistically 
only one per nanoparticle could be achieved. Reduction in the ability of the protein to bind 
its target on the scale observed for HRP above could not be compensated for by increased 
loadings of the biomolecule. 
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3.3.2 Immobilisation of HRP via reductive amination 
Mechanism of immobilisation
HRP has up to eight sugar side chains attached to amino acid residues throughout its 
structure.23 Treatment of the protein with sodium periodate (NaIO4) results in the oxidation 
of these sugars, generating up to two aldehyde groups per sugar monomer. Reaction of these 
aldehyde groups with deprotonated amines on the surface of the nanoparticles results in 
Schiff bases that must be stabilised by reduction. 
Figure 13. Glycoproteins (e.g. HRP, most mAbs) can be crosslinked to amine containing 
species, here a nanoparticle, by reductive amination. 
This approach has several advantages. First, the oxidised sugar group of HRP will have a 
large number of aldehyde groups available for reaction with amines, while HRP has only two 
amine groups for reaction with the aldehydes of glutaraldehyde. Second, the reactive groups 
exist away from the steric bulk of the protein and so are more able to react. Third, the sugar 
side chain to be used as a crosslinker between the protein and the nanoparticle will be 
considerably longer than the crosslink formed by glutaraldehyde. This will allow the enzyme 
to move more freely in space, increasing the likelihood of substrate binding. 
Calculation of immobilisation stoichiometry 
The same samples of APTES@SPION were used for immobilisation as described in section 
3.8.1 above; taking average values allowed an estimate that 1 mg of solid contained 9.88 × 
1014 nanoparticles. 
HRP was reacted with an excess of NaIO4 and the activated protein purified by size exclusion 
chromatography. The activated protein was eluted from the column in aliquots with a volume 
of 0.5 mL and the concentration of each fraction was determined spectroscopically from A280
by use of a NanoDrop spectrophotometer. The most concentrated fraction was typically the 
sixth eluted volume and was used immediately in further reactions; volumes of the activated 
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HRP solution were added to volumes of a nanoparticle dispersion to achieve the desired 
reaction stoichiometry (see Table 5 below).  
Relative activities of immobilised enzymes
Following reaction at room temperature for 2 h, the Schiff bases were reduced by NaCNBH3
and any remaining aldehyde groups blocked by ethanolamine. Centrifugation and washing of 
the particles allowed the removal of unbound enzyme and excess reagents. The enzyme 
coated particles were then dispersed in H2O (1 mL), diluted 1000-fold and 20 µL used for 
studies. As the theoretical number of particles in each volume is known, then assuming 
complete immobilisation the number of enzymes present is known.  
The change in A370 due to enzyme activity was measured over 150 seconds. Analysis of the 
initial rates of reaction were taken from the first 60 seconds of the experiments (Fig. 14). 
Activities relative to free HRP were then be calculated (Table 6). An example approach is 
shown in section 3 of Appendix II.  
Plotting the relative activities of the immobilised enzymes against the percentage of particles 
bearing an enzyme moiety yields the decay curve in Fig. 15 with equation: 
Plotting log10(relative activity) against log10(% nanoparticles singly labelled) results in the 
straight line observed in the inset figure with equation: 
which allows for the analysis of the relationship between activity and stoichiometry; the decay 
curve has a monomial formula where activity (y) is essentially (within error) inversely 
proportional (-1.164) to the percentage of nanoparticles bearing a biomolecule (x). Additional 
data would be required for greater confidence in the absolute value of the index. 
As well as allowing the estimation of the expected relative activities for samples having 
different initial reaction stoichiometries to those studied, this relationship shows that as the 
number of particles bearing an enzyme increases, the ability of the enzymes to function 
decreases in a non-linear fashion reflecting the multiple factors contributing to activity loss 
(i.e. change in speed in solution, different orientations upon immobilisation, intra- and inter-
particle steric effects and the formation of aggregate species). At the lowest studied 
percentage of nanoparticles with HRP (~ 2 %), the relative activity is 81.4 ± 8.0 % that of 
the free, freshly prepared enzyme. The reduction in activity in this case is likely due to the 
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small HRP enzyme molecule being attached to a large nanoparticle that limits the likelihood 
of collision with substrate molecules by slowing the motion of the enzyme in solution and 
by providing a steric hindrance to substrate molecules. The errors in the relative activity 
values given in Table 6 are sufficient to conclude with 95 % confidence that the trend 
observed is statistically significant. 
As more particles are conjugated to HRP moieties, the relative activity of these enzymes 
decreases markedly. It is likely that increasing the number of protein species changes the 
surface character of the particles and increases their propensity to aggregate. In aggregates 
of multiple particles the enzymes would experience greater steric hindrance, preventing the 
formation of substrate-enzyme complexes. 
When the number of immobilised enzymes in a sample is low the observed relative activity 
is comparatively high. Immobilisation by reductive amination does not negatively affect 
enzyme function as severely as immobilisation by use of glutaraldehyde and it can be 
concluded that the former approach is preferable for attempting antibody immobilisation. 
As antibodies are several times larger than HRP their effect on surface charge and the stability 
of the nanoparticle dispersion could be greater and a low biomolecule:nanoparticle ratio is 
even more important to ensure retention of biomolecule function.  
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V(APTES@SPION) /µL 
(conc. /mg.mL-1)
No. of nanoparticles V(HRP)
/µL (conc. /mg.mL-1)
No. of enzymes Enzyme:nanoparticle ratio
(% singly labelled)
500 (10) 4.95 × 1015 2.08 (3.14) 8.94 × 1013 1:55 (~2 %)
500 (10) 4.95 × 1015 4.15 (3.14) 1.78 × 1014 1:27 (~4 %)
500 (10) 4.95 × 1015 10.38 (3.14) 4.46 × 1014 1:11 (~9 %)
500 (10) 4.95 × 1015 20.75 (3.14) 8.92 × 1014 1:6 (~17 %)
500 (10) 4.95 × 1015 41.50 (3.14) 1.78 × 1015 1:3 (~33 %)
Table 5. Volumes of nanoparticle and HRP solutions and resulting enzyme:nanoparticle ratio (reductive amination method). 
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Enzyme:nanoparticle ratio 
(% singly labelled)
Observed rate ± S.E.
/ A.s-1 
No. of enzymes Rate per enzyme ± S.E. 
/ A.s-1.enz-1 
Activity relative to freshly 
prepared, free HRP ± S.E. 
(%)
1:55 (~2 %) 3.99 ± 0.39 × 10-4 1.78 × 109 2.23 ± 0.22 × 10-13 81.4 ± 8.0
1:27 (~4 %) 4.29 ± 0.47 × 10-4 3.66 × 109 1.17 ± 0.13 × 10-13 42.7 ± 4.7
1:11 (~9 %) 3.33 ± 0.36 × 10-4 8.91 × 109 3.74 ± 0.40 × 10-14 14 ± 1.5
1:6 (~17 %) 4.51 ± 0.65 × 10-4 1.80 × 1010 2.51 ± 0.36 × 10-14 9.2 ± 1.3
1:3 (~33 %) 2.92 ± 0.52× 10-4 3.66 × 1010 7.97 ± 1.42 × 10-15 2.9 ± 0.5
Table 6. Calculation of immobilised enzyme activity relative to the free species (reductive amination method) (n = 9).
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Figure 14. Absorbance vs. time for samples of nanoparticles having different percentages 
of immobilised HRP (reductive amination method). Error bars show standard error (n = 
9). 
Figure 15. Relative activity plotted against percentage of nanoparticles bearing an HRP 
moiety. log10(activity) against log10(% nanoparticles singly labelled) shows a linear 
relationship (inset). Error bars show standard error (n = 9). 
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3.3.3 Conjugation of HRP and trastuzumab 
Trastuzumab (Herceptin®) is a clinically approved monoclonal antibody used in the 
treatment of Her-2 positive breast cancers. A thorough discussion of this antibody is 
included in Chapter 4. As a glycoprotein bearing a sugar side chain at one N-glycosylation 
site in the Fc region (Asn297),56 immobilisation may occur by reductive amination in a 
manner analogous to that described for HRP. The determination of the success of the 
experiment requires modification of the native species by incorporating a tag (e.g. an enzyme 
or fluorescent dye) that allows tracking of the mAb.  
The number of fluorophores that can be conjugated to antibodies must be limited to prevent 
changing avidity (the antigen-antibody binding strength).7 Previous experiments have shown 
the need to limit the number of biomolecules (and therefore fluorophores) to be immobilised 
on the nanoparticles; also, the potential for fluorescence signal loss via quenching (see 
Chapter 4) means that linking the antibody to an enzyme that generates a product that can 
be observed in UV-Vis spectroscopy would give greater signal and greater tracking 
sensitivity. Neither approach directly assesses the retained function of the antibody, for 
which further experiments are required e.g. cell line studies discussed in Chapter 4.  
As the antibody has one glycosylated site it is possible to perform a reductive amination 
reaction with an amine group on HRP, and although the reaction proceeds in the presence 
of a 15-fold excess of enzyme to take the reaction to completion, the limited number of 
glycosylation sites on the mAb and the sizes of the proteins theoretically limit the conjugation 
ratio to 1:1. Affinity chromatography (IMAC) allows for the removal of excess free enzyme 
moieties from the reaction mixture. The sugars of the enzyme moieties may then be used in 
a second reductive amination to immobilise the conjugate species on to nanoparticles (Fig. 
16). In effect, the enzyme is being used as a crosslinker. Testing for enzymatic activity 
indicates the attachment of the antibody to the nanoparticle surface.  
110
Figure 16. Sequential reductive amination allows the synthesis of a mAb-enzyme 
conjugate and its immobilisation on an amine-functionalised nanoparticle. Not to scale. 
Circular dichroism spectroscopy  
The 1:1 conjugate of HRP (Mw = 44,000 g.mol-1) and trastuzumab (Mw = 145,421.5 g.mol-1, 
148,400 g.mol-1 glycosylated) would have a Mw of approximately 192,400 g.mol-1. Mass 
spectrometry of proteins often requires specialist techniques and/or equipment; in the 
current case, a representative mass spectrum could not be obtained. CD spectroscopy can 
be used to assess the structure of a conjugate species. The CD spectra of the enzyme, 
antibody and conjugate species were measured in millidegrees of ellipticity by dilution of 
stock solutions. By reference to the number of amino acid residues, degrees of ellipticity can 
be converted to mean residue ellipticity as discussed in the introduction to this chapter.  
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HRP 
(Mw = 44,000 Da)
Trastuzumab 
(Mw = 145,421.5 Da)
HRP-mAb conjugate 
(Mw ≈ 192,400 Da)
[Stock] = 10 mg.mL-1 
= 2.27 × 10-4 M
10 µL of stock solution 
diluted to 260 µL in 
sample.
 [Sample] = 8.74 × 10-6 
M 
N = 308 residues
 CMR = 2.69 × 10-3 M.res.
[Stock] = 21 mg.mL-1 
= 1.44 × 10-4 M
5 µL of stock solution 
diluted to 260 µL in sample.
[Sample] = 2.78× 10-6 M
N = 1330 residues
 CMR = 3.69 × 10-3 M.res.
[Stock] = 5.18 mg.mL-1 
= 2.73 × 10-4 M
10 µL of stock solution 
diluted to 260 µL in sample.
[Sample] = 1.06 × 10-6 M
N = 1638 residues
 CMR = 1.72 × 10-3 M.res.
Table 7. Calculation of CMR for HRP, trastuzumab, and the conjugate thereof. 
The CD spectra of HRP, trastuzumab and the conjugate species are shown in Fig. 17. The 
native proteins have significantly different spectra against which the conjugate can be 
compared. HRP can be seen to have a greater contribution of α-helices to its CD spectra 
than the antibody, in agreement with X-ray crystal structure analysis.23 The CD spectra of 
the conjugate species has a similar lineshape to the native antibody, but is sufficiently 
different that it can be judged to be a novel species. The peak at 289 nm seen in HRP’s 
spectrum is not seen in that of the conjugate, implying a low contribution from the α-helices 
of HRP.  
From the masses stated for glycosylated and non-glycosylated trastuzumab, it can be 
calculated that polysaccharides account for 2978.5 g.mol-1 of the antibody, equivalent to 
approximately 16.5 glucose monomers per protein (attached in one polymer chain at 
Asn297). Assuming a linear, non-branched polysaccharide, with a monomer length of 
approximately 9 Å (based on typical C-C and C-O bond lengths), the sugar side chain would 
be 149 Å (14.9 nm) in length. In reality such sugars are branched and folded, and would be 
shorter. Following conjugation to a single 3 nm diameter enzyme (‘spherical footprint’ of 7 
nm2), subsequent enzymes would be sterically hindered from approaching any remaining 
aldehyde moieties by the steric bulk of the enzyme and the antibody. 
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The most likely product of the bioconjugation is a 1:1 species. The CD spectra shown in Fig. 
17 below do not allow for the unequivocal assessment of the mAb:enzyme ratio on their 
own. Taking steric arguments into account and assuming that the reaction stoichiometry (a 
15-fold excess of the enzyme) will have been sufficient to take the reaction to completion, 
the CD spectra of the product is sufficiently unlike that of the enzyme that it can be 
concluded with confidence that reaction has taken place. Simulated CD spectra for 1:1 and 
1:2 species were obtained by addition of the spectra of the free enzyme and antibodies in 
different proportions; comparison to the experimentally obtained spectrum allows the 
conclusion that it is highly likely that a 1:1 bioconjugate has been formed (see Fig. 18). 
Figure 17. CD spectra of trastuzumab, HRP and the conjugate species. The line shape of 
the conjugate species is distinct from each of the starting species.  
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Figure 18. Comparison of the experimentally observed conjugate spectra to simulations 
allow the conclusion that a 1:1 conjugate has been formed.
‘Free’ HRP-Herceptin conjugate activity measurements 
The activity of the conjugate species was determined similarly to the approach taken for the 
native enzyme. Following chromatographic purification, the fractions containing the 
conjugate species were combined, concentrated in a protein concentrator ‘spin column’, and 
the final concentration made to 3 mg.mL-1 (determined spectroscopically from A280). An 
aliquot was taken and diluted 1000-fold, and 20 µL of this solution transferred to a well plate 
for study in the plate reader. Taking an approximate mass of 192,400 Da, the number of 
conjugate species (hence enzyme moieties) per well may be calculated: 
Measuring A370 against time (Fig. 19) yields an observed rate of 8.46 ± 0.15 × 10-3 A.s-1 from 
which the effective contribution per enzyme moiety can be determined as 4.50 ± 0.08 × 10-
14 A.s-1.enz-1. The activity of the immobilised conjugate can be calculated to be 16.4 ± 0.3 % 
relative to that of free, freshly prepared HRP; the low relative activity of the enzyme moiety 
in the conjugate reflects that it is considerably less able to perform catalysis than the free, 
native enzyme. Full calculations are shown in section 4 of the Appendix II. 
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From the decay curve shown in Fig. 15 above, it can be determined that a dispersion of 
SPION where all nanoparticles bear an HRP moiety would show significantly less enzymatic 
activity (< 1 % relative to free HRP) than the enzyme-antibody system described here despite 
the similar sizes of a SPION (~ 8 nm) and an antibody (~ 10 nm). This supports the 
argument that it is not steric bulk that is limiting activity but another characteristic of the 
labelled nanoparticles such as an increased propensity to aggregate. 
Figure 19. Absorbance at 370 nm versus time for free HRP-trastuzumab conjugate. Error 
bars show standard error (n = 6). 
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3.3.4 Immobilisation of the HRP-trastuzumab conjugate via reductive amination 
It would be expected that immobilisation of the HRP-trastuzumab conjugate species onto 
SPION via the enzyme moiety’s sugar side chain would reduce the observed relative 
enzymatic activity. The enzyme molecule would essentially exist as a small crosslinking 
moiety between two large, sterically hindering bodies which would limit collision with 
substrate molecules. If the presence of protein on nanoparticles is increasing the drive to 
aggregation, then as the percentage of nanoparticles bearing a conjugate species increases, 
the effect on activity would be expected to be similar to that observed for HRP alone.  
Calculation of immobilisation stoichiometry 
Immobilisation was achieved following a modified version of the protocol described by 
Hermanson, analogously to experiments discussed above.1 It was again estimated that 1 mg 
of APTES@SPION contained 9.88 × 1014 ‘theoretical average’ nanoparticles as described 
above. Table 8 below shows how different theoretical reaction stoichiometries were 
achieved. 
116
V(APTES@SPION) 
/µL (conc. /mg.mL-1)
No. of nanoparticles V(Conjugate)
/µL (conc. /mg.mL-1)
No. of enzyme moieties Conjugate:nanoparticle 
ratio (% singly labelled)
200 (10) 1.98 × 1015 8.46 (1.32) 3.506 × 1013 1:56 (~ 2 %)
200 (10) 1.98 × 1015 16.92 (1.32) 7.012 × 1013 1:28 (~ 4 %)
200 (10) 1.98 × 1015 33.85 (1.32) 1.403 × 1014 1:14 (~ 7 %)
200 (10) 1.98 × 1015 42.30 (1.32) 1.753 × 1014 1:11 (~ 9 %)
200 (10) 1.98 × 1015 84.60 (1.32) 3.506 × 1014 1:6 (~ 17 %)
Table 8. Volumes of nanoparticle and HRP-trastuzumab conjugate (Mw = 192,400 Da) solutions and resulting conjugate:nanoparticle ratio (reductive 
amination method).
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Relative activities of immobilised enzymes
The functionalised particles were washed to remove excess reagents and centrifuged for 
collection. They were dispersed in buffer (1 mL), and an aliquot was diluted tenfold. 20 µL 
of these dispersions were used for activity measurements (performed in triplicate). Fig. 20 
shows the average changes in A370 observed over the time frame of the experiment. 
Figure 20. Absorbance vs. time for samples of nanoparticles having different percentages 
of immobilised HRP-trastuzumab conjugate (reductive amination method). Error bars 
show standard error (n = 3).  
The particles were qualitatively observed to have a greater tendency to precipitate out of 
solution than the HRP-conjugated species studied previously. Differences in observed rates 
between samples having the same initial stoichiometry may be a result of different degrees 
of aggregation and precipitation between the identically prepared samples. The difference in 
qualitative behaviour compared to the enzyme bearing particles prepared by reductive 
amination (discussed above) and the observed activity of the HRP moiety confirms the 
presence of the antibody. 
Table 9 below shows the observed rate per immobilised enzyme moiety for the above 
samples when compared to that of the free, native enzyme. From the lowest stoichiometric 
loading (approximately 2 % of nanoparticles bearing a conjugate species), it can be seen the 
activity of the HRP moiety is reduced further by immobilisation from 16.4 ± 0.3 % of that 
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of the free enzyme following conjugation to a mAb to 4.6 ± 0.54 % as a result of the enzyme’s 
active site being subject to greater steric hindrance. As the number of particle-protein 
conjugates in a sample increases, the value of relative activity for the enzyme moieties present 
decreases resulting in the decay curve observed in Fig. 21 with equation: 
The standard errors calculated and shown on the plot reveal that the differences in relative 
activity are significant, with the possible exception of the case where approximately 7 per 
cent of particles bear a conjugate but which may be omitted with limited effect on the 
observed trend. Plotting log10(relative activity) against log10(initial stoichiometry) yields the 
straight line in the inset figure with equation:  
The linear relationship displayed in the log-log plot allows the formula of the decay curve to 
be seen as a monomial where relative activity (y) is inversely proportional to the percentage 
of particles bearing a conjugate species raised to the power -0.66. The presence of a fractional 
power in the formula is indicative of the growing complexity of the system compared to the 
enzyme-bearing particles studied analogously above. In the current instance, the products 
can be envisioned as much larger entities with a greater propensity to aggregate and 
precipitate out of solution. Multiple factors contribute to the systems’ drive to aggregate; the 
value of -0.66 is likely arrived at due to the different contributions of these factors, the 
elucidation of which is beyond the scope of this work. Again, further experiments would be 
required for greater confidence in the absolute value of the index. 
Increasing the amount of particles bearing HRP-trastuzumab conjugates in a sample results 
in an increased likelihood of precipitation and a marked decrease in the ability of the enzyme 
moieties to function. It can be concluded that in terms of the reaction conditions and 
reagents reductive amination can be used to link antibodies to enzymes and the resulting 
conjugates to nanoparticles, but the stoichiometry of the immobilisation reaction is crucial 
to retaining biological functionality in the end product. A compromise must be struck 
between retaining functionality and maximising the number of biomolecules that are present 
in a nanoparticle population. 
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Enzyme:nanoparticle ratio 
(% singly labelled)
Observed rate ± S.E.
/ A.s-1 
No. of enzymes Rate per enzyme ± S.E.
/ A.s-1.enz-1 
Activity relative to freshly 
prepared, free HRP ± S.E. 
(%)
1:56 (~2 %) 8.39 ± 1.00 × 10-4 6.73 × 1010 1.25 ± 0.15 × 10-14 4.56 ± 0.54
1:28 (~4 %) 1.23 ± 0.05 × 10-3 1.39 × 1011 8.85 ± 0.36× 10-15 3.23 ± 0.13
1:14 (~7 %) 1.74 ± 0.33 × 10-3 2.28 × 1011 6.28 ± 1.44 × 10-15 2.29 ± 0.53
1:11 (~9 %) 1.56 ± 0.22 × 10-3 3.48 × 1011 4.48 ± 0.63× 10-15 1.64 ± 0.23 
1:6 (~17 %) 2.12 ± 0.08 × 10-3 7.01 × 1011 3.02 ± 0.11 × 10-15 1.10 ± 0.04
Table 9. Calculation of immobilised HRP-trastuzumab conjugate activity relative to the free species (reductive amination method).
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Figure 21. Relative activity plotted against percentage of nanoparticles bearing an HRP-
trastuzumab conjugates moiety. log10(activity) against log10(% nanoparticles singly 
labelled) shows a linear relationship (inset). Error bars show standard error (n =3).  
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3.4 Conclusion 
APTES@SPION can be bioconjugated by various methods to biomolecules of interest. 
Although monoclonal antibodies are of clinical significance, their successful immobilisation 
cannot be directly proven without prior modification. Enzymes can be used as prototypes 
for antibodies in method development; observing the activity of the enzyme shows its 
presence and can be used as gauge for the effect of the immobilisation method on the 
protein’s structure.
HRP immobilised on SPION using glutaraldehyde shows a loss of activity relative to the free 
enzyme of over 99 % across all percentage loadings studied. This technique would appear to 
be unsuitable for the immobilisation of antibodies; it would likely completely remove the 
ability of the antibody to bind its target. A major contributing factor to the observed loss 
would appear to be reaction via one of HRP’s few available amine groups. When HRP is 
conjugated to trastuzumab via an amine group, the activity of the conjugate is 16.4 % of that 
of the native free enzyme (a loss of 83.6 %). There is a negative effect on the active site 
and/or the ability of substrate to bind. This likely contributes to the poor activity retained 
when HRP is immobilised using glutaraldehyde, but is not the sole factor; the tightness of 
the binding or an enforced orientation may also be limiting functionality. 
Greater retention of the enzymatic activity of HRP is observed when conjugation to 
nanoparticles occurs through the sugar side chain; retained activity is higher when the 
number of protein-nanoparticles conjugates within a SPION population is low. As the glycan 
of trastuzumab is on the Fc region and away from the antigen binding site, immobilisation 
by reductive amination onto SPION would not be expected to prevent antigen binding. 
Keeping the number of immobilised biomolecules in a nanoparticle population low is 
desirable; the apparent decreased colloidal stability of SPION following HRP conjugation or 
HRP-mAb conjugation suggests that as biomolecule size increases, samples may be more 
likely to aggregate. Unfortunately, DLS studies did not yield representative data on the degree 
of aggregation within the different samples. 
The synthesis of the HRP-trastuzumab conjugate species demonstrates the successful 
bioconjugation of an antibody via the sugar side chain at Asn297. The immobilisation of 
HRP by reductive amination shows how immobilisation via a sugar group may have a limited 
effect on enzyme function when protein content in a sample is low. To confirm that an 
antibody immobilised on SPION via reductive amination would be able to specifically bind 
its target cell-surface receptor, in vitro cell-line studies are required. The synthesis of such 
conjugates and their in vitro and in vivo testing is discussed in Chapter 4. 
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Chapter 4: In vitro and in vivo validation of Trastuzumab-conjugated 
SPION 
4.1 Introduction 
The development of reproducible syntheses of biocompatible SPION with the ability to bear 
biomolecules discussed in the previous chapters was intended as a precursor to the in vivo use 
of radiolabelled SPION bearing a clinically relevant antibody. Initial experiments were 
required to optimise the fluorescent labelling of an antibody, which could be immobilised 
and then followed in vitro to observe its’ pharmacologic behaviour. In vitro validation led to 
the design of in vivo experiments using animal breast cancer models (mice bearing xenograft 
tumours). Finally, the radiolabelling of APTES@SPION described in Chapter 2 was 
increased in preparation for the in vivo following of the biodistribution of PET active FITC-
Trastuzumab-APTES@SPION. This introduction is intended to introduce the antibody 
being used and the techniques and equipment employed in each step from the bench to the 
pre-clinical PET scanner. 
4.1.1 Clinical use of Trastuzumab 
Genetic mutations within cancer cell nuclei often results in the overexpression of growth 
factors and growth factor receptors; the EGFR (epidermal growth factor receptor) family 
consists of four related species, of which Her-2 is of great importance. The overexpression 
of this receptor is relatively common in breast cancers (20-30 %) and is negatively correlated 
with prognosis and survival.1,2 Overexpression can occur at up to one hundred times that of 
healthy tissues and is common in a high proportion of both primary and metastatic tumour 
cells, making anti-Her-2 therapy a desirable route for clinical management.1
Trastuzumab is an FDA-approved recombinant humanised mAb that is indicated for the 
treatment of adjuvant and metastatic breast cancers shown in ex vivo assays to overexpress 
the Her-2 receptor, although correlations between measured Her-2 overexpression and 
trastuzumab therapy effectiveness are imperfect.3,4 Although costly, when trastuzumab 
therapy is effective its effects are profound; however severe side effects such as cardiotoxicity 
occur independently of administered dose4 and patients can exhibit or develop trastuzumab 
resistance.5 A more direct and effective method of assessing a patient’s likely response to 
trastuzumab therapies is needed if this antibody is to remain a viable clinical option 
worldwide. 
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The mechanism of action of Trastuzumab is still a subject of research, but it seems clear that 
it downregulates tumour growth via multiple pathways. All members of the EGFR family 
have extra-cellular domains to which ligands or antibodies can bind. It is proposed that 
Trastuzumab binds to the extracellular domain of Her-2 and prevents receptor dimerisation 
and receptor shedding while promoting antibody dependant cell-mediated cytotoxicity 
(ADCC) and endocytosis, all of which contribute to the dampening of Her-2 mediated cell 
proliferation.3 The specificity of Trastuzumab for the extracellular domain of the Her-2 
receptor and the considerable excess of the latter in cancerous tissues over healthy tissues 
render this antibody suitable for use in the development of immunoPET agents as discussed 
in Chapter 1.  
Radiolabelling of Trastuzumab- therapy and diagnostics 
As was discussed in Chapter 1, long half-life radiometals have become the preferred agents 
for the radiolabelling of antibodies due to the need to ‘match’ the long biological half-life of 
the mAb.6 Because of its notable clinical successes Trastuzumab is relatively commonly used 
in the development of radiopharmaceuticals using metal isotopes, examples of which are 
shown in Table 1.  
Radiometal 
used (half-life)
Method of labelling Clinical purpose Sources
111In (67.3 h) DTPA chelation SPECT imaging 7,8
86Y (14.7 h) DTPA chelation PET imaging 9
99mTc (6 h) Direct coordination SPECT imaging 10
89Zr (78.4 h) DFO chelation
DOTAGA chelation
PET imaging 11
12
64Cu (12.7 h) DOTA chelation PET imaging 13,14
212Pb (10.6 h) TCMC chelation Radiotherapy 15
177Lu (159 h) DOTA chelation Radiotherapy 16
Table 1. Selected examples of radiometals used to label Trastuzumab for imaging or 
therapeutic purposes. 
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The methods described in Table 1 all require the direct radiolabelling of the antibody, an 
approach which is inherently limited by the need to avoid altering the protein structure by 
the addition of coordinating groups.12 This could theoretically be circumvented by 
conjugating Trastuzumab to a single nanoparticle bearing multiple radioisotopes. 
Trastuzumab has been the subject of bioconjugation to SPION via various methods reported 
in the literature,17–19 but to date only one research group has reported radiolabelled, 
Trastuzumab bearing SPION, and radiolabelling of the antibody occurs post-
immobilisation.20–22 Radiolabelling of SPION with a long half-life radioisotope (such as 89Zr) 
followed by conjugation to Trastuzumab has not previously been reported in the literature. 
4.1.2 PET isotope production, handling and storage 
In the field of immunoPET, zirconium-89 is king. This isotope has near ideal decay 
characteristics for use in immunoPET imaging: a long half-life (t1/2 = 78.4 h), an acceptable 
percentage of beta decay (22.7 %) and low energy emitted positrons (396 keV, leading to 
higher resolution).23 The coordination of zirconium by DFO or by novel ligand systems 
conjugated to an antibody is commonly reported in the literature and numerous articles 
reviewing the field exist for the interested reader.23–25 Leaching of the isotope from complexes 
in vivo can result in bone sequestration leading to additional radiation exposure for patients, 
hence the need to develop improved methods of 89Zr administration.23 The methods 
described in Chapter 2 for the 89Zr radiolabelling of APTES@SPION bear more in common 
with the methods of arsenic- or germanium-labelling SPION reported by the Cai group,26,27
who also reported the zirconium labelling of mesoporous silica nanoparticles where 
deprotected silanol groups act as hard electron donors for the radiometal.28 When the ability 
of iron oxides to accept other metal ions into the lattice is considered, it would seem that 
studies of directly 89Zr-labelled SPION are long overdue.  
89Zr production and purification 
The production of 89Zr most commonly occurs from commercially available, stable 89Y foil 
that is irradiated with a high energy proton beam (≥ 14 MeV).23,29 The inclusion of a proton 
into the nucleus of 89Y converts the atom into unstable 89Zr (Fig. 1a) 
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Figure 1a. Simplified decay scheme for 89Zr (EC = electron capture, IT = isomeric 
transition).23 b. Simplified illustration of Cationic Ion Exchange chromatography. 
Purification of the radioisotope from starting materials or impurities arising from side 
reactions is achieved chromatographically by dissolving the 89Zr enriched target in dilute 
hydrochloric acid then applying the radioactive solution to a hydroxamate functionalised 
acidic ion-exchange resin, for which Zr4+ has higher affinity than Y3+ (Fig. 1b).30 Washing 
away the starting material leaves the product radioisotope bound; elution is achieved by the 
application of 1 M oxalic acid.29 Standard operating procedures can be defined for these 
procedures within an imaging centre (see Appendix I), which can standardise the efficiency 
and yield of production while minimising operator exposure time (see below). 
Safe handling and exposure limits 
The use of any radioactive material is strictly controlled and subject to legislation for the 
protection of the operator and the public at large. In the context of research, facilities must 
be provided that allows for the safe manipulation of radioactive material. While the levels of 
radioactivity present in a hot cell or the lab in general should be constantly monitored, it is 
important that all persons present (especially the primary operator) wear personal dosimeters 
at all times during experimentation to prevent over-exposure to radiation. For classified 
radiation workers, the legal exposure limit per annum is 20 mSv.31 Local rules are often 
enforced to prevent workers reaching this limit; in PETIC, University Hospital Wales, an 
ALARA (As Low As Reasonably Achievable) daily limit of 20 µSv is imposed where if the 
limit is reached or exceeded regularly, the operator is encouraged to reassess risk and their 
laboratory practice. For example, increasing distance from a radiation source reduces the 
received dose according to the relationship:32
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Minimising exposure time and maintaining appropriate shielding also protects the operator. 
Zirconium-89 requires thicker shielding than the purely positron emitting fluorine-18; the 
909 keV gamma rays emitted by the former have a half-value in lead of 10 mm.23
Radioactivity units 
Radioactivity can be measured in multiple units depending on context. The energy that 
radiation imparts to a biological absorbent is measured in Gray (Gy), where 1 Gy is equivalent 
to 1 J.kg-1. The unit of absorbed radiation dose is the Sievert (Sv) which is referenced against 
the biological impact of 1 Gy of X-rays. Dose rates are measured in Sv.h-1 and dosimeters 
can be calibrated to give an alarm if a safe dose rate is exceeded.32
From an experimental perspective, the Becquerel (Bq) is used as the SI unit of radioactivity 
and is equivalent to 1 disintegration per second (and this linked to half-life). The measured 
activity, A, of a radiolabelled sample can be related to the number of radioisotopes present 
N:  
Because radioactive decay follows a natural logarithm, the half-life (t1/2) of an isotope in 
seconds relates to the decay constant λ by:
The number of radioisotopes can also be related to the mass of a radiotherapeutic or 
radiodiagnostic agent in terms of the Specific Activity (S) in units of Bq/g: 
Where mradio is the mass of the agent. Specific activity should ideally be high for radioimaging 
because a smaller molar quantity of the agent will be required to meet detection limits, 
limiting potential toxicity.32
4.1.3 Cell culture and xenotransplantation 
A thorough exploration of the theory and practice of in vitro cell culture in medical research 
is not appropriate to the current discussion but a brief overview is necessary to contextualise 
the experimental approach taken below. The in vitro maintenance of a healthy population of 
cells derived from living tissue requires careful attention to several key factors: 
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 The initial population must be pure and sterile (i.e. a monoculture) 
 Experimental conditions are optimised for growth of cells 
 Appropriate aseptic technique is used at all times to protect the cells. 
Typically, cells that express a particular disease characteristic (e.g. the Her-2 over-expressing 
cell line BT-474 or the ‘triple negative’ cell line MDA-MB-468)33 may be purchased in a sterile 
form from commercial suppliers and stored frozen prior to use.34 Similarly, a range of culture 
media (which provide nutrients for cell growth and protective broad-spectrum antibiotics) is 
available to purchase or may be prepared as needed and can be sterilised to avoid the 
introduction of competitive bacteria into cell culture. Assuming the use of suitable equipment 
and facilities such as cell culture hoods, incubators and non-porous surfaces (discussed 
below), the main concern of researchers practicing cell culture is ensuring aseptic technique. 
Cell culture equipment 
Initial choice of cell-line is dictated by the nature of the research question. Once a cell-line is 
selected, an initial population is taken from storage (typically at -78 °C) and resuscitated, then 
transferred to a disposable vessel of tissue-culture grade plastic and given an appropriate 
volume of a suitable media. All cell manipulations occur under sterile conditions in a laminar 
flow hood.32 There are three types of hood, designated Class I, II and III; while a Class I 
hood would be familiar to the chemist, Class II hoods are more commonly used in tissue 
culture as they provide protection to the operator and to the cells as air drawn into the hood 
is sterilised using a High Efficiency Particulate Air (HEPA) filter prior to being blown onto 
the cells. Class III hoods are sealed from the outside environment to maximise operator 
protection. 
All surfaces inside the hood are made from non-porous metals and plastics and are sterilised 
before and after use with 70 % alcohol or 70 % methylated spirits. The operator wears 
appropriate PPE while working in the hood and sterilises their hands using the same 
alcoholic solution. 
Once work in the hood is completed, the culture vessel is closed and transferred to a water 
jacketed incubator. Environmental conditions inside the incubator are optimised for cell 
culture growth by maintaining a temperature of 37 °C, constant humidity, and CO2-enriched 
air (5-10 %). The cells are incubated while they fix to the vessel surfaces and divide until they 
reach a maximum surface coverage. Sub-culturing may be required to maintain growth rates. 
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This is often performed using the proteolytic enzyme trypsin which breaks the bonds 
between cells and the vessel walls, allowing for the transfer of cells.32
Cell cultures may be monitored using optical microscopy, from which much information can 
be derived; cellular stress responses (e.g. to sub-optimal conditions, lack of nutrients or 
infection) can be observed and counter-acted rapidly. Throughout the culture stage, the cells 
should be checked and the media replaced regularly to encourage growth. 
Aseptic technique 
The first consideration when performing experimental manipulations under sterile 
conditions is the cleanliness of the facilities; as discussed, cleaning all surfaces inside a Class 
II fume hood ensures a clean working environment. All media should be prepared in such 
an environment and all equipment such as pipettes, pipette tips, centrifuge tubes and other 
vessels should be clean and autoclaved prior to use. All waste, spillages or excess reagents 
should be disposed of rapidly and the operator should ensure the cleanliness of their hands 
and lab coat prior to entering the hood.  
It is sometimes necessary to perform sterile work at the bench. For example, in the 
experiments discussed below, the preparation of antibody-nanoparticle conjugates could not 
be performed in a dedicated sterile lab. In this case, sterility inside the reaction vessel was 
obtained by virtue of the reagents present (e.g. sodium cyanoborohydride, ethanolamine) and 
maintained during washing by the use of buffers that had been sterilised in an autoclave. All 
manipulations were carried out in close proximity to a Bunsen burner on an orange flame. 
The flame destroys local airborne contaminants and creates a protective updraft.  
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Cell counting and viability 
When a cell culture is ready to use, the sample will be observed microscopically to check for 
any issues in the health or behaviour of the cells, the cells will be counted and the viability of 
the sample determined (the percentage of live cells present in the total population). These 
steps are commonly performed using a haemocytometer, in which a sample of the cell culture 
of known volume is transferred to a cell following incubation with a dye that colours dead 
or dying cells.32 A haemocytometer is a glass slide of known volume bearing an etched grid. 
Each square of the grid represents a volume of 0.1 mm3 and the number of cells present in 
this volume can be determined microscopically, allowing for a calculation of cells per unit of 
volume and the total number of cells in a sample of culture suspension. Within this number, 
the number of dead cells can be determined following incubation with a dye (e.g. Trypan 
blue or DAPI) which stains the nuclei of dead cells a different colour to those of living cells.35
The proportion of living cells in a sample is expressed as a percentage quantity referred to as 
cell viability, which can be useful in quantifying how the presence of a drug species or exposure 
to unfavourable conditions affects the well-being of a cell culture. Cell counting and cell 
viability assays can be performed together automatically with appropriate equipment.36
Figure 2a. Haemocytometer grid with a set of 16 squares for counting highlighted.37 b.
DAPI, a fluorescent stain that preferentially binds to DNA in dead cells; it is excreted by 
living cells.38
Xenotransplantation 
Xenotransplantation is the transfer of living cells, tissues or organs from one species into 
another. The ability to use animals as models for human diseases has been crucial in the 
development of drugs and therapies. They provide pharmacologic and toxicological 
information which can guide research prior to trials in human disease models, although their 
predictive power is disputed.39–41 Rodent models are commonly used in research due to their 
small size, short breeding cycle and limited cost, with the favoured model, mice, being 95 % 
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identical to humans on the genomic level.39 Within breast cancer research, the implantation 
of human breast cancer cells into immunocompromised mice is a common method of 
investigating the pathology of the disease, often viewed as the gold standard for therapy 
development.42 Cells from immortal cell lines are commonly used, although the use of cells 
taken directly from a human patient (patient-derived xenografts) is also possible.43 The use 
of immuno-deficient mice is necessary to ensure xenograft survival by limiting rejection of 
the foreign cells. In the experiments described below nude (nu) mice are used which are 
athymic and consequently have few or no T-cells which contribute to antibody formation 
and graft rejection.44,45 The most frequently used method of xenotransplantation is the 
subcutaneous injection into a mouse of a population of cancerous cells suspended in media 
such as Matrigel, an extracted protein from a murine cancer that is fluid at 4 °C but gels at 
physiological temperatures. The gelling of Matrigel increases the likelihood that the injected 
cells will ‘take’ and develop into a solid tumour in vivo.46
Once xenotransplantation has occurred, the mice must be kept in sterile conditions and cared 
for while the tumours grow. As part of the ethical guideline imposed on the use of animals 
in research, it is important to prevent pain and suffering and so regular checking on the 
overall health of the animals as well as the development of the tumour must be carried out. 
When undue suffering is identified e.g. the tumour has become necrotic, infected or is 
severely reducing motility, it is important that the animal in question is euthanised humanely 
as soon as possible.47 Experimental approaches often allow tumours to grow either for a 
defined period of time or until they reach a defined physical parameter e.g. volume in an 
effort to prevent this.48,49
Small animals bearing xenotransplant tumours can be administered PET contrast agents and 
imaged in ‘pre-clinical’ PET-CT scanners in an effort to bridge the gap between in vitro
validation and use in larger animals and humans.50,51 Care must be taken throughout with 
regards to anaesthesia and environmental conditions; rodents can die within minutes of 
hypothermia.52 As in clinical PET-CT scanners, the overlay of the location of annihilation 
events onto a reconstructed anatomical image allows for the following of the radioagent 
through the body, and the extraction of data from defined regions of interest (typically 
organs).52,53
4.1.4 Fluorescence- dyes, microscopy and FACS for in vitro cell studies 
To confirm the retention of antibody specificity following modification (e.g. bioconjugation 
to nanoparticles) requires the use of cell lines expressing the target antigen; for Trastuzumab, 
BT-474 (Her-2 overexpressing) cells are used. The binding of antibody and antigen can be 
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visualised directly when the antibody is fluorescently labelled, allowing the use of 
fluorescence microscopy and Fluorescence Activated Cell Sorting (FACS). 
Fluorescence is one of a number of luminescent processes by which a molecule can emit 
light when it relaxes from an electronically excited state (ES) to a ground state (GS) (see Fig. 
3). Because fluorescence imaging is most commonly used in cell studies, other luminescent 
processes will not be discussed in detail. Fluorescence occurs when the excited electron is 
spin paired to the ground state electron, relaxation is spin allowed and relaxation is fast  (less 
than 10 ns).54
Figure 3. Jablonskii diagram showing the energy levels and transitions available for 
fluorophores (IC = internal conversion, ISC = inter-system crossing). Adapted from 
multiple sources.32,54
A molecule at room temperature will typically be in a low electronic (S0) and vibrational 
energy level (v0). The absorption of a photon of light with energy hva will excite an electron 
to occupy any of a number of discrete higher electronic and vibrational levels.32 Vibrational 
relaxation to the ground vibrational level of S1 (i.e. S1vo) occurs rapidly (picosecond timescale) 
by non-radiative processes called Internal Conversion (IC).55 Further non-radiative transition 
from S1 to S0 can occur due to external factors (e.g. quenching, discussed below). The 
radiative relaxation of the electron from S1 to S0 can occur by the emission of a photon with 
energy hvf; this is fluorescence emission. Because energy is lost from the system due to IC, 
the emitted photon has a longer wavelength than the absorbed photon, a shift towards the 
red end of the spectrum referred to as a red, bathochromic or Stokes shift.55 The Stokes shift 
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is crucial to emission based technologies because it allows for the use of optical filters to 
prevent excitation wavelengths reaching the detector, decreasing the background against 
which fluorescence is detected.55 The average time taken for an excited electron to relax back 
to the ground state by fluorescence is known as the fluorescence lifetime (τ). The ratio of 
total photon emission over total photon absorption is called the Quantum Yield (Φ), and 
ranges from 0 to 1 as a measure of the fluorophore’s efficiency. An ideal fluorophore for 
biomolecule labelling will have a large Stokes shift, a lifetime on the order of nanoseconds 
and a high quantum yield, all of which aid in the in vitro detection of the species.56
Fluorophore design, selection and photophysical characteristics 
Fluorophores are comparatively rare because most molecules are structurally flexible and 
have vibrational energy levels of the electronic ground state that overlap with the vibrational 
energy levels of the excited state, permitting complete relaxation by non-radiative transitions. 
Most commercially available organic fluorescent dyes have rigid aromatic ring systems that 
prevent this overlap (see Fig. 4).32 A dye’s photophysical and chemical properties can be 
changed by exchanging functional groups around the fluorescent core to optimise their utility 
in different applications. The reactive groups present on the dyes will be familiar from the 
discussion of bioconjugation techniques in Chapter 3. 
Figure 4. Several commercially available fluorescent dyes commonly used in 
bioconjugation. Analogues bearing different reactive groups for different coupling 
methodologies are available.56
FITC (Fluorescein isothiocyanate) is one of the most commonly employed amine-reactive 
dyes for labelling biomolecules; although it is prone to photobleaching (irreversible loss of 
fluorescence due to chemical changes brought on by excitation),55 it’s photophysical 
properties, aqueous solubility and well-understood reactivity make it an excellent dye for 
initial research. Several general protocols for antibody labelling with FITC exist, but 
modification is required for each biomolecule to optimise the degree of labelling (the F/P 
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ratio).56,57 This can be determined spectroscopically from the ratio of the absorbance of the 
protein at 280 nm and the fluorophore at 495 nm for FITC-IgG conjugates: 
Having selected an appropriate fluorophore, the potential for quenching in the final species 
should be considered. Quenching is the reduction of fluorescence emission intensity, most 
commonly due to contact and energy transfer between the excited molecule and another 
species (collisional quenching). This can be due to dye-dye interactions at high degrees of 
substitution on a protein,56 the presence of molecular oxygen in solution55 or the action of 
uncoated iron oxide nanoparticles.58 Coated, stabilised SPION have little quenching effect 
on fluorophores, so it is more important to ensure that the F/P ratio is optimised to 
maximise emission intensity while avoiding self-quenching or the altering of the 
biomolecule’s structure and functionality. A ‘rule of thumb’ is between two and five 
fluorophores per biomolecule is acceptable, depending on the fluorophore.59
Fluorescence microscopy 
Fluorescence microscopy is commonly used to visualise fluorescence occurring in cell 
cultures or in thin tissues. Naturally non-emissive cells can be observed to fluoresce following 
incubation with dyes or dye-bearing biomolecules and appropriate excitation. This allows for 
greater signal-to-noise ratios than are available using conventional microscopy.53 Two 
commonly used forms are epifluorescence (or conventional fluorescence) and confocal 
fluorescence microscopy, of which the former is relevant here.53 Briefly, a light source is used 
to illuminate a sample, but with the use of a filter that only lets light with the appropriate 
excitation wavelength through. This reflects off a dichromatic mirror and is focussed on the 
subject by the objective lens. The emitted light has a longer wavelength and passes through 
the dichromatic mirror and an emission filter so that the emitted light is the only signal that 
forms an image.32 By this method, the binding of a fluorescently labelled antibody to a cell 
surface receptor can be visualised directly. 
FACS 
Fluorescent Activated Cell Sorting (FACS) is a technique used to sort live cells based on their 
fluorescence properties. This occurs by use of a flow cytometer, where cells in an aqueous 
medium are taken up, aerosolised and passed individually through a chamber where they are 
excited with light (Fig. 5). The light that is scattered, reflected or emitted by a cell is used to 
profile it and used to trigger electromagnetic sorting of cells into populations.32 Light 
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scattered forwards of the incident light beam is deemed ‘Front Scatter’ and gives an 
indication of cell or particle size; light scattered at 90 ° to the incident light beam (‘Side 
Scatter’) increases with cell internal granularity and the ‘roughness’ of the cell surface.60 This 
allows not only the type of cells present in a mixture to be identified but also allows live cells, 
debris, and other solid materials (e.g. nanoparticles) to be distinguished from one another. 
The presence of a fluorophore on a cell can be determined by irradiating at a suitable 
excitation wavelength and observing for emission indicative of the fluorophore. 
Figure 5. Simplified illustration of FACS. Cells are pumped into a conductive fluid sheath 
of buffered saline that is broken into droplets by vibration. The flow chamber charges the 
droplets, allowing for deflection when passing through the charged plates to achieve 
sorting. Profiling from front scatter, side scatter and fluorescence determine how cells 
are sorted. Adapted from multiple sources.32,60,61
FACS analysis can be based on multiple parameters such as front scatter, side scatter and 
fluorescence. Raw data for a sorted cell population is typically expressed as a dot-plot (or 
two-parameter histogram) of front scatter against side scatter for each cell studied; it is 
therefore the operator’s responsibility to determine the identity of observed groupings (by 
use of control and reference populations) and select sub-populations for further analysis (e.g. 
excitation to confirm fluorescent labelling) by gating.62 Because of the flexibility in 
experimental design, FACS is a common method for the observation of antibody binding in 
vitro with single cell resolution. 
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4.1.5 Aims and objectives 
This introduction has encompassed a broad range of topics needed to contextualise the 
experiments below. Direct relevance has taken precedence over depth for the sake of brevity, 
as is often necessary for experiments spanning multiple disciplines. Further information may 
be found in the referenced works.  
Methods of synthesising biocompatible SPION which could be radiolabelled efficiently are 
discussed in Chapter 2, while Chapter 3 details the design and study of bioconjugate species 
based on these particles. The aim of the current work was to combine and develop these 
previously described approaches. Initial efforts were focussed on achieving the fluorescent 
labelling of trastuzumab and its’ immobilisation by reductive amination on SPION. 
Incubation with breast cancer cell lines in vitro followed by FACS analysis and fluorescence 
microscopy was intended to show the retention of specificity by the mAb for the Her-2 
receptor. Finally, the synthesis of analogous bioconjugates based on 89Zr-labelled SPION 
preceded in vivo experiments utilising small animal cancer models that were intended to show 
directed contrast in the case of mice bearing Her-2 overexpressing solid tumours following 
administration of mAb-bearing SPION.  
Additional Experimental Section II details related work exploring the potential use of novel 
naphthalimide dyes for labelling antibodies. The synthesis and characterisation of the dyes in 
question is included, along with an exploration of the failure to achieve suitable levels of 
bioconjugation.  
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4.2 Experimental 
4.2.1 Material and methods 
Reagents were commercial grade and were used without further purification. All reagents 
and solvents were purchased from Alfa Aesar or Sigma Aldrich. Pharmaceutical grade 
Herceptin® was obtained by kind gift of Velindre Hospital, Cardiff, Wales. UV-Vis studies 
were performed on a Jasco V-570 spectrophotometer as solutions (5 × 10-5 M) in CHCl3 or 
H2O. Photophysical data was obtained on a JobinYvon-Horiba Fluorolog spectrometer 
fitted with a JY-TBX picoseconds photodetection module as CHCl3, H2O or DMSO 
solutions. Emission spectra were uncorrected and excitation spectra were instrument 
corrected. The pulsed source was a Nano-LED configured for 355 nm output operating at 
1 MHz. Luminescence lifetime profiles were obtained using the JobinYvon-Horiba 
FluoroHub single photon counting module and the data fitted using DAS6 deconvolution 
software. BT-474 and MDA-MB-468 cells were obtained by kind gift from the Smalley 
group, Cardiff School of Biosciences. Cell counting and viability assays were performed on 
a Chemometec Nucleocounter NC-200. Flow cytometry was performed on a BD FACSAria 
Fusion and analysed using BD FACSDiva 8.0.1. Fluorescence microscopy was performed 
and analysed on a Bio-rad ZOE fluorescent cell imager. All animal experiments were 
performed under protocols approved by the Cardiff School of Biosciences and Cardiff 
School of Medicine. PET of tumour bearing mice was performed on a pre-clinical Mediso 
Nanoscan PET/CT and analysed using VivoQuant V2.50(patch 1) to obtain imaging region-
of-interest (ROI) derived percentage of activity. 
4.2.2 Synthesis and analytical techniques 
FITC-labelling of Trastuzumab (1) 
Figure 6. Simplified synthetic scheme for FITC-labelling of Trastuzumab. F/P ratio 
scales linearly with initial fluorophore excess. i) Overnight, 4 °C, H2O. 
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Trastuzumab was dissolved in 0.1 M sodium carbonate buffer at pH 9.0 (5.0 mg.mL-1). FITC 
was dissolved in dry DMSO (1.0 mg.mL-1). The FITC solution was added to the antibody 
solution at 200 µL per 1 mL in the dark, achieving a 15-fold excess of the fluorophore. The 
reaction was mixed overnight at 4 °C. Excess reagent was quenched by the addition of NH4Cl 
to a concentration of 50 mM. The reaction mixture was purified by size exclusion 
chromatography on a PD-10 column, equilibrated with 10 mM sodium phosphate buffer, 
0.15 M NaCl, pH 7.2. Protein concentration was monitored via A280, and the most 
concentrated fractions were combined and concentrated to ~10 mg.mL-1 for storage. UV-
Vis spectrometry showed an F/P ratio of 4.2. Emission (H2O): λem = 520 nm (3.40 ns, χ2 = 
0.91).
Immobilisation of FITC-Trastuzumab on APTES@SPION (2) 
Figure 7. Simplified synthetic scheme for the immobilisation of FITC-Trastuzumab on 
APTES@SPION by reductive amination. i) NaIO4, H2O, RT, 20 min. ii) APTES@SPION, 
H2O, RT, 2 h. iii) NaCNBH3, RT, 30 min. 
FITC-Trastuzumab (Mw ~ 150 kDa) (1) was dissolved in 10 mM sodium phosphate buffer, 
0.15 M NaCl, pH 7.2 (10 mg.mL-1). NaIO4 (22 mg) was dissolved in H2O (1 mL) in the dark. 
100 µL of the periodate solution was added per 1 mL of protein solution. The mixture was 
allowed to react for 20 min at room temperature in the dark. Excess periodate was quenched 
by addition of a 2.5-fold excess of Na2SO3. The oxidised antibody species was isolated by 
size exclusion chromatography on a PD-10 column, equilibrated with 100 mM sodium 
phosphate buffer, 0.15 M NaCl, pH 7.2.  The most concentrated fraction was determined by 
monitoring A280, and suitable volumes were added to an aqueous dispersion of 
APTES@SPION (10 mg.mL-1) to achieve a desired percentage of nanoparticles bearing an 
antibody conjugate (see Results and Discussion). The reaction was mixed for 2h at room 
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temperature in the dark. The imine formed was reduced to a secondary amine by the addition 
of 5 M NaCNBH3 in 1 M NaOH (10 µL per 1 mL) and allowed to react for 30 min. Excess 
NaCNBH3 was quenched by the addition of 1 M ethanolamine, pH 9.6 (50 µL per 1 mL) 
and allowed to react for 30 min. The particles were collected by centrifugation (1 min, 1000 
rpm) and washed with 10 mM sodium phosphate buffer, 0.15 M NaCl, pH 7.2 (5 × 1 mL). 
The particles were dispersed in 10 mM sodium phosphate buffer, 0.15 M NaCl, pH 7.2 (1 
mL) for storage. Emission (H2O): λem = 520 nm.
FITC-APTES@SPION (3)
APTES@SPION was dispersed in H2O (10 mg.mL-1). FITC was dispersed in DMSO (1 
mg.mL-1). 11.5 µL of the fluorescent dye solution was added per 1 mL of nanoparticles, 
achieving an approximately two-fold excess. The solution was mixed and allowed to react at 
room temperature for 2 h. Excess FITC was quenched and the particles precipitated by the 
addition of 1 M ethanolamine, pH 9.6 (50 µL per 1 mL). The precipitated particles were 
collected by centrifugation (1 min, 1000 rpm) and washed with 10 mM sodium phosphate 
buffer, 0.15 M NaCl, pH 7.2 (5 × 1 mL) to give the title compound as a black solid. UV-vis 
(H2O): λmax = 495 nm. Emission (H2O): λem = 519 nm.
Cell culture and flow cytometry (FACS analysis) 
BT-474 cells (Her-2 overexpressing, Trastuzumab sensitive) were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) until near confluence. The media was removed, and 
DMEM (1.5 mL) with Trypsin (0.05 %) was added and incubated at 37 °C for 5 min to free 
cells from the container surface. Excess trypsin was quenched by addition of DMEM (15 
mL) and the media filtered with a 40 µm filter to remove cell aggregates. The cells were 
collected by centrifugation (5 min, 1200 rpm). The supernatant was removed and L-15 media 
(10 % serum, 0.0001 % DAPI) added to achieve a concentration of ~5 × 105 cells.mL-1. 
FITC-Trastuzumab-APTES@SPION (10 mg.mL-1) was added in excess (500 µL per 1 mL 
of cell media). The reaction mixture was incubated with mixing for 30 min at 37 °C and then 
analysed by flow cytometry. MDA-MB-468 (negative control) cells were treated analogously, 
but for initial growth in RPMI media. Control experiments were performed analogously but 
for the use of FITC-APTES@SPION. 
Synthesis and purification of 89Zr from 89Y foil 
Adapted from the method described by Walther et al.29 and developed into Standard 
Operating Procedures within PETIC, School of Medicine, Cardiff University (see Appendix 
I). Briefly, an 89Y solid target was placed in an Al support in a cyclotron, and was irradiated 
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with protons to form a 89Zr-enriched foil. The foil was delivered into an appropriately set-
up hot cell and its activity noted at the time of delivery. The foil was placed in a glass beaker 
and 2 M HCl (3 × 2 mL) was added slowly. Effervescence subsided to reveal a turbid grey 
solution. H2O2 (0.1 mL) and 6 M HCl (0.5 mL) was added to complete dissolution. The 
solution was heated to boiling point for 15 min then allowed to cool to room temperature. 
The solution was delivered by syringe to a lyophilised, hydroxamate functionalised ion 
exchange column. The column was washed with 2 M HCl (6 × 2 mL) to remove excess 89Y 
and by-products then washed with H2O (2 × 2 mL). 1 M oxalic acid solution was applied to 
the column as three fractions of 0.5 mL, 0.5 mL and 1.5 mL, yielding three fractions of 89Zr 
oxalate, of which the latter was observed to contain the majority of the radioactivity. 
89Zr-labelled APTES@SPION (4) 
Figure 8. Experimental set-up for 89Zr labelling of APTES@SPION.  Care must be taken 
to arrange hot cell interior prior to introduction of radiation to facilitate ease of 
manipulation. 
89Zr oxalate solution (1.5 mL) was brought to pH 7 by addition of saturated Na2CO3 solution. 
FeCl3.6H2O (0.135 g, 0.5 mmol) and FeCl2.4H2O (0.050 g, 0.25 mmol) was dissolved in the 
89Zr oxalate solution (1 mL, 802 MBq). 5 M NaOH (0.5 mL) was added, and the solution 
mixed at 25 °C for 5 min. The black precipitate was collected by use of a permanent magnet 
and washed with distilled H2O until the washings were measured to be pH 7. As much 
solvent was removed as was possible via pipette. Glycerol (0.3 mL) was added. APTES (80 
µL) and glacial acetic acid (80 µL) was added to H2O (0.72 mL) and then added to the glycerol 
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suspension of bare nanoparticles. The reaction mixture was heated at 75 °C for 3 h. Upon 
cooling, H2O (5 mL) was added and the reaction mixture poured into MeCN (10 mL) to 
cause precipitation. The particles were collected magnetically and washed with fresh MeCN 
(3 × 5 mL). Dispersion, precipitation and washing was repeated and the particles were dried 
in air inside the hot cell to give the title compound (15.8 mg, 108.4 MBq, 13 % recovery of 
activity, S = 6.86 GBq.g-1). A significant mass of particles was lost during washing and 
manipulation.  
Immobilisation of FITC-Trastuzumab on 89Zr-labelled APTES@SPION (5)
FITC-Trastuzumab (1) was dissolved in 10 mM sodium phosphate buffer, 0.15 M NaCl, pH 
7.2 (10 mg.mL-1). NaIO4 (22 mg) was dissolved in H2O (1 mL) in the dark. 100 µL of the 
periodate solution was added per 1 mL of protein solution. The mixture was allowed to react 
for 20 min at room temperature in the dark. Excess periodate was quenched by addition of 
a 2.5-fold excess of Na2SO3. The oxidised antibody species was isolated by size exclusion 
chromatography on a PD-10 column equilibrated with 100 mM sodium phosphate buffer, 
0.15 M NaCl, pH 7.2.  The most concentrated fraction was determined by monitoring A280
and suitable volumes were added to an aqueous dispersion of 89Zr-labelled APTES@SPION 
(10 mg.mL-1, 1 mL, 65.8 MBq) to achieve the desired percentage of particles bearing an 
antibody (see Results and Discussion). The reaction was mixed for 2h at room temperature 
in the dark. The imine formed was reduced to a secondary amine by the addition of 5 M 
NaCNBH3 in 1 M NaOH (10 µL per 1 mL) and allowed to react for 30 min. Excess 
NaCNBH3 was quenched by the addition of 1 M ethanolamine, pH 9.6 (50 µL per 1 mL) 
and allowed to react for 30 min. The particles were collected by centrifugation (1 min, 1000 
rpm) and washed with 10 mM sodium phosphate buffer, 0.15 M NaCl, pH 7.2 (5 × 1 mL). 
The particles were stirred in 10 mM sodium phosphate buffer, 0.15 M NaCl, pH 7.2 (5 % 
EtOH, 2 mL., 60.4 MBq) overnight at room temperature.  
In vivo biodistribution of radiolabelled SPION 
Animal studies were conducted in accordance with institutional guidelines. Twelve female, 
nude mice of similar age and weight were selected for inclusion in an in vivo study. BT-474 
(Her-2 overexpressing, ‘positive’) cells and MDA-MB-468 (‘negative’) cells were cultured on 
Matrigel at 4 °C (~5 × 106 cells/ 100 µL media). Random selection of the mice gave two 
populations of six for use respectively as a ‘positive group’ and as a ‘negative group’. 100 µL 
of the relevant Matrigel suspension was delivered via subcutaneous injection to the right 
flank of each mouse. The tumours were allowed to grow for 30 days with regular checking 
143
of the tumour size and overall health of the animals prior to the administration of the drug 
agents. 
89Zr-labelled APTES@SPION (4) was dispersed with mixing in sterile 10 mM sodium 
phosphate buffer, 0.15 M NaCl, pH 7.2 (2 mL) overnight as was the FITC-Trastuzumab-
89Zr-labelled APTES@SPION (5) in pH 7.2 buffer solution. Both samples were allowed to 
stand with no mixing for 30 min. Upon settling, undissolved aggregates were removed and 
the supernatant collected. Dissolution in both cases was observed to be poor. The 
supernatants were diluted to obtain solutions suitable for injection with activity of 
approximately 0.03 MBq per 100 µL injection volume. 200 µL of the appropriate nanoparticle 
solution (~0.06 MBq) were injected into each mice via the tail vein. PET-CT scans of the 
mice were taken at regular intervals over 7 days in a small animal PET-CT scanner. The 
health of the animals was monitored over this period and where appropriate they were 
sacrificed via typical humane methods. The PET scans were subjected to region of interest 
analysis to determine distribution of the nanoparticles in vivo. At the end of the experimental 
period, all remaining mice were euthanised humanely. 
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4.3 Results and discussion 
4.3.1 FITC labelling of trastuzumab 
The fluorescent labelling of the clinically used antibody Trastuzumab in different amounts 
was achieved by the use of different initial excesses of the dye FITC. The protocol used was 
based on a general procedure described in Bioconjugate Techniques;56 initial experiments yielded 
a conjugate species with an F/P value of approximately 2. Subsequent CD analysis (see 
below) showed that a higher F/P was desirable to maximise fluorescent signal from the 
immobilised species and could be achieved with little effect on protein structure. F/P for a 
FITC-IgG conjugate can be determined by:57
Increasing the initial excess of FITC over the antibody species results in a near linear increase 
in the F/P value derived from post-purification spectroscopic analysis (Table 2 and Fig. 9). 
Volume of FITC      
(1 mg.mL-1) added 
per mL mAb 
(5 mg.mL-1) / µL
FITC:mAb 
molar excess
A280(Product) 
/ A
A495(Product) 
/ A
F/P ratio
100 7.5 0.405 0.235 2.0
150 11.25 0.421 0.327 3.0
200 15 0.438 0.419 4.0
Table 2. Table showing how F/P ratio of product FITC-Trastuzumab conjugate varies 
with initial stoichiometric excess. 
The emission spectra of all FITC-trastuzumab conjugates were essentially identical with no 
observed effect of increasing F/P on the species’ photophysical properties (Fig. 10). 
Excitation at 495 nm results in an emission profile with maxima at 520 nm (as expected for 
any FITC-bearing species) and a lifetime of 3.40 ns (χ2 = 0.91).  
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Figure 9. UV-vis spectra of FITC-Trastuzumab conjugates with F/P values of 2 (blue), 3 
(orange) and 4 (grey). 
Figure 10. Example excitation (red) and emission spectra (blue) for FITC-Trastuzumab 
conjugates. Wavelengths below 505 nm were not measured due to the excitation 
wavelength used (λex = 495 nm). 
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UV-vis and fluorescence spectroscopy confirmed the success of the reaction methodology 
and the suitability of FITC as a fluorescent dye on Trastuzumab but gave no indication of 
the effect of labelling on protein tertiary structure. This was investigated by CD spectroscopy 
(see Chapter 3). It is generally accepted within the field of bioconjugation that fluorescently-
labelling a protein will have no substantive effect on protein structure or function as long as 
the number of fluorophores is limited,59 and this is supported by the spectra shown in Fig. 
11. By comparison to the spectra of clinical grade Trastuzumab, the conjugate species gave 
profiles with near identical lineshapes, suggesting little to no change in the protein’s tertiary 
structure as a result of FITC-labelling. These conjugates would be expected to bind to Her-
2 overexpressing cells and would be interesting moieties to immobilise on APTES@SPION. 
Figure 11. CD spectra of trastuzumab and FITC-conjugate species with differing values 
of F/P. The line shapes of the conjugate species are similar to that of the free antibody, 
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4.3.2 Immobilisation of FITC-Trastuzumab on APTES@SPION and the synthesis 
of FITC-APTES@SPION as a control species 
The immobilisation of FITC-Trastuzumab onto APTES@SPION was achieved via the 
reductive amination method discussed in Chapter 3. It was determined that the effect of 
immobilisation on protein function could be minimised by keeping the percentage of 
bioconjugated particles in a sample low. A compromise must however be found between the 
retention of function, and ensuring that a sufficient number of protein moieties are present 
in a sample population that a measurable degree of binding can be determined by FACS. To 
this end, the percentages shown in Table 3 (next page) were selected based on previous 
findings (see Chapter 3) and were subsequently found via FACS analysis to be suitable. In all 
cases, a FITC-Trastuzumab conjugate with an F/P of 4 was immobilised. Experiments to 
yield both theoretical immobilisation ratios were performed in triplicate and analysed 
independently. To act as a control species in flow cytometry experiments (i.e. to check for 
non-specific binding or uptake of nanoparticles to cells), FITC-APTES@SPION were 
synthesised (see Table 4). Aqueous dispersions of FITC-Trastuzumab-APTES@SPION and 
FITC-APTES@SPION were analysed to confirm their fluorescent properties (Fig. 12). 
Analysis showed near identical emission spectra and it was concluded that the synthesised 
particles were suitable for flow cytometry experiments.  
Figure 12. Emission spectra for FITC-Trastuzumab-APTES@SPION conjugates (2 % 
(blue) and 4 % (orange)) and FITC-APTES@SPION (grey). Wavelengths below 505 nm 
were not measured due to the excitation wavelength used (λex = 495 nm).
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V(APTES@SPION) /µL 
(conc. /mg.mL-1)
No. of nanoparticles V(FITC-mAb)
/µL (conc. /mg.mL-1)
No. of conjugates Conjugate:nanoparticle ratio 
(% singly labelled)
200 (10) 1.98 × 1015 3.5 (2.80) 3.96 × 1013 1:50 (~2 %)
200 (10) 1.98 × 1015 7.1 (2.80) 7.92 × 1013 1:25 (~4 %)
Table 3. Volumes of nanoparticle and FITC-Trastuzumab solutions used and resulting conjugate:nanoparticle ratio.  
V(APTES@SPION) /µL 
(conc. /mg.mL-1)
No. of nanoparticles V(FITC)
/µL (conc. /mg.mL-1)
No. of conjugates FITC:nanoparticle ratio 
200 (10) 1.98 × 1015 2.6 (1.0) 4.02 × 1015 2:1
Table 4. Volumes of nanoparticle and FITC solutions used and resulting FITC:nanoparticle ratio. The FITC-mAb conjugate has Mw ~ 150 kDa.
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4.3.3 Flow cytometry and in vitro validation 
To detect the binding of FITC-Trastuzumab-APTES@SPION to Her-2 overexpressing BT-
474 cells, a near confluent cell culture was trypsinised to facilitate removal, exposed to the 
nuclear stain DAPI (to allow assessment of cell viability and a measure of nanoparticle 
toxicity) and diluted to a concentration of approximately 5 × 105 cells.mL-1; each cell has an 
average of 7 × 105 Her-2 receptors, equivalent to 3.5 × 1011 receptors.mL-1. To this sample 
was added an excess of FITC-Trastuzumab-APTES@SPION: 500 µL of 10 mg.mL-1
nanoparticle solution per 1 mL of cell media, equivalent to approximately 4.95 × 1015
nanoparticles of which 9.90 × 1013 or 1.98 × 1014 are calculated to bear a FITC-Trastuzumab 
moiety, depending on the initial reaction stoichiometry. There is therefore an excess of 282 
or 565 antibodies per receptor.  
Determination of ‘population identities’
Flow cytometers measure a user-defined number of ‘events’ per experiment. An ‘event’ can 
be loosely defined as any object passing the laser which gives detectable values for Front 
(FSC) and Side (SSC) scatter.60 Typically these are cells, but nanoparticle aggregates, cell 
aggregates and debris can all register as an ‘event’. Initial experiments were performed on a 
dispersion of nanoparticles with no cells, and on a dispersion of cells with no nanoparticles 
to determine FSC and SSC ranges which would allow the unequivocal identification of cells 
(nanoparticle-bound or otherwise) from free nanoparticles and debris. 
Fig. 13a shows a two-parameter histogram for a dispersion of antibody-labelled SPION. 
Nanoparticles, nanoparticle aggregates and small debris have low FSC intensity; the intensity 
of FSC indicates the diameter of an ‘event’ with larger species giving greater FSC intensity, 
but entities smaller than the wavelength of light being used (e.g. nanoparticles) have little 
effect on FSC and may not register as an event.64
Fig. 13b shows histograms for BT-474 cells prior to incubation. The two-parameter dot-plot 
on the left shows that cells, cell debris and cell aggregates can have a range of values for FSC 
and SSC. The gated sub-population of events labelled ‘P1’ has values of FSC and SSC known 
to roughly signify single, healthy BT-474 cells and eliminates nanoparticles and debris. This 
population was refined into the smaller sub-population P2 by the exclusion of anomalous 
species based on the height and width (FSC-H and FSC-W) of the FSC signal. P2 was refined 
further into P3 by using the height and width (SSC-H and SSC-W) of the SSC signal. Thus, 
the events populating the group P3 can be determined to be individual, healthy cells only. By 
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comparison to Fig. 13a, it can be observed that single cells and nanoparticle species in a 
mixed sample will appear as different regions on a two-parameter histogram. 
Fig. 13c is a histogram of fluorescence intensity (FITC-A) against number of events (count) 
obtained when events in P3 are excited with 495 nm light and emission at 520 nm is 
measured. The population of single cells in gate P3 all have low fluorescence intensity, falling 
into a pre-determined region for FITC-negative events. 
Figure 13a. FSC vs. SSC for antibody-labelled SPION in aqueous solution. FSC is low, 
indicating sizes approaching the limit of detection.  
b. FACS analysis for BT-474 cells in solution. Gate P1 is known to approximate single, 
healthy cells. P2 and P3 refine this group. P3 is tested for FITC emission (λex = 495 nm). 
c. The fluorescence intensity of the population within P3 is low (~2 × 102 relative units), 
hence is not FITC emissive. FITC-A refers to emission intensity, count refers to number 
of events (here, single, healthy cells).
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Incubation of BT-474 cells with antibody-bearing SPION 
Nanoparticles with theoretical mAb percentage loadings of 2 % and 4 % were incubated 
together with BT-474 cells with regular mixing for 30 mins at 37 °C, after which the media 
was analysed by flow cytometry. Initial results for both loadings were similar but the higher 
percentage coating samples were more prone to precipitation and to blocking the cytometer 
uptake and were not studied further.  
Following incubation with trastuzumab-bearing SPION, FACS analysis of the same culture 
of BT-474 cells studied in Fig. 13b and Fig. 13c using the same gates to define event sub-
populations gave much greater fluorescence intensity upon excitation at 495 nm. Fig. 14a 
shows how the measured number of 10,000 events was divided into sub-populations P1, P2 
and P3 based on light scattering so that the events in sub-population P3 are known to be 
single, healthy cells. When excited with 495 nm light, the cells show fluorescence intensity at 
520 nm ten times that observed in the single parameter histogram Fig. 14c, and the intensity 
is sufficient to deem them ‘FITC positive’. From no FITC positive events prior to 
incubation, 77.2 % of the events in Gate P3 were definitively FITC emissive, indicating 
binding of the nanoparticles to the BT-474 cells.  
To confirm the strength of the binding, an aliquot of the experimental mixture was diluted 
by half with appropriate media. The cell media was vortexed vigorously and re-analysed using 
the same gating procedure (Fig. 14b). It would be expected that few FITC positive events 
would remain following this harsh treatment if weak, non-specific binding (i.e. adsorption) 
was occurring. Post-dilution, the percentage of FITC positive events recorded dropped to 
60.7 %, indicating some loss of binding. The binding of nanoparticles to cells is of significant 
strength, with most losses following dilution and vortexing likely due to the slow binding 
time of antibodies giving incomplete formation of the antigen-antibody interactions (see Fig. 
14c).65
Control experiments were performed where BT-474 cells were incubated with FITC-
APTES@SPION. Resulting FACS analysis (not shown) showed a sub-population P3 that 
was known to contain single, healthy cells but which had no fluorescence intensity arising 
due to the presence of FITC. No binding was observed when nanoparticles did not carry an 
antibody moiety, allowing the conclusion that the strong binding inferred from Fig. 14 is 
antibody mediated.  
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Population No. of events %Parent
Pre-dilution Post-dilution Pre-dilution Post-dilution
All events 10000 10000 - -
P1 (approx. single cells) 936 721 9.4 7.2
P2 (refined cells) 908 702 97.0 97.4
P3 (refined cells, λex =  495 nm) 893 700 98.3 99.7
FITC negative 125 191 14.0 27.3
FITC positive 689 425 77.2 60.7
Figure 14a. FACS analysis of BT-474 cells incubated with trastuzumab bearing SPION. 
Emission intensity of P3 was ~ 1 × 103 relative units (FITC positive).  
b. FACS analysis performed post-dilution and vortexing to remove weakly/non-
specifically bound species. Emission intensity remained high (~7 × 102 relative units). 
c. Table showing the numbers of events per subpopulation. The majority of FITC positive 
events are retaining following dilution and vortexing. 
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Incubation of MDA-MB-468 cells with antibody-bearing SPION 
MDA-MB-468 cells (not Her-2 overexpressing, ‘negative’) were incubated with FITC-
Trastuzumab-APTES@SPION to investigate the antibody’s specificity for the Her-2 
receptor upon immobilisation; limited binding was observed due to the presence of some 
Her-2 receptors (Fig. 15). 
Fig. 15a shows the identification of FSC and SSC parameters for individual healthy cells from 
the negative cell line; the negative cells have different scatter characteristics to the positive 
cell line shown in Fig. 13b, requiring different gates to be applied to achieve sub-population 
identification (P1, P2 and P3).  
Following incubation with the antibody-coated SPION, the presence of the nanoparticles 
can be seen by the increased side scatter and the changes in the nature of the cells in response 
to the change in the environment (Fig. 15b). The first two-parameter histogram shows the 
approximate region (within population P1) where single, healthy cells would be expected. 
The second and third show the refinement of this population to eliminate cell aggregates and 
cell debris. The single, healthy cells of P3 were excited at 495 nm, yielding the histogram of 
fluorescence intensity (FITC-A) versus count. Some events had intensity sufficient to register 
as ‘FITC positive’.
The number of FITC positive events within the cell population increases from 0 % prior to 
incubation with nanoparticles (not shown) to 5.4 % (Fig. 15c). MDA-MB-468 does have 
some Her-2 receptors (it is referred to as ‘negative’ because Her-2 is not ‘over-expressed’ as 
in BT-474),66 so some binding and fluorescence is to be expected but will be limited as the 
antibody should not bind to other surface receptors present. The difference to the percentage 
of positive events observed in the case of BT-474 cells is sufficient to conclude that 
immobilised Trastuzumab largely retains specificity to the Her-2 receptor and does not bind 
efficiently to other receptors.  
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Population No. of events %Parent
All events 10000 -
P1 (approx. single cells) 2552 25.5
P2 (refined cells) 2040 79.9
P3 (refined cells, λex = 495 nm) 2010 98.5
FITC negative 1880 93.5
FITC positive 108 5.4
Figure 15a. FACS analysis of MDA-MB-468 cells prior to incubation with trastuzumab 
bearing SPION. Different gates are required to the positive cell line discussed previously. 
b. FACS analysis post-incubation, showing gates for population identification. The 
majority of events have low emission intensity, and are therefore ‘FITC negative’.
c. Table of populations expressed in post incubation FACS plots above. Note the small 
percentage of FITC positive events (5.4 %) in comparison to that observed for BT-474 
cells previously (77.2 %). 
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Effects of incubation with nanoparticles on cell viability 
Experiments were performed to determine the effect of incubation with the antibody-
bearing nanoparticles on cell viability. Populations of BT-474 and MDA-MB-468 cells were 
cultured, exposed to a small quantity of DAPI dye and their cell viabilities assessed using 
FACS. Both cell lines were split into two centrifuge tubes each and to one of the tubes for 
each line was added antibody-bearing nanoparticles. The tubes were then incubated at 37 °C 
for 30 mins and their cell viability measured again (see Table 5 below).  
The initial viability of BT-474 cells was 96.8 %; this was reduced to 86.9 % by incubation 
alone, and to 84.8 % by incubation with the SPION sample. The initial viability of the MDA-
MB-474 was 98.5 %, dropping to 98.1 % following incubation alone, and 97.2 % following 
incubation with the particles. Incubation with the particles has limited effect on cell viability, 
showing that despite the harmful chemicals used to achieve immobilisation, repeated 
washing of the particles is efficient at removing these toxins, alleviating any concern that 
transfer to in vivo studies could involve accidental poisoning of the subject. Removal from 
ideal culture conditions in the incubator has a greater effect on cell viability than the presence 
of the nanoparticles. 
Summary of FACS analysis 
Flow cytometry confirmed the ability of FITC-labelled trastuzumab immobilised via 
reductive amination on APTES@SPION to bind strongly to the Her-2 surface receptor 
specifically with no significant effect on cell viability. Within populations of individual, living, 
healthy cells, the Her-2 overexpressing cell line BT-474 showed significantly greater binding 
to the antibody-directed nanoparticles than observed for the ‘negative’ cell line due to the 
greater number of Her-2 receptors present. Where binding was observed, the complexes 
formed were not easily disrupted by dilution or by vigorous agitation of the sample. Where 
nanoparticles did not carry the antibody, no binding was observed. The antibody-bearing 
nanoparticle species were deemed suitable for in vivo experimentation. 
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BT-474 / no. of events (%Parent) MDA-MB-468 / no. of events (%Parent)
Pre-incubation Post-incubation Post-incubation 
with nanoparticles
Pre-incubation Post-incubation Post-incubation 
with nanoparticles
All events 10000 (-) 10000 (-) 10000 (-) 10000 (-) 10000 (-) 10000 (-) 
P1
(approx. single cells)
8394 (83.9) 8694 (86.8) 2441 (24.4) 7296 (73) 7113 (71.1) 2428 (24.3)
P2
(refined cells)
7946 (94.7) 8234 (94.8) 2253 (92.3) 6040 (82.8) 5829 (81.9) 1901 (78.3)
P3
(refined cells, λex = 495 
nm)
6433 (81.0) 6603 (80.2) 2083 (92.5) 6017 (99.6) 5811 (99.7) 1883 (99.1)
FITC positive 27 (0.4) 21 (0.3) 1732 (83.1) 0 (0) 0 (0) 108 (5.7)
Live 6227 (96.8) 5739 (86.9) 1767 (84.8) 5925 (98.5) 5698 (98.1) 1831 (97.2)
Table 5. Table of FACS data relating how cell viability changes with incubation with particles. Note the case of BT-474 cells where there is greater loss 
in viability as a result of incubation, and the high number of cells which are live and FITC positive. 
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4.3.4 Fluorescence microscopy 
In addition to flow cytometry, the binding of FITC-trastuzumab-APTES@SPION to BT-
474 cells was visualised qualitatively by fluorescence microscopy using three fluorescence 
channels (‘blue’, λex = 355 nm, λem = 433 nm; ‘green’, λex = 480 nm, λem = 517 nm; ‘red’, λex
= 556 nm, λem = 615 nm). Excitation with the different wavelengths of light following 
incubation with DAPI and the nanoparticle agent and subsequent fixing of the cells allows 
the cells to be shown to have blue fluorescence (due to DAPI), green fluorescence (due to 
the FITC of the nanoparticle agent) but no red fluorescence, excluding the possibility that 
autofluorescence is occurring.  
In the top set of images in Fig. 16 below, three cells can be observed with black aggregates 
that show some green fluorescence. In the bottom set, two cells are visible on the right, while 
a piece of cell debris is expressing blue fluorescence on the left. This would not give a false 
positive in FACS analysis as it would have different front and side scatter characteristics from 
whole cells, and is likely an artefact of the fixing process. 
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Figure 16. Fluorescence microscopy images of BT-474 cells binding Trastuzumab-bearing SPION illuminated with different light sources. From left to 
right: white light, green fluorescence channel, all available fluorescence wavelengths, blue fluorescence channel.
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4.3.5 Synthesis of 89Zr-radiolabelled FITC-Trastuzumab-APTES@SPION 
An 89Y foil target was subjected to proton bombardment within a cyclotron by a 
radioengineer from PETIC, University Hospital of Wales, Cardiff. The impure reaction 
mixture containing 89Zr and waste products was transferred to a hot cell and purified by use 
of SOPs based on the method described by Walther et al.29 A sample of the product 89Zr 
oxalate solution was neutralised prior to addition to the iron salt-containing SPION-
precursor solution lest it affect pH adversely and change the properties of the reaction.  
Only a small proportion of the final radiolabelled particles (approximately 2 %) would be 
conjugated to antibodies in order to retain in vivo function and maximise solubility. It was 
important that as much radioactivity as possible should be incorporated into the 
nanoparticles to compensate for this and for losses going through the synthesis. For the in 
vivo experiments described below, a volume of 89Zr oxalate with activity of 802 MBq was 
used, approximately twenty times that which had been used in initial experiments which had 
shown high labelling efficiency. This was calculated to be equivalent to 0.54 nmol or 3.27 × 
1014 atoms using the equation:  
where N is the number of radioactive atoms, n is the number of moles of radioisotopes, NA
is Avogadro’s number, λ is the radioactive decay constant and t1/2 is the half-life of 89Zr in 
seconds (282600 s). Based on previous APTES@SPION preparations on this scale and on 
the average physical dimensions discussed in Chapter 3, it was estimated that a final yield of 
labelled particles would be approximately 50 mg, equivalent to 4.94 × 1016 nanoparticles. 
Taking the number of 89Zr atoms present at the start of the experiment, the theoretical 
maximum radiolabelling yield would be: 
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The initial co-precipitation of uncoated SPION occurred without incident, but of the 802 
MBq introduced into the system 406 MBq of 89Zr was not incorporated into the SPION and 
was contained in the washings from the reaction (see Table 6). This was not anticipated as 
preliminary investigations had shown the incorporation of approximately 90 % of the 
radioactivity at this stage of the reaction.  
The radiolabelled particles were coated with APTES and left to dry in air in the hot cell 
overnight. On the following morning, it was observed that drying was not complete; an 
additional cycle of dispersal in water, precipitation with MeCN, repeated washing with fresh 
water and further drying was required to achieve the radiolabelled APTES@SPION as a fine 
black powder that could be manipulated remotely. This resulted in some loss of product. 
The final mass of 89Zr-APTES@SPION (15.8 mg, 1.56 × 1016 nanoparticles) was measured 
to have activity of 108.4 MBq (Equivalent to 4.42 × 1013 89Zr atoms; specific activity = 6.86 
GBq.g-1). Using the same approach as described above for the theoretical case:   
This is equivalent to 1 in 353 of the synthesised nanoparticles being radiolabelled with one 
atom of 89Zr. This quantity is small but should be considered as an initial proof of concept; 
increased labelling efficiency may result from future experiments to optimise reaction times 
and conditions. The current experiment suffers from the need to perform the nanoparticle 
synthesis on a scale small enough that gigabecquerels of radioactivity is not needed to achieve 
a useful degree of labelling, but large enough that quantities can be accurately weighed and 
manipulated. 
Experimental step Sub-division of materiel Activity / MBq
i) Initial reaction mixture N/A 802
ii) Post-precipitation Washed uncoated SPION 396
Washings 406
iii) Post-coating Wet APTES@SPION 319
Washings 66.2
iv) Final drying Labelled APTES@SPION 108.4
Losses through manipulation 210.6 (estimated)
Table 6. Distribution of activity throughout synthesis of 89Zr-APTES@SPION. 
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The dried radiolabelled nanoparticles were dispersed in sterile saline (10 mg.mL-1) prior to 
bioconjugation to FITC-Trastuzumab. The fluorescent species was used for consistency with 
the in vitro studies described above and to offer the possibility of dissection and fluorescence 
microscopy should the in vivo biodistribution be favourable.  
The radiolabelled particle dispersion was split, with the equivalent of 10 mg (66 MBq) being 
the subject of bioconjugation experiments and the remainder (5.8 mg, 42 MBq) not receiving 
bioconjugation to act as a control species. Bioconjugation proceeded via reductive amination 
with the experimental stoichiometry shown in Table 7. No significant experimental losses of 
radioactivity were noted during this step of the reaction. 
V(APTES@SPION) /µL (conc. /mg.mL-1) 1000 (10)
No. of nanoparticles 9.88 × 1015
V(FITC-mAb)/µL (conc. /mg.mL-1) 40.0 (1.1)
No. of conjugates 1.77 × 1014
Conjugate:nanoparticle ratio (% singly labelled) 1:56 (~2 %)
Initial activity / MBq 65.8
Final activity / MBq 61.2
Table 7. Volumes of nanoparticles and FITC-Trastuzumab solutions used in preparation 
of 89Zr-radiolabelled FITC-Trastuzumab-APTES@SPION. Approximate Mw(FITC-mAb) 
= 150 kDa. 
Both the antibody-bearing and non-antibody-bearing nanoparticles were suspended in sterile 
pH 7.2 buffer overnight with mixing, then allowed to stand without agitation for 30 mins. In 
both cases the stabilities of the dispersions were much poorer than had been observed with 
‘cold’ analogous experiments, suggesting a higher drive to aggregate. The presence of 
aggregates that could not be dispersed satisfactorily at higher concentrations required dilution 
which significantly reduced the amount of radioactivity that could be used in vivo. Much of 
the 61.2 MBq discussed in Table 7 persisted as a black solid that would not disperse at high 
concentrations under the conditions used.  
Following dilution of a poorly dispersed sample until aggregates were not visible, 
supernatants were collected and confirmed to have retained some radioactivity (0.3 MBq.mL-
1). It was noted that the weakly radioactive dispersions may not be sufficient to observe 
contrast in the tumour, but the experiment was continued to the animal model phase as the 
mice already bore the xenograft tumours and the radioactivity present would at least be 
suitable to characterise the biodistribution of the particles and to assess their toxicity if any. 
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4.3.6 In vivo biodistribution of radiolabelled SPION 
Experimental design and approach 
Twelve female nude mice were housed at the School of Medicine, Cardiff University under 
conditions meeting institutional guidelines for live animal experiments. The mice were all 
determined to be of similar age and weight and the group was divided randomly into two 
cohorts of six mice. BT-474 and MDA-MB-468 cells were cultured on Matrigel matrix and 
a volume (100 µL) containing ~5 × 106 cells of a given cell-line was injected subcutaneously 
into the right flank region of each mouse. The Matrigel was observed to set with no 
immediate ill-effects on the mice. The tumours were allowed to develop with regular 
checking on the health and welfare of the mice for 30 days. The two types of tumours 
expressed different growth rates such that the MDA-MB-468 tumours were well developed 
and externally visible after 30 days and were in danger of becoming necrotic (at which point 
euthanisation would be performed); in contrast the BT-474 tumours, while palpable, were 
smaller and were not externally visible. 
Three of each group were to be administered with antibody-bearing nanoparticles and three 
were to be administered radiolabelled APTES@SPION with no degree of antibody 
conjugation (Table 8). For accurate comparisons between the cohorts, all of the mice would 
have to be administered particles from the same production. Because of this, the experiment 
proceeded despite the small size of the BT-474 tumours in an attempt to avoid the need to 
sacrifice the mice bearing MDA-MB-468 tumours. 
Cohort 1
No. of Mice = 3
Tumour type = BT-474
Administered species = 
mAb-conjugated 89Zr-APTES@SPION
Cohort 2
No. of Mice = 3
Tumour type = BT-474
Administered species =
89Zr-APTES@SPION
Cohort 3
No. of Mice = 3
Tumour type = MDA-MB-468
Administered species = 
mAb-conjugated 89Zr-APTES@SPION
Cohort 4
No. of Mice = 3
Tumour type = MDA-MB-468
Administered species =
89Zr-APTES@SPION
Table 8. Schematic of experimental groups. Specific binding of the radiolabelled 
nanoparticles to tumour tissue would only be expected in Cohort 1.  
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Drug formulation volumes administered to small animals must be small to prevent harm; 
200 µL is typically a safe maximum single-injection volume. The formulation must be clear 
from visible aggregates which can cause fatal blood vessel blockages. To satisfy these 
conditions, the supernatant solutions containing the bioconjugated and non-bioconjugated 
radiolabelled particles were diluted until they were observed to be clear from aggregates, at 
which point an activity of 0.03 MBq of radioactivity per 100 µL of solution was measured. 
The tumour bearing mice were separated into their cohorts and 200 µL (0.06 MBq) of the 
appropriate nanoparticle suspension was administered by injection into the tail vein. For both 
antibody-bearing and non-bearing radiolabelled APTES@SPION, 0.06 MBq can be 
converted to an equivalent number of 89Zr atoms: 
This number is equivalent to the number of radiolabelled nanoparticles administered to each 
mouse. Due to the immobilisation stoichiometry, 2 % of this number would be calculated to 
bear an antibody i.e. 4.90 × 108 nanoparticles or 8.13 × 10-16 moles of antibody-directed 
radiolabelled nanoparticles were administered to each mouse of Cohorts 1 and 2. An average 
mouse has a blood volume of 1.5 mL, hence particle concentration can be calculated to be: 
PET scanners are sensitive enough that contrast can be observed with sub-picomolar 
contrast agent concentrations,67,68 but a recent meta-analysis suggests that over 99 % of all 
nanoparticles will be prevented from reaching the target tumour due to physical and 
biological barriers.69 Unfortunately the experiments performed had antibody-directed 
nanoparticle concentrations approaching or below the limit of detection, and contrast in 
tumours deriving from the antibody-conjugated particles would not be expected. In addition, 
as only 2 % of the radiolabelled particles bear an antibody, background noise would be high 
compared to any ‘antibody-directed signal’. The mice were anesthetised prior to scanning; 
their heart rates and core body temperatures were monitored throughout to ensure welfare. 
PET scanning was carried out over seven days post-injection (Figs. 17-20). At no point was 
a significant signal corresponding to nanoparticle agents determined in the tumour of any 
mouse, regardless of tumour type or the presence of antibody-bearing nanoparticles.  
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Figure 17. Serial PET-CT imaging of Cohort 1: nude mice bearing Her-2 positive (BT-474) tumours administered with 89Zr-labelled Trastuzumab-
bearing SPION. Radioactivity rapidly accumulates in the liver. Approximate tumour location for each mouse indicated by arrow.  
(Note: following the 23 h scan, one mouse succumbed to hypothermia due to the low temperature in the scanner.) 
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Figure 18. Serial PET-CT imaging of Cohort 3: nude mice bearing Her-2 negative (MDA-MB-468) tumours administered with 89Zr-labelled 
Trastuzumab-bearing SPION. Radioactivity rapidly accumulates in the liver. Approximate tumour location for each mouse indicated by arrow. 
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Figure 19. Serial PET-CT imaging of Cohort 2: nude mice bearing Her-2 positive (BT-474) tumours administered with 89Zr-labelled SPION with no 
degree of bioconjugation. The degree of localisation in the spleen is higher than for antibody functionalised SPION. Approximate tumour location for 
each mouse indicated by arrow. 
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Figure 20. Serial PET-CT imaging of Cohort 4: nude mice bearing Her-2 negative (MDA-MB-468) tumours administered with 89Zr-labelled SPION with 
no degree of bioconjugation. The degree of localisation in the spleen is higher than for antibody functionalised SPION. Approximate tumour location 
for each mouse indicated by arrow. 
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Region of interest analysis 
Post-scan analysis was carried out by defining key organs as three-dimensional regions of 
interest (ROI) and determining the percentage of radioactivity in the region relative to the 
total radioactivity present in the mouse. Nine ROI were determined for the analysis of the 
radioactivity distribution: the mouse as a whole, the tail (the site of injection), the skeleton, 
the lungs, the kidneys, the bladder, the liver, the spleen and the tumour itself. By defining 
these regions in each mouse at each scan time, how activity distribution changes over time 
(i.e. the effects of metabolism or blood circulation) can be quantified.  
Administration of antibody-directed, radiolabelled SPION 
The results of ROI analysis for the surviving mice of Cohort 1 (BT-474 tumour, antibody-
bearing nanoparticles) are shown in Fig. 21. Upon administration, particles initially localised 
in the lungs before rapid uptake into the liver, where the majority of the radioactivity 
remained throughout the scanning period. Although some radiation was observed in the 
kidneys, no radiation was observed in the bladder, precluding excretion via the renal system. 
Radiation in the tail is an unavoidable artefact of injection via the tail vein.  
Levels of radioactivity in the tumour given in Fig. 21 below are likely to be noise arising from 
signal gain during analysis. The values are greater than if all of the antibody-directed particles 
that were administered and which avoided uptake into the liver or other organs were bound 
to the tumour cells within an hour of administration. In the first scan (see Fig. 21), 0.03 % 
(18 Bq) of the total activity at that time (approximately 60,000 Bq) is measured to be in the 
tumour. Of the 60,000 Bq, only 2 % would be expected to be in a particle bearing an antibody 
(1200 Bq), and as is discussed elsewhere, it would be estimated that only 1 % of these particles 
would avoid uptake by the liver and other organs (equivalent to 12 Bq).69 It is known that 
antibody-antigen interactions are strong but are typically slow to form, and it would not be 
expected for all possible particles to bind to the tumour immediately upon administration. 
Because the measured value is larger than would be plausible or possible, it may be concluded 
that it is likely inaccurate and not significant. 
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Figure 21. Average percentages of total activities for selected ROI for Cohort 1 mice (n 
= 2) at different scan times (blue = Scan 1, orange = Scan 2, grey = Scan 3).  
ROI analysis of the Her-2 negative MDA-MB-468 tumours of Cohort 3 (Fig. 22) showed 
similar tumour activity levels to those observed in Fig. 21, confirming that the measurement 
of radioactivity in the BT-474 tumours is likely an artefact of the analytical approach taken 
(i.e. system error or signal gain) and is not indicative of the specific binding of an antibody-
directed nanoparticle. 
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Figure 22. Average percentages of total activities for selected ROI for Cohort 3 mice (n 
= 3) at different scan times (blue = Scan 1, orange = Scan 2, grey = Scan 3). 
Administration of radiolabelled SPION with no antibody-conjugation 
Although only a small proportion of the particles described above bore an antibody, the 
methodology used for bioconjugation does have an effect on the nanoparticles’ 
biodistribution: when 89Zr-labelled APTES@SPION are administered, their biodistribution 
was nearly identical within the mice of Cohorts 2 and 4, but was different to that of the 
antibody bearing particles in Cohorts 1 and 3 (see Figs. 23 and 24). 
The non-bioconjugated particles persist in the lungs to a greater extent throughout the 
experiment, with the effect being most noticeable in the first scan. Approximately 50 % of 
the radioactivity was in the lungs one hour after administration, whereas 17-24 % was present 
in the lungs for the antibody-labelled SPION at the same time. The percentage of the activity 
present in the spleen increased throughout the experiment to between 12 and 17 % for non-
bioconjugated particles but remained much lower (≤ 6 %) and relatively constant throughout 
for the functionalised particles. Less radioactivity was observed in the liver when the particles 
were not functionalised (a maximum of ~70 %) compared to the functionalised species (85-
89 %).  
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Figure 23. Average percentages of total activities for selected ROI for Cohort 2 mice (n 
= 3) at different scan times (blue = Scan 1, orange = Scan 2, grey = Scan 3). 
Figure 24. Average percentages of total activities for selected ROI for Cohort 4 mice (n 
= 3) at different scan times (blue = Scan 1, orange = Scan 2, grey = Scan 3). 
172
Although only two per cent of nanoparticles in the ‘antibody-containing’ cohorts bear 
biomolecules, the effect of the immobilisation process on other parameters results in them 
being almost twice as likely (62-73 % vs. 36-37 %) to have been sequestered into the liver in 
less than one hour post-injection. The particles that were exposed to bioconjugation 
conditions were observed ex vivo to be more prone to aggregation than non-bioconjugated 
particles (most likely due to changes in their protonation state or surface charge) and this 
ROI data would suggest that in vivo this may result in an increased rate of detection by the 
immune system and sequestration into the liver. 
It is therefore likely that the differences in biodistribution described above are not directly 
related to the presence of antibody molecules on just two per cent of the nanoparticles (as 
the effect would be disproportionate) but arise indirectly due to the effect of the 
immobilisation methodology on the bulk physical parameters of the nanoparticles. Further 
research would be required to clarify the effect of the immobilisation method on the particles 
in general, and to identify the major factors that result in the different in vivo behaviour and 
which could inform future experiment design. 
The lack of significant signal in the tumours of any mice suggests that passive sequestration 
of any radiolabelled nanoparticles through porous blood vessels (the enhanced permeability 
and retention (EPR) effect) did not occur to an appreciable degree.70
Analysis of ROI data trends: protein adsorption, immune responses and RES uptake 
Mice urinate near constantly.71 This, and the small amount of radioactivity present at any 
time in the kidneys of any mouse studied is sufficient to conclude that renal excretion is not 
a major elimination pathway. As it is known that sub-10 nm particles are removed by this 
pathway,72 the particles must exist as aggregate species in vivo.  
While in vitro experiments allowed the confirmation of the specificity of SPION-immobilised 
trastuzumab, this was insufficient to predict in vivo behaviour. Nanoparticles aggregate to 
minimise energy due to their high surface area:volume ratio. This can also be achieved by the 
non-specific adsorption of proteins in vivo to give a ‘protein corona’.73 The size of the particles 
affects the amount and identities of the species in the protein corona, and the protein corona 
affects numerous physical quantities (e.g. surface charge, hydrophobicity, size and shape) in 
vivo, which affects biodistribution.73,74 Increased hydrophobicity results in an increased 
immune response to nanoparticles.75,76 Positively charged nanoparticles have shown a 
preference to bind ‘opsonins’, proteins that enhance the uptake of the nanoparticles by 
elements of the reticuloendothelial system (RES) which are part of the innate immune 
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response e.g. macrophages. Dispersed APTES@SPION will have positive surface charges 
and will likely bind opsonins; particles that are aggregating together become more 
hydrophobic. In either case, the nanoparticles administered to the mice will trigger an 
immune response. When comparing the different biodistribution patterns of particles that 
have or have not undergone bioconjugation conditions, it would seem that the process 
changes their aggregation behaviour, which ultimately affects how the nanoparticles are 
cleared in a manner which may not be related solely to the presence of the mAbs. 
The mice used in the current experiment are athymic but retain their innate immune response 
to foreign bodies. Particles are engulfed by macrophage cells in the blood, liver or spleen and 
are sequestered in the latter two organs to undergo degradation as part of the body’s attempt 
to protect itself.72,77,78 Although RES sequestration may be reduced by different coating 
species, it is a common and persistent problem in nanoparticle research in general;77 a recent 
meta-analysis calculated that on average less than one per cent of administered particles are 
delivered to a target tumour due to RES uptake.69  It was calculated that 4.90 × 108 antibody-
directed nanoparticles were injected into the mice of Cohorts 1 and 3, of which an estimate 
of one per cent (4.90 × 106 nanoparticles) might be expected to have been delivered to the 
tumours: a femtomolar ‘available concentration’ that is too low to be detected and which 
may have been indistinguishable from background noise even had the equipment used been 
more sensitive. For one of the mice of Cohort 2 at the time of Scan 3 (120 h, see Fig. 19), 
contrast can be observed in the tail corresponding to 1.4 % of the total activity present (0.02 
MBq maximum). This is equivalent to 1.1 × 108 nanoparticles, approximately twenty times 
that of the number of antibody-directed nanoparticles that may reach the tumours of Cohort 
1; however, this lower number is currently below detection. It may be hoped that future 
experiments with different methodologies to the one described above would improve the 
solubility of the protein-bearing nanoparticles or would increase the percentage of particles 
bearing a mAb, thus increasing the absolute concentration of antibody-bearing radiolabelled 
nanoparticles to within the limits of detection.  
The immediate value of the experiment above is in showing the lack of toxicity of the agent 
at the concentration used, which leaves the opportunity for future development. The 
approach described does not yet offer a viable alternative to more ‘traditional’ immunoPET 
agents, but future work may address improving the solubility of the antibody-bearing 
nanoparticles to obtain higher in vivo concentrations. 
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4.4 Conclusion 
The monoclonal antibody trastuzumab was fluorescently labelled and immobilised onto 
APTES@SPION via reductive amination of the sugar side chains. In vitro incubation of the 
antibody-bearing nanoparticles with Her-2 overexpressing cells was analysed by cytometry 
and observed to bind specifically, confirming the retention of antibody specificity following 
immobilisation. 
Water dispersible 89Zr-labelled SPION were synthesised on as small a scale as possible and 
using as much radioactive material as practicable to generate a species intended for 
administration to tumour-bearing mice. Of the twelve mice studied, eleven survived to the 
end of the PET-CT scanning window with the sole mortality due to hypothermia. The 
radiolabelled nanoparticles were not toxic in the quantity administered, which had been a 
concern due to difficulties observed in their solubilisation. Over the experimental timeframe, 
the radiolabelled nanoparticles were rapidly cleared from the bloodstream and sequestered 
into the liver and spleen, as has been reported as a common in vivo excretion route for 
nanoparticles. Several clinically approved SPION MRI agents have been used for the direct 
imaging of tumours of the liver and spleen,79,80 so in principle the 89Zr-labelled 
APTES@SPION synthesised as part of the current work could function as a bimodal 
PET/MRI agent in an analogous way. 
There are multiple ways to improve the methodology described. Reducing the rate of RES 
uptake of particles is crucial to ensuring that antibody-bearing SPION have a long enough 
blood clearance time to allow the opportunity to bind to tumour cells. This would require 
experiments to study the nature of the protein corona of the nanoparticles. Improvements 
to the method of APTES coating are also called for to improve their colloidal stability 
(unexpectedly poor dispersal resulted in the loss of most of the radioactive particles prior to 
administration).  This would be hoped to allow a greater degree of bioconjugation to occur 
without increasing the drive to aggregate. A greater number of nanoparticles bearing an 
antibody moiety would increase the likelihood of successful tumour-labelling events. 
The methodology used to radiolabel the particles is not easily modified to increase the degree 
of radiolabel inclusion while retaining the essence of the approach. To achieve  ‘one isotope 
to one nanoparticle labelling’ would require either reaction on an exceptionally small scale 
which would be beset by difficulties in terms of manipulations and reproducibility, or the use 
of large quantities of 89Zr which would by necessity require a different methodology (for 
example using automated steps to limit operator exposure). An alternative approach may be 
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required; the pre-forming of monodisperse oleic acid coated SPION was described in 
Chapter 2 and is known to be highly reproducible. Several methods for the removal of the 
organic coating from this species and its replacement to give hydrophilic surfaces with 
bioconjugation-ready functionalities have been reported,81–83 and it has been observed that 
radioarsenic labelling of such particles can be achieved by gentle heating (37 °C) in air for 
two hours.26 The use of OA@SPION as starting materials would in theory result in reduced 
polydispersity and increased colloidal stability in the hydrophilic product species. Reducing 
the scale of the radiolabelling step would be less susceptible to variable results as the particles 
are pre-formed and can be accurately handled on a small scale prior to the introduction of 
radiation. Radiolabelling efficiency could be increased due to the smaller iron oxide cores 
having a greater surface area:volume ratio and the particles having a reduced drive to 
aggregate. Experiments to validate this approach to radiolabelling prior to bioconjugation 
would be of great interest. 
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Chapter 5: The design and synthesis of Cu-ATSM-like complexes for 
use as haptens in custom antibody production 
5.1 Introduction 
As part of the initial proposal for this project, we determined to prepare a series of metal 
complexes analogous to the hypoxia-targeting contrast agent 64Cu-ATSM. These complexes 
would be used as haptens conjugated to carrier proteins and used to generate antibodies in 
sheep. It was hoped that from the antibodies produced in this manner some could be 
identified that could function as catalysts for the reduction by which 64Cu-ATSM selectively 
images hypoxia. Such an antibody would have been raised against a metal complex that 
showed a distorted geometry such that it could function as a model for the transition state of 
this process. A more thorough discussion of the different aspects and theory behind this 
proposition is given below. Difficulties in the synthesis of the target molecules prevented the 
production of chemical species that were of sufficient purity to be used in a bioconjugation 
context. Due to a corporate restructuring of sponsors, the opportunity to use the molecules 
in vivo did not arise (antibody generation in sheep is expensive). However, the materials 
prepared were successfully analysed in vitro for antibacterial and anthelmintic activity. 
5.1.1 Angiogenesis and hypoxia (reduced oxygen content) in cancer 
Solid cancerous tumours arise as a result of a number of genetic mechanisms that share a 
common result on the cellular level: rapid, excessive cell division where apoptosis is down 
regulated. Cancer cells require blood vessels for the delivery of nutrients and oxygen and to 
remove waste. These processes are necessary for continued growth and thus the 
development of new blood vessels (angiogenesis) is crucial. Studies have shown that cancer 
models stop dividing and become necrotic or apoptotic when deprived of the opportunity 
for angiogenesis.1 It has also been shown that the levels of angiogenic factors in tissue are 
indicative of the tumour’s ‘aggressiveness’ and are therefore of prognostic value. Cancer cells 
show the ability to penetrate the blood vessels that supply them and may travel to distant 
sites within the body, lodge and proliferate to give metastases.1 Any form of cancer becoming 
metastatic has a dramatic and negative effect on the prognosis of the patient; of all deaths 
attributed to cancer, 90% are due to metastases rather than the primary tumour.2
Angiogenesis is triggered by cells requiring nutrients or oxygen and is controlled by the 
interplay of activator or inhibitor molecules.1 In the case of cancer, up-regulation of 
activators and down-regulation of inhibitors synergistically promote development of 
vasculature to support the solid tumour. The exact nature of how angiogenesis has been 
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triggered may be referred to as the ‘angiogenic phenotype’. The onset of cellular hypoxia (a 
decrease in the concentration of dissolved oxygen, pO2) due to insufficient blood supply can 
trigger angiogenesis.1,3
Hypoxia is therefore part of a mechanism of cancer development: increased cell division 
reduces oxygen concentration within daughter cells, resulting in an increased demand for 
new blood vessels. As the tumour grows the daughter cells become distant from the blood 
vessels; the distance between vessels can exceed the diffusion distances of oxygen in the 
perivascular space (70-180 µL).4 This decreases the amount of oxygen that can be supplied 
to the cells, adding to the demand for new vasculature. New blood vessels allow for further 
cell division but architectural faults caused by the speed of their formation exacerbate 
hypoxia by making the vessels porous and inefficient.1,3 Hypoxia has been shown to drive 
many intra-cellular and extra-cellular changes that ultimately lead to intravasation and 
metastasis, the mechanisms of which have been extensively reviewed.2,5–8
In addition to its proliferative effects, hypoxia also shows protective effects for the tumour 
by limiting the efficacy of radio- and chemo-therapies (Fig. 1). In the case of radiotherapy 
the presence of oxygen allows the damage to DNA caused by ionising radiation to be made 
permanent. Molecular oxygen has a high affinity for the radical formed by radiation. Binding 
leads to a peroxy radical that can be protonated, essentially trapping the damage, a process 
known as the ‘oxygen enhancement effect’.9 In hypoxic cells, the peroxy radical formation is 
prevented. Rather, endogenous thiols donate protons that return DNA to its undamaged 
form such that hypoxic cells can be referred to as ‘radiation resistant’ or ‘desensitised’.10 For 
chemotherapy, several mechanisms for resistance exist (see Fig. 1).10
Due to its contribution to the growth and spread of tumours and the resistance to therapies 
to which it contributes, the state of hypoxia in a solid mass is of great diagnostic and 
prognostic value. Early attempts to use the level of oxygen in a tissue diagnostically were 
focussed on direct, invasive methods. The polarographic O2 electrode (Eppendorf electrode) 
is a 17 µm gold micro-electrode mounted on a needle that is advanced through a tissue; the 
current measured is proportional to the oxygen tension present.10,11 Although effective, this 
technique is limited to superficial tumours and so research has tended to focus on indirect 
identification of hypoxic tissues throughout the body using molecular imaging.  
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Mechanism of radiotherapy resistance imbued by hypoxia
Mechanisms of chemotherapy resistance imbued by hypoxia
 Increased distance from blood vessels limit exposure to agents
 Cellular proliferation decreases as a function of distance from blood vessel, 
limiting effect of proliferation-limiting agents.
 Hypoxia selects for loss of p53 and reduced sensitivity to p53-mediated 
apoptosis, which is a target mechanism for some agents.
 Some agents’ methods of action is similar to that of radiation, and so similar 
desensitisation mechanisms as discussed above apply.
 Hypoxia upregulates several genes involved in drug resistance e.g. the 
multi-drug resistance gene MDR1, upregulating efflux of drugs.
Figure 1. Hypoxic tumour resistance to radiotherapy arises from the loss of the oxygen 
enhancement effect ‘fixing’ DNA damage (top). Several mechanisms of hypoxic tumour 
resistance to chemotherapy exist (bottom). Adapted from Brown10and Bertout et al.5
5.1.2 64Cu-ATSM – a hypoxia selective PET imaging agent 
Although other modes of molecular imaging have been used to study hypoxia, in practice 
most interest is centred on the use of PET as the tracers used can directly report pO2 levels 
and do not rely on hypoxia-related cell phenotypes.4 The majority of research is focussed on 
two tracers, 18F and 64Cu via the 18F-labelled nitroimidazoles and 60/62/64Cu-labelled 
bis(thiosemicarbazones) (BTSC) compared in Fig. 2.4
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Properties 
required 
of an ideal 
hypoxia-
imaging 
probe
 Agent retained in regions of low pO2, but not normoxic or necrotic cells.
 Mechanism of retention should be understood and general for multiple 
cell/tumour types.
 Lipophilic enough to cross cell membranes but sufficiently hydrophilic to 
prevent membrane sequestration.
 Pharmoacokinetic behaviour should be dependent solely on pO2 i.e. 
independent of blood flow, pH etc.
 Metabolically stable except in the case of hypoxic surroundings.
 Kinetics allow for imaging on a practicable timescale.
 Repeatable to allow for observation of hypoxia and recovery to normoxia.
Nitroimidazole analogues bis(thiosemicarbazone) analogues
 Enters cells by passive diffusion.
 Reduced in cells to nitro-radical anion.
 In normoxic cells, species is re-oxidised 
and diffuses out.
 In hypoxic cells, further reduction 
occurs, trapping the species at rates 
inversely proportional to pO2.
 Reduction requires active reductases, 
thus accumulation only occurs in viable 
cells.
 R-groups typically contain 18F, t1/2 = 
109.8 min.
 Enters cells by passive diffusion.
 Reduced in cells by endogenous thiols 
or redox-active proteins.
 In hypoxic cells, the reduced form is 
unable to diffuse back out and persists; 
protonation is followed by metal 
dissociation and sequestration by 
proteins in the cell.
 Multiple isotopes have been 
investigated; different imaging modes, 
timescales and therapeutic effects are 
possible.
 R-groups can be changed 
independently to adapt characteristics.
Figure 2. Ideal characteristics for a hypoxia-selective PET imaging probe (top) and brief 
profiles of the mechanisms of the two main agent families being investigated today 
(bottom).4
While nitroimidazole species are numerous, one of the most commonly studied has 
considerable disadvantages. 18F-FMISO shows slow pharmacokinetics and slow clearance 
from normoxic tissues. Physicians must wait approximately 2 hours for 18F-FMISO to clear 
normoxic tissues, during which time the radioactivity will have decayed significantly. Modest 
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tumour-to-background ratios (> 1.2) limit the contrast observed. Other nitroimidazole 
species designed to improve upon 18F-FMISO are not currently widely available.4
Cu-ATSM is a square-planar BTSC complex that overcomes many of the limitations of the 
nitroimidazoles. Localisation within hypoxic tissue occurs within an hour of administration 
with high tumour-to-background ratios (>> 2.0).12 A range of positron emitting copper 
isotopes have been used of which 64Cu is the most common. With a 12.7 h radioactive half-
life (several times that of 18F), repeat scanning of the patient can occur over a longer period 
of time (approximately 48 h). The longer half-life also allows for distribution of the isotope 
to facilities without direct production capabilities.12 The complexation of the isotope by the 
ligand occurs rapidly and with a minimum of manipulation and purification, an advantage 
over the often harsh, multistep syntheses of organic agents such as the fluorinated 
nitroimidazoles.13
Figure 3. Diagram of Cu-ATSM (left) showing the electronic nature of tetradentate 
coordination, and an ORTEP representation of crystalline Cu-ATSM (right) 
demonstrating square planar geometry, taken from Blower et al.14
Cu-ATSM was first noted as displaying hypoxia-selectivity in 1997.15 In 1998, Dearling et al. 
carried out a systematic study which showed that manipulating the ligand framework of 
BTSC complexes could change the observed selectivity for hypoxic cells and correlated this 
to the reduction potential of the metal atom.16 Later in vitro and in vivo studies further 
characterised different aspects of Cu-ATSM’s pharmacokinetic behaviour, an excellent 
introduction to which is available.12 In 2006 in vivo studies confirmed that 64Cu-ATSM could 
function as a hypoxia-targeting PET agent in most tumour types.17 Human clinical trials using 
Cu-ATSM for the imaging of different cancer types have been carried out since 200018–20 and 
novel uses of Cu-ATSM for imaging and treatment continue today.21
Several copper bis(thiosemicarbazones) including Cu-ATSM and Cu-GTSM (see below) 
have been shown to also have antibacterial properties against pathogenic bacteria such as 
Neisseria gonorrhoeae,22,23 Mycobacterium tuberculosis24 and Staphylococcus aureus.25 The ability of 
lipophilic BTSC compounds to transport copper ions across cell membranes into bacterial 
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cell cytoplasms leads to inhibition of cellular processes and/or increased redox stress 
(depending on the bacterium) that ultimately renders the species toxic; copper BTSC 
complexes may be of great interest in the development of the next generation of antibiotics.22
5.1.3 The mechanism of Cu-ATSM’s hypoxia selectivity
A diagram of the proposed biphasic mechanism of Cu-ATSM’s in vivo hypoxia selectivity is 
shown in Fig. 4. This mechanism has been the subject of much research and debate 
worldwide.12 The observed tendency for Cu-ATSM to label hypoxic tissues is generally 
agreed to be dependent largely on the Cu2+/Cu1+ redox potential and lipophilicity of the 
complex.14,16,26 Research into ‘tuning’ these properties in novel species to optimise hypoxia 
selectivity is ongoing.27
Figure 4. Bioreductive trapping of Cu-ATSM is dependent on the ability of the complex 
to enter the cell (lipophilicity), and how readily the metal can dissociate from the ligand. 
Cytosolic thiols replace the ATSM. Adapted from Dearling and Packard.28
The neutral, lipophilic complex Cu-ATSM can diffuse across cell membranes. Once inside 
the cytoplasm, thiol groups on endogenous redox-active proteins can react with the oxidising 
metal centre (forming disulphide bonds as part of a common mechanism of protecting 
cellular function), resulting in a reduction of the metal from the +II oxidation state to the +I 
oxidation state.28–34
The charged complex [Cu1+-ATSM]- is less lipophilic and is unable to diffuse out of the cell. 
In normoxic cells oxygen content is sufficient to reoxidise the metal centre and allow egress 
of the complex, but in hypoxic cells the equilibrium of the redox is shifted and the reduced 
form persists. Cu1+ is a 3d10 metal centre and has a ligand field stabilisation energy (LFSE) of 
zero. It is a soft acid with a preference for soft donors, hence sulphur donors are bound 
more strongly by Cu1+ than by Cu2+ which is an intermediate/hard acid with a preference for 
intermediate/hard donors e.g. N, O.35
Although BTSC complexes bind strongly to Cu2+ (KD ~ 10-17 M-1) and Cu1+ (KD ~ 10-13 M-1), 
reduction followed by ligand distortion would allow ligand donor groups to be replaced by 
S-donors (via dissociative ligand substitution) from competing cytosolic thiols that may be 
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present in millimolar quantities and which can function as a thermodynamic sink for Cu1+ 
(KD ~ 10-39 M-1).36 The reducing environment within a hypoxic cell aids this acid-catalysed 
dissociation; N-donors will be replaced by the preferred S-donors, and the ligand-based S-
groups can be protonated and out-competed by the endogenous donors. Upon dissociation, 
the metal will be sequestered by the cell’s endogenous proteins, irreversibly trapping the 
radionuclide.28
The study of the in vivo behaviour of analogues of Cu-ATSM allowed this mechanistic 
understanding to be arrived at. Although some lipophilicity (the affinity for a molecule for a 
lipophilic (i.e. non-polar) environment, often quantified as the partition coefficient Kow
measured by extraction of the species into octanol from water) is necessary for complexes 
of this family to enter cells (i.e. the molecules must have log10Kow > 0), it has been found that 
structural changes that result in moderate lipophilicity differences show little correlation to 
hypoxia selectivity.16,26
Changing the redox potential of the metal centre has a marked effect on hypoxia selectivity 
(Table 1).12,14,16,26 Cu-BTSC complexes that are ‘hypoxia-selective’ (i.e. which preferentially 
accumulate in hypoxic tissues as observed from radiotracer studies) have more negative 
redox potentials than their analogues which show no selectivity or which are normoxia-
selective.  
Complex R1 R2 R3 R4 E1/2 Cu2+/+ 
V vs. 
Ag/AgCl
Backbone C-
C bond 
length (Å)
Selectivity 
in CHO320 
cells
Cu-GTSM H H CH3 H -0.43 1.452(3) Normoxia
Cu-PTS CH3 H H H -0.50 1.470(4) Insignificant
Cu-ATSM CH3 CH3 CH3 H -0.59 1.479(3) Hypoxia
Cu-DTS C2H5 C2H5 CH3 H -0.59 1.480(6) Hypoxia
Table 1. Data for selected BTSC complexes. Note how as C-C bond lengths increase, 
redox potential decreases and hypoxia is selected for. Adapted from Blower et al.14 and 
Vavere and Lewis.12
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Having a more negative redox potential indicates that the Cu2+ centre is less readily reduced 
(and Cu1+ is more readily oxidised) when bound as Cu-ATSM (E1/2 = -0.59 V vs Ag/AgCl) 
than for Cu2+ coordinated in Cu-GTSM (E1/2 = -0.43 V vs Ag/AgCl).12 Hypoxic cells must 
have a greater reduction from normal oxygen levels in order to reduce Cu2+, to prevent 
reoxidation of Cu1+ and to facilitate radioisotope dissociation and sequestration when 64Cu-
ATSM is administered. For complexes with less negative redox potentials, Cu2+ can be 
reduced at oxygen levels that are lower than normal but which are not indicative of truly 
chronic hypoxia, allowing sequestration to occur in cells that are not cancerous; the complex 
is not ‘hypoxia-selective’.
The redox potential may be reduced by introducing electron donating backbone constituents 
that have a two-fold effect (structural changes away from the co-ordination sphere have little 
effect on selectivity).14 First, increased electron donation stabilises the higher oxidation state. 
More importantly, steric clash between the groups leads to a lengthening of the backbone C-
C bond.14 This results in the sulphur arms moving inward, allowing the ligand to coordinate 
in a manner closer to an ideal square-planar geometry. In the work by Blower et al. the average 
N-Cu-S angle increases from 84.24 to 85.16 °, while the average S-Cu-S angle decreases from 
109.75 to 108.99 °.14 Both angles are closer in value to the bond angles measured in Ni-
ATSM, showing an improved ‘metal-ligand fit’ along with reduced reduction potential and 
enhanced hypoxia-selectivity as a result of backbone alkylation. This is also reflected in the 
planarity of the complexes as expressed by torsion angles: the angles are lowest in the almost 
planar Ni-ATSM, increase for Cu-ATSM (reflecting the poorer fit of the larger metal ion 
forcing a geometric distortion), and increase again when the alkyl groups are not present in 
Cu-GTSM, as the shorter backbone results in a smaller ligand cavity and worse fit.14
Cu2+ (intermediate/hard acid, d9) typically coordinates in a Jahn-Teller distorted octahedral 
geometry, while Cu1+ (soft acid, d10) prefers tetrahedral coordination, most commonly with 
soft sulphur donors. The release of Cu1+ that is necessary for hypoxia-selective contrast is 
blocked by several energetic barriers: the initial one-election reduction of Cu2+ is disfavoured 
as it results in the loss of the Jahn-Teller stabilisation energy, the coordination sphere (N2S2) 
is not the preferred donor set of Cu1+, and the ligand must twist to change to the preferred 
coordination geometry of Cu1+. Backbone alkylation improves the metal-ligand fit for Cu2+ 
by limiting strain within the molecule that can contribute to a distortion towards tetrahedral 
geometry, promoting planarity and increasing the energy barrier to reduction. 
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To conclude, reductive 64Cu-ATSM dissociation in hypoxic cells results in tracer 
accumulation. The ability of the cell to reduce the metal ion and the maintenance of the lower 
oxidation state is crucial to the selectivity of the agent. Once reduced, a distortion of the 
square planar ligand system can result in dissociation. A protein binding 64Cu-ATSM in a way 
that induces tetrahedral distortion increases strain and would increase the likelihood of the 
radioisotope dissociating by reducing the energetic barrier that must be overcome (‘the 
entatic effect’). If such a protein could be directed to internalise in cancer cells, the selectivity 
for 64Cu-ATSM to dissociate and label cancer cells would be enhanced. 
5.1.4 The use of haptens in polyclonal antibody development 
The generation of antibodies within a living creature is the result of the immune system 
recognising a foreign entity. Any species identified as ‘non-self’ is defined as an antigen. If 
an immune response such as antibody production is elicited, the antigen is an immunogen.37
To generate an immune response a species must have a recognisable epitope and be 
physically large enough to initiate lymphocyte activation. Small molecules and ions with 
molecular weights less than approximately 1000 are not large enough to elicit an immune 
response, but if the molecule in question can be attached to a ‘carrier protein’, the size of the 
protein will stimulate an immune response and the bound molecule will serve as the 
recognised epitope.38 In this case the small molecule is referred to as a ‘hapten’. The most 
common carrier proteins used today are Bovine Serum Albumin (BSA) and Keyhole Limpet 
Hemocyanin (KLH). KLH is extremely immunogenic due to its non-mammal origin, 
extremely large molecular weight and complex structure. With several hundred lysine groups 
per molecule to allow hapten conjugation KLH is the most widely used carrier protein.37
Antibodies raised in an animal will be polyclonal. Released by different B cell lines within the 
body, they will identify different epitopes of an immunogen. In the context of a hapten-
carrier conjugate, a population of polyclonal antibodies will contain immunoglobulins that 
recognise the hapten when it is in different states or will bind the hapten in different ways.   
5.1.5 Enzymes, catalytic antibodies and the proposed use of M-BTSC complexes 
as haptens 
Enzymes catalyse biological processes by offering a binding site that has geometric and 
electronic complementarity to a substrate molecule. This binding site is largely preformed 
but is changed upon binding according to the ‘induced fit’ model of enzyme catalysis. 
However this is insufficient to explain the large rate enhancements seen in enzymatically 
catalysed reactions. It is known that enzymes bind the transition state of a process with 
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greater affinity than the product or substrate molecules.39 Transition states cannot be isolated, 
but computational studies and an understanding of the likely mechanism can allow 
researchers to hypothesise the nature of the transition state for a given process, allowing 
stable mimics of the transition state to be synthesised. Using such analogues as haptens has 
allowed researchers to generate antibodies that stabilise the transition state of a chemical 
process and which function as catalysts by straining the substrate, reducing the energetic 
barrier that must be overcome.40 The first catalytic antibodies were reported in the 1986 
independently by the Schultz and Lerner groups (Fig. 5).41,42 Early work focussed on the use 
of ‘abzymes’ for small molecule transformations in industrial contexts but more recently 
diverse applications of this technology have been investigated, including the treatment of 
addiction, Alzheimer’s disease and the degradation of chemical warfare agents.43
Figure 5. One of the first catalytic antibodies catalysed the hydrolysis of a carbonate 
group. The monoanionic tetrahedral transition state is mimicked by the stable 
phosphonate group of the analogue.41
It was postulated that antibodies could be raised that would catalyse the reduction of Cu-
ATSM. As has been described, the sensitivity of the hypoxia-targeting function of 64Cu-
ATSM is dependent on the ability of the complex to undergo a twist from square-planar to 
tetrahedral following reduction of the metal. It has been reported that deviations in planarity 
reported in the crystal structure of Cu-BTSC complexes are a result of external packing forces 
and not inherent in the structures of the ligands themselves, which energetically would favour 
the square planar geometry when coordinating a metal.14 However, the nature of the metal 
may contribute to deviations from ideal geometry. A study of bond angles in Cu-BTSC 
complexes showed that the cavity presented in these ligands is too small to ideally 
accommodate the Cu2+ ion; N-Cu-N bond angles are typically 80 ° (compared to an ideal 
value of 90 °), and the sulphur donors are pushed out to approximately 120 °. The 
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coordination of the smaller Ni2+ (d8) ion by the ATSM ligand show angles at the metal centre 
closer to 90 °, more closely approximating ideal square planar coordination (see Fig. 6).14
Moving to a larger ion, Zn-ATSM shows a distorted square pyramidal crystal structure in the 
solid state.44 As a d10 centre, no ligand field stabilisation energy (LFSE) is gained by 
coordination of the metal to offset the increased energy resulting from ligand strain. It can 
be assumed that in the solution phase, the Zn analogue of Cu-ATSM tends to twist away 
from square planar to minimise the strain. Other studies have shown that the larger Cd2+ can 
be accommodated by similar ligands opening further to give a distorted octahedral geometry 
with solvent molecules in apical positions.45
Figure 6. Cu-ATSM and Ni-ATSM share a tetradentate coordination sphere, but the 
nickel complex shows bond angles in closer agreement with ideal square planar 
geometry. Analysis of displacement of ligands atoms from a plane defined by the metal 
show a more planar complex for Ni2+. Adapted from Blower et al.14
Bifunctional chelators based on Cu-ATSM are known.46 Introduction of functional groups 
away from the coordination sphere does not significantly affect the coordination or redox 
potential of the copper centre. Asymmetric ligands displaying carboxylate and amine groups 
for conjugation have been studied.47 In the current work, three ligands (Fig. 7) were 
synthesised and characterised, along with their complexes with Cu2+, Ni2+, Zn2+ and Cd2+. 
H2L1 and H2L2 are based respectively on 2, 3-butandione and glyoxal backbones and have 
2-carbon linker arms terminating in ethyl ester protected carboxylic acids. The loss of the 
backbone methyl groups from H2L1 would theoretically result in shorter C-C backbone 
bonds in H2L2.14 This would in effect make the ligand cavity smaller and would force greater 
deviation from planarity when coordinating a metal centre. H2L3 is an analogue for H2L1
where the terminal groups are t-Butoxycarbonyl protected amine groups. Deprotection of 
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these species would give functionalities which could be used to achieve bioconjugation to a 
carrier protein. The deprotected forms of the three ligands and their complexes would 
coordinate differently to a carrier protein due to the different functionalities and so would 
present different recognisable epitopes for antibody generation. The relatively short linker 
arms were chosen to force the complex close to the bulky carrier protein, increasing steric 
effects that could distort the ligand cavity. 
Figure 7. Structures of ligands H2L1-3. Transition metal complexes were synthesised and 
are discussed below. 
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5.1.6 Aims and objectives 
Three ligands and their metal complexes were designed for use as haptens for antibody 
generation in sheep. Ligands were designed to be similar to known BTSC ligands (e.g. 
ATSMH2 and GTSMH2) but which could be bioconjugated to proteins via two groups. The 
use of different metals with different ionic sizes and coordination preferences was intended 
to maximise the potential for identifying an antibody that would bind Cu-ATSM in a 
geometry approaching tetrahedral and act as a catalyst for demetallation. The target antibody 
was then to be used along with a relevant clinically approved therapeutic monoclonal 
antibody (mAb) to create a bispecific antibody capable of first internalising in cancerous cells 
and then catalysing the reduction of 64Cu-ATSM, enhancing the in vivo selectivity of the 
copper species for cancer cells based on their hypoxic environment and on their phenotype. 
Additionally, it was considered that several of the BTSC complexes synthesised for use as 
haptens may have antibacterial or anthelmintic activity. Experiments were performed to 
identify whether such complexes satisfied unmet clinical needs. 
Unfortunately, deprotection conditions to give forms of the complexes and ligands suitable 
for bioconjugation could not be identified. Example procedures that were unsuccessful are 
given in Additional Experimental Section III. For all conditions trialled an uncharacterisable 
mixture of multiple species resulted. Future work on this project could focus on developing 
conditions that deprotect the complexes and ligands without significant decomposition. 
Other ligands designed and synthesised as part of this work are also discussed in Additional 
Experimental Section III. They are not included here because in all cases, the syntheses 
resulted in an impure sample that due to their limited solubility and stability under harsh 
conditions could not be purified or characterised satisfactorily. 
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5.2 Experimental  
5.2.1 Materials and Methods 
All reactions were performed with the use of vacuum line and Schlenk techniques. Reagents 
were commercial grade and were used without further purification. All reagents and solvents 
were purchased from Alfa Aesar or Sigma Aldrich. 1H and 13C-{1H} NMR spectra were 
recorded on an NMR-FT Bruker 400 MHz or Joel Eclipse 300 MHz spectrometer and 
recorded in CDCl3, CD3OD or d6-DMSO. 1H and 13C-{1H} NMR chemical shifts (δ) were 
determined relative to internal TMS and are given in ppm. Coupling constants J are given in 
hertz (Hz). Low- and high-resolution mass spectra were obtained using a Waters LCT 
Premier XE instrument and are reported as m/z (relative intensity). IR spectra are recorded 
as solid samples on a Shimadzu IRAffinity-1 FTIR spectrometer. UV-Vis studies were 
performed on a Jasco V-570 spectrophotometer as MeCN solutions (5 × 10-5 M). 
Microanalyses were performed by London Metropolitan University, UK. X-ray 
crystallography was performed by the UK National Crystallography Service.48 Anti-parasitic 
assays were kindly performed by K. Whatley, Parasitology and Epidemiology Group, 
Aberystwyth University, UK. Antibacterial MIC determination experiments were performed 
by Sion Edwards and Prof. D.W. Williams School of Biosciences, Cardiff University, UK 
and were carried out on a BMG LabTech FLUOstar Omega plate reader. 
5.2.2 Synthesis and analytical techniques 
Ethyl-2-(hydrazinecarbothioamido)acetate (1)
Ethyl isothiocyanatoacetate (3 mL, 24.2 mmol) was dissolved in EtOH (60 mL) at 0 °C. 
Hydrazine hydrate (1.22 mL, 25 mmol) in cold EtOH (20 mL) was added dropwise over 30 
mins with stirring. The mixture was stirred for a further 30 mins, allowed to reach room 
temperature, stirred for 30 mins, then cooled to 0 °C once again. The precipitate was 
collected by filtration, washed with cold EtOH (20 mL) and dried to give the product as a 
white solid (3.56 g, 20.1 mmol, 83%). 1H NMR (400 MHz, CDCl3) δH = 7.82 (1H, br s, NH), 
7.14 (1H, br s, NH), 4.38 (2H, d, 3JHH = 5.2 Hz, CH2NH), 4.18 (2H, q, 3JHH = 7.2 Hz, 
CH2CH3), 3.79 (2H, br s, NH2), 1.24 (3H, t, 3JHH = 7.2 Hz, CH2CH3) ppm. 13C NMR (75 
MHz, CDCl3) δC = 183.1 (CS), 169.8 (CO), 61.7 (CH2CH3), 45.8 (CH2NH), 14.3 (CH2CH3) 
ppm. HR-MS (EI+) found m/z 177.0571, calculated m/z 177.0572 for [C5H11N3O2S]+. IR 
(ATP) υ = 3341 (NH), 3311 (NH), 3264 (NH), 1743 (CO), 1079 (CS) cm-1.
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Figure 8. Synthetic schemes for ligand and complexes described in this report. i) N2H4.H2O, EtOH, 0 °C, 1 h. ii) Boc2O, DCM, 0 °C, 0.5 h, RT, overnight. 
iii) CS2, NEt3, TsCl, THF, RT, overnight. iv) N2H4.H2O, EtOH, 0 °C, 1 h. v) 2, 3-butandione or glyoxal, EtOH, reflux, 4 h or overnight. vi) M(OAc)2.xH2O, 
EtOH, reflux, 4 h. 
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Ligand H2L1
Ethyl-2-(hydrazinecarbothioamido)acetate (1) (1.062 g, 6.00 mmol) and 2,3-butanedione 
(0.263 mL, 3.00 mmol) in EtOH (20 mL) were heated at reflux with H2SO4 (1 drop) for 4 h. 
The mixture was allowed to cool to room temperature, the precipitate collected by filtration, 
washed with cold EtOH (10 mL) and dried in vacuo to give the product as a white solid (1.12 
g, 2.76 mmol, 92 %). 1H NMR (400 MHz, d6-DMSO) δH = 10.60 (2H, s, 2 × NH), 8.69 (2H, 
t, 3JHH = 5.9 Hz, 2 × NHCH2), 4.33 (4H, d, 3JHH = 5.9 Hz, 2 × NHCH2), 4.16 (4H, q, 3JHH = 
7.1 Hz, 2 × CH2CH3), 2.26 (6H, s, 2 × CCH3), 1.22 (6H, t, 3JHH = 7.1 Hz, 2 × CH2CH3) ppm. 
13C NMR (75 MHz, d6-DMSO) δC = 179.5 (CS), 169.9 (CO), 149.1 (CCH3), 61.1 (CH2CH3), 
46.1 (CH2NH), 14.7 (CH2CH3), 12.4 (CCH3) ppm. HR-MS (ES+) found m/z 427.1183, 
calculated m/z 427.1198 for [C14H24N6O4S2 + Na]+. IR (ATP) υ = 3335 (NH), 3190 (NH), 
2997 (CH), 1730 (CO), 1487, 1200 (CS) cm-1.
Ligand H2L2
Prepared similarly from ethyl-2-(hydrazinecarbothioamido)acetate (1) (1.062 g, 6.00 mmol) 
and glyoxal (6.33 mL, 40 % aqueous solution, 3.00 mmol) in EtOH (20 mL) to give the 
product as a pale yellow solid (0.96 g, 2.55 mmol, 85 %). 1H NMR (400 MHz, d6-DMSO) δH
= 8.88 (2H, t, 3JHH = 5.9 Hz, 2 × NHCH2), 7.86 (2H, s, 2 × NCH), 4.32 (4H, d, 3JHH = 5.9 
Hz, 2 × NHCH2), 4.18 (4H, q, 3JHH = 7.1 Hz, 2 × CH2CH3), 1.27 (6H, t, 3JHH = 7.09 Hz, 2 
× CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 178.6 (CS), 169.8 (CO), 141.2 (NCH), 
61.0 (CH2CH3), 45.7 (CH2NH), 14.7 (CH2CH3) ppm. HR-MS (ES+) found m/z 399.0869, 
calculated m/z 399.0885 for [C12H20N6O4S2 + Na] +. IR (ATP) υ = 3285 (NH), 3250 (NH), 
2988 (CH), 1740 (CO), 1479, 1200 (CS) cm-1.
Complex CuL1
Ligand H2L1 (0.500 g, 1.24 mmol) and Cu(OAc)2·H2O (0.247 g, 1.24 mmol) were heated at 
reflux in EtOH (20 mL) for 4 h. The solution turned dark purple over the 4 h. The solvent 
was removed in vacuo, the crude product dissolved in CH2Cl2 (15 mL) and washed with water 
(2 × 25 mL) and brine (25 mL). The organic phase was collected, dried over Na2SO4 and 
filtered. The solvent was then removed in vacuo to give the product as a dark purple solid 
(0.416 g, 0.89 mmol, 72 %). Elemental analysis: Calcd. (%) for C14H22N6O4S2Cu: C, 36.08, H, 
4.76, N, 18.03; Found: C, 35.93, H, 4.85, N, 17.95. HR-MS (ES+) found m/z 466.0522, 
calculated m/z 466.0518 for [C14H23N6O4S263Cu]+. IR (ATP) υ = 3390 (NH), 3321 (NH), 
2972 (CH), 1738 (CO), 1445, 1215 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 
522(2610) 473(4868), 346(8981), 306(18732), 250(10265) nm. 
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Complex ZnL1
Prepared similarly from ligand H2L1 (0.150 g, 0.37 mmol) and Zn(OAc)2·2H2O (0.107 g, 0.37 
mmol) in EtOH (20 mL). A precipitate formed, which was filtered and washed with EtOH 
(10 mL) to give the product as a bright yellow solid (0.147 g, 0.31 mmol, 85 %). 1H NMR 
(400 MHz, d6-DMSO) δH = 7.69 (2H, br s, NH), 4.14 (4H, q, 3JHH = 7.2 Hz, 2 × CH2CH3), 
3.98 (4H, br s, 2 × NHCH2), 2.20 (6H, s, 2 × CCH3), 1.24 (6H, t, 3JHH = 7.2 Hz, 2 × CH2CH3) 
ppm. 13C NMR (75 MHz, d6-DMSO) δC = 170.7 (CO), 147.1 (CN), 60.5 (CH2CH3), 44.2 
(CH2NH), 14.7 (CH2CH3), 14.2 (CCH3) ppm. Elemental analysis: Calcd. (%) for 
C14H22N6O4S2Zn: C, 35.94, H, 4.74, N, 17.96; Found: C, 35.81, H, 4.73, N, 17.82. HR-MS 
(ES+) found m/z 467.0521, calculated m/z 467.0514 for [C14H23N6O4S264Zn]+. IR (ATP) υ
= 3399 (NH), 3316 (NH), 2968 (CH), 1783 (CO), 1543, 1198 (CS) cm-1. UV-Vis (MeCN): 
λmax (ε / L mol-1 cm-1) 424(9950), 305(12600), 258(11000) nm.
Complex NiL1
Prepared similarly from ligand H2L1 (0.250 g, 0.62 mmol) and Ni(OAc)2·4H2O (0.154 g, 0.62 
mmol) in EtOH (10 mL). A precipitate formed, which was filtered and washed with EtOH 
(10 mL) to give the product as a brown solid (0.234 g, 0.51 mmol, 82 %). 1H NMR (400 
MHz, d6-DMSO) δH = 8.17 (2H, br s, 2 × NH, 4.11 (4H, br, 2 × CH2CH3), 4.04 (4H, br s, 2 
× NHCH2), 1.88 (6H, br s, 2 × CCH3), 1.20 (6H, br, 2 × CH2CH3) ppm. 13C NMR (75 MHz, 
CDCl3) δC = 169.2 (CO), 158.0 (CN), 61.7 (CH2CH3), 40.0 (CH2), 14.2 (CH2CH3), 14.0 
(CCH3) ppm. Elemental analysis: Calcd. (%) for C14H22N6O4S2Ni: C, 36.46, H, 4.81, N, 18.22; 
Found: C, 36.53, H, 4.93, N, 18.17. HR-MS (ES+) found m/z 461.0585, calculated m/z 
461.0576 for [C14H23N6O4S258Ni]+. IR (ATP) υ = 3377 (NH), 3333 (NH), 2968 (CH), 1724 
(CO), 1497, 1198 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 392(12118), 330(6556), 
255(27184) nm.
Complex CdL1
Prepared similarly from ligand H2L1 (0.500 g, 1.24 mmol) and Cd(OAc)2·2H2O (0.330 g, 1.24 
mmol) in EtOH (10 mL). A precipitate formed, which was filtered and washed with EtOH 
(10 mL) to give the product as a bright yellow solid (0.581 g, 1.13 mmol, 91 %). 1H NMR 
(400 MHz, d6-DMSO) δH = 7.60 (2H, br s, 2 × NHCH2), 4.75 (4H, q, 3JHH = 7.1 Hz, 2 × 
CH2CH3), 3.91 (4H, m, 2 × NHCH2), 2.16 (6H, s, 2 × CCH3), 1.18 (6H, t, 3JHH = 7.1 Hz, 2 
× CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 170.0 (CO), 144.8 (CN), 61.3 
(CH2CH3), 40.5 (CH2NH), 15.3 (CH2CH3), 14.3 (CCH3) ppm. Elemental analysis: Calcd. (%) 
for C14H22N6O4S2Cd: C, 32.66, H, 4.31, N, 16.32; Found: C, 32.76, H, 4.26, N, 16.25. HR-
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MS (ES+) found m/z 517.0250, calculated m/z 517.0256 for [C14H23N6O4S2114Cd]+. IR 
(ATP) υ = 3404 (NH), 2968 (CH), 1736 (CO), 1201 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L 
mol-1 cm-1) 410(8760), 298(9400), 263(7680), 206(26360) nm.
Complex CuL2
Prepared similarly to CuL1 from ligand H2L2 (0.200 g, 0.53 mmol) and Cu(OAc)2·H2O (0.107 
g, 0.53 mmol) in EtOH (20 mL) yielding the product as a dark red solid (0.169 g, 0.39 mmol, 
73 %). Elemental analysis: Calcd. (%) for C12H18N6O4S2Cu: C, 32.77, H, 4.13, N, 19.11; 
Found: C, 32.84, H, 4.08, N, 19.04. HR-MS (ES+) found m/z 438.0200, calculated m/z 
438.0205 for [C12H19N6O4S263Cu]+. IR (ATP) υ = 3316 (NH), 2972 (CH), 1734 (CO), 1215 
(CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 544(4164), 503(6650), 359(11550), 
312(20300) nm. 
Complex ZnL2
Prepared similarly to ZnL1 from ligand H2L2 (0.200 g, 0.53 mmol) and Zn(OAc)2·2H2O 
(0.117 g, 0.53 mmol) in EtOH (10 mL) yielding the product as a bright yellow solid (0.200 g, 
0.46 mmol, 86 %). 1H NMR (400 MHz, d6-DMSO) δH = 7.90 (2H, br s, 2 × NH), 7.60 (2H, 
s, 2 × NCH), 4.14 (4H, q, 3JHH = 7.1 Hz, 2 × NHCH2), 4.04 (4H, m, 2 × CH2CH3), 1.25 (6H, 
t, 3JHH = 7.1 Hz, 2 × CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 169.4 (CO), 137.1 
(CHN), 61.7 (CH2CH3), 14.3 (CH2CH3) ppm. Elemental analysis: Calcd. (%) for 
C12H18N6O4S2Zn: C, 32.91, H, 4.14, N, 19.19; Found: C, 32.95, H, 4.30, N, 18.99. HR-MS 
(ES+) found m/z 439.0207, calculated m/z 439.0201 for [C12H19N6O4S264Zn]+. IR (ATP) υ
= 3352 (NH), 2968 (CH), 1738 (CO), 1215 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-
1) 445(22100), 424(20479), 318(10480), 262(6250) nm.
Complex NiL2
Prepared similarly to NiL1 from ligand H2L2 (0.100 g, 0.27 mmol) and Ni(OAc)2·4H2O (0.067 
g, 0.27 mmol) in EtOH (10 mL) yielding the product as brown solid (0.104 g, 0.24, 89 %). 
1H NMR (400 MHz, CDCl3) δH = 1H NMR (400 MHz, d6-DMSO) δH = 8.42 (2H, br s, 2 × 
NHCH2), 6.98 (2H, br s, 2 × NCH), 4.12 (4H, m, 2 × CH2CH3), 3.93 (4H, d, 3JHH = 5.8 Hz, 
2 × NHCH2), 1.19 (6H, t, 3JHH = 7.1 Hz, 2 × CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) 
δC = 179.0 (CN), 169.6 (CO), 146.2 (CNH), 61.2 (CH2CH3), 47.2 (CH2NH), 14.6 (CH2CH3) 
ppm. Elemental analysis: Calcd. (%) for C12H18N6O4S2Ni: C, 33.28, H, 4.19, N, 19.40; Found: 
C, 33.15, H, 4.10, N, 19.27. HR-MS (ES+) found m/z 433.0264, calculated m/z 433.0263 
for [C12H19N6O4S258Ni]+. IR (ATP) υ = 3339 (NH), 3304 (NH), 2972 (CH), 1738 (CO), 1570, 
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1215 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 414(10240), 334(4860), 257(22240) 
nm.
Complex CdL2
Prepared similarly to CdL1 from ligand H2L2 (0.100 g, 0.27 mmol) and Cd(OAc)2·2H2O 
(0.072 g, 0.27 mmol) in EtOH (10 mL) yielding the product as a bright yellow solid (0.122 g, 
0.25 mmol, 93 %). 1H NMR (400 MHz, d6-DMSO) δH = 7.65 (2H, br s, 2 × NHCH2), 7.48 
(2H, br s, 2 × NCH), 4.02 (4H, m, 2 × CH2CH3), 3.88 (4H, br s, 2 × NHCH2), 1.12 (6H, t, 
3JHH = 7.1 Hz, 2 × CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 170.6 (CO), 138.0 
(CSN), 137.8 (CHN), 60.7 (CH2CH3), 40.9 (CH2NH), 14.7 (CH2CH3) ppm. Elemental 
analysis: Calcd. (%) for C12H18N6O4S2Cd: C, 29.60, H, 3.73, N, 17.26; Found: C, 29.78, H, 
3.68, N, 17.11. HR-MS (ES+) found m/z 488.9937, calculated m/z 488.9943 for 
[C12H19N6O4S2114Cd]+. IR (ATP) υ = 3416 (NH), 3325 (NH), 2972 (CH), 1738 (CO), 1540, 
1200 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 441(13178), 416(14166), 310(10545), 
272(9976) nm. 
N-Boc-ethylenediamine (2)
Prepared by modification of literature methods.49 Ethylenediamine (24 mL, 36.8 mmol) was 
dissolved in dry DCM (150 mL) and cooled to 0 °C. Boc2O (8.0 g, 36.8 mmol) was dissolved 
in dry DCM (50 mL) and added dropwise over 30 mins. The reaction mixture was allowed 
to come to room temperature and stirred overnight. A white suspension was seen to form. 
The reaction mixture was diluted with DCM (50 mL), washed with H2O (5 × 40 mL), and 
the organic layer dried over Na2SO4. The solvent was removed in vacuo to give the product 
as a colourless oil (4.2 g, 26.2 mmol, 71 %) that was used without further purification. 1H 
NMR (400 MHz, CDCl3) δH = 4.94 (1H, br, NHBoc), 3.10 (2H, dd, NH2CH2), 2.73 (2H, t, 
3JHH = 6.03 Hz, CH2), 1.38 (9H, s, C(CH3)3) ppm. HR-MS (APCI+) found m/z 161.1291, 
calculated m/z 161.1290 for [C7H17N2O2]+. 
N-Boc-2-Isothiocyanatoethylamine (3)
Prepared by modification of literature methods.50 N-Boc-ethylenediamine (2) (4 g, 25 mmol) 
was dissolved in dry THF (50 mL) and cooled to 0 °C. Carbon disulfide (1.5 mL/, 25 mmol) 
and NEt3 (12.2 mL, 87.7 mmol) were added, and the ice was removed to allow the reaction 
mixture to be stirred for 1 h at room temperature. The reaction mixture was cooled back to 
0 °C, and tosyl chloride (7.16 g, 37.6 mmol) was added. The solution was stirred at room 
temperature for 3 h, DCM (50 mL) was added, and the solution stirred overnight. The 
reaction was washed with 10 % citric acid solution (5 × 20 mL), H2O (3 × 20 mL), and the 
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organic fraction was dried over anhydrous Na2SO4. The solvent was removed in vacuo to give 
the product as an off-white solid (3.54 g, 17.5 mmol, 70 %) that was used without further 
purification. 1H NMR (400 MHz, CDCl3) δH = 4.90 (1H, br, NHBoc), 3.58 (2H, b, NH2CH2), 
3.31 (2H, br, CH2), 1.39 (9H, s, C(CH3)3) ppm. 13C NMR (100 MHz, d6-DMSO) δC = 130.3 
(CO), 127.1 (CS), 80.2 (C(CH3)3), 45.5 (CH2NCS), 40.6 (CH2NH), 28.4 (C(CH3)3) ppm. HR-
MS (APCI+) found m/z 202.0773, calculated m/z 202.0776 for [C8H14N2O2S]+. IR (ATP) υ
= 3343 (NH), 2097 (NCS), 1688 (CO) cm-1 
N-Boc-2-thiocarbohydrazidoethylamine (4)
N-Boc-2-Isothiocyanatoethylamine (3) (3 g, 14.8 mmol) was dissolved in EtOH (20 mL) and 
cooled to 0 °C. Hydrazine hydrate (0.8 mL, 16.4 mmol) was dissolved in cold EtOH (20 mL) 
and added dropwise over 30 min. The reaction mixture was stirred for 30 min, allowed to 
come to room temperature, stirred for another 30 min, then cooled and the solvent removed 
in vacuo to give a colourless oil, which was triturated with CHCl3 to give the product as an 
off-white solid (3.16 g, 13.5 mmol, 91 %). 1H NMR (400 MHz, CDCl3) δH = 7.76 (1H, br, 
NH), 7.30 (1H, br, NH), 4.93 (1H, br, NHBoc), 3.70 (2H, m, CH2), 3.33 (2H, m, CH2), 1.37 
(9H, s, C(CH3)3) ppm. 13C NMR (100 MHz, CDCl3) δC = 182.5 (CS), 156.6 (CO), 79.6 
(C(CH3)3), 44.3 (CH2), 40.2 (CH2), 28.6 (C(CH3)3) ppm. HR-MS (APCI+) found m/z 
235.1219, calculated m/z 235.1229 for [C8H19N4O2S]+. IR (ATP) υ = 3298 (NH), 2972 (NH), 
2934 (NH), 1686 (CO), 1533, 1161 (CS) cm-1. 
Ligand H2L3
N-Boc-2-thiocarbohydrazidoethylamine (4) (2.24 g, 9.57 mmol) was suspended in EtOH (20 
mL), and 2, 3-butanedione (0.41 mL, 4.668 mmol) added dropwise over 10 min before the 
reaction mixture was heated at reflux for 24 h. The precipitate formed was collected by 
filtration, washed with cold EtOH, and dried in vacuo to give the product as a yellow solid 
(1.67 g, 3.22 mmol, 69 %). 1H NMR (400 MHz, d6-DMSO) δH = 10.45 (2H, s, 2 × NH), 8.52 
(2H, t, 3JHH = 6.0 Hz, 2 × NHCH2), 7.12 (2H, t, 3JHH = 4.0 Hz, 2 × NHBoc), 3.65 (4H, m, 2 
× CH2), 3.25 (4H, m, 2 × CH2NHBoc), 2.30 (6H, s, 2 × CH3), 1.43 (18H, s, 2 × C(CH3)3). 
13C NMR (75 MHz, d6-DMSO) δC =178.6 (CS), 156.7 (CO), 148.7 (CN), 78.4 (C(CH3)3), 45.0 
(CH2), 28.8 (C(CH3)3), 12.3 (CH3) ppm. HR-MS (EI+) found m/z 518.2454, calculated m/z 
518.2457 for [C20H38N8O4S2]+. IR (ATP) υ = 3377 (NH), 3316 (NH), 2968 (CH), 1738 (CO), 
1667 (CN), 1200 (CS) cm-1.
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Complex CuL3
Ligand H2L3 (0.100 g, 0.19 mmol) and Cu(OAc)2·H2O (0.040 g, 0.20 mmol) were heated at 
reflux in EtOH (20 mL) for 4 h. The solution turned dark purple over the 4 h. The solvent 
was removed in vacuo, the crude product dissolved in CH2Cl2 (15 mL) and washed with water 
(2 × 25 mL) and brine (25 mL). The organic phase was collected, dried over Na2SO4 and 
filtered. The solvent was then removed in vacuo to give the product as a dark red solid (0.080 
g, 0.14 mmol, 73 %). Elemental analysis: Calcd. (%) for C20H36N8O4S2Cu: C, 41.40, H, 6.25, 
N, 19.31; Found: C, 58.48, H, 6.06, N, 18.19. HR-MS (ES+) found m/z 578.1516, calculated 
m/z 578.1524 for [C20H35N8O4S263Cu]-. IR (ATP) υ = 3310 (NH), 2972 (CH), 1740 (CO), 
1364, 1215 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 472(6135), 354 (10738), 
308(21767) nm. 
Complex ZnL3
Prepared similarly from ligand H2L3 (0.100 g, 0.19 mmol) and Zn(OAc)2·2H2O (0.043 g, 0.20 
mmol) in EtOH (20 mL) to give the product as a bright yellow solid (0.088 g, 0.152 mmol, 
80 %). 1H NMR (400 MHz, d6-DMSO) δH = 7.23 (2H, br, 2 × NH), 6.89 (2H, t, 3JHH = 6.6 
Hz, 2 × NHCH2), 3.11 (4H, q, 3JHH = 6.6 Hz, 2 × CH2), 2.21 (6H, s, 2 × CH3), 1.88 (4H, br, 
2 × CH2), 1.38 (18H, s, 2 × C(CH3)3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 155.6 (CS), 
145.0 (CO), 77.6 (C(CH3)3), 28.2 (C(CH3)3), 13.9 (CH3) ppm. Elemental analysis: Calcd. (%) 
for C20H36N8O4S2Zn: C, 41.27, H, 6.23, N, 19.25; Found: C, 41.43, H, 6.36, N, 19.11. HR-
MS (ES+) found m/z 581.1699, calculated m/z 581.1666 for [C20H37N8O4S264Zn]+. IR (ATP) 
υ = 3298 (NH), 3228 (NH), 2972 (CH), 1740 (CO), 1504, 1215 (CS) cm-1. UV-Vis (MeCN): 
λmax (ε / L mol-1 cm-1) 418(9040), 316(10241) 273(20742) nm.
Complex NiL3
Prepared similarly from ligand (0.100 g, 0.19 mmol) and Ni(OAc)2·4H2O (0.050 g, 0.20 
mmol) in EtOH (20 mL) to give the product as a brown solid (0.090g, 0.156 mmol, 83 %). 
1H NMR (400 MHz, d6-DMSO) δH = 7.82 (2H, br, 2 × NH), 6.91 (2H, br, 2 × NH), 3.28 
(4H, br, 2 × CH2), 3.10 (4H, br, 2 × CH2), 2.01 (6H, s, 2 × CH3), 1.44 (18H, s, 2 × C(CH3)3) 
ppm. 13C NMR (75 MHz, d6-DMSO) δC = 156.1 (CS), 155.8 (CO), 78.3 (C(CH3)3), 28.8 
(C(CH3)3) ppm. Elemental analysis: Calcd. (%) for C20H36N8O4S2Ni: C, 41.75, H, 6.31, N, 
19.48; Found: C, 43.78, H, 5.82, N, 19.35. HR-MS (ES-) found m/z 573.1577, calculated 
m/z 573.1582 for [C20H35N8O4S258Ni]-. IR (ATP) υ = 3298 (NH), 2972 (CH), 1740 (CO), 
1215 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-1 cm-1) 396(14893), 328(8599), 257(33833) 
nm.
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Complex CdL3
Prepared similarly from ligand H2L3 (0.100 g, 0.19 mmol) and Cd(OAc)2·2H2O (0.053 g, 0.20 
mmol) in EtOH (20 mL) to give the product as a bright yellow solid (0.112 g, 0.177 mmol, 
94 %). 1H NMR (400 MHz, d6-DMSO) δH = 7.19 (2H, br, 2 × NH), 6.90 (2H, t, 3JHH = 4 Hz, 
2 × NH), 3.13 (4H, dt, 3JHH = 8, 4 Hz, 2 × CH2), 2.24 (6H, s, 2 × CH3), 1.39 (18H, s, 2 × 
C(CH3)3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 156.1 (CO), 147.8 (CN) 78.2 (C(CH3)3), 
42.8 (CH2), 28.8 (C(CH3)3), 15.2 (CH3) ppm. Elemental analysis: Calcd. (%) for 
C20H36N8O4S2Cd: C, 38.19, H, 5.77, N, 17.81; Found: C, 38.29, H, 5.86, N, 17.76. HR-MS 
(ES+) found m/z 631.1403, calculated m/z 631.1407 for [C20H37N8O4S2114Cd]+. IR (ATP) υ
= 3304 (NH), 2968 (CH), 1734 (CO), 1518, 1324 (CS) cm-1. UV-Vis (MeCN): λmax (ε / L mol-
1 cm-1) 412(7800), 300(7440), 266(5840) nm.
Electrochemistry 
Cyclic voltammograms were measured using a Princeton Applied Research PARSTAT 2273 
using Electrochemistry Powersuite V.2.58 software and a cell with a MW2013 Pt working 
electrode, a MW4130 Pt wire auxiliary electrode and a Au pseudo-reference electrode. Scans 
were measured at 50, 100, 250 and 500 mV/s. Measurements were carried out on solutions 
of CuL1, CuL2 and CuL3 in anhydrous, degassed DCM containing NBu4PF6 as a support 
electrolyte, and referenced against an internal ferrocene/ferrocene+ redox couple. The 
Cu2+/Cu+ and Cu2+/Cu3+ potentials are reported as the mid-point between the reduction and 
oxidation current peaks. 
Crystallography 
Suitable crystals of ZnL1 and CdL1 were selected for analysis by the UK National 
Crystallography Service and measured following a standard method on a Rigaku AFC12 
goniometer equipped with an enhanced sensitivity (HG) Saturn724+ detector mounted at 
the window of a FR-E+ SuperBright molybdenum rotating anode generator with VHF 
Varimax optics (100m) focus at 100 K. Cell determination and data collection were carried 
out using CrystalClear-SM Expert 2.0 r11. Data reduction, cell refinement, and absorption 
correction were carried out using CrystalClear-SM Expert 2.1 r29. Structures were solved 
using SUPERFLIP51 and refined using SHELXL-2013.52
Determination of Antibacterial Minimum Inhibitory Concentrations (MIC) 
Stock cultures of strains of Staphylococcus aureus (NCIMB 9518), Pseudomonas aeruginosa (ATCC 
15692) and Escherichia coli (NCTC 12923) were maintained on MicrobankTM plastic beads at  
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-80 °C. Working cultures were maintained at 4 °C on tryptone soy agar culture media (TSA, 
Sigma Aldrich). For each organism, a single colony was transferred to Mueller Hinton Broth 
(MHB, Sigma Aldrich) (10 mL) and incubated at 37 °C for 14 h. Cultures were then diluted 
to 1 × 108 CFU.mL-1 through use of spectroscopic analysis (Ultraspec 2000, Pharmacia 
Biotech) and comparison to MacFarland standard 0.5, and then serially diluted to 1 × 106
CFU.mL-1. 
Ligands H2L1-3 and complexes CuL1-3 were dissolved in DMSO to give stock solutions (10 
mg.mL-1). These stock solutions were serially diluted with DMSO before addition to MHB 
broth (100 µL) in a well of a 96-well plate. To the compound-containing broth (100 µL) was 
added a broth-bacteria inoculum (100 µL, 1 × 106 CFU.mL-1) to give final compound 
concentrations ranging from 25 µg.mL-1 to 0.78 µg.mL-1 for MIC testing. Each concentration 
was prepared in triplicate for each chemical species and bacterium. Positive controls of the 
appropriate organism (1 × 106 CFU.mL-1) in broth containing 1 % v/v DMSO were prepared 
in triplicate, as were negative controls (broth containing 1 % v/v DMSO). The plates were 
incubated for 24 h at 37 °C before bacterial growth in each well was assessed by absorption 
at 600 nm. The lowest concentration resulting in an 80 % reduction in A600 relative to the 
positive control is the MIC for the compound against the organism being studied. 
Determination of Antiparasitic potential 
Samples of H2L1, H2L2, H2L3 and their complexes with Cu, Zn, Ni and Cd were assessed for 
anti-parasitic capability against Schistosoma mansoni by use of the automated, high through-put 
Roboworm drug-discovery platform, Parasitology and Epidemiology Group, Aberystwyth 
University, Wales, UK. Schistosomula populations were incubated for 72 hr at 37 °C under 
5 % CO2 enriched atmosphere with a given compound (10 µM). Compounds were dissolved 
in DMSO prior to addition. Following incubation, larva phenotype and motility were 
assessed by bright field imaging analysis and scored where compounds were considered a hit 
with a score value of -0.15 for phenotype and -0.35 for motility.53 Auranofin and praziquantel 
were used as positive controls; DMSO was used as a negative control.  
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5.3 Results and discussion 
5.3.1 Preparation and characterisation of complexes 
The synthesis of the bis(thiosemicarbazone) ligands H2L1, H2L2 and H2L3 proceeded using 
typical methodologies for this class of ligand.54–56 The intermediates 1 and 3 were synthesised 
by the modification of literature methods.50,57 The complexation reactions utilised the acetate 
salts of the metal to be coordinated with EtOH as a solvent. The basic nature of the acetate 
anion aids in the deprotonation of the ligand and the formation of the neutral complex. In 
the case of copper, other salts have been studied previously but have resulted in charged 
complexes.44, 45 In all cases, metalation was rapid and gave strongly coloured dispersions from 
which solid products could be isolated and purified for analysis.  
The complexes of H2L1, H2L2 and H2L3 were observed to be insoluble in water, ethanol, 
diethyl ether and hexane and displayed sparing solubility in chloroform, dichloromethane, 
ethyl acetate, methanol, acetonitrile, DMF and DMSO. The ligands and intermediates were 
characterised using 1H and 13C-NMR spectroscopies, HR-MS and FT-IR spectroscopy. The 
complexes were characterised by 1H and 13C-NMR spectroscopies, HR-MS, elemental 
analysis, FT-IR spectroscopy, UV-Vis studies and where suitable cyclic voltammetry.  
5.3.2 NMR Spectroscopy 
The 1H NMR spectra of H2L1, H2L2 and H2L3 show several common features. Geminal 
coupling between alkyl groups present allowed for the unequivocal identification of peaks 
with little to no discrepancy when considering integration values. When measured in d6-
DMSO all three ligands gave spectra containing peaks for all proton environments present 
in the molecule but when measured in protic solvents (e.g. MeOD), one or more NH 
environments were not observed due to the deuterium exchange. The only exception is in 
the case of H2L2 where an expected NH peak between 10-11 ppm was not observed. This 
may be due to transient deprotonation of the ligand by water impurities in the sample. The 
identification of all three ligands was aided by use of 13C NMR. Peaks for all carbon 
environments present in each of the molecules could be observed. 
The coordination of metals by the three novel ligands required an initial deprotonation. The 
loss of two secondary amine protons allowed for the donation of electron density to a metal 
ion using an N2S2 coordination sphere. A lack of NH peaks above ~10 ppm in the 1H NMR 
spectra of the complexes is therefore indicative of complexation. An upfield shift of the 
remaining secondary amine proximal to the coordination sphere arises due to the presence 
of two resonance formula for the complexes (see Fig. 8); for H2L1 forming ZnL1, NiL1 and 
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CdL1, a shift from 10.60 ppm to 7.69, 8.17 and 7.60 ppm respectively is observed. Similar 
shifts are observed between H2L2, H2L3 and their respective complexes. The values of the 
chemical shifts of environments not directly involved with metal coordination show little 
change between ligand and complex. The 1H NMR spectra of the nickel complexes are 
typically broadened implying that these complexes exist in equilibrium between the expected 
square planar geometries and octahedral geometries formed by the coordination of solvent 
molecules. Such complexes would be high spin and paramagnetic, giving rise to the observed 
broadening.60
Some environments in the complexes, namely C=S and C=N, can be difficult to observe 
using 13C NMR spectroscopy due to the lack of a hydrogen resulting in a poor signal. HMBC-
NMR spectroscopy was used to elucidate coupling behaviour and on occasion yielded an 
additional peak for the imine carbon arising from 2, 3-butandione. When observed this imine 
peak was seen to be upshifted 2-4 ppm in the case of zinc and cadmium complexes, but 
downshifted 5-9 ppm for nickel complexes, reflecting the considerable back donation of 
electron density from nickel into the π-system.61
5.3.3 IR Spectroscopy 
The carbonyl groups present in all ligands and complexes gave the strongest bands visible in 
the IR spectra, occurring between 1700-1750 cm-1 (similarly to as reported by Waghorn et al. 
for the glyoxal-based analogue of H2L3 species with a strong carbonyl group absorbance at 
1697 cm-1)62. Bands between 3200-3400 cm-1 (NH stretching modes) can be observed, along 
with CH stretches occurring between 2900-3000 cm-1. Related compounds in the literature 
show similar values e.g. NH stretches at 3315 cm-1 and 3355 cm-1 for Ni-GTSM and Cu-
GTSM.60
Bands for the imine stretches in these molecules would be expected between 1640-1690 cm-
1 for the free ligands with lower values for the complexes as electron density is donated from 
the bonds to the metal centre, weakening them; from the literature, the ligand H2GTSM has 
an imine stretch at 1560 cm-1 versus 1555 cm-1 and 1540 cm-1 for its Ni2+ and Cu2+ complexes 
respectively, reflecting the higher effective nuclear charge of the copper ion.60 The IR spectra 
of H2L3 shows such a band at 1667 cm-1 but in all other cases the high number of bands in 
this region prevent the unambiguous identification of the desired absorption.  
Strong absorptions observed in all spectra between 1190-1220 cm-1 can with reasonable 
confidence be assigned to the thiocarbonyl groups, which typically give strong absorptions 
between 1050-1200 cm-1 as observed for the precursors (1) (1079 cm-1) and (4) (1161 cm-1).  
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5.3.4 UV-Vis Spectroscopy 
Solutions of the complexes studied showed intense colour; copper complexes appeared dark 
red, zinc complexes appeared orange or yellow, nickel complexes appeared green or greenish-
brown, while cadmium complexes gave canary yellow solutions. According to the literature, 
all of the bands present may be described as ligand centred one electron π  π* transitions. 
Absorption occurs with the movement of electrons from the sulfur atoms to the carbon 
backbone of the ligand.63 The exact transitions and their contribution to given bands in the 
electronic spectra of Cu-ATSM and Zn-ATSM have been defined.55,63 Given the similarities 
between these reference spectra and those of the complexes described here, and that 
computational studies are beyond the focus of this report, the exact nature of these 
transitions will not be discussed in detail. Figures 9-12 show the electronic spectra of the 
complexes grouped by metal. 
The electronic spectra of the copper complexes CuL1-3 (Fig. 9) show considerable similarity 
to that observed for Cu-ATSM and are all generally alike.55 The low energy bands observed 
at 473, 495 and 472 nm respectively for the three complexes represent HOMOLUMO 
transitions with shoulder peaks at 522, 544 and 529 nm most likely arising from 
conformational changes in the coordination of the ligand; such bands occur at 476 nm and 
525 nm for Cu-ATSM. The intense peaks observed at 306, 312 and 308 nm with shoulder 
peaks at 346, 359 and 354 nm occur at very similar wavelengths to similar features in the 
spectra of Cu-ATSM (314 nm and 355 nm) and it can be concluded that these peaks are 
composed from the same or similar transitions as previously described.55 The lowest energy 
peaks seen in the spectra of the copper complexes all occur at longer wavelengths than for 
the analogous transitions seen for the other metal complexes, while other peaks occur at 
comparable wavelengths. The HOMOLUMO transition requires less energy for the Cu2+
complexes due to the d9 configuration of the metal. Orbital mixing would result in an 
unpaired electron occupying the HOMO, and excitation to the LUMO would not require 
the energetically unfavourable separation of spin coupled electrons. 
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Figure 9. UV-Vis spectra of the copper complexes CuL1-3, measured as 5 × 10-5 M MeCN 
solutions. 
Figure 10. UV-Vis spectra of the zinc complexes ZnL1-3, measured as 5 × 10-5 M MeCN 
solutions. 
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The zinc complexes (Fig. 10) all show similar spectroscopic features and the spectra of ZnL1
and ZnL3 are comparable to that observed for Zn-ATSM, where peaks at 405 and 305 nm 
are assigned to HOMOLUMO and HOMO-1LUMO transitions respectively.63 These 
assignments would be consistent with the peaks observed in the spectra above. The spectrum 
of ZnL2 shows the interesting feature that the HOMOLUMO band at 445 nm showing a 
shoulder peak at 424 nm is considerably more intense than the peak seen at 318 nm. The 
ratio of these peaks are shown in Table 2. As such high ratios between the two peaks are not 
seen for the zinc complexes of H2L1 and H2L3, it may be concluded that the lack of alkyl 
groups on the ligand backbone and the coordination of a d10 ion is the origin of this effect. 
A preference by the metal for tetrahedral geometry combined with a shortened C-C bond in 
the ligand would result in a distortion towards tetrahedral geometry.14 This is in agreement 
with the electrochemical observation that CuL2 is easier to reduce than CuL1 and CuL3 (see 
below), implying that the ligand more readily assumes a twist away from planarity as observed 
for Cu-GTSM.14 The ligand’s propensity to distort away from a plane is overcome by Cu2+
and Ni2+ having an energetic drive to form square planar complexes. When the complex 
binds Zn2+ and is more tetrahedral-like in geometry different orbital mixing occurs, giving a 
different absorption profile to that observed for Zn-ATSM, ZnL1 and ZnL3. The lineshape 
is more similar to that observed for the cadmium complexes (Fig. 11) 
Figure 11. UV-Vis spectra of cadmium complexes CdL1-3, measured as 5 × 10-5 M MeCN 
solutions. 
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The cadmium complexes (Fig. 11) show εHOMO->LUMO:εHOMO-1LUMO ratios of 0.93 or greater 
(see Table 2) within spectra that are broadly similar. This reflects that for all ligands discussed 
here the large cadmium cation exists in a non-square planar geometry. From analogous 
compounds in the literature and the experimentally observed crystal structure for CdL1 (see 
below) the complexes will be in a distorted octahedral geometry in the solid state, where the 
ligand will coordinate in an approximate plane (with significant distortions) about the 
equatorial positions with other complexes coordinating in the apical positions via sulphur 
atoms. In the solution phase, the apical positions may be occupied by solvent molecules with 
less steric bulk, and the ligand will distort further away from a planar geometry towards a 
more tetrahedral-like form, yielding spectra lineshapes closer to that observed for ZnL2. As 
the peaks observed occur from ligand based electronic transitions, it can be assumed that the 
identity of these transitions is analogous to those described above. 
Figure 12. UV-Vis spectra of nickel complexes NiL1-3, measured as 5 × 10-5 M MeCN 
solutions. 
The nickel complexes all yield similar spectra (see Fig. 12). By reference to analogous 
compounds such as Ni-ATSM,14 it is likely that these complexes are square planar with little 
deviation from planarity. The features within the spectra (HOMOLUMO transitions at 
392, 414 and 396 nm for NiL1-3, HOMO-xLUMO transitions at approximately 255, 257 
and 257 nm with shoulder peaks at 330, 334 and 328 nm) are broadly similar to those 
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observed for the copper complexes. The peaks observed for NiL2 occur at marginally longer 
wavelengths, indicating a lower HOMOLUMO gap than for the alkylated analogues. 
Backbone alkylation has previously been calculated to raise the energy of the LUMO of 
similar molecules.14
εHOMO->LUMO:
εHOMO-1LUMO
εHOMO->LUMO:
εHOMO-1LUMO
εHOMO->LUMO:
εHOMO-1LUMO
CuL1 0.26 CuL2 0.33 CuL3 0.28
ZnL1 0.79 ZnL2 2.11 ZnL3 0.44
NiL1 0.45 NiL2 0.46 NiL3 0.44
CdL1 0.93 CdL2 1.34 CdL3 1.05
Table 2. Ratios of εHOMO->LUMO:εHOMO-1->LUMO for metal complexes of ligands H2L1-3. Note 
that the highest ratios are generally observed for complexes with the highest likelihood 
of forming non-square planar geometries (ZnL2 and the cadmium complexes). 
The d-d transitions that would be expected for these complexes were not observed in the 
spectra measured. These transitions have relatively low values of ε: ~ 10 mol-1.cm-1.L for the 
‘Spin’ and ‘LaPorte’ forbidden Ni complexes up to several hundred for the ‘Spin’ allowed 
and ‘LaPorte’ partially allowed Cu complexes, and can be difficult to observe in dilute 
solutions. Unfortunately, the limited solubility of these complexes prevented the study of 
more concentrated samples. 
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5.3.5 Cyclic voltammetry  
The complexes CuL1, CuL2 and CuL3 were studied using cyclic voltammetry to ascertain the 
effect of the ligand framework on the copper centre’s redox potential. Reduction and 
oxidation potentials for these complexes referenced against an internal Fc/Fc+ standard are 
shown in Fig. 13. The limited solubility of the complexes necessitated the use of non-aqueous 
conditions with a supporting electrolyte (NtBu4PF6) and an internal Fc/Fc+ reference.  
Figure 13. Cyclic voltammograms of CuL1-3 at 250 mV/s scan rate, showing reduction 
(left) and oxidation (right) processes, later referenced against Fc/Fc+. 
All three complexes showed two quasi-reversible one electron redox couples; the 
electrochemical properties are shown in Table 3. In all cases the anodic and cathodic peak 
separations varied with scan rate with values typically close to those observed for the 
standard. However, the anodic and cathodic peak currents were generally similar with a ratio 
that approximated that observed for the standard, and a plot of the square root of the scan 
rate versus anodic peak current showed a close-to-linear relationship (Fig. 14). Analysis of 
cyclic voltammograms of Cu-ATSM and related species reached similar conclusions.26,55 The 
quasi-reversible character of the reduction peaks arises from the need of the ligand to twist 
and change geometries about the metal centre as the oxidation state (and therefore 
coordination preferences) of the metal changes. For the oxidation processes, decomposition 
of the complexes may be occurring.64
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Complex E1/2
Cu2+/Cu+(V)
ΔE (V) ia/ic E1/2
Cu3+/Cu2+
(V)
ΔE (V) ia/ic
CuL1 -1.12 0.203 0.87 0.43 0.090 1.01
CuL2 -0.81 0.118 0.89 0.64 0.094 1.45
CuL3 -1.10 0.137 0.83 0.41 0.056 1.07
Cu-ATSM -0.99 - - 0.32 - -
Cu-GTSM -0.83 - - - - -
Table 3. Electrochemical properties of complexes CuL1-3 measured at 100 mV/s scan rate 
and referenced against a Fc/Fc+ internal reference. Calculated values for Cu-ATSM and 
Cu-GTSM based on studies against Ag/AgCl are included for comparison.50
The selectivity of a BTSC complex for hypoxic tissue is related to the reduction potential of 
the Cu2+/Cu+ couple.12 Reduction being less favoured enhances the selectivity of the complex 
for tissues with severe hypoxia. In the absence of biological studies it can be predicted that 
the complexes CuL1 and CuL3, having lower reduction potentials than Cu-ATSM, would 
display a similar or greater selectivity for hypoxic cells. As the effect of modifications away 
from the ligand backbone have been shown to be slight in related molecules, deprotected 
analogues of these species would likely show similar reduction potentials.14 CuL2 has a 
reduction potential similar to Cu-GTSM and would probably select for normoxic tissue.  
Figure 14. Plot of scan rate-1/2 versus anodic peak currents for CuL1-3. Deviations from 
a linear relationship and variance of peak separation with scan rate confirm that the 
processes are quasi-reversible. 
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5.3.6 Crystallography  
Suitable crystals for structural determination of ZnL1 (Fig. 15) were obtained by the slow 
evaporation of a MeOH solution. Data collection parameters are given in Appendix III. The 
structure shows that in the solid state two molecules of ZnL1 exist as a dimer. Each Zn centre 
receives electron donation from four donor atoms from one ligand, with a sulphur atom 
from the neighbouring ligand occupying the fifth coordination site to give a distorted square 
pyramidal coordination geometry where the metal lies slightly above the plane of the ligand. 
DFT and crystallographic studies of the similar species Zn-ATSM have shown a similar 
dimeric configuration, and it can be predicted from experimental observations that the 
presence of a fifth donor atom (e.g. from solvent molecules) is likely in solution.63
Figure 15. X-Ray crystal structure of ZnL1 with ellipsoids at 50 % occupancy. The Zn 
centre lies slightly out of the plane of the square pyramidal geometry. The coordination 
sphere has Zn-S bonds longer than Zn-N bonds where d(Zn-S1), d(Zn-S2), d(Zn-N3), d(Zn-
N4) and d(Zn-S1i) are 2.4197(18) Å, 2.3384(15) Å, 2.119(4) Å, 2.115(5) Å and 2.504(2) Å 
respectively. The bond angles (S2-Zn-S1) and (S2i-Zni-S1i) are 114.73(6) ° and 108.65(5)° 
respectively, with (N4-Zn-N3) being 74.95(17) °. 
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Figure 16. X-Ray crystal structure of CdL1 with ellipsoids at 50 % occupancy. In the 
assymetric part of the unit cell, Cd-S bonds are longer than Cd-N bonds; d(Cd-S1), d(Cd-
S2), d(Cd-N1), d(Cd-N4) are 2.5029(12) Å, 2.5239(12) Å, 2.326(4) Å and 2.327(3) Å 
respectively. Here the bond angles (S1-Cd1-S2) and (N4-Cd-N1) are 138.58(4) ° and 
69.59(12) ° respectively, due to the greater ionic size of Cd2+ (compared to Zn2+ in ZnL1). 
Suitable crystals for structural determination of CdL1 (Fig. 16) were obtained by the slow 
diffusion of Et2O into a solution of the complex in CHCl3. CdL1 shows a polymeric structure 
in the solid state, with sulfur atoms bridging six-coordinate cadmium centres in a distorted 
octahedral geometry, where the ligand defines the equatorial plane (Fig. 17).  
Figure 17. Polymeric structure of CdL1. The structure may be described as ‘distorted 
octahedral’ as the elongated apical bonds (d(Cd1-S2’) = 2.8706(12) Å, d(Cd1-S1’) = 
2.9574(12) Å) exist at approximately 90 ° to the plane defined by the ligand, but the bond 
angles within the plane are not equivalent ((N1-Cd1-N4) = 69.59(12) °, (N1-Cd1-S1) = 
76.08(9) °, (N4-Cd1-S1) = 143.77(9) °, (N1-Cd1-S2) = 145.30(9) °) and out-of-plane 
twisting is observed. 
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Apical positions are filled by sulfur atoms from neighbouring molecules to form an ‘off-set’ 
polymer chain. In the plane of the ligand bond lengths and angles are typical of this class of 
complex (Table 4), with the apical bonds showing a lengthening away from true octahedral 
geometry due to the electron density of the bridging sulfurs being donated mainly to the 
cadmium centre in the equatorial plane. Bond angles within the equatorial plane deviate from 
90 ° as a result of strain imposed by bond lengths within the ligand backbone when 
coordinating the large Cd2+ ion (0.92 Å). The S(2)’-Cd(1)-S(1)’ angle of 170.68(4) ° that gives 
the ‘off-set’ nature likely arises as a result of compromise between satisfying electronic and 
steric demands. Cadmium complexes of thiosemicarbazones have previously been shown to 
assume a number of coordination geometries and to form similar polymeric structures.65–68
Cd(1)-N(1) 2.326(4) N(1)-Cd(1)-N(4) 69.59(12)
Cd(1)-N(4) 2.327(3) N(1)-Cd(1)-S(1) 76.08(9)
Cd(1)-S(1) 2.5029(12) N(4)-Cd(1)-S(1) 143.77(9)
Cd(1)-S(2) 2.5239(12) N(1)-Cd(1)-S(2) 145.30(9)
Cd(1)-S(2)’ 2.8706(12) N(4)-Cd(1)-S(2) 76.14(9)
Cd(1)-S(1)’’ 2.9574(12) S(1)-Cd(1)-S(2) 138.58(4)
N(1)-Cd(1)-S(2)’ 89.57(9)
N(4)-Cd(1)-S(2)’ 100.34(9)
S(1)-Cd(1)-S(2)’ 90.57(4)
S(2)-Cd(1)-S(2)’ 91.17(3)
N(1)-Cd(1)-S(1)’’ 81.27(9)
N(4)-Cd(1)-S(1)’’ 74.36(9)
S(1)-Cd(1)-S(1)’’ 89.56(3)
S(2)-Cd(1)-S(1)’’ 94.90(4)
S(2)’-Cd(1)-S(1)’’ 170.68(4)
Table 4. Selected bond lengths (Å) and bond angles (°) for CdL1. 
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5.3.7 Stability under deprotection conditions 
In the forms presented here the complexes ML1-3 would be of limited use in the context of 
imaging disease states. Their poor solubility in aqueous conditions may inhibit their 
applicability for in vivo studies as small molecule drugs and the presence of protecting groups 
prevents their use as haptens in bioconjugate species. Unfortunately, deprotection conditions 
for these molecules that did not degrade the ligand could not be determined despite the 
successful deprotection of similar molecules being reported in the literature.47,62,69 The use of 
strong basic conditions (e.g. 6 equivalents of NaOH in THF) to deprotect H2L1, H2L2 and 
their respective complexes gave inconclusive results. Basic hydrolysis of the ligand may be 
occurring as result of nucleophilic attack at the imine groups. Although TFA has been used 
to remove the Boc groups from the terminal amines of molecules similar to H2L3 and its 
complexes, all efforts in the current case were unsuccessful. This may indicate that such 
experiments require the use of anhydrous conditions and purified, dried reagents (although 
TFA is typically used without further purification) to prevent hydrolysis. It may be 
considered that the ethyl ester protecting group used for H2L1 and H2L2 is unsuitable for the 
synthesis of bis(thiosemicarbazones) due to the associated deprotection conditions. Other 
protecting groups for carboxylic acids do not present particular attractive alternatives; the 
inclusion of terminal acid groups may require alternative routes of synthesis that avoid the 
need for protecting groups.70 Further experiments are therefore required to allow the use of 
analogous products to the complexes described in this report in bioconjugate systems. 
5.3.8 Anti-bacterial MIC assessments 
The effects of incubation with different concentrations (0.78 – 25 µg.mL-1) of the ligands 
H2L1-3 and the copper complexes CuL1-3 on three bacterial strains (E. coli, S. aureus and P. 
aeruginosa) were measured by observing changes in a population’s absorbance at 600 nm 
relative to a control population to determine a Minimum Inhibitory Concentration (MIC).71
The MIC is the lowest agent concentration required to inhibit measurable bacterial growth 
following overnight incubation. Higher concentrations were unavailable due to the limited 
solubilities of the species. For a species to be a hit, an 80 % or greater decrease in A600 relative 
to the positive control in two or more of the triplicate experiments must be observed.  
In a 2014 study, Cu-GTSM was found to have antibacterial properties against only S. aureus
from a panel of 50 Gram-positive and Gram-negative bacteria including E. coli and P. 
aeruginosa; bactericidal properties of Cu-GTSM, Cu-PTSM and Cu-ATSM against S. aureus
were related to the redox potential of the metal centre (Cu-GTSM most active, Cu-ATSM 
inactive) (see Table 5).25
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E1/2 / V CLogP MIC90 
/µM 
E1/2 / V CLogP MIC80 
/µM
Cu-GTSM -0.83 0.07 0.30 CuL2 -0.81 1.05 3.57
Cu-PTSM -0.91 0.48 1.25 CuL1 -1.12 2.47 Inactive
Cu-ATSM -0.99 0.89 Inactive CuL3 -1.10 3.95 Inactive
Table 5. Redox potentials, calculated Log P values and MICs for copper complexes 
discussed. Redox potentials for literature compounds against Fc/Fc+ calculated from 
experimental values elsewhere.12 CLogP calculated for the metal complexes using the 
commercial software package ChemBioDraw Ultra 13.0. MIC values for literature 
compounds against S. aureus quoted from Haeili et al.25
Although the three complexes were all lipophilic, neutral species able to diffuse passively 
into bacteria, Cu-GTSM had the highest redox potential and was most rapidly reduced in the 
cell, resulting in metal dissociation, the rapid overwhelming of the bacteria’s protective 
metabolic pathways and copper poisoning.  The complexes with lower redox potentials may 
also be more susceptible to efflux prior to copper release.22 The ligands themselves did not 
display antibacterial properties against S. aureus.25
Experimentally, the only compound with sufficiently bacteriostatic effects to qualify as a hit 
was CuL2 against S. aureus (Table 6). No other compounds at any concentrations reduced any 
bacterial population enough to be a hit. CuL2 serves as a Cu-GTSM analogue, CuL1 and CuL3
as Cu-ATSM analogues with no effect at any concentration used (not shown).  
While Cu-ATSM is more hydrophobic than Cu-GTSM (CLogP = 0.89 and 0.07 respectively), 
CuL2 (CLogP = 1.05) is more hydrophobic than Cu-ATSM, indicating that lipophilicity is 
not the major contributing factor to the antibacterial properties of the glyoxal-based species. 
The redox potentials of CuL2 (E1/2 = -0.81 V) and Cu-GTSM (E1/2 = -0.83 V) are nearly 
identical, but comparing the experimentally derived MIC80 of 1.56 µg.mL-1 or 3.6 µM to the 
MIC90 of Cu-GTSM against wild-type S. aureus  (0.3 µM) shows that  increasing lipophilicity 
approximately eleven-fold  increases the MIC approximately twelve-fold. Although it must 
be considered that the bacterial strains used here and in the literature were different, it 
appears that the more lipophilic species may be subject to retention while passively crossing 
the phospholipid membrane,72 introducing a rate determining step that slows the delivery of 
the metal and that allows S. aureus to counteract copper toxicity.  Further experimentation to 
determine the Minimum Bactericidal Concentration of CuL2 would be of interest, but it can 
be concluded that Cu-GTSM remains a better option for development as a novel antibiotic.
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Conc 
/ µg.mL-1 
25 12.5 6.25 3.13 1.56 0.78 Positive 
control
CuL2 A600 /nm 
(% positive control)
0.055
(23.0 %)
0.032
(13.4 %)
0.031
(13.0 %)
0.031
(13.0 %)
0.032
(13.4 %)
0.240
(100 %)
0.239
A600 /nm
(% positive control)
0.054
(24.4 %)
0.031
(14.0 %)
0.030
(13.6 %)
0.031
(14.0 %)
0.281
(127 %)
0.215
(97.3 %)
0.221
A600 /nm
(% positive control)
0.046
(18.4 %)
0.035
(14.0 %)
0.031
(12.4 %)
0.031
(12.4 %)
0.030
(12.0 %)
0.184
(73.6 %)
0.250
Result HIT HIT HIT HIT HIT- MIC No hit
H2L2 A600 /nm
(% positive control)
0.246
(122 %)
0.216
(107 %)
0.193
(96.0 %)
0.216
(107 %)
0.236
(117 %)
0.178
(88.6 %)
0.201
A600 /nm
(% positive control)
0.285
(125 %)
0.238
(104 %)
0.032
(14.0 %)
0.158
(69.3 %)
0.280
(123 %)
0.235
(103 %)
0.228
A600 /nm
(% positive control)
0.277
(107 %)
0.214
(82.9 %)
0.224
(86.8 %)
0.251
(97.3 %)
0.271
(105 %)
0.227
(88.0 %(
0.258
Result No hit No hit No hit No hit No hit No hit
Table 6. MIC determination for CuL2 and H2L2 against S. aureus.. Bacteriostatic effects were observed for CuL2 at concentrations of 25 to 1.56 µg.mL-
1. The MIC is 1.56 µg.mL-1.
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5.3.9 Anti-parasitic assessments 
The effect of incubation of the ligands H2L1-3 and their respective complexes with Cu, Zn, 
Ni and Cd on the larval stage of Schistosoma mansoni was assessed by an automated, high 
throughput optical assay similar to that described in described in Paveley et al.53 This parasitic 
flatworm is one of several related species that cause Schistosomiasis, a ‘neglected tropical 
disease’ which kills over 200,000 people per year and for which there is currently only one 
chemotherapeutic agent (praziquantel).73,74 However, praziquantel has limited effect on the 
immature worm and resistance can be developed, highlighting the need for a diversification 
in clinical management options.75
Figure 18. Chemical agents with anthelmintic properties a. Praziquantel. b. EPI, an 
imidazole alkaloid derived from a Brazilian plant.76 c. Copper oxindolimine complexes 
(note the similarity between the top complex and the BTSC complexes described herein.)77
In the 1950’s, copper oleate was reported as having potential as a barrier ointment for rice 
farmers due to its’ demonstrated toxicity against the infective phase of S. japonicum.78 More 
recently, the alkaloid epiisopiloturine (EPI) derived from the Brazilian ‘jaborandi’ plant has 
been shown to have anthelmintic activity (against all life cycle phases of S. mansoni)76 which 
is enhanced by coordination to copper but reduced by coordination to zinc; the authors of 
the research hypothesise that coordination to copper aids in alkaloid delivery into the worm, 
whereupon the metal is released and causes oxidative stress that is synergistic to the effects 
of the ligand.75 In addition, oxindolimine complexes of copper (which are structurally similar 
to BTSC complexes) have shown significantly greater antischistosomal activity than zinc and 
vanadyl analogues.77 While the study of organometallic agents against S. mansoni is in its’ 
infancy,79 the to-date unexplored copper bis(thiosemicarbazones) (e.g. CuL1, CuL2 and CuL3) 
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could offer effective new routes of Schistosomiasis therapy, especially since in vivo
schistosomal granulomas display a hypoxic tissue microenvironment for which BTSCs would 
be expected to show selectivity.80
The results of the high-throughput automated assay are shown in Figs. 19, 20 and Table 7. 
Compounds that were found to give an average phenotype score below -0.15 and an average 
motility score below -0.35 were considered a hit. Of the compounds studied, four registered 
as consistent hits: CuL1, CuL2, CdL1 and CdL3. Automated analysis gave H2L2 and CuL3 as 
inconsistent hits, but direct observation concluded that the discrepancy was an artefact of 
the experiment and that both compounds were likely hits. CdL2 (not shown) displayed 
considerably more toxicity than other non-hit compounds (consistent hits on motility and a 
near hit on phenotype in Scan 1), but was insufficiently effective to be deemed a hit. 
Auranofin has been shown to be 100 % lethal to schistosomula at 10 µM following 24 hours 
incubation as a result of enzyme inhibition and increased oxidative stress.73 By comparison 
of the observed phenotype and motility scores, in both scans CuL1 and CuL2 showed similar 
levels of toxicity as auranofin against the schistosomes (see Table 7) suggesting that similarly 
to as observed in antibacterial studies,22 the copper complexes are taken into the worm, where 
the metal can be released with a resulting toxic effect on metabolic processes. This is likely 
due to the metal being redox active and able to form reactive oxygen species (ROS);81 redox 
inactive zinc and nickel analogues were non-hits. The exact nature of how free copper 
disrupts metabolism or otherwise kills schistosomulae requires further investigation. There 
is insufficient data to assess the relationship of toxicity to the redox potential or lipophilicity 
of the compounds. All of the copper complexes studied satisfy Lipinski’s ‘Rule of Five’, a 
useful although imperfect set of criteria often used in drug discovery by which the likelihood 
of absorption and permeation in vivo is predicted.82,83
Although auranofin is clinically approved for the treatment of rheumatoid arthritis and has 
a known toxicity profile which would reduce development costs relative to a new species,84
on the scale needed to replace praziquantel for combatting schistosomiasis in the developing 
world  its unit cost as a gold containing compound would probably render it economically 
unviable. Cu-ATSM or novel BTSC complexes as described here may offer an alternative. 
The cadmium-containing hit compounds CdL1 and CdL3 were not significantly or 
consistently more toxic than auranofin or the copper hits. Cadmium has previously been 
shown to have anthelmintic properties against a parasite in fish,85 but as the metal is extremely 
toxic to humans the barriers to development of a cadmium-based antischistosomiasis drug 
would be considerable.  
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Figure 19. Graphical representation of anthelmintic properties of selected compounds. 
Results from Scan 1 denoted by triangle, Scan 2 by circles. 
Figure 20. Schistosomula treated with CuL1 (left), Praziquantel (centre) and DMSO i.e. 
healthy (right). 
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Screen 
No.
Compound 
(10 µM)
Average Phenotype 
Score (# larva seg)
Average Motility 
Score (# larva seg)
Hit Status
1 H2L1 -0.08876 (61) 0.54063 (80) Non-hit
H2L2 -0.43538 (27) -0.85493 (38) Hit
H2L3 0.05112 (41) -0.12105 (53) Non-hit
CuL1 -0.59315 (45) -0.94621 (52) Hit
CuL2 -0.75162 (33) -0.76071 (37) Hit
CuL3 0.1737 (32) 0.88356 (33) Non-hit
CdL1 -0.62528 (63) -0.92407 (61) Hit
CdL2 -0.13805 (56) -0.71746 (81) Non-hit
CdL3 -0.57992 (66) -0.68172 (90) Hit
Auranofin -0.759 -0.852 Hit 
(Positive control)
DMSO -0.029 -0.000 Non-hit
Negative control
2 H2L1 -0.00833 (78) 0.39619 (77) Non-hit
H2L2 -0.15182 (49) -0.33941 (63) Non-hit
H2L3 -0.02032 (59) -0.33941 (63) Non-hit
CuL1 -0.69323 (54) -0.81174 (65) Hit
CuL2 -0.4822 (32) -0.71841 (49) Hit
CuL3 -0.28459 (51) -0.63766 (69) Hit
CdL1 -0.33541 (57) -0.78952 (71) Hit
CdL2 -0.06167 (83) -0.44709 (90) Non-hit
CdL3 -0.2418 (61) -0.80255 (78) Hit
Auranofin -0.578 -0.793 Hit 
(Positive control)
DMSO -0.034 0.000 Non-hit
Negative control
Table 7. Selected results from anthelmintic screening. Scores reaching relevant hit-
boundariess shown in bold; a compound must reach both to be considered a hit.
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5.4 Conclusion 
The synthesis of three novel bis(thiosemicarbazone) ligands, H2L1-3 and their complexes with 
copper, zinc, nickel and cadmium are reported. The metal complexes are spectroscopically 
and electrochemically similar to literature compounds. Depending on the metal used, 
different coordination geometries may be inferred based on the characterisation given; CuL1-
3 exist as square planar complexes about Cu2+, but reduction of the metal induces a twist in 
the ligand to give a tetrahedral geometry. ZnL1 and ZnL3 exist as approximately square planar 
complexes in solution; ZnL1 is seen to form dimers in the solid state where the metal centre 
is in a square pyramidal geometry. From the electronic spectrum, ZnL2 appears to assume a 
different geometry, most likely tetrahedral, as both metal and ligand would be energetically 
most satisfied in this case. As is typical for a d8 metal the nickel complexes NiL1-3 are square 
planar in nature. Cadmium complexes CdL1-3 appear square planar based on the study of 
electronic spectra but reference to crystal structures reported here and in the literature reveal 
a distorted octahedral geometry where apical positions are filled by coordinated solvent 
molecules in solution or by polymers in the solid state. From the electronic spectra it is likely 
that the nickel complexes show too great a tendency to assume a square planar geometry to 
serve as a transition state analogue for Cu-ATSM demetallation. Further work using the other 
metal complexes described here would be speculative as what epitopes the complexes would 
present upon bioconjugation is unknown. 
The ligands reported here represent a proof of concept for the generation of 
bis(thiosemicarbazone) haptens. Although the optimisation of synthetic routes to include 
particular functionalities is required, preferably avoiding the use of protecting groups, 
observed similarities to Cu-ATSM, Cu-GTSM,14,26 Zn-ATSM63 and Ni-ATSM14 suggest that 
the complexes discussed above may show similar behaviour in vivo and therefore warrant 
further investigation. 
CuL2 registered as a hit compound against S. aureus with a MIC80 of 3.57 µM. Additional 
research may yield elucidation of the exact nature of the ‘delivery system’ provided by copper 
bis(thiosemicarbazones) against some bacteria i.e. how lipophilicity and redox potential 
interplay in the determination of antibacterial activity.  CuL1, CuL2, CdL1 and CdL3 all 
registered as hit compounds in an assay to determine toxicity against parasitic worm larvae 
(S. mansoni), with the copper species showing similar results to a known lethal agent 
(auranofin). Copper bis(thiosemicarbazones) may warrant investigation as potential novel 
agents in the struggle against a neglected tropical disease. 
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Chapter 6: Concluding remarks 
Introduction 
The research presented in Chapters 2, 3 and 4 of this thesis represent an investigation into 
the possibility of taking a relatively simple approach to iron oxide nanoparticle synthesis and 
developing from it a novel immunoPET agent that could help meet unmet clinical need in 
the developed world. Chapter 5 related the synthesis of novel bis(thiosemicarbazone) 
complexes intended for use in antibody production but which were shown to have 
antibacterial and antiparasitic properties against a neglected tropical disease. This final 
discussion gives a brief overview and critical analysis of the work reported above. 
ImmunoPET agents from SPION 
The importance of immunoPET imaging and the considerations that go into agent design 
were discussed in Chapter 1. Zirconium-89 is currently the favourite isotope for use in 
immunoPET agents due to its’ long half-life but there is a need for improved methods of 
using this isotope that avoid the side-effects reported with coordination via DFO.1,2 The 
method reported in Chapters 2 and 4 where 89Zr is incorporated into SPION forming via 
co-precipitation is novel in this regard. Initial experiments utilising smaller quantities of 
radioactive material proceeded with higher radiolabelling efficiency than later, larger scale 
approaches, an issue that will require further study if this approach were to be repeated.  
Although APTES@SPION could be synthesised ‘hot’ with the use of remote manipulators, 
refinement of the experimental methodology, even automation, would be preferable to 
scaling the reaction up or down from that reported here. It is likely that an alternative 
synthetic approach is required to significantly improve upon the in vivo results shown in 
Chapter 4. 
Bioconjugation of glycoproteins (both antibodies and enzymes) to APTES@SPION by 
reductive amination is an efficient and cost-effective method of immobilising biomolecules 
of interest onto particles that may be used as MRI contrast agents or which may be made to 
incorporate other functionalities with relative ease. Low solubility of some bioconjugate 
products under certain conditions were observed; while aqueous solubility is a requirement 
for in vivo use, it may be less necessary for in vitro purposes. A magnetically recoverable 
dispersion of enzyme- or antibody-bearing particles synthesised as described may find 
purpose outside of the body e.g. in vitro assays,3–5 environmental clean-up and water 
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remediation6–14 or biofuel and chemical feedstock production15–19. The potential applications 
of SPION are restricted only by imagination. 
The conclusion to be drawn from the above is that Chapter 4 records first steps into a 
complex field of research where multiple disciplines intersect. Although biocompatible, 
radiolabelled particles could be synthesised and bioconjugated antibodies on the surface of 
such nanoparticles retained their activity, in vivo studies showed that the antibody-bearing, 
radiolabelled particles were not ‘greater than the sum of their parts’, and that the successful 
implementation of immunoPET-active SPION remains to be reported. 
Bis(thiosemicarbazones) in the imaging and treatment of disease 
Chapter 5 presents a record of the syntheses of a number of novel metal 
bis(thiosemicarbazone) complexes that were initially intended for use as haptens in antibody 
production to develop improved methods of hypoxia imaging. This was not achieved. 
However, it could be argued that the identification of CuL2 as having antibacterial activity 
against S. aureus and CuL1 and CuL2 having anthelmintic activity against S. mansoni is of 
greater importance. Antibiotic resistant bacterial drug strains (e.g. MRSA) have become 
global epidemics,20 and schistosomiasis is a chronic and debilitating disease afflicting 
populations across the developing world, with relatively little effort being expended upon 
research into novel treatments.21 Research into the use of copper BTSC complexes in 
developing novel disease treatments could be of great significance in the coming years. 
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Additional Experimental Section I: Selected attempted methods of 
synthesising APTES@SPION 
1.1 Introduction 
A crucial part of the work described in Chapter 2 was the development of reproducible 
methods of synthesising biocompatible SPION that could be characterised fully and serve 
as a foundation for subsequent bioconjugation. As has been shown, APTES@SPION were 
synthesised in the chemistry laboratory and were dispersible in aqueous media; their 
analogues produced in the radioisotope laboratory had near identical characteristics when 
analysed. SPION produced in this manner could be radiolabelled with high efficiency and 
retain their aqueous solubility. The use of APTES as a coating agent was desirable for the 
stability with which the coating is attached to the iron oxide surface and for the amine 
functionality which was predicted to be crucial for future functionalisation. Before the 
approach described above was developed, other approaches were attempted which resulted 
in particles which had little or no solubility in aqueous conditions and which were deemed 
unsuitable for further analysis. Two such methods are described below and are typical of 
many synthetic approaches reported in the literature.  
An attempt to improve the Massart co-precipitation methodology by use of a ‘rapid mixing’ 
reactor is also described. It was hoped that the use of such an approach would reduce 
variation in several parameters that have been reported to affect nanoparticle size and 
monodispersity (such as rate of reactant addition, reaction time, degree of mixing) by 
reducing researcher intervention to the rapid squeezing of two syringes. Unfortunately, 
inconsistencies in qualitative behaviours, quantitative measurements and low yields showed 
this approach to be unsuitable for further development. 
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1.2 Experimental 
1.2.1 Methods and materials 
Reactions were performed with the use of vacuum line and Schlenk techniques where 
appropriate. Reagents were commercial grade and were used without further purification. All 
reagents and solvents were purchased from Alfa Aesar or Sigma Aldrich, except APTES 
which was purchased from TCI Chemicals. FeCl2.4H2O and APTES were stored under inert 
atmospheres. The aluminium mixing head described was made by the Workshops 
department, School of Chemistry, Cardiff University. 
1.2.2 Synthesis and analytical techniques 
Uncoated SPION via the Massart method 
Water (50 mL) was added to a two-neck round bottom flask (250 mL), the system was sealed 
and degassed under nitrogen for 30 min. FeCl3.6H2O (2.322 g, 8.6 mmol) and FeCl2.4H2O 
(0.854 g, 4.3 mmol) was added carefully under a blanket of nitrogen and the solution mixed 
to homogenise. 1 M NaOH (40 mL) was added in a rapid single addition with vigorous 
stirring and the reaction mixture seen to turn black immediately. The reaction mixture was 
stirred at room temperature for 10 min. The black precipitate was collected by use a 
permanent magnet and washed with EtOH (3 × 10 mL) and MeOH (3 × 10 mL) then dried 
in vacuo to give the title compound (1.13 g). IR (ATP) υ =631 (Fe-O-Fe stretch), 590 (Fe-O-Fe 
stretch), 431 cm-1.
NB. If subsequent coating was required, the final drying was omitted. 
Method 1: Heating in EtOH 
Uncoated SPION (0.25 g) and APTES (100 µL, 4.29 mmol) were heated to reflux in degassed 
EtOH (25 mL) for 2h, collected with a permanent magnet and washed with fresh EtOH (3 
× 10 mL) then dried in vacuo. The resulting black particles could not be fully dispersed in 
aqueous media. 
Method 2: Heating in toluene 
Uncoated SPION (0.1 g) and APTES (10 µL, 0.43 mmol) were heated to reflux in degassed 
toluene (25 mL) under nitrogen overnight, collected with a permanent magnet and washed 
with fresh MeOH (3 × 10 mL) then dried in vacuo. The resulting black particles could not be 
fully dispersed in aqueous media except at pH 1. 
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Use of a ‘Mixing Head Reactor’ followed by APTES coating based on a modified Stöber method
Figure 1. Custom built mixing head reactor cell for SPION synthesis. Note the two 
syringes (left) for iron salt solution and base, and the T-joint (right) where mixing occurs. 
Based on the methods developed by Olsson et al.31,32,34 Water (20 mL) was degassed 
thoroughly using the freeze-pump-thaw method. A stock solution of iron salts was made 
using FeCl3.6H2O (360 mg, 1.33 mmol) and FeCl2.4H2O (133 mg, 0.69 mmol) in degassed 
H2O (10 mL). 4M NH3 was prepared from the dilution of 35 % NH3 (2.2 mL) with degassed 
H2O. 1 mL of each of the above solutions was transferred into one of the two syringes on 
the stop flow reactor, and rapid mixing was achieved by injection of the two syringes, such 
that the black solution produced was collected in an Eppendorf tube. The reaction mixture 
was sonicated at room temperature for 5 min. The black precipitate of uncoated SPION was 
collected by centrifugation (13200 rpm, 5 min) and was washed with fresh H2O (3 × 2 mL). 
The washed particles were suspended and sonicated for 3 min in a stock solution (3 mL) 
made by mixing H2O (2.8 mL) isopropyl alcohol (12.6 mL) and 35 % NH3 (0.32 mL). APTES 
(90 µL) was added and the reaction mixture mixed with use of an inverting carousel mixer. 
The particles were collected by centrifugation (13200 rpm, 5 min), washed with fresh EtOH 
(3 × 2 mL) and allowed to dry in air to give APTES@SPION as a black solid (8-12 mg). 
Yields from this approach varied significantly and DLS analysis of 1 mg.mL-1 solutions in 1 
M acetic acid showed large hydrodynamic sizes (300-500 nm) with little agreement between 
samples. 
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Additional Experimental Section II – Novel naphthalimide species 
synthesised for use as fluorescent dyes 
1.1 Introduction 
In addition to the use of the commercial dye FITC as a fluorescent marker described in 
Chapter 4, it was proposed that the development of a number of novel fluorophores might 
be an interesting addition to the work described above. Previous research has shown that 1, 
8-naphthalic anhydride reacts with the amine groups of APTES@SPION, forming 
naphthalimide groups on the particle surface which could be seen to fluoresce despite their 
proximity to the strongly quenching iron oxide core. This observation prompted us to 
investigate the usefulness of naphthalimide fluorophores in the field of SPION research.  
1.2 Naphthalimide fluorophores in bioconjugate chemistry 
1, 8- naphthalimide derivatives have several properties that make them of great interest to 
researchers looking for novel fluorophore species for bioconjugate purposes. Beginning 
from commercially available species such as 4-Chloro-1,8-naphthalic anhydride, stepwise 
reactions allow for the synthesis of the imide and the functionalisation of the ring system. 
These reactions can typically occur on a large scale and with excellent yields. The ease of 
their synthesis has contributed to the large number of naphthalimide species reported in the 
scientific literature and their use in such varied fields as cellular imaging (marketed as ‘Lucifer 
yellow’ derivatives1), drug discovery, DNA binding2, as small molecule probes3, as dyes and 
pigments4 and as metal sensors5. In addition, the ease of their synthesis can allow for the 
‘fine-tuning’ of the molecule’s properties including solubility, lipophilicity and their 
photophysical characteristics.6
Figure 1. General synthesis and numbering scheme for naphthalimides. i) EtOH, reflux, 
24 h. ii) DMSO, 90 °C, 3-5 days. 
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Naphthalimide species having an electron donating group at the 4-position show highly 
efficient fluorescence in the yellow-green region of the visible spectrum.4 The inclusion of 
an amino group increases the charge transfer character of the excited state and increases the 
Stokes shift observed for such a naphthalimide.6 This allows for greater distinction between 
the fluorescence of the probe and any autofluorescence that would be observed in a 
biological context.6 However, Lucifer yellow probes used for cell imaging bear two 
sulphonate groups to increase aqueous solubility to approximately 1.5 %,1 and so researchers 
must be conscious of inherently limited aqueous solubility when designing novel 
naphthalimides. 
Within the context of fluorescently labelling either a SPION or synthesizing a fluorescent 
bioconjugate based on such nanoparticles one must be aware of the risk of ‘quenching’. As 
has been discussed in Chapter 4, fluorescence quenching occurs when the interaction 
between a fluorophore and its local environment results in a diminishing of the intensity of 
emitted light. The iron oxide core of the SPION is a very efficient quenching agent although 
as quenching is often distance dependent the presence of a coating agent can partially 
compensate for this. APTES@SPION solutions absorb most strongly at the blue end of the 
visible spectrum. Naphthalimides, having typically lower absorbance maxima than FITC 
(between 400-450 nm versus 495 nm) but displaying much larger bathochromic shifts 
(emitting at 530-550 nm versus 519 nm for FITC) are more able to overcome quenching by 
the core.  
Given their inexpensive starting materials, facile syntheses and desirable photophysical 
characteristics, naphthalimides make excellent candidates for novel fluorophores for use in 
bioconjugation.  
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1.3 Experimental 
1.3.1 Materials and Methods 
All reactions were performed with the use of vacuum line and Schlenk techniques where 
appropriate. Reagents were commercial grade and were used without further purification. All 
reagents and solvents were purchased from Alfa Aesar or Sigma Aldrich. 1H and 13C-{1H} 
NMR spectra were recorded on an NMR-FT Bruker 400 MHz or Joel Eclipse 300 MHz 
spectrometer and recorded in CDCl3 or d6-DMSO. 1H and 13C-{1H} NMR chemical shifts 
(δ) were determined relative to internal TMS and are given in ppm. Coupling constants J are 
given in hertz (Hz). Low- and high-resolution mass spectra were obtained using a Waters 
LCT Premier XE instrument and are reported as m/z (relative intensity). IR spectra are 
recorded as solid samples on a Shimadzu IRAffinity-1 FTIR spectrometer. UV-Vis studies 
were performed on a Jasco V-570 spectrophotometer as solutions (5 × 10-5 M) in CHCl3 or 
H2O. Photophysical data was obtained on a JobinYvon-Horiba Fluorolog spectrometer 
fitted with a JY-TBX picoseconds photodetection module as CHCl3, H2O or DMSO 
solutions. Emission spectra were uncorrected and excitation spectra were instrument 
corrected. The pulsed source was a Nano-LED configured for 355 nm output operating at 
1 MHz. Luminescence lifetime profiles were obtained using the JobinYvon-Horiba 
FluoroHub single photon counting module and the data fitted using DAS6 deconvolution 
software. 
1.3.2 Synthesis and analytical techniques 
Napthalimide-APTES@SPION (1)
APTES@SPION synthesised as described in Chapter 2 (0.100 g) and naphthalic anhydride 
(0.35 g, 0.18 mmol) were heated to 70°C in DMF (10 mL) for 5 h. The black solid was 
collected with a permanent magnet and washed with acetone (3 × 5 mL), then dried in vacuo
to give the title compound as a sparingly soluble black solid (0.070 g). IR (ATP) υ = 2924 (CH), 
1698 (amide CO), 1625, 1654 (NH), 1589, 1016 (CN), 780, 545 cm-1. UV-vis (H2O): λmax = 
345 nm. Emission (H2O): λem = 400 nm.
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4-Chloro-(N-(3-triethooxysilyl(propyl))-1, 8-naphthalimide (2) 
.  
Figure 2. Synthetic scheme for naphthalimide (2). i) 2 eq. APTES, EtOH, reflux, 24h 
APTES (1 mL, 4.3 mmol) and 4-Chloronaphthalic anhydride (0.498 g, 2.15 mmol) were 
heated to reflux in EtOH (10 mL) for 24 h. The pale white suspension becomes a bright 
orange solution within 1 h. Upon cooling to room temperature, a precipitate formed, was 
collected by filtration and washed with cold EtOH (3 × 5 mL) to give the title compound as a 
yellow solid (0.622 g, 1.43 mmol, 66.5 %). 1H NMR (400 MHz, CDCl3) δH = 8.53 (1H, d, 
3JHH = 6.50 Hz, CH), 8.45 (1H, d, 3JHH = 8.48 Hz, CH), 8.36 (1H, d, 3JHH = 7.89 MHz, CH), 
7.76-7.68 (2H, m, 2 × CH), 4.07 (2H, t, 3JHH = 7.66 MHz, CH2N), 3.74 (6H, q, 3JHH = 6.99 
MHz, 3 × CH2CH3) 1.82-1.71 (2H, m, CH2CH2CH2), 1.13 (9H, t, 3JHH = 6.96 MHz, 3 × 
CH2CH3) ppm. 13C NMR (300 MHz, CDCl3) δC = 164.1 (C=O), 139.4 (CCl), 132.1 (CH), 
131.5 (CH), 131.0 (CH), 128.3 (CH), 127.8 (CH), 58.9 (CH2O), 43.4 (CH2N), 21.9 
(CH2CH2Si), 18.7 (CH3), 8.4 (CH2Si) ppm. LR-MS (APCI) found m/z 458.06, calculated m/z 
458.12 for [C21H26NO5SiCl+Na]+. IR (ATP) υ = 2968 (CH), 2880 (CH), 1701, 1662 (amide 
CO), 1587, 1572, 1379, 1342, 1244, 1076 (SiO) cm-1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) 
= 343(9700), 358(8220) nm. Emission (CHCl3) λem = 506 nm (9.12 ns, χ2 = 0.97)
Attempted synthesis of 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino-(N-(3-triethooxysilyl(propyl))-1, 8-
naphthalimide (3) 
Figure 3. Synthetic scheme for naphthalimide (3). i) 10 eq. 2,2'-
ethylenedioxybisethylamine, DMSO, 8 C, 5 days. The presence of hydrolisable ethoxy 
groups prevented the isolation of the target species. 
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2, 2’-ethylenedioxybisethylamine (0.34 mL, 2.3 mmol) was added to dry DMSO (2 mL) under 
N2. Naphthalimide (2) (0.100 g, 0.23 mmol) in DMSO (2 mL) was added, and the reaction 
mixture stirred at 80 °C for 5 days. The orange solution was allowed to cool to room 
temperature, and added to H2O (50 mL). The solution was neutralised by addition of 2 M 
HCl. The coloured compound was extracted into DCM (3 × 10 mL). The organic fraction 
was washed with H2O (3 × 10 mL), brine (3 × 10 mL), and dried over MgSO4. The drying 
agent was removed by filtration, and the solvent removed in vacuo to give a brown oil that 
contained multiple species that could not be characterised satisfactorily.  
4-Chloro-(N-(propyl))-1, 8-naphthalimide (4) 
Propylamine (0.15 mL, 1.82 mmol) and 4-Chloronaphthalic anhydride (0.212 g, 0.91 mmol) 
were heated to reflux in EtOH (10 mL) for 24 h. The pale white suspension becomes a bright 
yellow solution within 1 h. Upon cooling to room temperature, a precipitate formed, was 
collected by filtration and washed with cold EtOH (3 × 5 mL) to give the title compound as a 
yellow solid (0.200 g, 0.73 mmol, 81 %). 1H NMR (400 MHz, CDCl3) δH = 8.60 (1H, d, 3JHH 
= 7.11 Hz, CH), 8.54 (1H, d, 3JHH = 8.14 Hz, CH), 8.44 (1H, d, 3JHH = 7.92 Hz, CH), 7.83-
7.73 (2H, m, 2 × CH), 4.08 (2H, t, 3JHH = 7.58 Hz, CH2N), 1.75-1.64 (2H, m, CH2CH3), 0.95 
(3H, t, 3JHH = 7.42 Hz, CH3) ppm. 13C NMR (400 MHz, CDCl3) δC = 164.0 (CO), 139.4 (CH), 
132.4 (CH), 131.6 (CH), 131.0 (CH), 129.7 (CH), 129.5 (CH), 128.3 (CH), 127.8 (CH), 123.5 
(CH), 122.1 (CH), 42.5 (CH2), 21.8 (CH2), 12.0 (CH3) ppm. LR-MS (EI+) found m/z 273.03, 
calculated m/z 273.06 for [C15H12NO2Cl]+. IR (ATP) υ = 3065 (CH), 2949 (CH), 2873 (CH), 
1695, 1653 (amide CO), 1585, 1348 cm-1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) = 
342(14060), 358(11880) nm. Emission (CHCl3) λem = 501 nm (9.30 ns, χ2 = 0.92)
4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino-(N-(propyl))-1,8-naphthalimide (5)
2, 2’-ethylenedioxybisethylamine (0.54 mL, 3.7 mmol) was added to DMSO (2 mL) under 
N2. Naphthalimide (4) (0.100 g, 0.37 mmol) in DMSO (2 mL) was added, and the reaction 
mixture stirred at 80 °C for 5 days. The orange solution was allowed to cool to room 
temperature, and added to H2O (50 mL). The solution was neutralised by addition of 2 M 
HCl. The coloured compound was extracted into DCM (3 × 10 mL). The organic fraction 
was washed with H2O (3 × 10 mL), brine (3 × 10 mL), and dried over MgSO4. The drying 
agent was removed by filtration, and the solvent removed in vacuo to give the title compound as 
a bright yellow solid (0.121 g, 0.31 mmol, 85 %). 1H NMR (400 MHz, CDCl3) δH = 8.52 (1H, 
d, 3JHH = 8.00 Hz, CH), 8.39 (1H, d, 3JHH = 8.37 Hz, CH), 8.14 (1H, d, 3JHH = 8.05 Hz, CH), 
7.58-7.53 (1H, m, CH(CH)2), 6.64 (1H, d, 3JHH = 8.44 Hz, CH(CN)), 5.95-5.91 (1H, m, NH), 
4.08-4.03 (2H, m, CH2N), 3.83 (2H, t, 3JHH = 5.24 Hz, CH2O), 3.69-3.60 (4H, m, 2 × CH2O), 
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3.55-3.50 (2H, m, CH2NH2), 3.48 (2H, m, CH2), 2.83 (2H, t, 3JHH = 5.20 Hz, CH2N), 1.73-
1.63 (2H, m, CH2CH3), 0.94 (3H, t, 3JHH = 7.43 Hz, CH3) ppm. 13C NMR (400 MHz, CDCl3) 
δC = 165.2 (CO), 164.7 (CN), 134.8 (CH), 131.6 (CH), 126.9 (CH), 125.1 (CH), 70.8 (CH2O), 
70.6 (CH2O), 69.1 (CH2O), 42.1 (CH2N), 42.0 (CH2N), 41.4 (CH2N) 21.8 (CH2CH3), 12.0 
(CH3) ppm. LR-MS (ES+) found m/z 386.19, calculated m/z 386.21 for [C21H28N3O4]+. IR 
(ATP) υ =3529 (NH), 3354 (NH), 2874 (CH), 1680, 1643 (amide CO), 1585, 1342, 1066 cm-
1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) = 424 (9760), 278(13100), 261(15560) nm. Emission 
(CHCl3) λem = 510 nm (8.73 ns, χ2 = 1.07)
Figure 4. Synthetic scheme for naphthalimides (6) and (7). i) 2 eq. 2-aminoethanethiol 
hydrochloride, 4 eq. NEt3, EtOH, reflux, 24. ii) 4 eq. morpholine, DMSO, 95 °C, 72 h.  
4-Chloro-(N-(2-mercaptoethyl))-1, 8-naphthalimide (6) 
4-Chloronaphthalic anhydride (0.200 g, 0.86 mmol) and NEt3 (0.24 mL, 1.7 mmol) were 
added to a solution of 2-aminoethanethiol hydrochloride (0.195 g, 1.70 mmol) in EtOH (20 
mL) under N2. The reaction mixture was heated to reflux overnight, then allowed to cool to 
room temperature. A precipitate was collected on a filter, washed with cold EtOH (3 × 10 
mL) and dried in vacuo to give the title compound as a yellow solid (0.195 g, 0.67 mmol, 78 %). 
1H NMR (400 MHz, CDCl3) δH =8.59-8.52 (2H, m, 2 × CH), 8.41 (1H, d, 3JHH = 7.90, CH), 
7.81-7.74 (2H, m, 2 × CH), 4.49 (2H, t, 3JHH = 7.27 Hz, CH2N), 3.09-3.02 (2H, m, CH2SH) 
ppm. 13C NMR (400 MHz, CDCl3) δC = 163.9 (CO), 131.7 (CH), 128.3 (CH), 127.9 (CH), 
121.9 (CH), 45.1 (CH2N), 36.0 (CH2SH) ppm. LR-MS (EI+) found m/z 258.03, calculated 
m/z 258.03 for [C14H9NO2Cl]+ ([M-SH]+). IR (ATP) υ = 3067 (CH), 2949, 2926, 1697 (amide 
CO), 1657 (amide CO), 1589, 1570, 1338, 1232 cm-1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) 
= 359(11940), 344(14200), 327(10000) nm. Emission (DMSO) λem = 519 nm (2.64 ns, χ2 = 
0.93)
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4-morpholinyl-(N-(2-mercaptoethyl))-1, 8-naphthalimide (7)
Naphthalimide (6) (0.060 g, 0.21 mmol) and morpholine (72 µL, 0.825 mmol) were dissolved 
in DMSO (3 mL) under N2. The reaction mixture was heated at 95 °C for 3 days, and then 
allowed to cool to room temperature. The reaction mixture was added to H2O (30 mL) and 
neutralised with 2 M HCl. The organic content was extracted into DCM (3 × 10 mL), washed 
with H2O (3 × 10 mL) and brine (3 × 10 mL), then dried over MgSO4. The drying agent was 
removed by filtration and the solvent removed in vacuo to give the title compound as a bright 
yellow solid (0.020 g, 0.06 mmol, 28 %). 1H NMR (400 MHz, CDCl3) δH = 8.50 (1H, d, 3JHH
= 7.303 Hz, CH), 8.45 1H, d, 3JHH = 8.243 Hz, CH), 8.35 (1H, d, 3JHH = 8.353 Hz, CH), 7.63 
(1H, m, 7.66-7.60 Hz, CH(CH)2, 7.16 (1H, d, 3JHH = 7.95 Hz, CH), 4.49 (2H, t, 3JHH = 7.07 
Hz, CH2N(CO)2), 3.99-3.91 (4H, m, 2 × CH2O), 3.24-3.14 (4H, m, 2 × CH2N), 3.05 (2H, t, 
3JHH = 7.21 Hz, CH2SH) ppm. 13C NMR (125 MHz, CDCl3) δC = 164.3 (CO), 155.7 (CN), 
132.7 (CH), 131.3 (CH), 130.2 (CH), 126.2 (CH), 125.9 (CH), 123.2 (CH), 117.0 (CH), 115.0 
(CH), 67.0 (CH2O), 53.5 (CH2N(CH2)2), 39.5 (CH2N(CO)2), 35.7 (CH2SH) ppm.  LR-MS 
(ES+) found m/z 381.31, calculated m/z 381.07 for [C18H18N2O3S+K]+. IR (ATP) υ = 2959 
(CH), 2847 (CH), 1697 (amide CO), 1657 (amide CO), 1585, 1570, 1379, 1231 cm-1. UV-vis 
(CHCl3): λmax (ε / L mol-1 cm-1) = 387(11160), 334(4020), 319(2880) nm. Emission (CHCl3) 
λem = 501 nm (4.52 ns, χ2 = 0.92)
Figure 5. Simplified scheme for attempted labelling of trastuzumab with naphthalimide 
(7).i) 10 eq. MBS, pH 7.4 buffer. ii) 100 eq. naphthalimide probe (12), pH 7.4 buffer. F/P 
ratio for the antibody species is unknown. 
Attempt to label trastuzumab with naphthalimide (7) (MBS mediated method) 
Trastuzumab was dissolved in 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.2 (0.5 mL, 10 
mg.mL-1). The crosslinker MBS (16.5 mg) was dissolved in DMSO (100 µL), and 5 µL was 
added to the antibody solution achieving an 80-fold excess. The microemulsion observed is 
typical of the use of MBS. The reaction mixture was mixed at room temperature for 1 h. The 
solution was applied to a PD-10 column equilibrated with 0.1 M sodium phosphate, 0.15 M 
NaCl, pH 7.2, and 0.5 mL fractions eluted using the same buffer. The concentration of the 
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protein was measured by monitoring absorbance at 280 nm, and the two most concentrated 
fractions were added together. The naphthalimide probe (12) was dissolved in DMSO at a 
concentration of 0.02 mg.mL-1 and an appropriate volume added to the antibody solution to 
achieve a 100-fold excess over the protein. The mixture was mixed at room temperature 
overnight, before purification on a PD-10 column using 0.1 M sodium phosphate, 0.15 M 
NaCl, pH 7.4. By monitoring the absorbance at 280 nm, the most concentrated fraction was 
determined and analysed by UV-vis and fluorescence analysis. Emission (H2O) λem = 540 nm.
Figure 6. Synthetic scheme for naphthalimides (9), (10) and (11). i) EtOH, SOCl2, RT, 2 
h. ii)2 eq. (13),  EtOH, NEt3, reflux, 24 h. iii) 4 eq. morpholine, DMSO, 90 °C, 72 h. iv) 
NaOH, acetone, RT, 24 h. v) 2 M HCl, H2O, RT, 10 min. 
β-alanine ethyl ester (8)
β-alanine (1.016 g, 11.4 mmol) was suspended in cold EtOH (50 mL). SOCl2 (10 mL) was 
added dropwise with stirring. The reaction mixture was observed to become clear, and was 
allowed to come to room temperature, then stirred for 2 h. The solvent was removed under 
reduced pressure, and the beige solid recrystallised from hot EtOH. The solid was collected 
by filtration, washed with cold Et2O (3 × 5 mL) and dried in vacuo to give the title compound as 
a white solid (0.901 g, 7.68 mmol, 67 %). 1H NMR (400 MHz, CDCl3) δH = 8.11 (2H, br s, 
NH2), 4.10 (2H, q, 3JHH = 7.38 Hz, CH2CH3), 3.30 (2H, t, 3JHH = 6.83 Hz, CH2NH2), 2.86 
(2H, t, 3JHH = 6.83 Hz, CH2CO2Et), 1.20 (3H, t, 3JHH = 7.54 Hz, CH3CH2) ppm. 13C NMR 
(100 MHz, CDCl3) δC = 171.3 (CO2Et), 61.4 (CH2CH3), 35.6 (CH2NH2), 31.3 (CH2CO2), 
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14.4 (CH3) ppm. HR-MS (EI+) found m/z 117.0788, calculated m/z 117.0790 for 
[C5H11NO2]+. 
4-Chloro-(N-(3-ethylpropanoate))-1, 8-naphthalimide (9) 
β-alanine ethyl ester (8) (0.600 g, 5.16 mmol), 4-chloro-naphthalic anhydride (0.600 g, 2.58 
mmol) and NEt3 (1.08 mL, 7.74 mmol) were added to EtOH (15 mL) under N2. The reaction 
mixture was heated to reflux for 24 h, and seen to turn bright orange. The reaction was 
cooled to room temperature, and a yellow precipitate collected by filtration. The solid was 
washed with cold EtOH (3 × 5 mL) and cold Et2O (3 × 5 mL), then dried in vacuo to give 
the title compound as a yellow solid (0.695 g, 2.10 mmol, 81 %). 1H NMR (400 MHz, CDCl3) 
δH = 8.62-8.50 (2H, m, 2 × CH), 8.44 (1H, d, 3JHH = 8.10 Hz, CH), 7.84-7.73 (2H, m, 2 × 
CH), 4.41 (2H, t, 3JHH = 7.56 Hz, CH2N), 4.08 (2H, q, 3JHH = 7.13 Hz, CH2CH3), 2.69 (2H, t, 
3JHH = 7.12 Hz, CH2CO2), 1.16 (3H, t, 3JHH = 7.00 Hz, CH3CH2) ppm. 13C NMR (100 MHz, 
CDCl3) δC = 171.4 (CO2Et), 163.5 (CO), 139.3 (CCl), 132.2 (CH), 131.2 (CH), 129.4 (CH), 
127.8 (CH), 127.4 (CH), 122.9 (CCH), 121.5 (CCH), 60.8 (CH2CH3), 36.2 (CH2N), 32.9 
(CH2CO2), 14.2 (CH3) ppm. HR-MS (ES+) found m/z 332.0696, calculated m/z 332.0690 
for [C17H15NO4Cl]+.. IR (ATP) υ = 1714, 1699 (amide CO), 1661 (amide CO), 1587, 1573, 
1502, 1342, 1259, 1201, 1014, 783 cm-1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) = 359(13240), 
343(16200), 327(10740) nm. Emission (CHCl3) λem = 501 nm (8.96 ns, χ2 = 1.05). 
4-Morpholino-(N-(3-ethylpropanoate))-1, 8-naphthalimide (10) 
Naphthalimide (9) (0.600 g, 1.81 mmol) and morpholine (0.62 mL, 7.23 mmol) were added 
to DMSO (3 mL) under N2, and the reaction mixture heated to 90 °C for 72 h. The reaction 
mixture was cooled and diluted with H2O (30 mL). The solution was neutralised with 1 M 
HCl. The yellow precipitate was collected by filtration, washed with cold H2O (3 × 5 mL), 
then dissolved in DCM (20 mL). The organic solution was washed with H2O (3 × 10 mL), 
brine (3 × 10 mL), and then dried over Na2SO4. The solvent was removed under reduced 
pressure and precipitate recrystallised from hot EtOH to give the title compound as a yellow 
solid. (0.420 g, 1.10 mmol, 61 %). 1H NMR (400 MHz, CDCl3) δH = 8.54-8.50 (1H, m, CH), 
8.47 (1H, d, 3JHH = 9.79 Hz, CH), 8.36 (1H, d, 3JHH = 9.79 Hz, CH), 7.67-7.61 (1H, m, CH), 
7.17 (1H, d, 3JHH = 8.16 Hz, CH), 4.42 (2H, t, 3JHH = 7.34 Hz, CH2N), 4.08 (2H, q, 3JHH = 
7.07 Hz, CH2CH3), 3.95 (4H, m, 2 × CH2O), 3.20 (4H, m, 2 × CH2N), 2.68 (2H, t, 3JHH = 
7.34 Hz, CH2CO2), 1.16 (3H, t, 3JHH = 7.35 Hz, CH3CH2) ppm. 13C NMR (100 MHz, CDCl3) 
δC = 171.4 (CO2Et), 164.3 (CO), 163.8 (CO), 155.8 (CN(CH2)2), 132.7 (CH), 131.3 (CH), 
130.2 (CH), 130.0 (CH), 126.2 (CH), 125.9 (C=C), 123.1 (C=C), 117.0 (C=C), 115.0 (C=C), 
67.0 ((CH2)2O), 58.0 (CH2CH3), 53.4 ((CH2)2N), 36.0 (CH2N), 32.8 (CH2), 14.2 (CH3) ppm. 
240
HR-MS (ES+) found m/z 383.1590, calculated m/z 383.1607 for [C21H23N2O5]+. IR (ATP) 
υ = 2970, 2818, 1718, 1687 (amide CO), 1651 (amide CO), 1586, 1514, 1352, 1195 (CO), 
1113 (CO), 1024 cm-1. UV-vis (CHCl3): λmax (ε / L mol-1 cm-1) = 395(11400), 343(3700), 
328(2160) nm. Emission (CHCl3) λem = 501 nm (8.84 ns, χ2 = 0.98). 
4-Morpholino-(N-(3-propanoic acid))-1, 8-naphthalimide (11)
Naphthalimide (10) (0.400 g, 1.05 mmol) was dissolved in acetone (10 mL). 1 M NaOH (3 
mL) was added dropwise and the solution stirred at room temperature for 24 h. The reaction 
mixture was placed in the freezer for 1 h. The yellow precipitate was collected by filtration 
and washed with cold 95:5 acetone:water (3 × 5 mL). The yellow solid was dissolved in H2O 
(10 mL) and washed with CHCl3 (3 × 5 mL). The aqueous fraction was acidified with 2 M 
HCl, and a yellow precipitate seen to form. This was collected by filtration, and washed with 
fresh H2O (3 × 5 mL) and cold EtOH (3 × 5 mL). The solid was dried in vacuo to give the 
title compound as a yellow solid (0.257 g, 0.726 mmol, 69 %). 1H NMR (400 MHz, CDCl3) δH
= 8/50-8.43 (2H, m, 2 × CH), 8.39 (1H, d, 3JHH = 8.40 Hz, CH), 7.84-7.75 (1H, m, CH), 7.34 
(1H, d, 3JHH = 8.40 Hz, CH), 4.20-4.10 (2H, m, CH2N), 3.97-3.87 (4H, m, 2 × CH2O), 3.27-
3.17 (4H, m, 2 × CH2N), 2.25-2.18 (2H, m, CH2CO2H) ppm. 13C NMR (100 MHz, CDCl3) 
δC = 173.0 (CO2H), 163.9 (CO), 163.4 (CO), 156.0 (CN(CH2)2), 132.7 (CH), 131.1 (CH), 
129.7 (CH), 126.6 (CH), 125.8 (CH), 123.0 (C=C), 116.3 (C=C), 115.6 (C=C), 66.7 (CH2O), 
53.5 (CH2N), 36.1 (CH2N), 32.8 (CH2CO2H) ppm. HR-MS (ES+) found m/z 355.1283, 
calculated m/z 355.1294 for [C19H19N2O5]+. IR (ATP) υ = 2982 (br, CO2H), 1734, 1687 
(amide CO), 1645 (amide CO), 1576, 1510, 1358, 1177, 1098, 1029 cm-1. UV-vis (H2O): λmax
(ε / L mol-1 cm-1) = 395(7740), 346(3480), 331(2460) nm. Emission (H2O) λem = 506 nm (3.79 
ns, χ2 = 0.95). 
Attempt to label trastuzumab with naphthalimide (11) (EDC, sulfo-NHS mediated method) 
Trastuzumab was dissolved in 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.4 (0.5 mL, 10 
mg.mL-1). The naphthalimide probe (11) was dissolved in 0.1 M sodium phosphate, 0.15 M 
NaCl, pH 7.4 (2.5 mg.mL-1). 100 µL of the probe solution was added to the antibody solution, 
yielding a 10 fold excess of dye to antibody. EDC (16 mg, 0.10 mmol) was added to 0.1 M 
sodium phosphate, 0.15 M NaCl, pH 7.4 (1 mL). 10 µL was taken and added to the reaction 
mixture and mixed, achieving a 12 fold excess over the antibody. Sulfo-NHS (10.8 mg, 5 × 
10-5 mmol) was added to 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.4 (0.1 mL). 10 µL 
was taken and added to the reaction mixture to achieve a 120 fold excess over the antibody. 
The reaction mixture was mixed by gentle inversion at room temperature for 2 h. Purification 
was achieved by use of a PD-10 size exclusion chromatography column. The column was 
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equilibrated with 0.1 M sodium phosphate, 0.15 M NaCl, pH 7.4, the reaction mixture 
applied, and fractions of 0.5 mL were collected using the same buffer as an eluent. 
Absorbance at 280 nm was measured to isolate the protein-containing fractions. These 
fractions were collected and concentrated using a 10,000 MWCO protein concentrator spin 
column. At antibody concentrations of 6.57 mg.mL-1 as determined from A280, the solution 
was colourless to the naked eye, and no absorbance was measured in the UV-vis spectrum 
between 300-400 nm. Labelling was not observed to occur to any appreciable degree. 
Figure 7. Simplified scheme for attempted labelling of trastuzumab with naphthalimide 
(11).i) 1.2 eq EDC, pH 7.4 buffer. ii) 12 eq. sulfo-NHS, pH 7.4 buffer. iii) 0.1 eq. amine 
bearing trastuzumab, pH 7.4 buffer. This last step was not observed to occur. 
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1.4 Results and discussion 
1.4.1 Direct labelling of nanoparticles 
Initial experiments were intended as a proof of concept that 1,8-naphthalimides could be 
immobilised directly onto the surface of nanoparticles and could be observed 
spectroscopically. Heating a suspension of APTES@SPION and 1,8-naphthalic anhydride 
in DMF allowed the isolation of a black solid (1), showing a sharp peak in the IR spectrum 
at 1698 cm-1 that could be unequivocally assigned to the naphthalimide carboxyl stretches. 
Concerns that this may be adsorbed 1,8- naphthalic anhydride or residual starting material 
were assuaged by the presence of an absorbance maxima at 345 nm in the UV-vis spectrum 
(Fig. 8) and by the emission maxima at 400 nm in the excitation emission spectrum (Fig. 9) 
which is indicative of naphthalimide formation. However, this experiment had several 
drawbacks not least of which was the lack of control over the degree of labelling. An 
approximately 1100-fold excess of the anhydride was used but the observed fluorescence 
was weak and the degree of labelling cannot be determined from the absorbance spectra. In 
addition, the final product showed reduced solubility in aqueous conditions compared to the 
parent nanomaterial. It is likely that quenching occurred due to fluorophore-fluorophore 
interaction that reduced the observed fluorescence intensity below what would be expected; 
saturation of the nanoparticle surface with hydrophobic fluorophores would also explain 
reduced aqueous solubility. 
Figure 8. Absorbance spectra of naphthalimide labelled APTES@SPION (orange) and 
unlabelled APTES@SPION (blue). 
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Figure 9. Excitation (blue) and emission (orange) spectra for naphthalimide-labelled 
APTES@SPION. 
1.4.2 Naphthalimide derivatives of APTES 
One method of controlling the degree of labelling of directly labelled nanoparticles would 
be to incorporate naphthalimide-bearing derivatives of APTES in an appropriate quantity 
into the coating step of the nanoparticle synthesis. For the photophysical reasons discussed 
in the introduction to this section, it would be desirable for such a naphthalimide to be 
functionalised in the 3- or 4- position. In addition to the effect this would have on the Stokes 
shift of the species, it could also be an opportunity to counteract the inherent hydrophobicity 
of the naphthalimide core by introducing a polar character to the molecule. The PEG-like 
species 2, 2’-ethylenedioxybisethylamine would be an ideal species for this task (see Fig. 10). 
The initial reaction between the anhydride and APTES occurred giving a yellow solid (2) in 
satisfactory yield. Peaks in the NMR spectrum above 7 ppm were similar to those reported 
in the literature for similar naphthalimide species and integrated well with respect to peaks 
at 4.07, 3.74, 1.82-1.71 and 1.13 ppm pertaining to the APTES-like fragment of the molecule. 
All other spectroscopic and spectrometric methods supported the conclusion that the 
reaction had occurred as expected. However, a subsequent reaction between the chloro-
bearing species (2) and 2, 2’-ethylenedioxybisethylamine gave a mixture of species that could 
not be satisfactorily separated by chromatographic methods.  
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Figure 10. Synthetic schemes for napthalimides (2), (4) and (5). The presence of 
hydrolisable ethoxy groups prevent the isolation of species (3). i) 2 eq. APTES, EtOH, 
reflux, 24 h. ii) 10 eq. 2,2’-ethylenedioxybisethylamine, DMSO, 80 °C, 5 days. iii) 2 eq. 
Propylamine, EtOH, reflux, 24 h. iv) 10 eq. 2,2’-ethylenedioxybisethylamine, DMSO, 80 
°C, 5 days. 
The naphthalimide species (4) and (5) shown in Fig. 10 were synthesised in an attempt to 
clarify whether the failure to isolate the naphthalimide (3) was due to hydrolysis of the 
ethoxysilyl groups or due to other factors. Propylamine was chosen for its structural similarity 
to APTES. As the synthesis of species (5) occurred without issue and yielded a satisfactory 
quantity of the pure compound as a yellow solid, it was concluded that hydrolysis of the 
ethoxysilyl groups of species (2) occurs as a side-reaction to the functionalisation of the 
naphthalimide ring. Thin layer chromatography showed more than the four species that 
would result from partial hydrolysis (Fig. 11a below) and it may be concluded that additional 
side reactions also occur e.g. cross-reaction to form dimers or polymeric species.  
Although dried DMSO was used in the attempt to synthesise (3) and every effort was taken 
to exclude moisture from the glassware employed, it is likely that given the long reaction time 
and elevated temperatures employed, the sensitivity of the ethoxysilyl groups to trace 
amounts of water was too great to prevent hydrolysis. Future work on this concept would 
focus either on alternative methods to preclude hydrolysis, to re-instate the ethoxy groups 
post hydrolysis, or alternatively to focus on the use of the species formed by reaction between 
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APTES and 1, 8-naphthalic anhydride (Fig. 11b below). Although this species would not 
allow for the tuning of its photophysical characteristics, it would still allow for a degree of 
control over the labelling of APTES@SPION. 
Figure 11a. Partial hydrolysis would lead to 4 potential end species; side reactions are 
proposed to be occuring in addition to this. b. Although this species will not have the 
Stokes shift associated with its functionalised derivatives, its use would offer better 
control in comparison to the direct reaction between the anhydride and the nanoparticles. 
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1.4.3 Naphthalimides for bioconjugation 
Thiol bearing naphthalimides (6) and (7) 
The labelling of antibodies with fluorescent dyes is a common and well-understood area of 
research, with a multitude of activated species available commercially. As seen in 
bioconjugation in general, the approaches most commonly employed include amine-to-thiol 
and amine-to-acid crosslinking and often require a suitable activating or crosslinking agent. 
The thiol-bearing naphthalimides (6) and (7) (see Fig. 12) were synthesised for the purpose 
of achieving amine-to-thiol linking with amine groups on Trastuzumab. It has been shown 
from the FITC-labelling described in Chapter 4 of this work that there are multiple amines 
present on the antibody that are able to react. The inclusion of a morpholine group was based 
upon the requirement for an amine group in the 4-position of the naphthalimide system (for 
photophysical characteristics) and the need for such a moiety to have a reasonably polar 
nature (to aid in solubility of the dye and of any conjugate species). A morpholine-moiety 
has previously been reported in a similar species by Langdon-Jones et al.7, and of the seven 
analogues described in that work the morpholine-bearing species was shown to have the 
largest Stokes shift (130 nm).  
Figure 12. Synthetic scheme for naphthalimides (6) and (7). i) 2 eq. 2-aminoethanethiol 
hydrochloride, 4 eq. NEt3, EtOH, reflux, 24. ii) 4 eq. morpholine, DMSO, 95 °C, 72 h.  
The spectra below (Figs. 13 and 14) show naphthalimide (6) had an absorbance maxima of 
344 nm and an emission maxima of 519 nm (a Stokes shift of 175 nm), while naphthalimide 
(7) had an absorbance maxima of 387 nm and an emission maxima of 501 nm (a Stokes shift 
of 114 nm). Species (7) fluoresces with a significantly increased lifetime (4.52 ns, χ2 = 0.92) 
compared to (6) (2.64 ns, χ2 = 0.93). Photophysically, both would be suitable for use in 
bioconjugation but the increased lifetime of (7) would aid in the differentiation of dye and 
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background autofluorescence, hence the morpholine bearing species would be the preferred 
candidate.  
Figure 13. Absorbance spectra of thiol-bearing naphthalimides (6) (orange) and (7) 
(blue). 
.  
Figure 14. Emission spectra of thiol-bearing naphthalimides (6) (orange) and (7) (blue) 
and trastuzumab labelled with (7) (grey). 
The monoclonal antibody trastuzumab has been discussed in detail in Chapters 3 and 4 of 
the current work, and was labelled with FITC for use in in vitro FACS analysis. The thiol-
248
bearing species (7) has a larger Stokes shift than FITC (114 nm compared to 25 nm 
respectively, and has a comparable lifetime when free (4.52 ns versus approximately 4.1 ns). 
Coupling of (7) to trastuzumab using an amine-to-thiol cross linker MBS was attempted to 
explore the potential of the naphthalimide in a bioconjugation context. 
Figure 15. Simplified scheme for the attempted labelling of trastuzumab with 
naphthalimide (7). i) 10 eq. MBS, pH 7.4 buffer. ii) 100 eq. naphthalimide probe (12), pH 
7.4 buffer. F/P ratio for the antibody species is unknown. 
The MBS-mediated coupling shown in Fig. 15 was based on a procedure described by 
Hermanson.1 Although not optimised for the experiment, such an approach is typically 
successful in labelling antibodies. Purification and concentration gave an aqueous sample 
that had a measurable absorbance at 280 nm, confirming the presence of the antibody, but a 
value for A350 for the fluorophore could not be measured despite an initial excess of 100 
fluorophores per protein. The F/P ratio could not be determined for this species. An 
emission at 540 nm was measured and is shown in Fig. 14 but the solution was at that point 
too dilute to allow measurement of fluorescence lifetime. The increase in the emission 
maxima from 501 nm when free to 540 nm confirms the labelling of the antibody. The 
limited success of this approach suggests that a side reaction is occurring to limit fluorescent 
labelling e.g. degradation of the maleimide intermediate or cross-linking between monomers 
of the antibody. Future studies could focus on overcoming these to improve labelling 
efficiency. 
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Carboxylic acid bearing naphthalimide (11) 
The sequential synthesis of (8), (9), (10) and finally deprotection was intended to yield the 
carboxylic acid bearing naphthalimide (11) (see Fig. 16) that would offer nearly identical 
photophysical characteristics to the thiol-bearing species discussed above but which could 
be attached to an antibody using a different and hopefully more efficient methodology. 
Characterisation of all species was performed by 1H NMR, 13C NMR, HR-MS and IR, 
confirming the nature of all species. Suitable crystals (see Fig. 17) for structure determination 
for (9) and (10) were obtained by the slow diffusion of ethyl acetate into an ether solution, 
and by slow diffusion of hexane into an ethyl acetate solution respectively. Data collection 
parameters are given as Appendix III. 
Figure 16. Synthetic scheme for naphthalimides (9), (10) and (11). i) EtOH, SOCl2, RT, 
2 h. ii) 2 eq. (13),  EtOH, NEt3, reflux, 24 h. iii) 4 eq. morpholine, DMSO, 90 °C, 72 h. 
iv) NaOH, acetone, RT, 24 h. v) 2 M HCl, H2O, RT, 10 min. 
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Figure 17a. X-Ray crystal structure of naphthalimide (9) with ellipsoids at 50 % 
occupancy. b. X-Ray crystal structure of naphthalimide (10) showing a dimeric 
arrangement  with ellipsoids at 50 % occupancy. 
UV-vis studies of the naphthalimides (Fig. 18) show that (9) has a near identical absorbance 
profile to its analogue species (6) as expected because the functional groups attached to the 
nitrogen of the ring are known to have little effect on the photophysical properties of the 
molecule as a whole.3 The ethyl ester protected species (10) and its deprotected acid analogue 
(11) both have absorbance maxima at 395 nm. Exciting at this wavelength gives the emission 
spectra shown in Fig. 19. The free acid species (11) has an emission maxima at 506 nm 
(corresponding to a Stokes shift of 111 nm) with a lifetime of 3.79 ns (χ2 = 0.95) in water, 
marginally shorter than that reported for the commercially available naphthalimide dye 
Lucifer yellow.8 The photophysical characteristics of this species show it to be suitable for 
use as a fluorophore in bioconjugation.  
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Figure 18. Absorbance spectra of naphthalimide species (9) (blue), (10) (orange) and the 
deprotected species (11) (grey).  
Figure 19. Emission spectra of protected naphthalimide (10) (orange) and its deprotected 
free acid analogue (11) (grey). 
Coupling between the carboxylic acid group of naphthalimide (11) and amine groups on 
trastuzumab was attempted using a general approach described in Hermanson1 for amine-
acid linking by use of sulfo-NHS and EDC (see Fig. 20). 
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Figure 20. Simplified scheme for attempted labelling of trastuzumab with naphthalimide 
(11).i) 1.2 eq EDC, pH 7.4 buffer. ii) 12 eq. sulfo-NHS, pH 7.4 buffer. iii) 0.1 eq. amine 
bearing trastuzumab, pH 7.4 buffer. This last step was not observed to occur. 
In theory, reaction between the acid and EDC and then sulfo-NHS yields a water-soluble 
activated ester intermediate that is reasonably stable to hydrolysis and reactive to amines. 
However, despite the fluorophore being in tenfold excess to the protein and the EDC and 
sulfo-NHS being in even greater excess as described by the protocol, isolation of the 
antibody following the experiment yielded a sample that had significant absorbance at 280 
nm (corresponding to an antibody concentration of approximately 6.57 mg.mL-1) but which 
did not show absorbance at 395 nm, was not seen to be coloured and did not fluoresce. 
Fluorescent labelling had not occurred to an observable degree. Although this may be due in 
part to suboptimal reaction conditions for the probe, the similarity in outcome to the 
experiment described for the thiol-bearing naphthalimide (7) suggests that there may be an 
intrinsic issue arising from the naphthalimide core used in both of these experiments. The 
hydrophobic naphthalimide ring system may be showing a propensity to π-stacking in 
aqueous solution that limits the ability of the probes to react with functional groups on 
protein molecules. The use of more hydrophilic alternatives (such as Lucifer yellow 
derivatives) may be required to introduce a naphthalimide to Trastuzumab. 
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1.5 Conclusion 
Several novel naphthalimide species were synthesised and characterised in an effort to 
produce an alternative to commercial dyes for use in bioconjugation. Thiol- and acid-bearing 
naphthalimides were used in attempts to label the clinically used antibody Trastuzumab with 
limited success. The amine-to-thiol linking method described above showed the most 
promise; although an F/P ratio could not be determined, the conjugate did at least fluoresce. 
It would be interesting to determine whether changing the morpholine functionality for a 
more hydrophilic species would improve the outcome of similar future experiments. 
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Additional Experimental Section III - Small molecules arising from the 
study of bis(thiosemicarbazone) ligands and complexes 
1.1 Introduction 
In addition to the ligands and complexes described and characterised in Chapter 5, additional 
novel chemical species and observations arising from the current work are described below. 
They are not included in the main body of the report for a number of reasons, given in the 
relevant sections: either the work failed to achieve the desired result, did not yield a product 
that could be characterised sufficiently to allow conclusions to be drawn, or is of passing 
relevance to the main aims of the project. 
1.2 Experimental  
1.2.1 Materials and Methods 
All reactions were performed with the use of vacuum line and Schlenk techniques. Reagents 
were commercial grade and were used without further purification. 1H and 13C-{1H} NMR 
spectra were recorded on an NMR-FT Bruker 400 MHz or Joel Eclipse 300 MHz 
spectrometer and recorded in CDCl3, CD3OD or d6-DMSO. 1H and 13C-{1H} NMR 
chemical shifts (δ) were determined relative to internal TMS and are given in ppm. Coupling 
constants J are given in hertz (Hz). Low- and high-resolution mass spectra were obtained 
using a Waters LCT Premier XE instrument and are reported as m/z (relative intensity). IR 
spectra are recorded as solid samples on a Shimadzu IRAffinity-1 FTIR spectrometer. UV-
Vis studies were performed on a Jasco V-570 spectrophotometer as MeCN solutions (5 × 
10-5 M) except where stated.  
1.2.2 Synthesis and analytical techniques 
Attempted deprotection of H2L1 
H2L1 (0.100 g, 0.25 mmol) was suspended in THF (5 mL). NaOH (0.060 g, 1.5 mmol) was 
dissolved in H2O (5 mL) and added dropwise over 10 minutes. Upon the first addition, the 
solution turned bright yellow, and throughout the addition the suspension is removed as the 
species dissolved. The reaction mixture was stirred for 10 minutes, then neutralised with the 
addition of 2 M HCl. The solvent was removed in vacuo to give a white residue that was not 
soluble in organic solvents. An NMR spectrum was obtained from a d6-DMSO solution of 
the residue, which showed a large number of environments which could not be satisfactorily 
identified. It was noted that the yellow colour that had been observed upon addition of base 
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was now dissolved in the trap of the Schlenk line, and had a strong odour of 2, 3-butandione. 
It was concluded that the ligand had decomposed upon addition of strong base. 
Other methods were independently trialled at Mologic Ltd., with similar results. 
Attempted deprotection of H2L3 using neat TFA 
H2L3 (0.200 g, 0.39 mmol) was added to neat TFA (1 mL) giving a strong yellow colour and 
stirred for 10 min. The acid was removed in vacuo, MeCN (5 mL) was added, and the solution 
neutralised with 2 M NaOH. The reaction mixture was taken to dryness, and the yellow oily 
residue dissolved in d3-MeCN. A 1H NMR spectrum was measured which showed partial 
loss of the Boc groups based on peak integration, but a significant number of peaks which 
could not be positively identified. It was concluded that the use of neat TFA was too harsh 
in terms of reaction conditions, and caused decomposition. 
Attempted deprotection of H2L3 – TFA in DCM 
H2L3 (0.050 g, 0.10 mmol) was dissolved in dry DCM (5 mL) under a blanket of N2. TFA (1 
mL) was dissolved in dry DCM (5 mL) and the acidic solution added dropwise. The yellow 
solution was seen to turn light brown, and was stirred overnight at room temperature. The 
solution was added dropwise to cold Et2O (20 mL) with vigorous stirring. The solvent was 
removed in vacuo to give the target compound (H2L4) as a colourless oil (0.004 g, 0.013 mmol, 
13 %). 1H NMR (400 MHz, D2O) δH = 3.89 (4H, t, 3JHH = 5.81 Hz, 2 × CH2NH), 3.16 (4H, 
t, 3JHH = 5.62 Hz, 2 × CH2NH), 2.05 (6H, s, 2 × CH3) ppm. There was insufficient material 
to measure a 13C NMR spectrum. A representative mass spectrum was not obtainable.  
Complex ZnL4
The oil recovered from the attempted deprotection of H2L3 (0.004 g, 0.013 mmol) was 
dispersed in EtOH (5 mL), and Zn(OAc)2.2H2O (0.004 g, 0.018 mmol) was added. The 
mixture was heated to reflux for 4 hours, and seen to turn yellow. Upon cooling to room 
temperature, a yellow solid was seen to form. The solvent was removed in vacuo, and the 
yellow residue washed with cold H2O (3 × 0.5 mL). The solid was dried in vacuo to give the 
target compound as a hygroscopic yellow solid (0.001 g, 0.003 mmol, 20 %). 1H NMR (400 
MHz, D2O) δH = 3.89 (4H, t, 3JHH = 5.81 Hz, 2 × CH2NH), 3.16 (4H, t, 3JHH = 5.62 Hz, 2 × 
CH2NH), 2.05 (6H, s, 2 × CH3) ppm. There was insufficient material to measure a 13C NMR 
spectrum. A representative mass spectrum was not obtainable. 
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N-boc-diaminohexane (5)
Diaminohexane (11.6 g, 100 mmol) was dissolved in dry DCM (400 mL) and cooled to 0 °C. 
Boc2O (2.25 g, 10 mmol) was dissolved in dry DCM (50 mL) and added dropwise over 30 
mins. The reaction mixture was allowed to come to room temperature and stirred overnight. 
A white suspension was seen to form. The reaction mixture was diluted with DCM (50 mL), 
washed with H2O (5 x 40 mL), and the organic layer dried over Na2SO4. The solvent was 
removed in vacuo to give the title compound as a colourless oil (1.53 g, 7.08 mmol, 71 %). 1H 
NMR (400 MHz, CDCl3) δH = 4.56 (1H, br s, NH), 3.05 (2H, m, CH2), 2.61 (2H, t, 3JHH = 
6.96 Hz, CH2), 1.60 (2H, m, CH2), 1.40 (2H, m, CH2), 1.37 (9H, s, C(CH3)3), 1.27 (4H, m, 2 
× CH2) ppm. 
N-boc-2-isothiocyanatohexylamine (6)
Compound (5) (2.85 g, 13.2 mmol) was added to THF (40 mL) in an ice bath. CS2 (0.79 mL, 
13.2 mmol) and triethylamine (5.0 mL, 37.5 mmol) were added, and the ice bath removed. 
The reaction mixture was stirred at room temperature for 15 min, and then reintroduced to 
the ice bath. Tosyl chloride (2.70 g, 15 mmol) was added in aliquots over 5 mins, and the 
solution stirred at room temperature for 25 min. DCM (20 mL) was added, and the organic 
solution washed with 10 % citric acid (3 × 10 mL), H2O (3 × 10 mL), and brine (3 × 10 mL), 
and then dried over anhydrous sodium sulphate. The reaction mixture was filtered to remove 
the drying agent, and the solvent removed in vacuo. The product was dissolved in 1:4 ethyl 
acetate:hexane (5 mL), and flash columned on silica. The solvent was removed in vacuo to 
give the title compound as a yellow oil (2.55 g, 9.88 mmol, 75 %). 1H NMR (400 MHz, CDCl3) 
δH = 4.52 (1H, br s, NH), 3.45 (2H, t, 3JHH = 6.60 Hz, CH2), 3.04 (2H, m, CH2), 1.63 (2H, m, 
CH2), 1.41 (2H, m, CH2), 1.39 (9H, s, C(CH3)3), 1.28 (4H, m, 2 × CH2). 
N-Boc-2-thiocarbohydrazidohexylamine (7)
Compound (6) (1.02 g, 3.95 mmol) was dissolved in EtOH (30 mL) in an ice bath. A solution 
of hydrazine hydrate (9.5 mL, 4.74 mmol) in EtOH (10 mL) was added dropwise over 10 
min, and the reaction mixture was stirred at 0 °C for 30 min, then at room temperature for 
a further 30 minutes. The solvent was reduced in vacuo and the reaction mixture placed in a 
freezer overnight. A white solid was collected by filtration and washed on the pump with 
cold EtOH (3 × 5 mL), before being dried in vacuo to give the title compound as a white solid 
(0.705 g, 2.43 mmol, 62 %). 1H NMR (400 MHz, CDCl3) δH = 7.37 (1H, br s, NH), 7.14 (1H, 
br s, NH), 6.40 (2H, br s, NH2), 4.47 (1H, br s, NHBoc), 3.55 (2H, dt, 3JHH = 6.60 Hz, 
CH2NH), 3.06 (2H, dt, 3JHH = 6.66 Hz, CH2NH), 1.57 (2H, m, CH2), 1.42 (2H, m, CH2), 1.38 
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(9H, s, C(CH3)3), 1.30 (4H, m, 2 × CH2) ppm. 13C NMR (75 MHz, CDCl3) δC = 182.7 (CS), 
163.9 (CO), 80.2 (C(CH3)3), 44.4 (CH2), 42.9 (CH2), 30.4 (CH2), 29.6 (CH2), 28.9 (C(CH3)3), 
26.8 (CH2) ppm. LR-MS (ES+) found m/z 313.17, calculated m/z 313.17 for 
[C12H26N4O2S+Na]+. IR (ATP) υ = 3173 (NH), 2924 (NH), 1680 (CO), 1623, 1521, 1364, 
1153 (CS) cm-1.
Ligand H2L5
Compound (7) (0.524 g, 1.81 mmol) and 2, 3-butandione (77 µL, 0.88 mmol) were dissolved 
in EtOH (10 mL) and heated to reflux for 24 h. The reaction was allowed to cool to room 
temperature, and the solvent removed in vacuo to give a yellow oil. DCM (10 mL) was added 
and the organic solution washed with H2O (3 × 10 mL) and brine (3 × 10 mL), then dried 
over MgSO4. The drying agent was removed by filtration, and the solvent removed in vacuo 
to give the title compound as a yellow oil (0.400 g, 0.63 mmol, 72 %). 1H NMR (400 MHz, 
CDCl3) δH = 8.64 (2H, br s, 2 × NH), 7.55 (2H, br s, 2 × NH), 4.48 (2H, m, 2 × NHBoc), 
3.65 (4H, dt, 3JHH = 6.63 Hz, 2 × CH2NH), 3.06 (4H, m, 2 × CH2NH), 1.94 (6H, s, 2 × CH3), 
1.64 (4H, m, 2 × CH2), 1.42 (4H, m, 2 × CH2) 1.38 (18H, s, 2 × C(CH3)3), 1.33 (8H, m, 4 × 
CH2) ppm. 13C NMR (75 MHz, CDCl3) δC = 178.1 (CS), 156.1 (CO), 145.0 (CN), 79.5 
(C(CH3)3), 44.7 (CH2), 40.4(CH2), 30.1 (CH2), 29.0 (CH2), 28.9 (C(CH3)3), 26.4 (CH2), 24.5 
(CH2), 8.6 (CH3) ppm. LR-MS (ES-) found m/z 629.37, calculated m/z 629.37 for 
[C28H54N8O4S2]-. IR (ATP) υ = 3357 (NH), 2931 (NH), 1683 (CO), 1590, 1531, 1364, 1163 
(CS) cm-1. Due to impurities visible in the 1H NMR spectrum that could not satisfactorily be 
removed, complexes of this ligand were not synthesised.
t-Butyl (L)-2-isothiocyanatopropanoate (8) 
L-alanine t-butyl ester hydrochloride (1 g, 5.5 mmol) was dissolved in dry DCM (10 mL). 
DIPEA (1.35 mL, 7.5 mmol) was added dropwise and the mixture stirred for 10 minutes at 
room temperature. The solution was then added dropwise to a dispersion of thiophosgene 
(1.3 mL, 16.5 mmol) in DCM (20 mL) in an ice bath under a blanket of N2. Crushed NaOH 
(0.66 g, 16.5 mmol) was added, and the solution allowed to come to room temperature over 
3 h. The reaction mixture turns black, dried in vacuo, and is then diluted with DCM (10 mL) 
to allow for transfer to a silica flash column. The eluent was 1:5 v/v DCM:Petroleum ether, 
increasing to pure DCM to collect the target compound. The solvent was removed in vacuo
to give the title compound as a yellow oil (0.788 g, 4.20 mmol, 72%).  1H NMR (400 MHz, 
CDCl3) δH = 4.13 (1H, q, 3JHH = 7.20 Hz, CH), 1.48 (3H, d, 3JHH = 7.10 Hz, CH3), 1.44 (9H, 
s, C(CH3)3) ppm. 13C NMR (75 MHz, CDCl3) δC = 137.2 (CSN), 83.6 (C(CH3)3), 55.6 
(C(CH3)H), 27.8 (C(CH3)3), 19.5 (CH3) ppm. LR-MS (ES-) found m/z 186.06, calculated m/z 
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186.06 for [C8H12NO2S]-. IR (ATP) υ = 2982, 2046 (N=CS), 1740 (CO), 1456, 1370, 1150 
cm-1.
t-Butyl (hydrazinecarbonothioyl)-L-alaninate (9) 
Compound (8) (0.77 g, 4.1 mmol) was dissolved in EtOH (20 mL) in an ice bath. Hydrazine 
hydrate (0.21 mL, 4.32 mmol) was added to EtOH (5 mL), and added dropwise to the chilled 
solution over 30 min. The mixture was allowed to come to room temperature and stirred 
overnight. The reaction mixture was reduced in vacuo, chilled, and a white solid was seen to 
form. The solid was collected on a sinter and washed with cold EtOH (3 × 5 mL), then dried 
in vacuo to give the title compound as a white solid (0.321 g, 1.47 mmol, 36 %). 1H NMR (400 
MHz, CDCl3) δH = 7.85 (1H, s, NH), 7.40 (1H, s, NH), 4.86 (1H, q, 3JHH = 7.30 Hz, CH), 
3.70 (2H, br s, NH2), 1.43 (3H, m, CH3), 1.42 (9H, s, C(CH3)3) ppm. 13C NMR (75 MHz, 
CDCl3) δC = 180.2 (CS), 172.8 (CO), 82.6 (C(CH3)3), 53.2 (CH), 28.4 (C(CH3)3), 19.2 (CH3) 
ppm. LR-MS (ES+) found m/z 219.10, calculated m/z 219.10 for [C8H17N3O2S]+. IR (ATP) 
υ = 2528, 1730 (CO), 1637, 1534, 1443, 1253, 1155 (CS) cm-1.
Ligand H2L6
Compound (9) (0.321 g, 1.47 mmol) was dissolved in EtOH (15 mL). 2, 3-butandione (64 
µL, 0.74 mmol) was added. The solution was seen to turn yellow, and then heated to reflux 
overnight. The solution was allowed to cool to room temperature, then chilled in the freezer 
for 2 h. A yellow solid separated from the blue-green solution. The solid was collected on a 
Buchner funnel, washed with cold EtOH (3 × 5 mL) and dried in vacuo to give the title 
compound as a yellow solid (0.250 g, 0.51 mmol, 69 %). 1H NMR (400 MHz, CDCl3) δH = 8.65 
(2H, s, 2 × NH), 8.04 (2H, d, 3JHH = 7.20 Hz, 2 × NHCH), 4.86 (2H, q, 3JHH = 7.10 Hz, 2 × 
CH), 2.11 (6H, s, 2 × CH3), 1.49 (6H, d, 3JHH = 7.10 Hz, 2 × CH3), 1.44 (18H, s, 3 × C(CH3)3) 
ppm. 13C NMR (75 MHz, CDCl3) δC = 177.2 (CS), 172.3 (CO), 146.1 (CN), 83.1 (C(CH3)), 
53.7 (CHNH), 28.4 (C(CH3)3), 19.1 (CH3CH), 10.9 (CH3) ppm. LR-MS (ES+) found m/z 
511.20, calculated m/z 511.21 for [C20H36N6O4S2+Na]+. IR (ATP) υ = 2973 (NH), 1735 (CO), 
1516, 1480, 1362, 1015 (CS) cm-1.
Metal complexes of H2L6
The syntheses of metal complexes of H2L6 were approached analogously to the complexes 
described in the Chapter 5. In all cases, H2L6 (0.050 g, 0.2 mmol) was dispersed in EtOH (5 
mL) with 1.2 molar equivalents of the relevant metal acetate hydrate. The reaction mixtures 
were refluxed for 4 hours, during which time colour changes were observed, indicating 
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complexation. However, the complexes could not be isolated or purified at the end of the 
reaction, hence characterisation was limited to 1H NMR and mass spectrometry. 
For CuL6: HR-MS (ES+) found m/z 550.1451, calculated m/z 550.1457 for 
[C20H35N6O4S263Cu]+.
For ZnL6: 1H NMR (400 MHz, d6-DMSO) δH = 5.72 (2H, br s, 2 × NH), 4.45 (2H, br s, 2 
× CH), 2.16 (6H, s, 2 × CH3), 1.63 (6H, m, 2 × CH3), 1.39 (18H, m, 2 × C(CH3)3) ppm. HR-
MS (ES+) found m/z 551.1458, calculated m/z 551.1453 for [C20H35N6O4S264Zn]+.
For NiL6: 1H NMR (400 MHz, d6-DMSO) δH =5.56 (2H, br s, 2 × NH), 4.26 (2H, br s, 2 × 
CH), 1.84 (6H, s, 2 × CH3), 1.54 (6H, m, 2 × CH3), 1.39 (18H, m, 2 × C(CH3)3) ppm. HR-
MS (ES+) found m/z 545.1516, calculated m/z 545.1515 for [C20H35N6O4S258Ni]+.
For CdL6: 1H NMR (400 MHz, d6-DMSO) δH =5.67 (2H, br s, 2 × NH), 4.41 (2H, br s, 2 × 
CH), 2.19 (6H, s, 2 × CH3), 1.53 (6H, m, 2 × CH3), 1.37 (18H, m, 2 × C(CH3)3) ppm. HR-
MS (ES-) found m/z 631.0817, calculated m/z 631.0802 for [C20H34N6O4S2110Cd+Cl]-.
Attempt to synthesise HgL1
Ligand H2L1 (0.200 g, 0.5 mmol) and HgCl2 (0.150 g, 0.55 mmol) were dissolved in EtOH 
(10 mL) and the reaction mixture heated to reflux. A precipitate formed, which was filtered 
and washed with EtOH (10 mL) to give the starting ligand as a yellow solid (0.140 g, 0.35 
mmol, 70 %). Spectroscopic and mass spectrometric analysis showed that no complex had 
been formed. 
1, 10-Phenanthroline-5, 6-dione (10)
1, 10-phenathroline (0.81 g, 4.52 mmol) was added to H2SO4 (60 % v/v, 20 mL) and the 
colourless solution stirred at room temperature to ensure thorough mixing. KBrO3 (0.83 g, 
4.97 mmol) was added in batches over 30 min. The solution was seen to turn orange. Br2(g) 
was released by the reaction but maintained in the reaction vessel throughout. The reaction 
was stirred overnight at room temperature. The mixture was then poured over ice and 
neutralised with 2M NaOH(aq). The product was extracted by washing with DCM (3 × 10 
mL). The organic fraction was washed with brine (3 × 10 mL) and dried over MgSO4. The 
solution was filtered and the solvent removed in vacuo to give a yellow powder, which was 
recrsytallised from hot EtOH to give the title compound as a green-yellow solid (0.35 g, 1.67 
mmol, 37 %). The product had identical spectroscopic properties to that recorded in the 
literature.1 1H NMR (400 MHz, CDCl3) δH = 9.17 (2H, d, 3JHH = 4.64 Hz, 2 × CHN), 8.55 
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(2H, d, 3JHH = 7.86 Hz, 2 × CH), 7.64 (2H, dd, 3JHH = 7.84 Hz, 3JHH = 4.74 Hz, 2 × 
CH(CH)(CH) ppm.  
Cyclised product (11)
1, 10- Phenanthroline-5, 6-dione (10) (0.1 g, 0.48 mmol) and ethyl-2-
(hydrazinecarbothioamido)acetate (0.179 g, 1.01 mmol) were dissolved in dry EtOH (5 mL). 
A catalytic amount of H2SO4 was added. The reaction mixture was refluxed under N2 for 4 
h. Upon cooling to room temperature, a red precipitate formed. The solid was collected on 
a sinter and washed with cold EtOH (3 × 10 mL), dryed in vacuo and recrystallised from hot 
EtOH to give the title compound as a red solid (0.083 g, 0.21 mmol, 44 %). 1H NMR (400 MHz, 
d6-DMSO) δH = 10.23 (1H, t, 3JHH = 5.73 Hz, NH), 9.42 (1H, d, 3JHH = 8.22 Hz, CH), 9.20 
(1H, d, 3JHH = 3.20 Hz, CH), 8.99 (1H, d, 3JHH = 4.76 Hz, CH), 8.79 (1H, d, 3JHH = 8.10 Hz, 
CH), 8.01 (1H, dd, 3JHH = 8.03, 5.09 Hz, CH), 7.95 (1H, dd, 3JHH = 7.85, 4.78 Hz, CH), 4.46 
(2H, d, 3JHH = 5.86 Hz, CH2N), 4.17 (2H, q, 3JHH = 7.03 Hz, CH2CH3), 3.75 (2H, q, 3JHH = 
7.11 Hz, CH2CH3), 1.24 (3H, t, 3JHH = 7.08 Hz, CH2CH3), 1.05 (3H, t, 3JHH = 7.00 Hz, 
CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 180.0 (CS), 168.9 (CO), 137.6 (CH), 
130.6 (CH), 128.9 (CH), 128.7 (CH), 127.0 (CH), 61.7 (CH2O), 61.4 (CH2O), 56.6 (CH2N), 
15.7 (CH3), 14.7 (CH3) ppm. LR-MS (ES+) found m/z 466.93, calculated m/z 466.1525 for 
[C19H19N5O3S+Na+EtOH]+. IR (ATP) υ = 3300 (NH), 3204 (NH), 3066 (CH), 2986 (CH), 
1748 (CO), 1015 (CS) cm-1. UV-vis (DMSO): λmax (ε / L mol-1 cm-1) 439 (11440) nm.
Open chain product (12)
1, 10- Phenanthroline-5, 6-dione (10) (0.1 g, 0.48 mmol) and ethyl-2-
(hydrazinecarbothioamido)acetate (0.179 g, 1.01 mmol) were dissolved in dry EtOH (5 mL). 
A catalytic amount of H2SO4 was added. The reaction mixture was stirred at room 
temperature under N2 overnight. An orange solid was seen to form. The solid was collected 
on a sinter and washed with cold EtOH (3 × 10 mL) and dryed in vacuo to give the title 
compound as an orange solid (0.103 g, 0.28 mmol, 58 %). 1H NMR (400 MHz, d6-DMSO) δH
= 10.15 (1H, t, 3JHH = 5.92 Hz, NH), 9.27 (1H, d, 3JHH = 7.88 Hz, CH), 9.17 (1H, d, 3JHH = 
4.64 Hz, CH), 8.94 (1H, d, 3JHH = 5.97 Hz, CH), 8.72 (1H, d, 3JHH = 8.16 Hz, CH), 7.87 (2H, 
m, 2 × CH), 4.45 (2H, d, 3JHH = 5.90 Hz, CH2NH), 4.18 (2H, q, 3JHH = 7.02 Hz, CH2CH3),
1.24 (3H, t, 3JHH = 7.07 Hz, CH2CH3) ppm. 13C NMR (75 MHz, d6-DMSO) δC = 179.6 (CS), 
168.9 (CO), 154.6 (CH), 147.4 (CH), 141.3 (CH), 138.3 (CH), 130.9 (CH), 129.0 (CH), 61.4 
(CH2O), 56.6 (CH2N), 14.7 (CH3) ppm. LR MS (APCI) found m/z 370.05, calculated m/z 
370.10 for [C17H16N5O3S]+. IR (ATP) υ = 3248 (NH), 3055 (CH), 2982 (CH), 1734 (CO) cm-
1. UV-vis (DMSO): λmax (ε / L mol-1 cm-1) 439 (9900) nm.
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1.3 Results and discussion 
1.3.1 Attempted deprotection of ligands 
As has been discussed above, conditions that satisfactorily deprotected the ligands H2L1, 
H2L2 and H2L3 could not be found. Typical efforts are described in the experimental section 
above. Ethyl esters such as those found in H2L1 and H2L2 are not as commonly used as 
protecting groups as methyl esters, but may be cleaved in a similar fashion by use of a strong 
mineral base in a suitable solvent.2 H2L1 showed sparing solubility in H2O and only dissolved 
in EtOH with heating. It did dissolve in THF. When an aqueous solution of NaOH was 
added, it was immediately apparent that decomposition was occurring; a colour change from 
near colourless to bright yellow was accompanied by the pungent odour of 2, 3-butandione, 
indicating hydrolysis of the backbone Schiff bases. It was reasoned that H2L2, due to its lack 
of methyl groups and their associated steric hindrance, would be more susceptible to basic 
hydrolysis. The metal complexes would also be susceptible due to the polarising effect of 
coordination. For these reasons, focus was shifted to H2L3. 
Boc protecting groups are deprotected by the use of strong protic acids. Initial experiments 
with neat TFA were unsatisfactory. After 10 minutes of being exposed to the acid, an aliquot 
of H2L3 was studied by NMR. Although the integration showed a decrease in the intensity 
of the Boc signal, indicating deprotection, a significant number of impurity peaks had 
appeared which could not be unambiguously identified. With increasing reaction time, the 
Boc signal continued to decrease, but the spectrum became poor. It was concluded that the 
use of neat TFA may be too harsh, leading to acid hydrolysis of the ligand, despite similar 
conditions having been reported in the literature.3
Diluting both the ligand and the acid in DCM showed promise (Fig. 1). Stirring overnight at 
room temperature allowed the isolation of a low quantity of a colourless oil. The only 
characterisation data obtainable was a 1H NMR spectrum which showed complete loss of 
the Boc group, limited impurities and significant differences in the chemical shifts of the CH2
groups between this and the protected ligand. It was concluded that it was likely that 
deprotection had occurred, but given that no other data was available it could not be 
unambiguously confirmed. The decision was made to attempt an in situ synthesis of the Zn 
complex of the deprotected ligand (see below). Again, low yields suggest that the method 
described needs optimisation for future work to be carried out on this complex, but as a 
proof of principle supports the argument that deprotection occurred with a sufficient 
quantity of the desired ligand resulting to allow the coordination of a metal. Further study of 
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this species was not possible due to the reallocation of resources following our colleagues at 
Mologic restructuring.  
Figure 1. Deprotection of H2L3 and subsequent complexation. i) TFA, DCM, RT, 
overnight. ii) Zn(OAc)2.2H2O, EtOH, reflux, 4 h. 
1.3.2 The use of a diaminohexane-based side arm- H2L5
It was hypothesised that the side arms of the ligands H2L1, H2L2 and H2L3 may be too short 
to allow bidentate coupling to a carrier protein subsequent to deprotection. As a 
precautionary measure, it was decided that an alternative species with a similar coordination 
sphere but longer side arms should be synthesised for inclusion in antibody generation. By 
having a longer linker arm, the coordination sphere would in theory be further away from 
the steric bulk of the protein and subject to less spatial pressures, offering further alternatives 
in terms of epitopes. The stepwise synthesis of such a ligand, here designated H2L5, is 
described in the experimental section below. The ligand was synthesised and characterised 
unambiguously, but impurities present in TLC analysis and the 1H NMR spectrum could not 
be removed. Again, further study was not possible due to the changing nature of the project. 
Figure 2. Synthesis of H2L5. i) Boc2O, DCM, RT, overnight. ii) CS2, THF, NEt3, TsCl, 30 
min, RT. iii) N2H4.H2O, EtOH, RT, 30 min. iv) 2, 3-butandione, EtOH, reflux, overnight.  
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1.3.3 A chiral side arm- H2L6 and its complexes 
As a response to the need to investigate other protection methodologies, the use of t-butyl 
ester groups to protect the acid of an amino acid side arm was decided upon. t-butyl esters 
may be removed by the use of aqueous acids under relatively mild conditions, and so offered 
a suitable alternative to the issues encountered with the groups described above. The use of 
an L-alanine backbone was of interest as it would make the complex chiral, and would 
theoretically have an effect on the binding of the complexes to carrier proteins. The synthesis 
of the ligand H2L6 and its metal complexes are described in the experimental section. Limited 
spectroscopic data relating to the metal complexes was obtainable, and the species could not 
be isolated in a pure form, precluding them from further discussion in this report. 
Nevertheless, future efforts could find this ligand framework fruitful. 
Figure 3. Synthesis of H2L6 and subsequent metal complexes. i) DIPEA, CSCl2, NaOH, 
DCM, 3 h, 0°C. ii) N2H4.H2O, EtOH, 0 °C, 30 min. iii) 2, 3-butandione, EtOH, reflux, 
overnight. iv) Metal acetate, EtOH, reflux, 4 h. 
1.3.4 Attempted synthesis of complex HgL1
In the course of the current work, suitable crystals for single crystal X-ray diffraction were 
obtained for ZnL1 and CdL1. If the crystal structure of the analogous Hg complex were to 
be obtained, it would allow an interesting crystallographic discussion of the coordination 
preferences of different metals going down a periodic group. This was not possible. As 
described below, a typical approach to the synthesis of such a complex was taken, but analysis 
of the yellow solid obtained showed no differences between this and the staring ligand. The 
coordination of Hg could not be observed spectroscopically, suggesting that this larger metal 
ion could not be accommodated easily by the ligand. 
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1.3.5 Attempted synthesis of a fluorescent bis(thiosemicarbazone), leading to an 
unusual cyclic structure 
As part of the development of novel bis(thiosemicarbazone) ligands for antigenic purposes, 
it was suggested that a fluorescent derivative could be of interest in terms of tracking the 
pharmacological behaviour of the proposed species. A species based on a 1, 10-
phenanthroline-5, 6-dione back bone would be expected to show some luminescent 
character due to the extensive π-system that would be observed in a 1:2 condensation project 
(shown in Fig. 4). As well as the proposed spectroscopic behaviour, the ligand backbone 
would be particularly rigid, which would have interesting effects on the coordination 
geometry in metal complexes which could be investigated electrochemically. Electrochemical 
studies of a benzil-based analogue showed a reduction potential similar to that of Cu-ATSM,4
but the rigid phenanthroline moiety may act to make reduction less easily achieved. Finally, 
the inclusion of the large, aryl moiety would give a planar, hydrophobic character to the 
desired compound. Monosemicarbazone ligands and complexes based on a phenanthroline 
moiety have previously been shown to have an apoptotic-inducing effect on drug-sensitive 
and drug-resistant tumour cell lines (including triple negative cell lines), possibly due to an 
ability to intercalate in DNA structures.5–8 It was hypothesised that cytotoxicity studies of the 
desired complexes could also be of interest from a pharmaceutical viewpoint. 
Figure 4. Proposed synthesis of a phenanthroline based bis(thiosemicarbazone). This 
was not achieved. 
Research showed that the synthesis would be difficult. In the work reported by Calatayud et 
al., it was noted that the synthesis of benzil-based BTSC species was complicated by the 
propensity for the 1:1 intermediate to cyclise to give a stable 1, 2, 4-triazine ring. The end-
products of the reactions detailed in the 2007 paper were highly dependent on the reaction 
conditions used.9 The phenyl rings allow for delocalisation of electron density, and the 
presence of a primary amine allows for double condensations. The use of tertiary amines 
seems to prevent cyclising.10 It would be expected that a phenanthroline moiety would favour 
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the forming of a triazine, expanding the delocalised π-system and providing a rigid 
environment for the reaction to occur in. A stable open chain monosemicarbazone with a 
phenanthroline moiety has been reported however, and so the synthesis was approached 
with an eye to prevent the triazine forming instead of the BTSC.5,6
 A typical approach to the synthesis of the desired species was taken (see experimental section 
below). The conditions used were similar to those reported in Afrasiabi et al.6 2 equivalents 
of the thiocarbohydrazide were heated to reflux in an acidified, protic solvent with 1 
equivalent of the dione. The presence of a secondary amine was considered a potential route 
to the formation of a triazine, but less so than had there been a primary amine. However, as 
shown in the experimental section, the closed ring, triazine species (11) was synthesised and 
characterised. A proposed mechanism for the formation is shown in Fig. 5.  
Figure 5. Proposed mechanism of triazine (11) formation from monothiosemicarbazone 
(12). 
Allowing longer reaction time at lower temperatures allowed the synthesis of the open chain 
analogue (12). Both species were characterised unambiguously. Additional conditions were 
trialled that are not described in the experimental section, as all gave either the triazine or the 
monothiosemicarbazone. Results were definitive; mixtures of the two products were not 
observed, and the desired BTSC was not observed. 
267
Figure 6. Synthesis of cyclised and open chain phenanthroline based species. i) KBrO3, 
H2SO4, H2O. ii) Ethyl-2-(hydrazinecarbothioamido)acetate, EtOH, cat. H2SO4, reflux, 4 
h. iii) Ethyl-2-(hydrazinecarbothioamido)acetate, EtOH, cat. H2SO4, RT, overnight. 
It was concluded that the energetic sink provided by the open intermediate (12) forming a 
triazine (11) was too great to allow a second condensation with another equivalent of the 
thiocarbohydrazide. Future work on this project could develop the use of the species (12) 
and its metal complexes. As similar species have shown anti-tumour abilities, cytotoxicity 
studies could be of interest. 
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Appendix I: PETIC Standard Operating Procedures for 89Zr production 
and purification 
The following pages are examples of the SOPs used within PETIC to facilitate the production, 
purification, safe handling and use of 89Zr. Similar documents are referred to when using other 
radioisotopes. As with all laboratory research, risk assessments should be carried out fully before 
any experiment using radioisotopes and health and safety measures (e.g. the wearing of personal 
exposure monitors) must be adhered to fully.   
RH 3000 PETIC
School of Medicine
Cyclotron Manual Preparation of HC 7 for Zr-89 
Separation
Principle 
This procedure describes how to prepare R & D Hot Cell 7 for Zr-89 separation prior to the 
introduction of the radioactive material into the hot cell. 
Ensure that the following procedures have been completed before performing this procedure: 
RH 3001 Preparation for Zr-89 
Note: All glassware and plastics should be prewashed with 6M HCl (see RH 3001) and then 
deionised water before use. No metallic items should be used at any stage.
Procedure 
1. Wear appropriate protective clothing (lab coat, safety glasses and gloves). 
2. Check the compressed air gas supply is in the hot cell. Turn it on and test the needle 
valve to allow small amounts of compressed air to be released (left side manifolds 
outside). Turn needle valve off again and close supply. 
3. Have a look at the hot cell pressures over the hot cell door. The door seal pressure 
should be around 1 bar and hot cell pressures should be around 300 Pa. 
4. Check if there is residual activity in the hot cell by looking on the appropriate reading on 
the radiation monitoring node. If the residual activity is higher than 10 uS/hr contact the 
RPS. 
5. Check the calculated residual activity of the multiple use Zr glassware and Zr waste bin. 
For this use Isostock as described RS 4103. 
6. Place the absorbent mat under the delivery position for the Zr delivery lance (black circle 
drawn on base of hot cell) and place Zr opening tool (consisting of  a short stiff needle 
attached to a 5ml syringe s in picture) in the centre of the mat (not blocking the delivery 
lance as well as other stuff). 
7. Arrange the dispensing cassette and syringe driver as pictured below making sure that 
the taps on the dispensing cassette can be easily turned with the tongs from the south 
side of the hot cell. The taps should be in the following positions: 
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8. Check all connections on the dispensing cassette that they are tight. Especially the 
compressed air line going into the top left and the syringe driver line going into the top 
right of the dispensing cassette. 
9. Place the hotplate in its location as shown on the picture below and check that the vial 
containing the temperature probe is filled with silicon oil and set the temperature probe 
to 110oC. Check it is working and then switch off the heater at the appropriate switch 
on the right side of the hot cell door using the one for the appropriate socket.  
10. Place a yellow small sharp bin on the right side of the hot cell to dispose of any sharps 
and radioactive waste during the Zr-89 purification. 
11. Transfer two white wide bore lead pots into the hot cell (labelled with Zr-89 separation, 
date, operator). 
12. Double check that either the solid target delivery lance or access to the well counter is 
not blocked in any way.
13. Prepare a hydroxamate functionalised separation column in a pre-washed washed 2 ml 
plastic syringe (see RH 3001).  
 Insert 1 cm3 of prewashed glass wool into the syringe with the help of the green 
plastic tweezers and the syringe plunger. 
 Take the plunger out and place a red bung at the bottom end.  
 Weigh 125 mg of lyophilised hydroxamate functionalised ion exchange resin 
(stored in freezer in R&D QC) into the syringe (prepared as described in RH 
3003). 
a b c d e
f
j
g, q, r
h, i
k
m
r
y
no
p
l
s
271
 Insert the other 1 cm3 of prewashed glass wool into the syringe with the help 
of the green plastic tweezers 
 Take of the red bung at the bottom end and insert the syringe plunger. 
14. Condition the separation column in the following order using the prewashed 50 ml 
syringe and made up adaptor (RH 3001): 
 75 ml Acetonitrile  (measure with a 100 ml measuring cylinder) 
 10 ml of 0.9% saline (use 10 ml syringe + half vigon line) 
 2 ml of 2M metal free HCl using 2 ml syringe + half vigon line (see RH 3001, step 
10). 
15. Arrange the following items as shown above making sure that they can be manipulated 
by tongs with the door is shut.  
Into / beside the tube rack: 
a,b,c) 3 x 2 ml of 2 M metal free HCl in a 5 ml syringe with red cap (see RH 3001, 
step 10). 
d) 0.1 ml of 30% H2O2 in a 1ml syringe with red cap 
e) 0.5 ml of 6M HCl in a 1ml syringe with red cap (see RH 3001, step 5). 
l) 12 ml of 2 M metal free HCl in a 20 ml syringe with red cap (see RH 3001, step 
10). 
In tray / on absorbent mats: 
f) 25 ml beaker for Zr dissolution with stirrer bar for the reaction,
stoppers from beaker f and k, Watch glass 
In holder at back of dispensing cassette: 
h) falcon tube containing 1M Oxalic acid 3 ml  (see RH 3001, step 9) connect to 
lead with tube (r) and insert to the bottom of the vial,  
i) falcon tube containing deionised H2O 15.5ml connect to lead with tube (y) and 
insert to the bottom of the vial, 
Bottom of dispensing cassette with syringe + adaptor: 
j) Pre-prepared hydroxamate functionalised resin column (from step 21)  
k) 25 ml beaker for Y-89 waste run through,  
On the right of hot cell:
m) Zr Waste bin (2L yellow sharps bin labelled with Isostock CW number) behind 
lead bricks.
On the left side of Cell 
3 white lead pots and their lids with 3 crimptop vials (without lids on) labelled 
ZrOxF1, ZrOxF2 and ZrOxF3 crimptops for vials. Ensure the lead pots are 
positioned so the tongs can reach them and their lids without blocking access to 
the well counter. 
16. Close both doors and clear low pressure alarms. 
17. The hot cell is now ready for delivery of Zr-89 (CO 3103). 
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RH 3001 PETIC
School of Medicine
Cyclotron Manual Preparation for Zr-89 Separation -
day before
Principle 
This procedure describes how to prepare the appropriate solutions and consumables a day 
ahead of the Zr-89 separation. 
Procedure 
1. Wear appropriate protective clothing (Lab coat, safety glasses and gloves). 
2. Collect all the consumables needed for Zr-89 separation as listed in RH 4001. These are: 
 4 x 15ml falcon tubes 
 6 x red bungs 
 2 x 20ml syringes 
 3 x 5ml syringes 
 1 x 2ml syringe 
 2 x 1ml syringes 
 2 x ~1cm3 glass wool 
 2 x1.5ml screw cap sample tube 
 3 x disposable plastic pipette 
 1 x plastic spoons 
 1 x plastic tweezers 
 3 x Weighing boats 
 2 x 1L sharps bins with lids removed 
3. The glassware should be clean and dry. 
 2 x glass 25ml beakers with appropriate stoppers 
 1 x Watchglass (reaction vial lid) 
 3 x 10ml Crimptop vials 
 1 x 100 ml measuring cylinder 
4. To prepare 100ml of 6 M HCl from conc. HCl (metal free, glass cabinet in R&D, Zr tray), 
dispense 50 ml Millipore water into the lidless 1L sharps bin labelled 6M HCl acid bath 
and add 50ml conc HCl. 
5. Dispense 0.6 ml of 6 M HCl using a disposable plastic pipette into a small screw cap vial 
labelled (6 M HCl, preparation date and initials).  
6. Wash all consumables and glass ware in the 6 M HCl bath and then transfer to the second 
lidless 1L sharps bin and rinse 3 x with Millipore water. 
7. Place all consumables into a labelled sealable plastic bag (preparation date and initials) 
and put it into the Zr preparation tray to be used the next day. 
8. Label a falcon tube with 1 M Oxalic acid, preparation date and initials.  
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 Using an acid washed falcon tube and a plastic spoon (handle) weigh out 270 mg of 
oxalic acid (metal free, glass cabinet in R&D, Zr tray).  
 Top up with Millipore water to 3 ml, close and shake well. Place into stand for Zr 
preparation. 
9.  Label two falcon tubes with 2 M HCl, preparation date and initials. Dispense 9.2 ml 
Millipore water into each labelled falcon tube and add to each 1.8 ml conc HCl using a 
disposable plastic pipette. 
Solutions of HCl
Solution Density 
(grams/ml)
Concentration 
(moles/liter)
To make a liter of solution
36.6-38% HCl 1.18 12.0 Concentrated hydrochloric 
acid
6 M HCl 1.10 6.0 500 ml conc. HCl + 500 ml 
H2O
2 M HCl 1.03 2.0 167 ml conc. HCl + 833 ml 
H2O
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RH 3002 PETIC
School of Medicine
Cyclotron Manual Separation of Zr-89 from solid 
target
Principle 
This procedure describes how to separate Zr-89 from the Y-86 solid target. 
Ensure that the following procedures have been completed before performing this procedure. 
RH 3000 Preparation of Hot Cell 7 for Zr-89 Separation
RH 3001 Preparation for Zr-89 Separation day before 
Note: All glassware and plastics should be prewashed with 6M HCl and then deionised water 
before use. The radioactivity of all waste items should be measured and logged before 
disposal in the Zr specific waste bin.  
Procedure 
1. Wear appropriate protective clothing and radiation monitoring equipment. 
2. Record Activity and time of the foil target on RH 4002. 
3. Remove the foil target from the dose calibrator and place in glass beaker (f) (see photo 
below) using the tongs. 
4. Using tongs remove stopper from syringe (a) and place in syringe holder (n) above vial 
(f) and cautiously dispense 2 ml of 2M HCl syringe a onto the foil target as slowly as 
possible. 
5. Once the frothing has subsided remove empty syringe from holder and dispense a 
further 2 ml of 2M HCl syringe b into glass beaker (f). 
6. Repeat step 4 with 2 ml of 2M HCl syringe (c). 
7. Once the frothing has subsided this should reveal a grey cloudy solution. Add 0.1 ml of 
H2O2 syringe (d) and 0.5ml of 6M HCl from syringe (e). 
8. Place the watch glass (tray) on glass beaker (f) and switch on the heater using the switch 
on the outside of the hot cell. Allow to heat up to a slow boil for 15 min. 
9. Turn off the heater and allow to cool. 
10. After 15 min place the plastic tubing connected to the cassette’s blue tap on the right 
side into glass beaker (f). 
11. Using tongs pull up the syringe to draw the now yellow solution into the syringe. 
12. Switch the blue tap on the right side to the  position. Using tongs slowly push down 
on the syringe to dispense the Zr/Y solution onto the column. 
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13. If the flow of solution through the column stops or is slow under gravity you can apply 
a small amount of pressure with compressed air to increase the flow rate. If required 
open the compressed air on the left side of the hot cell and operate gently the needle 
valve. Only use very small compressed air flows the liquid flow should always remain 
dropwise.
14. Repeat steps 11-13 to fully empty the reaction vial (f). 
15. Once the liquid flow has stopped dispense 12 ml of 2M HCl syringe (l) into glass beaker 
(f). 
16. Set the blue tap on the top right corner to the     position and then using tongs 
pull up the syringe to draw the new solution into the syringe. 
17. Switch the top right blue tap back to the  position (and ensure the right hand red 
and yellow taps are also in the same orientation) and then tongs push down the syringe 
to dispense the 2M HCl solution onto the column in 2 ml batches (increase the flow 
through the column with compressed air if required). 
18. Repeat steps 16-17 until reaction vial (f) is fully empty then measure the activity of the 
reaction vessel f and record on RH 4002. 
19. Now set the yellow tap on the right hand side to the     position and using tongs 
pull up the syringe to draw 4 ml of H2O sample tube (i) into the syringe. 
20. Now switch the right hand yellow tap to the  position, then using tongs push down 
the syringe to dispense the water onto the column in 2 ml batches (increase the flow 
through the column with compressed air if required). 
21. Repeat steps 16 and 17 to dispense the remainder of water. 
a b c d e
f
j
g, q, r
h, i
k
m
r
y
no
p
l
s
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22. Once the water has all flowed through the column and the dripping has stopped remove 
vial (k) (Y-89 waste fraction) and place the stopper on it. Measure the activity and 
record the time. Record on RH 4002. Place the vial in a wide bore lead pot. 
23. Place vial (g) under the column to collect the first Zr Oxalate fraction. 
24. Now set the red tap on the bottom right corner to the     position and using tongs 
pull up the syringe to draw 3ml of 1.0M oxalic acid from sample tube (h) into the syringe. 
25. Switch the bottom right corner red tap to the  position, then using tongs press down 
the syringe to dispense 0.5 ml of the oxalic acid onto the column. ZrOxF1 (increase the 
flow through the column with compressed air if required). Take care not to force the 
liquid through too quickly. 
26. Remove the vial and place in a white lead pot and replace with a clean crimptop vial (q) 
and dispense a further 1ml of oxalic acid in the same way (ZrOxF2) this should contain 
the bulk of the activity.
27. Remove this vial and place in a white lead pot and replace with a clean crimptop vial (r) 
and dispense the remaining 1.5ml of oxalic acid in the same way (ZrOxF3).
28. Measure and record the activity and time on RH 4002 of vials g, q and r (Zr-89 Oxalate 
fraction) and place the vials in lead pots for removal from the hot cell. 
29. Measure and record (on RH 4002) the activity of any radioactive waste items including 
the column before disposal in the Zr waste bin. 
30. Place the tray used vials, waste solutions and Zr waste bin in the lead safe in the corner 
of the R&D lab. 
31. Transcribe all measured activities into isostock 
32. Fill in RH 4702 and leave the form attached to the hot cell. 
33. There will be residual activity in the hotcell and on the magnetic stirrer / syringe driver. 
Label the cell as containing long lived radioactivity check yourself for activity and 
perform a contamination survey of the lab. 
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Appendix II: Calculations of relative enzyme activity values 
1 Calculation of activities of free HRP 
The observed rates of enzymatic activity are expressed in units of A.s-1 and are shown in Fig. 
11. The following calculations describe the analysis performed to populate Fig. 12. 
The molecular weight of the isoform of HRP used is known to be: 
The concentration (c) of enzyme per well in mg.mL-1 is known from the absorbance of a stock 
solution at 280 nm as determined by UV-Vis spectrometry and subsequent serial dilution, and may 
be converted to molar concentration and thence to a number of molecules per unit volume: 
As the volume of the sample is known to be 200 µL, the enzymes present may be arrived at. 
For the four conditions described in Fig. 12: 
For a given sample: 
e.g. for NaBH4-reduced HRP: 
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2 Calculation of relative activities for gluteraldehyde immobilised HRP 
For each sample having a different initial enzyme:nanoparticle ratio, the number of 
nanoparticles present is determined based on the known concentration of nanoparticles in 
milligrams of solid per volume of stock solution (mg.mL-1) and the average mass of each 
nanoparticle calculated from XRD and TEM characterisation (see Fig. 13). If the average 
mass is taken to be 1.01 × 10-18 g per nanoparticle, then for the case where the initial 
enzyme:nanoparticle ratio is intended to be 3: 
@
And 
After the immobilisation of the enzymes, each sample was dispersed in 1 mL of an 
appropriate buffer, diluted 100 fold, and 20 µL of this solution transferred into each well of 
a 96 well plate. In the case above: 
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The relative activity of these enzymes may then be calculated from the observed rate in A.s-
1 as shown in section 1 above. 
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3 Calculation of relative activities for reductive amination immobilised HRP 
Taking the same approach as shown in section 2 above, in the case of a 17 % enzyme 
conjugated population: 
@
and 
After the immobilisation of the enzymes, each sample was dispersed in 1 mL of an 
appropriate buffer, diluted 1000 fold, and 20 µL of this solution transferred into each well 
of a 96 well plate. In the case above: 
The relative activity of these enzymes may then be calculated from the observed rate in A.s-
1 as shown in section 1 above. 
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4 Calculation of relative activities for reductive amination formed HRP-
trastuzumab conjugates, free form and immobilised 
The conjugate species synthesised was characterised by circular dichroism to be a 1:1 
conjugate with an approximate molecular mass of 192,400 Da. The concentration (c) of a 
stock solution was determined spectroscopically, and an aliquot was taken and diluted 1000-
fold for use in kinetic studies, thus: 
Spectroscopic studies yielded an observed rate, from which an activity per enzyme relative 
to that of the freshly prepared and unmodified enzyme can be found: 
The conjugate species was immobilised on nanoparticles analogously to the immobilisation 
of the enzyme. Taking the case of an approximately 2 % protein conjugated SPION 
population: 
@
And 
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For the assessment of relative enzymatic activity, the particles were dispersed in 1 mL of an 
appropriate buffer, diluted tenfold and 20 µL transferred to each well of 96 well plate: 
The relative activity of these enzymes may then be calculated from the observed rate in A.s-
1 as shown in section 1 above. 
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Appendix III: Crystallographic data 
1 Crystallographic data for naphthalimide (9) 
Table 1. Crystal data and structure refinement details for naphthalimide (9). 
Identification code  2016ncs0906r1x
Empirical formula  C17H14NO4Cl
Formula weight  331.74
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group P21/c
Unit cell dimensions a = 9.4534(6) Å  = 90.0 °
b = 5.3568(3) Å  = 98.800(5) °
c = 28.9389(15) Å  = 90.0 °
Volume 1448.23(13) Å3
Z 1 
Density (calculated) 1.522 Mg / m3
Absorption coefficient 0.284 mm1
F(000) 488 
Crystal Plate; yellow  
Crystal size 0.10  0.07  0.02 mm3
 range for data collection 2.180  27.485°
Index ranges 12  h  11, 6  k  5, 37  l  37
Reflections collected 12815 
Independent reflections 3306 [Rint = 0.0445] 
Completeness to  = 27.5° 100 % 
Absorption correction Semiempirical from equivalents
Max. and min. transmission 1.000 and 0.813 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3306 / 0 / 209 
Goodness-of-fit on F2 1.008 
Final R indices [F2 > 2(F2)] R1 = 0.1245, wR2 = 0.3077
R indices (all data) R1 = 0.1472, wR2 = 0.3205 
Extinction coefficient n/a 
Largest diff. peak and hole 2.200 and 0.750 Å3
______________________________________________________________________ 
Diffractometer: Rigaku FRE+ equipped with VHF Varimax confocal mirrors and an AFC12 
goniometer and HG Saturn 724+ detector. Cell determination and data collection: CrysAlisPro 
(Rigaku, V1.171.39.9g, 2015) Data reduction, cell refinement and absorption correction:
CrysAlisPro (Rigaku, V1.171.39.9g, 2015). Structure solution: ShelXT (Sheldrick, 2015). 
Structure refinement: ShelXL (Sheldrick, 2015). Special details: Large Q-peak suggests Cl is 
disordered over two sites but modelling leads to unrealistic bond lengths
Citations
CrysAlisPro Software System, Rigaku Oxford Diffraction, Yarnton, Oxford, UK (2016). 
CrystalClear, Rigaku Corporation, The Woodlands, Texas, U.S.A., (2008-2014). 
O.V. Dolomanov and L.J. Bourhis and R.J. Gildea and J.A.K. Howard and H. Puschmann, Olex2: 
A complete structure solution, refinement and analysis program, J. Appl. Cryst., (2009), 42, 339-341. 
Sheldrick, G.M., Crystal structure refinement with ShelXL, Acta Cryst., (2015), C27, 3-8. 
Sheldrick, G.M., ShelXT-Integrated space-group and crystal-structure determination, Acta Cryst., 
(2015), A71, 3-8. 
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2 Crystallographic data for naphthalimide (10) 
Table 2. Crystal data and structure refinement details for naphthalimide (10). 
Identification code  2016ncs0907xaCAP
Empirical formula  C21H22N2O5
Formula weight  382.40
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  P21/n
Unit cell dimensions a = 25.7629(5)  Å  = 90.0 °
b = 4.83852(9) Å  = 99.154(2) °
c = 29.4982(6) Å  = 90.0 °
Volume 3630.24(13)  Å3
Z 8 
Density (calculated) 1.399 Mg / m3
Absorption coefficient 0.101 mm1
F(000) 488 
Crystal Plate; yellow  
Crystal size 0.20  0.02  0.01 mm3
 range for data collection 2.393  27.485°
Index ranges 33  h  30, 6  k  6, 37  l  38
Reflections collected 46525 
Independent reflections 8338 [Rint = 0.0480] 
Completeness to  = 27.5° 99.9 % 
Absorption correction Semiempirical from equivalents
Max. and min. transmission 1.000 and 0.857 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 6864 / 0 / 507 
Goodness-of-fit on F2 1.090 
Final R indices [F2 > 2(F2)] R1 = 0.0590, wR2 = 0.1273
R indices (all data) R1 = 0.0759, wR2 = 0.1362 
Extinction coefficient n/a 
Largest diff. peak and hole 0.648 and 0.345 Å3
______________________________________________________________________ 
Diffractometer: Rigaku FRE+ equipped with VHF Varimax confocal mirrors and an AFC12 
goniometer and HG Saturn 724+ detector. Cell determination and data collection: CrysAlisPro 
(Rigaku, V1.171.39.9g, 2015) Data reduction, cell refinement and absorption correction:
CrysAlisPro (Rigaku, V1.171.39.9g, 2015). Structure solution: ShelXT (Sheldrick, 2015). 
Structure refinement: ShelXL (Sheldrick, 2015). 
Citations
CrysAlisPro Software System, Rigaku Oxford Diffraction, Yarnton, Oxford, UK (2016). 
CrystalClear, Rigaku Corporation, The Woodlands, Texas, U.S.A., (2008-2014). 
O.V. Dolomanov and L.J. Bourhis and R.J. Gildea and J.A.K. Howard and H. Puschmann, Olex2: 
A complete structure solution, refinement and analysis program, J. Appl. Cryst., (2009), 42, 339-341. 
Sheldrick, G.M., Crystal structure refinement with ShelXL, Acta Cryst., (2015), C27, 3-8. 
Sheldrick, G.M., ShelXT-Integrated space-group and crystal-structure determination, Acta Cryst., 
(2015), A71, 3-8. 
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3 Crystallographic data for complex ZnL1
Table 3. Crystal data and structure refinement details for ZnL1. 
Identification code  2014ncs0434 (ZnL1)
Empirical formula  C28H48N12O8S4Zn2
Formula weight  939.76 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 9.944(8) Å  = 110.88(2)°
b = 10.072(9) Å  = 92.672(14)°
c = 10.2874(10) Å  = 90.046(12)°
Volume 961.5(12) Å3
Z 1 
Density (calculated) 1.623 Mg / m3
Absorption coefficient 1.528 mm1
F(000) 488 
Crystal Column; orange 
Crystal size 0.200  0.040  0.020 mm3
 range for data collection 2.165  27.534°
Index ranges 12  h  12, 13  k  12, 12  l  13
Reflections collected 12230 
Independent reflections 4325 [Rint = 0.1355] 
Completeness to  = 25.242° 98.8 % 
Absorption correction Semiempirical from equivalents
Max. and min. transmission 1.000 and 0.131 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 4325 / 0 / 248 
Goodness-of-fit on F2 0.921 
Final R indices [F2 > 2(F2)] R1 = 0.0839, wR2 = 0.1911
R indices (all data) R1 = 0.0987, wR2 = 0.1974 
Extinction coefficient n/a 
Largest diff. peak and hole 1.941 and 0.759 e Å3
______________________________________________________________________ 
Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) 
Saturn724+ detector mounted at the window of an FR-E+ SuperBright molybdenum 
rotating anode generator with HF Varimax optics (100m focus). Cell determination and 
data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011). Data reduction, cell 
refinement and absorption correction: CrystalClear-SM Expert 2.1 r29 (Rigaku, 2011). 
Structure solution: SUPERFLIP (Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 
786-790). Structure refinement: SHELXL-2013 (Sheldrick, G.M. (2008). Acta Cryst. A64, 
112-122). Special details: The crystal used gave split (twinned) diffraction pattern. However, 
integrating one component was enough to solve structure.
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Table 4. Selected Bond lengths [Å] and angles [°]for ZnL1. 
Zn1N4 2.115(5)
Zn1N3 2.119(4)
Zn1S2 2.3384(15)
Zn1S1 2.4197(18)
Zn1S1i 2.504(2)
S2C10 1.748(6)
S1C5 1.794(5)
N2C5 1.306(7)
N2N3 1.378(6)
N3C6 1.302(7)
N5C10 1.325(7)
N5N4 1.371(6)
N4C8 1.289(7)
C9C8 1.498(7)
C8C6 1.506(7)
C7C6 1.491(7)
N4Zn1N3 74.95(17)
N4Zn1S2 81.39(13)
N3Zn1S2 144.80(14)
N4Zn1S1 152.91(12)
N3Zn1S1 80.26(13)
S2Zn1S1 114.73(6)
N4Zn1S1i 98.15(15)
N3Zn1S1i 100.29(13)
S2Zn1S1i 108.65(5)
S1Zn1S1i 96.84(8)
Zn1S1Zn1i 83.15(7)
C5N2N3 113.6(4)
C10-N5-N4  112.3(4) 
N5C10S2 127.4(4)
N2C5S1 126.7(4)
Symmetry transformations used to generate equivalent atoms:  
(i) x,y,z+1 
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4 Crystallographic data for complex CdL1
Table 5. Crystal data and structure refinement details for CdL1. 
Identification code  2014ncs0633 (CdL1)    
Empirical formula  C29H45Cd2Cl3N12O8S4
Formula weight  1149.16 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Monoclinic 
Space group  C2/c
Unit cell dimensions a = 26.9437(19) Å  = 90°
b = 11.8945(9) Å  = 111.132(8)°
c = 15.0987(11) Å  = 90°
Volume 4513.5(6) Å3
Z 4 
Density (calculated) 1.691 Mg / m3
Absorption coefficient 1.363 mm1
F(000) 2312 
Crystal Needle; pale yellow 
Crystal size 0.250  0.020  0.010 mm3
 range for data collection 3.205  27.483°
Index ranges 34  h  34, 15  k  15, 19  l  19
Reflections collected 29354 
Independent reflections 5179 [Rint = 0.1006] 
Completeness to  = 25.242° 99.8 % 
Absorption correction Semiempirical from equivalents
Max. and min. transmission 1.000 and 0.567 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 5179 / 490 / 304 
Goodness-of-fit on F2 1.003 
Final R indices [F2 > 2(F2)] R1 = 0.0497, wR2 = 0.1038
R indices (all data) R1 = 0.0867, wR2 = 0.1186 
Extinction coefficient n/a 
Largest diff. peak and hole 0.826 and 0.778 e Å3
______________________________________________________________________ 
Diffractometer: Rigaku AFC12 goniometer equipped with an enhanced sensitivity (HG) 
Saturn724+ detector mounted at the window of an FR-E+ SuperBright molybdenum 
rotating anode generator with HF Varimax optics (100m focus). Cell determination and 
data collection: CrystalClear-SM Expert 2.0 r11 (Rigaku, 2011). Data reduction, cell 
refinement and absorption correction: CrystalClear-SM Expert 2.1 r29 (Rigaku, 2011). 
Structure solution: SUPERFLIP (Palatinus, L. & Chapuis, G. (2007). J. Appl. Cryst. 40, 
786-790). Structure refinement: SHELXL-2013 (Sheldrick, G.M. (2008). Acta Cryst. A64, 
112-122).Special details: In the crystal structure one CHCl3 is disordered 50/50 ratio over 
centre of inversion. Additionally, in the main residue one C9-C10 being part of aliphatic 
chain was modelled as disordered over two sites with 54/46 ratio. DFIX as well as SIMU, 
DELU and RIGU restraints have been used to maintain sensible molecular geometry and 
atomic displacement parameters.
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Table 6. Selected Bond lengths [Å] and angles [°] for CdL1. 
Cd1N1 2.326(4)
Cd1N4 2.327(3)
Cd1S1 2.5029(12)
Cd1S2 2.5239(12)
Cd1S2i 2.8706(12)
Cd1S1ii 2.9574(12)
S2Cd1i 2.8706(12)
N2C5 1.322(6)
N2N1 1.367(5)
N4C3 1.280(6)
N4N5 1.372(4)
N1C2 1.289(6)
N5C9 1.315(6)
C12C11 1.501(6)
C2C3 1.490(6)
S1Cd1ii 2.9574(12)
N1Cd1N4 69.59(12)
N1Cd1S1 76.08(9)
N4Cd1S1 143.77(9)
N1Cd1S2 145.30(9)
N4Cd1S2 76.14(9)
S1Cd1S2 138.58(4)
N1Cd1S2i 89.71(9)
N4Cd1S2i 100.34(9)
S1Cd1S2i 90.57(4)
S2Cd1S2i 91.17(3)
N1Cd1S1ii 81.27(9)
N4Cd1S1ii 74.36(9)
S1Cd1S1ii 89.56(3)
S2Cd1S1ii 94.90(4)
S2iCd1S1ii 170.68(4)
C9S2Cd1 96.26(15)
C9S2Cd1i 96.40(15)
Cd1S2Cd1i 86.29(3)
C5N2N1 112.9(4)
C9N5N4 114.1(3)
N1C2C3 116.3(4)
N4C3C2 117.0(4)
Symmetry transformations used to generate equivalent atoms:  
(i) x+1,y,z+3/2    (ii) x+1,y+1,z+1 
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